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Background: Many patients awaiting lung transplantation die before a donor organ becomes available.
Ex vivo lung perfusion (EVLP) allows initially unusable donor lungs to be assessed and reconditioned for
clinical use.
Objective: The objective of the Donor Ex Vivo Lung Perfusion in UK lung transplantation study was to
evaluate the clinical effectiveness and cost-effectiveness of EVLP in increasing UK lung transplant activity.
Design: A multicentre, unblinded, non-randomised, non-inferiority observational study to compare
transplant outcomes between EVLP-assessed and standard donor lungs.
Setting: Multicentre study involving all five UK officially designated NHS adult lung transplant centres.
Participants: Patients aged ≥ 18 years with advanced lung disease accepted onto the lung transplant
waiting list.
Intervention: The study intervention was EVLP assessment of donor lungs before determining suitability
for transplantation.
Main outcome measures: The primary outcome measure was survival during the first 12 months
following lung transplantation. Secondary outcome measures were patient-centred outcomes that are
influenced by the effectiveness of lung transplantation and that contribute to the health-care costs.
Results: Lungs from 53 donors unsuitable for standard transplant were assessed with EVLP, of which 18
(34%) were subsequently transplanted. A total of 184 participants received standard donor lungs. Owing
to the early closure of the study, a non-inferiority analysis was not conducted. The Kaplan–Meier estimate
of survival at 12 months was 0.67 [95% confidence interval (CI) 0.40 to 0.83] for the EVLP arm and 0.80
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(95% CI 0.74 to 0.85) for the standard arm. The hazard ratio for overall 12-month survival in the EVLP arm
relative to the standard arm was 1.96 (95% CI 0.83 to 4.67). Patients in the EVLP arm required ventilation
for a longer period and stayed longer in an intensive therapy unit (ITU) than patients in the standard arm,
but duration of overall hospital stay was similar in both groups. There was a higher rate of very early grade 3
primary graft dysfunction (PGD) in the EVLP arm, but rates of PGD did not differ between groups after
72 hours. The requirement for extracorporeal membrane oxygenation (ECMO) support was higher in the
EVLP arm (7/18, 38.8%) than in the standard arm (6/184, 3.2%). There were no major differences in rates
of chest radiograph abnormalities, infection, lung function or rejection by 12 months. The cost of EVLP
transplants is approximately £35,000 higher than the cost of standard transplants, as a result of the cost
of the EVLP procedure, and the increased ECMO use and ITU stay. Predictors of cost were quality of life
on joining the waiting list, type of transplant and number of lungs transplanted. An exploratory model
comparing a NHS lung transplant service that includes EVLP and standard lung transplants with one
including only standard lung transplants resulted in an incremental cost-effectiveness ratio of £73,000.
Interviews showed that patients had a good understanding of the need for, and the processes of, EVLP. If
EVLP can increase the number of usable donor lungs and reduce waiting, it is likely to be acceptable to
those waiting for lung transplantation. Study limitations include small numbers in the EVLP arm, limiting
analysis to descriptive statistics and the EVLP protocol change during the study.
Conclusions: Overall, one-third of donor lungs subjected to EVLP were deemed suitable for transplant.
Estimated survival over 12 months was lower than in the standard group, but the data were also
consistent with no difference in survival between groups. Patients receiving these additional transplants
experience a higher rate of early graft injury and need for unplanned ECMO support, at increased cost.
The small number of participants in the EVLP arm because of early study termination limits the robustness
of these conclusions. The reason for the increased PGD rates, high ECMO requirement and possible
differences in lung injury between EVLP protocols needs evaluation.
Trial registration: Current Controlled Trials ISRCTN44922411.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 20, No. 85. See the NIHR Journals Library website
for further project information.
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Plain English summary
Donor lungs are frequently found to be unsuitable for transplantation. Ex vivo lung perfusion, known asEVLP, is a process that involves circulating a nutrient solution through the lungs, and attaching them
to a ventilator machine once they have been removed from the donor. EVLP allows unsuitable donor lungs
to be assessed outside the body to see if their function can be improved to make them suitable
for transplantation.
The Donor Ex Vivo Lung Perfusion in UK lung transplantation study was designed to test if EVLP could
safely increase lung transplant activity at an acceptable cost to the NHS. The aim was to find out if patients
transplanted with a perfused donor lung were as likely to survive for 1 year after surgery as those receiving
standard donor lungs. A total of 53 donor lungs were assessed ex vivo and 18 were transplanted. Twelve
patients (67%) were alive after 1 year, compared with 80% of 184 patients who received standard
donor lungs.
Patients who received an EVLP transplant had longer intensive care stays and needed more specialist
support of the lungs, but recovered at a similar time to the standard transplant group. A lung transplant
performed using perfused lungs costs about £35,000 more than a standard transplant. In addition to the
type of transplant, an important determinant of cost was quality of life when an individual joined the
waiting list. Those who received perfused lungs waited less time for a transplant, and patients felt that this
was an acceptable technology to use. An exploratory model estimated the cost-effectiveness, and the
results suggested that incorporating EVLP lung transplants into the NHS lung transplant service would not
be cost-effective, as we found that the rate of converting lungs from unsuitable to suitable for transplant
was low and that the rate of complications after transplantation was high.
The deaths that occurred after EVLP were not directly related to the perfusion process; they were due to
recognised complications that can occur in any lung transplant patient. The small number of patients
transplanted with perfused lungs compared with the number who received standard lungs limits
conclusions, but the technique did improve access to lung transplant at an increased cost.
Further research is needed to improve the way in which suitability of donor lungs for EVLP reconditioning
is decided and to assess why there is higher risk after transplanting EVLP donor lungs.
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Scientific summary
Introduction
Respiratory diseases account for one in five deaths in the UK. Lung transplantation is the only realistic
therapeutic option for selected patients with end-stage chronic lung disease, and provides dramatic
improvements in both survival and quality of life. In younger patients with life-threatening cystic fibrosis
lung disease, median survival after lung transplant now exceeds 10 years. However, 20–30% of patients
waiting for lung transplantation will die before a donor organ becomes available. Although a shortage of
multiorgan donors contributes, the main problem is that donor lungs are very susceptible to dysfunction,
and about 80% of potential donor lungs in the UK are deemed unusable for transplantation. It has been
suggested that, in addition to promoting more organ donation, better use of existing organ donors is an
important way in which to increase the numbers of lung transplants performed; many centres worldwide
have thus increased activity by accepting more ‘extended criteria’ donors. This strategy, however, is not
without risks to early outcomes. The major early cause of death after lung transplantation is primary graft
dysfunction (PGD), a severe lung injury akin to acute respiratory distress syndrome. Evidence that PGD has a
major impact on survival comes from experience in several centres worldwide and from the International
Society for Heart and Lung Transplantation: the reported incidence of PGD is up to 25%, and PGD is
associated with a 30-day mortality of 50%, compared with < 10% among those without PGD. There is,
therefore, an urgent clinical need to safely increase the utilisation of donor lungs from the existing donor
pool without negatively impacting on early survival after lung transplant.
Ex vivo lung perfusion (EVLP) is a novel technique in which donor lungs that are unusable because of poor
or uncertain function can be assessed objectively and potentially reconditioned for safe use in clinical lung
transplantation, thereby increasing the donor pool. Evaluation of human donor lungs in isolated perfusion
circuits offers unique advantages, as isolation of the lung may alleviate injurious factors associated with the
donor or recipient haemodynamics, hormonal derangements and their proinflammatory milieu. This allows
time for optimisation of the donor lung without the immediate risk associated with fully supporting the
recipient. EVLP can also objectively identify lungs that are not suitable for transplantation either because
poor function is a result of irreversible damage or because pre-existing lung disease, such as emphysema,
is identified in the donor lung. In this respect, EVLP may provide reassurance to potential recipients that
‘extended criteria’ donor lungs that might have been previously considered unusable are acceptable for
lung transplantation.
As of June 2011, approximately 25% of the world’s early experience with EVLP, 17 out of 65 cases, had
been gained in the UK. Although initial experience was promising, a large-scale trial of the procedure was
felt to be required to demonstrate its effectiveness in increasing lung transplant activity in a safe and
cost-effective way. The Donor Ex Vivo Lung Perfusion in UK lung transplantation (DEVELOP-UK) study was
therefore designed to address this urgent clinical need by assessing how effective EVLP assessment and
reconditioning of donor lungs is at safely increasing UK lung transplant activity.
Objective
The aim of DEVELOP-UK was to evaluate the clinical effectiveness and cost-effectiveness of the technique
of donor EVLP in increasing UK lung transplant activity by allowing previously unusable donor lungs to be
safely used in clinical lung transplantation. Furthermore, the study allowed the applicability of EVLP to lung
transplant services in the UK NHS to be determined.
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The study was designed as a multicentre, unblinded, non-randomised, non-inferiority observational study,
with an adaptive design to evaluate the clinical and economic effectiveness of EVLP in assessing and
reconditioning donor lungs for transplantation compared with standard lung transplantation. The study also
included an embedded qualitative substudy to determine the experiences of, and hopes and fears around,
EVLP use in patients waiting for, or after, lung transplantation.
As a UK-based multicentre study, it involved all five officially designated NHS lung transplant centres:
Birmingham, Harefield (London), Manchester, Newcastle and Papworth (Cambridge). These five tertiary
centres provide all adult lung transplant activity to potential recipients with end-stage chronic lung disease
in England, Scotland, Wales and Northern Ireland.
Methods
The target population for the study was adult patients (aged ≥ 18 years) with advanced lung disease who
had already been accepted (at study inception) onto an active lung transplant waiting list in one of the five
UK centres, plus any new adult patients who were added to the active waiting list during the course of the
study recruitment from 1 April 2012 to 9 July 2014. The experimental intervention was EVLP. EVLP was
performed outside the donor and recipient bodies by connecting the lungs to a semiautomated EVLP
machine (Vivoline Medical AB, Lund, Sweden), which warmed lungs to body temperature and circulated
a specialised perfusate solution through their vasculature. Following slow rewarming to 32 °C, the lungs
were ventilated with supplementary oxygen by connecting them to a standard intensive therapy unit (ITU)
ventilator. EVLP provides the opportunity to carefully assess donor lung function, including gas exchange,
over a number of hours before making a decision on their usability for transplantation. The study was
commenced using a hybrid EVLP protocol, combining elements of the EVLP protocols previously developed
in Toronto and Lund. After 22 EVLP assessments using the hybrid protocol and following an interim
evaluation of some early adverse events after the first eight EVLP transplants, the protocol was changed
entirely to the Lund protocol for the remaining 31 EVLP assessments and subsequent 10 transplants.
When a lung suitable for potential transplantation became available, the NHS Blood and Transplant
organ retrieval team was dispatched to the donor hospital to assess the donor lungs. After careful
assessment, a decision was made using study criteria whether the lungs could be used immediately for
standard transplantation, should undergo EVLP assessment and reconditioning, or were unsuitable
for transplantation.
The primary outcome measure was survival during the first 12 months following lung transplantation.
Secondary outcomes were clinically relevant patient-centred outcomes that are influenced by the
effectiveness of lung transplantation, and that contribute to the health-care costs, impact on recipients’
quality of life and cost-effectiveness.
Results
A total of 487 patients from the UK lung transplant waiting list either completed an expression of interest
(EOI) form, or fully consented to participate in the study. EOI forms allowed those living a significant
distance from the transplant centre to confirm their interest in participating without the need for
face-to-face interaction with the research team.
Donor lungs from 53 donors deemed unsuitable for standard transplantation were assessed with EVLP,
of which 18 (34%) were transplanted, constituting the EVLP arm of the study. A total of 184 patients
received standard donor lungs and constitute the control arm of the study. Other than a higher proportion
of donation after circulatory death and of male donors in the EVLP arm, there were no differences in the
donor or recipient characteristics between the two arms.
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The study did not reach target recruitment: only 184 standard transplants out of a target of 206 (60.1%),
and only 18 EVLP transplants out of a target of 102 (17.6%), were achieved before the independent Trial
Steering Committee advised that the study should be stopped early. This was because of poor enrolment in
the EVLP arm, and because there was no indication that the rate of EVLP assessments was increasing
sufficiently. In addition, there was a signal of a higher rate of serious adverse events, mainly requirement for
unplanned extracorporeal membrane oxygenation (ECMO) support in the EVLP arm. The final EVLP sample
size limited the subsequent comparisons to mainly descriptive statistics.
The Kaplan–Meier estimate of survival at 12 months was 0.67 [95% confidence interval (CI) 0.40 to 0.83]
for the EVLP arm and 0.80 (95% CI 0.74 to 0.85) for the standard arm. Based on Cox regression, the
hazard ratio for overall survival in the EVLP arm relative to the standard arm over the 12-month follow-up
was 1.96 (95% CI 0.83 to 4.67).
The median duration of invasive ventilation in the EVLP arm was 72 hours, and the median ITU stay was
14.5 days. In the standard arm, the corresponding values were 38 hours and 4.3 days. Overall, post-operative
hospital stay was similar in the two arms. The rate of grade 3 PGD at 24 hours was 44.4% in the EVLP arm
and 17.8% in the standard arm. The rates decreased in both arms by 72 hours, to 27.8% versus 22.5%.
ECMO support was required in 7 of 18 (38.8%) transplant recipients in the EVLP arm, and in 6 of 184 (3.2%)
recipients in the standard arm.
There were no anastomotic complications in the EVLP arm, but 14 of 146 (9.5%) transplants in the
standard arm exhibited anastomotic complications by 12 months, including two instances of bronchial
dehiscence. Rates of chest radiograph abnormalities over the 12-month follow-up period were similar in
the two arms, and there was a trend towards lower rates of infection in the EVLP arm. Lung function tests
were similar between the groups during 12 months of follow-up. The risk of rejection was highest in the
first 3 months, but there was no difference between rates of A2 rejection in the two arms of the study.
The median waiting time from listing was 197 days [interquartile range (IQR) 95–373 days] for a standard
transplant and 142 days (IQR 60–199 days) for those receiving an EVLP-evaluated donor.
Owing to the small numbers in the EVLP arm of the study, the economic analysis was limited to a within-trial
analysis, and the two transplant procedures were not compared directly in terms of their cost-effectiveness.
The total cost of lung transplant in the EVLP arm was estimated to be around £98,186 [standard deviation
(SD) £60,231]. The cost of a standard transplant was £63,637 (SD £44,047). The mean cost of the EVLP
procedure itself was £14,066. The variability in the total EVLP cost is marked, with a SD in costs of £60,231.
This is because of the increased use of ECMO and the increased length of ITU stay after EVLP transplant.
The total quality-adjusted life-years (QALYs) gained per EVLP recipient were estimated to be 0.527 and
0.533 in the standard arm. A regression model on cost identified three statistically significant predictors of
increased total cost: (1) higher quality of life when the person joined the waiting list; (2) use of EVLP
procedure; and (3) transplanting two lungs (as opposed to one). An exploratory model compared a NHS lung
transplant service that included both EVLP and standard lung transplants with one that included only
standard lung transplants. The incremental cost per QALY was £73,000, well above values normally
considered acceptable to the NHS. There was, however, considerable uncertainty around these results.
A total of 44 interviews were conducted with 24 men and 20 women, aged 21–69 years. The qualitative
study suggests that patients had a good understanding of the need for, and the processes of, EVLP,
although clinicians may want to consider exploring different ways and modes of providing information,
depending on patient preferences. Overall, this work suggests that if EVLP can increase the number of
suitable donor lungs available and reduce waiting times, then it is likely to be regarded as an acceptable
technology to patients waiting for lung transplantation in the UK.
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Conclusions
Overall, one-third of the donor lungs found unsuitable for standard transplantation that were subjected to
EVLP in the study were subsequently deemed suitable for transplant. Estimated survival over 12 months in
this EVLP group was lower than in the standard lung transplant group, but the data were also consistent
with no difference in survival between groups. These additional EVLP transplants were associated with a
higher rate of early severe graft injury and need for unplanned ECMO support, and were, on average,
more costly. However, limited data mean that comparisons should be treated cautiously; the small number
of participants in the EVLP arm (17.8% of the target), owing to slow enrolment in the EVLP arm and
early study termination, limits the robustness of conclusions drawn, and results must be interpreted
with caution.
Implications for practice
The DEVELOP-UK study is the first to report poorer outcomes in a group of EVLP transplants than in a
contemporaneous standard lung transplant group, but few data were available for comparison. The study
is the first non-commercial, multicentre EVLP study performed, and relied on a small number of centres
in a single country to deliver a substantial target of EVLP assessments and subsequent EVLP transplants.
To date, two commercially funded multicentre EVLP studies have been performed but have not yet fully
published their results.
The slow enrolment into the EVLP arm of the study was because of a combination of the low number
of EVLP assessments performed and the low conversion rate from EVLP assessment to transplant. This
demonstrates the challenge of running an EVLP assessment service alongside an active clinical transplant
programme when logistics and staff availability, due to competing transplant activity, can significantly
affect units’ ability to perform EVLP assessments.
The higher rate of early PGD grade 3 and need for ECMO support in the EVLP arm has raised issues about
the selection of the best lungs on which to perform EVLP. Although there was a much higher ECMO rate,
it was not associated with a higher mortality risk in the recipients undergoing ECMO, which, in most cases,
was limited to a few days of support. The almost uniform use of cardiopulmonary bypass in recipients of
EVLP donor lungs (89%) may also have contributed to the high early PGD grade 3 rates and the frequent
use of ECMO as a second hit to donor lungs that already have disrupted vascular integrity.
Implications for research
The findings of the DEVELOP-UK study will help to direct further research in the area of EVLP. The high
rate of early severe PGD and need for ECMO in this study makes it necessary to further investigate
whether or not a combination of EVLP followed by transplant surgery on cardiopulmonary bypass causes
a second hit that increases vascular leak and early reperfusion injury.
There is also work to be done to explore why only 30–40% of the lungs perfused in this study satisfied
transplant criteria, and whether this was a problem with donor organ selection for EVLP or a result of the
rigidity of following a multicentre prospective study protocol, which imposes stricter decision-making than
would happen in a single centre outside of a formal study setting.
Trial registration
This trial is registered as ISRCTN44922411.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxix

Chapter 1 Introduction and background
Introduction
Respiratory diseases account for one in five deaths in the UK.1 Lung transplantation is the only realistic
therapeutic option for selected patients with end-stage chronic lung disease and provides dramatic
improvements in both survival and quality of life. In younger patients with life-threatening cystic fibrosis
(CF) lung disease, median survival after lung transplant now exceeds 10 years. However, 20–30% of
patients waiting for lung transplantation will die before a donor organ becomes available. Although a
shortage of multiorgan donors contributes, the main problem is that in multiorgan donors lungs are very
susceptible to dysfunction, and about 80% of potential donor lungs in the UK are deemed unusable for
clinical lung transplantation. It has previously been suggested that, in addition to promoting more organ
donation, better use of existing organ donors is an important way to increase the numbers of lung
transplants performed,2 and many centres worldwide have increased donor lung use by accepting more
‘marginal’ or ‘extended criteria’ donors. This, however, is not without risks to early post-transplantation
outcomes.3 The major early cause of death after lung transplantation is primary graft dysfunction (PGD),
a severe lung injury akin to acute respiratory distress syndrome. Evidence that PGD has a major impact on
survival comes from experience in several centres worldwide,4 and from the International Society for Heart
and Lung Transplantation (ISHLT); the reported incidences of PGD are up to 25%, and PGD is associated
with 30-day mortality of 50%, compared with < 10% among those without PGD.5 There is, therefore, an
urgent clinical need to safely increase the utilisation of donor lungs from the existing donor pool without
negatively impacting on early survival after lung transplant.
Background
Ex vivo lung perfusion (EVLP) is a novel technique in which donor lungs that are unusable because of poor or
uncertain function can be assessed objectively and potentially reconditioned for safe use in clinical lung
transplantation, thereby increasing the donor pool. Evaluation of human donor lungs in isolated perfusion
circuits, as seen in Figure 1, offers unique advantages, as isolation of the lung may alleviate injurious factors
associated with the donor or recipient haemodynamics, hormonal derangements and their pro-inflammatory
milieu. This allows time for optimisation of the donor lung without the immediate risk associated with fully
supporting the recipient. EVLP can also objectively identify lungs that are not suitable for transplantation
either because poor function is a result of irreversible damage, or because pre-existing lung disease is
identified in the donor lung. In this respect, EVLP may provide reassurance to potential recipients that
‘marginal’ or ‘extended criteria’ donor lungs that might previously have been considered unusable are now
acceptable for lung transplantation.
As of June 2011, approximately 25% of the world’s early experience with EVLP, 17 out of 65 cases, had
been gained in the UK. Although initial experience has been very promising, a large-scale trial of the
procedure was required to demonstrate its effectiveness in increasing lung transplant activity in a safe and
cost-effective way.
The Donor Ex Vivo Lung Perfusion in UK lung transplantation (DEVELOP-UK) study was therefore designed
to address this urgent clinical need by assessing how effective EVLP assessment and reconditioning of
donor lungs is at safely increasing UK lung transplant activity. The overall objective of this study was to
evaluate the clinical effectiveness and cost-effectiveness of the novel technique of donor EVLP in increasing
UK lung transplant activity by allowing previously unusable donor lungs to be safely used in clinical lung
transplantation. Furthermore, the DEVELOP-UK study would allow the applicability of EVLP to lung
transplant services in the NHS to be determined.
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(a)
(b)
FIGURE 1 Schematic diagram of an EVLP circuit. HCU, heater cooler unit; LA, left atrium; PA, pulmonary artery.
(a) A line diagram of an EVLP circuit; and (b) a donor lung undergoing EVLP on the Vivoline LS1 system (Vivoline
Medical AB, Lund, Sweden). Reproduced from Wallinder et al., Early results in transplantation of initially rejected
donor lungs after ex vivo lung perfusion: a case-control study. Eur J Cardiothorac Surg 2014;45:40–4, by permission
of the European Association for Cardio-Thoracic Surgery.6
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Impact of donor lung injury
The lung is very susceptible to injury in the critical care environment, and the vast majority of donor lungs
become unusable because of the dysfunction that develops in the hours or days leading up to the donor’s
death. Korovesi et al.7 observed that pulmonary and systemic inflammation occurred in patients who
required mechanical ventilation for severe head injury. Characteristic changes in lung mechanics, suggesting
subclinical pulmonary inflammation, also developed before the patients became eligible to be organ
donors.7 Fisher et al.8 have shown that acute inflammation in the donor lung with elevated levels of
interleukin 8 in donor bronchoalveolar lavage (BAL) is important in determining early outcomes after human
lung transplantation.9 These observations have subsequently been reproduced elsewhere in the world.10
In addition, an imbalance between inflammatory interleukin 6 and anti-inflammatory interleukin 10 (IL-10)
gene expression in the donor lung predicts adverse early outcomes after human lung transplantation.11 These
clinical observations have been modelled by Avlonitis et al.12 using a rat model of brain death-induced donor
lung injury and subsequent rat lung transplantation. Brain death, together with trauma, infection, aspiration
or transfusions, is now considered an important cause of donor lung inflammation and significant progress
in understanding its pathophysiology has been made.13 Other animal models of lung transplantation have
demonstrated that adenoviral gene therapy to upregulate expression of the anti-inflammatory cytokine
IL-10 in the donor lung downregulates inflammation and improves function in the recipient animal after
transplant.14–17 These observations suggest that attenuating the donor lungs’ inflammatory response before
implantation may improve early outcome after lung transplantation, and help to safely maximise lung use
from the existing donor pool.
Assessment of donor lung usability
Assessing whether or not potential donor lungs are usable for transplantation is a process that takes into
consideration available donor history, subjective evaluation of chest radiograph appearance, bronchoscopy
and more exact physiological data such as arterial blood gases (ABGs) following high-concentration oxygen
challenge. Despite improvements in donor management practices, currently < 20% of lungs from multiorgan
donors in the UK are accepted for transplantation. The internationally accepted selection criteria of the
‘optimal donor’ are primarily opinion based rather than evidence based, and their accuracy in determining
the physiological status of the donor lung and predicting post-operative lung function is not optimal.18
Fisher et al.19 have shown that current clinical donor lung assessment criteria are poor predictors of existing
inflammation or infection in the donor lung, suggesting that many donor lungs deemed unusable may be
unnecessarily excluded. Ware et al.20 evaluated 29 pairs of unusable lungs by physiological, microbiological
and histological methods, and concluded that as many as 40% of these lungs would have been potentially
suitable for transplantation. Thus, there is urgent need to improve the donor lung selection process through
more objective physiological assessment; EVLP can provide a platform to achieve this. In practice, not all of
the unused donor cohort will be suitable donors, as some will have absolute contraindications to lung
donation, while for others there will not be a suitable matching recipient on the waiting list. It is nonetheless
suggested that EVLP could have the potential to increase availability of donor lungs for transplant by
50–100%. However, the current clinical transplantation infrastructures would not cope with a near doubling
in activity, therefore, in this study, we were aiming for a 30% overall increase in lung transplant activity.
Early pathway development
Ex vivo lung perfusion was first reported in a canine model in 1970 as a technique to assess the quality of
the donor organ in animal models of lung transplantation.21 Subsequently, porcine studies showed that
maintenance of intact vascular function was achievable for up to 24 hours using EVLP, and that functioning
lungs could be obtained from donors after circulatory arrest in a porcine model. The clinical EVLP technique
was initially developed by Steen et al.22 in Sweden to assess lungs from donation after circulatory death
(DCD) before transplantation. Their initial work in animal models was subsequently translated into the
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world’s first successful clinical report in 2001 of a lung transplant performed using lungs from a human
DCD donor assessed by EVLP prior to successful transplantation.22 Further experimental work in human
donor lungs demonstrated that assessment and reconditioning of unusable organs using EVLP could result
in significant improvements in arterial oxygenation and pulmonary vascular resistance.23 This led to the
first clinical report in 2007 of actual reconditioning of an unusable donor lung prior to successful
lung transplantation.24
Clinical ex vivo lung perfusion experience worldwide
Publication of the first successful lung transplantation using a reconditioned donor lung led to a rapid
growth in interest in the EVLP technique.22 The Steen group described successful reconditioning and
transplantation of six out of nine donor lungs previously deemed unusable for transplant.24 All six survived
the first 3 months and four of the six were alive and well 12 months after transplant.25 Subsequently,
Cypel et al.26 in Toronto modified the EVLP protocol significantly to include an acellular perfusate, a closed
perfusion circuit and low perfusion pressures of no more than 40% of calculated cardiac output, and
demonstrated that lungs can be maintained on EVLP for more prolonged periods with this approach.26
This group have published their experience of the Human Ex-vivo Lung Perfusion study27 performing EVLP
on 23 donor lungs unacceptable for transplant that translated into 20 clinical lung transplants. Outcomes
in this group were comparable to that achieved with standard transplants performed over the same
time period, with a 15% incidence of PGD in the EVLP group and of 30% in the standard transplant
group (p = 0.11).
The UK was the third country worldwide to perform a lung transplantation using EVLP-assessed and
-reconditioned donor lungs. The first case was performed by the Manchester group, followed rapidly by the
programmes in Harefield,28 Newcastle and Cambridge. By June 2011, UK activity had totalled 17 transplants
performed with lungs that would not have been used without EVLP assessment and reconditioning.
The 90-day survival in these 17 cases was 100%, with one subsequent death from pneumonia at 9 months,
and one further death at 18 months due to rejection. When the Swedish and UK experience was added to the
Toronto experience, the findings suggested that early survival is very good, with only two deaths within 90 days
among over 65 EVLP transplants. The UK experience revealed that the successful conversion rate during EVLP
from unusable to usable donor organs was approximately 50%, which was lower than that reported in the
Toronto experience. This may represent the high proportion of DCD donors in Toronto, where EVLP was being
used primarily for assessment rather than for reconditioning.
International experience has since grown, with case series now reported by multiple groups internationally,
including in Paris, Madrid, Vienna, Milan and Gothenburg, with patients successfully transplanted with
EVLP lungs recovered from uncontrolled and controlled DCD donors.29,30
In 2010–11, the UK was in a unique position, with four of its five adult lung transplant centres having
already developed clinical experience in EVLP. At that time, there had been no systematic studies powered
to evaluate the clinical effectiveness, safety and cost-effectiveness of EVLP performed anywhere in the
world, and this was the impetus for the UK lung transplant community to come together in a collaborative
effort in the DEVELOP-UK study.
Keshavjee et al., in Toronto, have, with their extensive contributions, changed the landscape of EVLP into a
technique to significantly expand the limited donor pool currently used in transplant centres all around the
world.27,30–32 The focus of Keshavjee and Cypel’s studies in Toronto has not been just to evaluate whether
a graft is usable or not, but also to prolong the perfusion times to be able to potentially treat and better
recondition injured lungs before transplantation. They have most notably revised the Lund protocol to
potentially increase the option of longer-term perfusion with an acellular perfusate to avoid potential
detrimental haemolysis. This is combined with a low-flow strategy with only 40% of estimated cardiac
output to reduce pulmonary vascular shear stress and oedema formation, and closed circuit with both the
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pulmonary artery and left atrium cannulated, creating a positive left atrium pressure. The prospective,
non-randomised, multicentre study NOVEL (NOrmothermic ex Vivo lung perfusion as an assessment
of Extended/marginal donor Lungs) has recently been completed in the USA with the Toronto EVLP
protocol and the XPSTM system (XVIVO Perfusion AB, Gothenburg, Sweden) to approve its clinical use.
Warnecke et al.,33 in 2012, investigated the effect of normothermic preservation and transportation of
standard criteria human donor lungs on a portable EVLP system. Twelve pairs of standard donor lungs
were, instead of being brought to their centres by means of cold preservation on ice, preserved by
normothermic perfusion and ventilation on the transportable Organ Care SystemTM (OCS) lung
(TransMedics Inc., Andover, MA, USA). This was the first report of a portable EVLP system used in clinical
transplantation, with short-term outcomes shown to be non-inferior to controls.33
The OCS protocol used in this pilot study was a hybrid of the Lund and Toronto EVLP protocols. A cellular
perfusate based on Steen Solution™ (XVIVO Perfusion AB, Gothenburg, Sweden) supplemented with
erythrocytes and an open left atrium was combined with a perfusate flow limited to 2.5 l/minute, resembling
the protective approach developed by the Toronto group. The OCS protocol is currently being evaluated on
a larger scale in a prospective, randomised multicentre pivotal trial, OCS International Randomized Study of
the TransMedics Organ Care System for Lung Preservation and Transplantation (INSPIRE), comparing
transplant outcomes of standard criteria lungs preserved and transported by either normothermic EVLP
or standard cold preservation.34 Moreover, the international EXPAND (Evaluate the Safety and Effectiveness
of The Portable OCS Lung For Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for
Transplantation) trial was recently launched as a clinical pilot to evaluate the more traditional use of
assessing and, possibly, reconditioning lungs deemed unusable for standard transplantation on the OCS
lung portable system.35
The development of semiautomated systems with disposable kits has made conducting EVLP more
standardised, and has allowed protocols to be developed, as seen in the Vivoline LS1 (Vivoline Medical AB,
Lund, Sweden) in Figure 2. The LS1 is a semiautomated EVLP system that was used at all sites in the
DEVELOP-UK study.
Ex vivo lung perfusion biological mechanisms of action
There are a number of mechanisms by which the reconditoning effects of EVLP are believed to occur.
These are outlined in the following sections.
Haemodynamic factors
Controlling the speed and pressure of initial reperfusion of the transplanted lung in animal models reduces
the risk of developing PGD.28 The EVLP protocol allows initiation of controlled reperfusion after ischaemia,
and preservation and controlled perfusion throughout EVLP, which is rarely available in routine clinical
transplantation. This allows slow rewarming of the lung tissue and incremental perfusion of pulmonary
vasculature over a prolonged period of time with continuous limitation of pulmonary artery pressures and,
thereby, arterial and capillary hydrostatic forces to prevent further pulmonary oedema. Conducting EVLP at
equivalent to very low left atrial pressures helps further by limiting hydrostatic forces in post-capillary
venules and capillaries.
Protective lung ventilation
Protective lung ventilation strategies are the standard of care for intensive therapy unit (ITU) management
of injured lungs. However, the need for hyperventilation in the management of head injury generally
overrides this principle in potential lung donors, and avoidance of hypercapnia may limit the use of these
strategies in transplant recipients. EVLP, therefore, provides a unique opportunity to adopt ventilation
strategies that reduce excessive mechanical stretch (low tidal volume) and oxidative stress [low fraction of
inspired oxygen (FiO2)] and to employ sustained positive end expiratory pressures to overcome atelectasis
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without deleterious effects on systemic haemodynamics. Bronchial toilet with site-directed BAL limits
ventilation–perfusion mismatch, thus avoiding regional hypoxia with high pulmonary vascular resistance
and parenchymal damage. Immediate results from Gram stains of BAL directs antibotic therapy, with
perfusion itself reducing microbacterial load.36
Perfusate-related factors
One of the major mechanistic benefits of EVLP is the use of Steen Solution, an albumin- and dextran-rich
perfusate solution with a high oncotic pressure. The solution can alter filtration forces to remove interstitial
lung water and reduce pulmonary oedema. This may be responsible for the improved oxygenation observed
between assessment in the donor and assessments during EVLP. In addition, albumin may act as an
antioxidant, and dextran limits cell aggregation and microthrombi formation. The retrograde and antegrade
perfusion during EVLP with use of a leucocyte filter in the circuit will also facilitate removal and prevent
recirculation of intravascularly primed or activated leucocytes. Indeed, experimental models indicate reduced
myeloperoxidase content of EVLP lungs, which are a biomarker of neutrophil-mediated responses.
Removal from the inflammatory donor environment
Another potential mechanism of lung reconditioning using EVLP may simply be the relocation of the donor
organ from the suboptimal brain death environment in the donor. Eliminating the ongoing triggers of
donor lung inflammation, including the endogenous toll-like receptor ligands and activated donor
leucocytes, in a normothermic perfusion state may allow reduced inflammatory gene expression and
restore protective anti-inflammatory mechanisms.
Opportunities for pharmacological-, genetic- and cell-based therapies
Along with steroids, heparin and antibiotics, a potential future option may be supplementation of
perfusate with cytoprotective pharmacological substances including vasodilators, antioxidants, cytokine
blockers, established inhibitors of inflammatory pathways, fibrinolytics and immunomodulators. Such
strategies may facilitate better reconditioning of the lungs to increase conversion rates to successful
transplantation and long-term survival. A genetic approach to improve cytokine balance has been shown
to be beneficial in a large animal model of EVLP and transplantation, and IL-10 gene therapy has been
applied to human EVLP lungs.37 Similarly, a stem cell therapy approach via EVLP has been shown to
improve acute lung injury in human lungs.38
(a) (b)
FIGURE 2 Photograph of (a) the Vivoline LS1 EVLP machine and (b) the disposable lung kit.
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Chapter 2 Study rationale and design
Study design
The DEVELOP-UK study was designed as a multicentre, unblinded, non-randomised, non-inferiority
observational study with an adaptive design, to evaluate the clinical and economic effectiveness of EVLP in
assessing and reconditioning donor lungs for transplantation compared with standard lung transplantation.
The study also includes an embedded qualitative substudy.
Primary outcome measure
Survival during the first 12 months following lung transplantation was chosen as the primary outcome
measure in the study. It is a robust, well-recognised, clinically relevant outcome that is used in the Royal
College of Surgeons national audit of UK cardiothoracic transplant activity and in the ISHLT lung transplant
registry. A dichotomous outcome such as survival ‘yes/no’ at 30 or 90 days would be less informative, and
would omit valuable information about potentially differing survival patterns between the two study groups.
Secondary outcome measures
The secondary outcome measures in this study were all deemed to be important, clinically relevant,
patient-centred outcomes that are influenced by the effectiveness of lung transplantation, contribute to
the health-care costs and impact on health-related quality of life (HRQoL).
Primary graft dysfunction is a clinical entity that reflects the development of early acute lung injury after
lung transplantation. PGD was first defined by a working group (which included a number of the study
investigators) of the ISHLT in 2005.39 Its severity is graded between 0 and 3 and it is measured at 0–6, 24,
48 and 72 hours after lung transplantation. The grade is determined by the degree of gas exchange
impairment, and by the presence of infiltrate on the post-operative chest radiograph. The PGD grade has
been validated in both retrospective and prospective studies, and presence of PGD grade 3 at 72 hours is
associated with a reduced early survival. A full PGD score was requested to be determined for all patients
in the study.
The durations of invasive ventilation and ITU stay after lung transplantation were collected for all study
participants, and provide a valuable source of a range of complications in early post-operative course.
In addition, the duration of hospital stay before first discharge home gives a good indication of how
effectively the patient is rehabilitating after their lung transplant. These measurements also provided useful
information on health resource utilisation for economic evaluation.
The presence of specific post-operative complications was also collected as a secondary outcome measure.
These complications included anastomotic complications scored using the recognised and validated Couraud
Classification (see Appendix 1),40 which scores airway complications including dehiscence or stricture
requiring dilatation or stent placement. Episodes of infection requiring treatment with or without associated
hospital admission during the first year, and episodes of acute rejection of ISHLT grade A2 or higher, B1 or
higher, or clinically diagnosed acute rejection requiring treatment during the first year, were also collected.
Details of lung function measurements by forced expiratory volume in 1 second (FEV1) and vital capacity at
1, 3, 6 and 12 months post transplant were collected to demonstrate changes in lung allograft function
in the first year. Data on chest radiograph appearance at the same time points as lung function were
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collected to look for any persistent abnormalities such as effusions, cavitation or chronic scarring from the
time of transplantation.
Patient survival rate at 90 days post transplantation was collected as an internationally recognised outcome
measure in lung transplantation that can be benchmarked against outcomes reported in both the UK and
international (ISHLT) registries.
An assessment of HRQoL using the Short Form questionnaire-36 items (SF-36) was collected at three time
points in the study (while participants were waiting for transplant and again at 90 days and 1 year post
lung transplantation) allowing comparison of HRQoL measured while on the waiting list with that
measured post transplant. The HRQoL scores have allowed health state utility scores to be determined
using the Short Form questionnaire-6 Dimensions (SF-6D) as part of the economic evaluation.
Health economic assessment
In addition, the full economic impact of using EVLP-reconditioned lungs was assessed, allowing policy-makers
to consider these costs in comparison with benefits of increased donor utilisation and reduced waiting list
mortality. We aimed to determine whether or not EVLP is a cost-effective intervention for the NHS to support
as standard care within UK lung transplant centres in the future.
Patients’ attitudes and experiences
To gain an understanding of the potential impact of EVLP provision to service users, we explored attitudes
towards EVLP in patients awaiting lung transplantation, and the experiences of patients receiving
EVLP-reconditioned lungs, in a qualitative interview substudy.
Predicting ex vivo lung perfusion success or failure
The DEVELOP-UK study provided a unique opportunity to better understand the donor- and procedure-related
clinical determinants of successful or failed EVLP donor lung reconditioning. Objective clinical and physiological
indices in the donor lungs before and during EVLP can therefore be correlated with the decision of whether or
not to accept the donor lungs for transplant and with clinical outcomes in recipients of EVLP donor lungs.
Sample collection and storage
To add significant value to the DEVELOP-UK study, standardised protocols for BAL, perfusate and lung
tissue sampling during EVLP and subsequent storage have been developed. The collection and storage of
samples during EVLP was part of the DEVELOP-UK study, and allowed complementary mechanistic studies
of EVLP to be performed from the data set. Details of the laboratory-based mechanistic work are, however,
not included in this report, as this element of the study was funded from sources other than the National
Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme.
Justification for non-randomised design
This is a non-randomised study, as randomisation between EVLP and standard lung transplantation was not
considered a viable option. The matching of potential donor lungs to potential recipients is dictated by a
number of independent factors, including donor and recipient size, blood group and, if applicable, human
leucocyte antigen (HLA) tissue matching to avoid any pre-formed HLA antibodies in the recipient. It was,
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therefore, not logistically possible to randomise recipients to receive either standard or EVLP donor lungs as
part of the study. Furthermore, any attempt to randomly pre-allocate patients on the waiting list to an EVLP
or standard group could give rise to a situation where a recipient may not be able to access a well-matched
donor organ because it did not fall into his or her pre-allocated group, which would not be ethically
acceptable. Randomisation would be possible only if all donor organs were being randomly allocated to EVLP
or control, but this is a different research question and was not an objective of this study.
Lung donations from donors with brain death and DCD donors were considered in both arms of this study.
The number of DCD donors is increasing year on year in the UK.41 Evidence has emerged that, when lungs
from these donors are transplanted, outcomes in recipients are comparable to those achieved with lungs
from donation after brain death (DBD) donors.42 However, only a fraction of the UK DCD donors, currently
about 5%, have their lungs used for standard transplantation.41 Frequently, there are insufficient data
available to be able to objectively assess the function of the lungs from DCD donors, or there is a
prolonged warm ischaemic phase after withdrawal of life support that renders the lungs unusable for
standard transplantation. EVLP does, however, provide the potential to assess and potentially recondition
lungs from DCD donors that cannot be used for standard transplantation.
It was anticipated that a direct result of the DEVELOP-UK study would be an increase in the proportion
of DCD donor lungs being used, as DCD donor lungs are often deemed unusable because functional
information about the organs is unavailable, which is an indication for use of EVLP assessment. It was
considered likely that as the number of DCD donors increases, more lungs from this cohort of donors
would be transplanted in the EVLP arm of the study than in the standard arm. This reflects the potential
for EVLP to significantly increase the use of lungs from DCD donors. To ensure that the possible higher
proportion of DCD donor lungs in the EVLP arm of the study did not bias the results, we planned to use
the donor type (DCD or DBD) as a covariate in the multiple regression analysis of the primary and
secondary outcome measures to determine their influence.
Justification for adaptive study design
The study statistics and trial methodology teams, in consultation with the clinical investigators, made the
decision to use an adaptive design for the DEVELOP-UK study, to allow for the possibility of stopping
the trial early should non-inferiority in our primary outcome be determined at an interim analysis, and to
allow for re-evaluation of the sample size requirements on the basis of a potentially improved standard of
care. It was felt that a total of three analyses, two interim and one final, would achieve a suitable balance
between allowing for early stopping and ensuring that sufficient data were collected on secondary
outcome variables to make these meaningful. The plan was for the interim analyses to be carried out once
a prespecified number of patients had been recruited to each arm (see Power calculation and definition of
non-inferiority). The O’Brien–Fleming critical values for the analyses during our study were chosen so that
the overall study would have sufficient power to detect our target differences at a significance level of
0.05 once allowance had been made for the interim analyses.
Power calculation and definition of non-inferiority
In the standard arm, the initial best available estimate for survival to 30 days was 94.2%, for survival to
90 days was 91.2% and for survival to 1 year was 78.7%. These data were determined from the Royal
College of Surgeons’ UK national audit of lung transplant outcomes. Our aim was to demonstrate that
using reconditioned EVLP lungs does not increase the hazard rate of death during the first year by a factor
of > 2. A doubling of the hazard rate would imply that survival rates on EVLP would be 88.7% for 30 days,
83.2% for 90 days and 61.9% for 1 year. It was considered that such a difference is not clinically significant
and still represents an advantage over waiting longer for a transplant.
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It was anticipated that over the predicted 3 years of the study, about 100 EVLP lungs would be transplanted
and ≥ 300 normal lung transplants would take place. If both treatment arms matched the standard 78.7%
rate of survival over 12 months, then approximately 85 deaths would occur within 1 year of transplantation.
Using a fixed sample design, this would be sufficient to ensure 80% power of claiming a significant finding
of non-inferiority (at a one-sided 5% level) if both treatment groups actually have the same survival pattern.31
The study was therefore powered to detect a difference of 2, meaning that non-inferiority is assumed to
have been achieved if the hazard rate of 12-month survival is not doubled by the use of EVLP.
To obtain sample sizes for an adaptive design, we took the standard sample size and multiplied it by
the appropriate inflation factor (which depends on the choices of critical values, number of analyses,
significance level and power). For our choices, the inflation factor was 1.0128, resulting in a sample size of
304 in the standard arm and 102 in the EVLP arm. We increased the sample size to 306 in the standard
arm while keeping it at 102 in the EVLP arm so that the sample size in both arms would be divisible by 3,
to allow for equally spaced interim analyses. This resulted in a required minimum total sample size of
408 with interim analyses after 12-month survival data were available from 102 and 204 patients in the
standard arm (34 and 68 in the EVLP arm).
Risks and anticipated benefits for study participants, NHS and society
There is a huge discrepancy between the supply of usable donor lungs and the number of patients with
end-stage lung disease who could potentially benefit from lung transplantation surgery in terms of extended
longevity and improved quality of life. As a result, many patients die on the waiting list before suitable donor
lungs become available. EVLP allows otherwise unusable donor lungs to be meticulously assessed and
potentially reconditioned for successful transplantation. The study would also help to understand better how
to optimise the use of lungs procured from DCD donors. This technology, therefore, has the potential to
expand the donor pool and increase UK lung transplant activity, thereby shortening time spent on the
waiting list and reducing waiting list deaths.
The primary risk for the individual participant awaiting lung transplantation is that if they are enrolled in the
EVLP arm they may receive a lung or lungs that do not function well, but that risk also exists for standard
donor lungs accepted by the current assessment methods. Compared with standard criteria organs, it was
not anticipated that EVLP should expose recipients to any different risk profile in terms of microbiological
exposure, intensity of induction and maintenance immunosuppression or early post-transplant complications.
This was based on reported worldwide experience with EVLP at the time (2010–11) the study was designed
and launched. Patients awaiting lung transplantation have severe, often complex, morbidity and place a
heavy resource burden on both health and social services. Data from the ISHLT registry clearly demonstrate
that nearly 80% of successful lung transplant recipients have no or little functional limitation and around
40% return to either full- or part-time employment, the rest being close to or over retirement age.43 Fewer
than 20% of transplant recipients require inpatient treatment related to their lung disease post hospital
discharge following the transplant procedure. Thus, by increasing the numbers of successful transplants,
EVLP may help to reduce the UK health- and social-care costs of patients awaiting lung transplantation.
Furthermore, by assessing the economic impact of using EVLP-reconditioned lungs, the study results should
allow policy-makers to balance these costs against the benefits of increased donor utilisation and reduced
waiting time mortality. The study aimed to help determine if EVLP is a cost-effective use of tax-payers’ money
and an intervention applicable to NHS lung transplant services.
Study population
The DEVELOP-UK study was a UK national multicentre study involving all five officially designated NHS
lung transplant centres: Freeman Hospital, Newcastle upon Tyne; Harefield Hospital, London; Papworth
Hospital, Cambridge; Wythenshawe Hospital, Manchester; and Queen Elizabeth Hospital, Birmingham.
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These five centres provide all adult lung transplant activity to potential recipients with end-stage chronic
lung disease in England, Scotland, Wales and Northern Ireland.
The target population for the study was adult patients aged ≥ 18 years with advanced lung disease,
who had already been accepted (at study inception) onto an active lung transplant waiting list in one of
the five UK centres, plus any new adult patients who were added to the active waiting list during the study
recruitment period of April 2012 to June 2014. The full network coverage means all patients awaiting lung
transplantation in the UK, at any one time approximately 250, had the opportunity to take part in the
study, and our previous pilot experience suggested that > 90% would consent to take part. The study was
designed to have no effect on how potential lung transplant recipients were assessed or selected, or the
timing of when they were added to the active transplant waiting list. The flow chart in Figure 3 shows the
planned recruitment targets and summary of data collection for the DEVELOP-UK study.
Study inclusion criteria
Male or female adult patients (aged ≥ 18 years) who were either already on or added to the active waiting
list for their first lung transplant while the DEVELOP-UK study was in its recruitment phase were eligible
to participate; patients provided informed consent for participation in the DEVELOP-UK study at the time
of study commencement or time of listing for transplant and reconfirmed informed consent for the
DEVELOP-UK study on the day of lung transplant.
Study exclusion criteria
Patients aged < 18 years and adult patients listed for lung retransplantation, heart–lung transplantation,
multiorgan transplantation including lung or live donor lobar transplantation were excluded. Patients
not in possession of the patient information sheets for the DEVELOP-UK study prior to the day of lung
transplantation or those not reconfirming consent for the DEVELOP-UK study on the day of lung transplant
were excluded. Patients in the ITU requiring invasive ventilation, extracorporeal membrane oxygenation
(ECMO) or interventional lung assist (iLA) support when a donor lung became available were excluded.
Patients enrolled in other trials within the preceding 12 months of signing an expression of interest (EOI) or
giving full consent had to be discussed with the principal investigator (PI) and chief investigators before
being excluded on this basis.
Inclusion and exclusion criteria for interview substudy
All patients who were eligible for the DEVELOP-UK study at The Newcastle Hospitals NHS Foundation Trust
and the Royal Brompton and Harefield NHS Foundation Trust were eligible for the interview study. All
patients who consented to the DEVELOP-UK study, as a whole, at the above centres were eligible to take
part in the interview substudy regardless of whether or not they received a transplant. All patients who
consented to the DEVELOP-UK study from Manchester, Papworth and Birmingham sites were excluded
from the qualitative study.
Concomitant medications
All standard prescribed medications taken by patients on the waiting list for lung transplantation were
permitted in the study. Some medications are stopped at the time of transplant or in the perioperative
period. These changes are in line with standard clinical processes and were felt to be equally likely to occur
in lung transplant recipients in both arms of the study.
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Peri- and post-transplant immunosuppression, including any induction therapy and maintenance
immunosuppression, may vary slightly between centres, but continued as per usual practice during the
study. In any of the centres, patients in both the EVLP and standard arms of the study got the same
standard routine immunosuppressive approach normally used in that centre. The immunosuppressive
regimes could, however, be changed, intensified or reduced in line with standard transplant clinical
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FIGURE 3 Diagram to explain planned recruitment targets, study end points and planned analysis. QoL, quality
of life.
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management of the individual patient and his or her circumstances. It was possible that patients awaiting
lung transplantation might already be enrolled in a clinical trial of investigational medicinal product
(CTIMP) for their underlying disease. Such medications were stopped at the time of transplant and
participation in the CTIMP was censored as an event and, therefore, the participation of these patients in
the DEVELOP-UK study was not affected.
Patients enrolled in the DEVELOP-UK study who underwent lung transplant in either the standard or EVLP
arm should not have been enrolled in any other interventional study in their first 12 months post transplant
that might have an effect on 12-month survival. If there was any question of this, then the local PI discussed
this with the DEVELOP-UK study chief investigator, who then liaised with the chief investigator of the other
study and reported back to the trial steering committee. Observational non-interventional studies were
allowable but, again, the local PI had to check with the chief investigator to make sure that there was no
interference between the studies. Participants were free to be entered in interventional studies started after
their first 12 months post lung transplantation.
Limiting the potential for bias
As a non-randomised, non-blinded study, it was important that the potential for bias in the selection of
recipients to receive donor lungs from the EVLP or standard arms was considered and carefully monitored.
There was, however, no a priori reason to expect a systematic difference to exist in characteristics between
the recipients in the two arms of the study. This is because the donor–recipient match was established
before the clinical decision on the usability of the donor lungs was made, meaning that recipient selection
should not be influenced by whether EVLP-conditioned or standard lung donation occurs. In particular,
there was no evidence to suggest that sicker recipients, whose transplant might be seen as more urgent,
would be more likely to receive EVLP-reconditioned lungs than standard donor lungs.
Only when donor lungs were available that had more than one potentially matching recipient was urgency
taken into account by the transplant centre. This scenario would be likely to happen as frequently in the
standard transplant arm as in the EVLP arm. The two arms of the study were monitored carefully to ensure
that no systematic differences occurred in the recipient characteristics. Additionally, it was planned that
recognised covariates that are known from the international registry to influence outcomes after lung
transplantation would be adjusted for in the statistical analysis. Our pilot experience of transplants
performed using EVLP-reconditioned lungs across the UK centres indicated that patients with a range of
disease indications, ages, disease severity and both single and bilateral transplants have been included,
reflecting the variability that exists on the lung transplant waiting list.
Interventions common to experimental (ex vivo lung perfusion) and
control (standard) groups
Donor pathway
Any potential offer of donor lungs was communicated to the transplant centres by standard procedures via
the specialist nurses for organ donation (SNODs). Each of the five centres was then responsible for making
an initial assessment of the suitability of the donor lungs for transplant, and for determining if they had an
appropriately matched potential recipient on their waiting list. If a centre did not have a suitably matched
recipient, then the donor lungs were offered to another centre in a controlled rotational manner as part of
the standard donor organ placement protocol by NHS Blood and Transplant (NHSBT). The donor lung
indices were compared against the donor lung selection criteria for the study and, if suitable for potential
transplantation, then the NHSBT zonal organ retrieval team were dispatched to the donor hospital to
further assess the donor lungs. After careful assessment, a decision was made using the donor lung
acceptance criteria whether the lungs could be used immediately for standard transplantation, should
undergo EVLP assessment and reconditioning or were contraindicated completely for transplantation.
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If appropriate for transplant, the donor lungs were then transported back to the transplant centres in
accordance with standard practice.
Donor lung procurement for all lungs in the DEVELOP-UK study
A standard lung procurement procedure was followed for donor lungs used for EVLP in the study. In brief,
the organs were antegradely flushed with supplemented PERFADEX® (XVIVO Perfusion AB, Gothenburg,
Sweden) [3.3 ml of 3.6% trometamol (THAM), 0.6 ml of calcium chloride (CaCl2) ± 2.5 ml of prostacyclin/l],
initially at room temperature and then the remainder at 4 °C. A minimum volume of 60 ml/kg was given.
After the antegrade dose, 200 ml was given down each pulmonary vein as a final retrograde flush. An
adequate portion of main pulmonary artery, left atrial cuff and, particularly, at least 4 cm of trachea was
taken by the retrieval surgeon.
Donor and next of kin consent
Consent for potential donor lungs to be used for lung transplantation was obtained from the donor’s next
of kin at the donor hospital by the SNODs, who were employed by NHSBT. This process is standardised
nationally and was performed completely independently of the DEVELOP-UK study.
If standard consent for lung donation was granted, the SNODs also asked the next of kin for generic
research consent, which is a standard part of the donor consent process. This allowed the study team to
collect and store samples from the donor lung before and after EVLP, as described in Appendix 2, for
parallel mechanistic studies even if the donor lungs were not deemed transplantable after EVLP. If the
donor’s next of kin did not provide generic research consent, then only clinical data measured during the
EVLP process were collected and used in the study, and no lung tissue samples were taken for mechanistic
work. This did not compromise the delivery of the primary and secondary end points of the study.
Lung recipient pathway pre and post transplantation
Patients referred to any of the five participating sites for consideration of lung transplantation over the
course of the study recruitment phase underwent a standard clinical assessment. Those deemed eligible
for, and who consented to, lung transplantation were added to the active lung transplant waiting list.
Those on the transplant list at the time of study inception would already have been through the same
assessment process.
At the time of listing for transplant, patients were offered the opportunity to take part in the DEVELOP-UK
study. In addition, at the time of study inception, any patient who was already on the active lung transplant
list was also offered the opportunity to take part in the DEVELOP-UK study. The consent process was
performed in accordance with National Research Ethics Service guidance, as described in Lung recipient
consent. As the period of waiting for lung transplantation can vary widely and commonly exceeds 12 months,
it was necessary to reconfirm consent for the study at the time when a potential donor lung(s) became
available and the study participant was called in for possible transplantation. However, if the original consent
form had been signed on the day of transplant, reconfirmation of consent was not required.
Patients were told on the day of transplant whether they were to receive a donor lung that had undergone
EVLP assessment and reconditioning or a standard donor lung. Patients received either standard donor lungs
direct from a donor (standard transplant, control arm) or donor lungs after EVLP assessment and reconditioning
(intervention arm) in accordance with donor organ–recipient matching. Transplanted lungs, whether ‘standard’
or EVLP reconditioned, always remain vulnerable to the possibility of rejection and one of the main risk factors
is low immunosuppression levels. For this reason, patients were thoroughly counselled prior to being accepted
onto the transplant list about the need for absolute concordance with their treatment and to attend all
arranged post-transplant follow-up visits. As a result, during the multidisciplinary pre-transplant assessment,
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a considerable amount of time was spent explaining this aspect of care to the patients. If, despite these
attempts, there remained evidence of likely non-compliance with treatment, these individuals were not usually
offered the option of transplantation.
Lung recipient consent
Informed and voluntary consent was obtained via an iterative process, first at the initial discussion of the
clinical and research aspects of the study, and then again, provided this occurred not less than 24 hours
later, on the day of possible transplant. If, however, the consent form was signed on the day of transplant,
reconsent was not required. Consent for the DEVELOP-UK study participation was sought separately from
the standard consent for lung transplant surgery. No additional screening procedures, over and above
those necessary to determine eligibility and suitability for lung transplant, were required to determine
eligibility for the trial element of the DEVELOP-UK study. Therefore, all adult patients being considered for
lung transplant who satisfied the inclusion criteria were approached to take part in the DEVELOP-UK study.
Patients waiting for transplantation are desperately sick, very vulnerable and grasping at any lifeline.
Securing genuinely informed consent was therefore an important consideration. The initial consent process
took place well ahead of the time of transplant and the stressful environment that this generates. Consent
was taken either at inception of the study for those already on the transplant waiting list or at the time of
listing for transplant for those added to the active transplant list during the course of the study. A copy of
the consent documentation is included in Appendices 3 and 4.
Consent was taken by the site PI or a member of the study team with appropriate designated responsibility
on behalf of the local PI. In the consent process, care was taken not to unjustifiably inflate hope of a
shorter waiting time for transplantation as a result of EVLP being available. A clear definition of what
constitutes an unusable donor lung in the study was explained; definitions of acceptability of lungs for
standard transplantation and for transplantation after EVLP were agreed and standardised across all
centres. Patients were offered firm reassurance that if donor lungs did not improve sufficiently after EVLP
reconditioning to satisfy acceptability criteria, they would not be used. Any potential recipient who decided
not to participate in the DEVELOP-UK study continued to have equal access to donor lungs for standard
transplant. Those choosing not to give consent were not obliged to give a reason, but if they provided a
reason this was recorded in an anonymised way to inform the Trial Steering Committee.
Additional informed consent, using a separate participant information sheet and consent form, was sought
from the subset of patients approached to take part in the qualitative interviews. Lack of consent to take
part in this element of the study did not preclude participation in the trial.
For both the trial and the qualitative substudy, if a potential participant had the capacity to consent for
him/herself, but was unable to provide written consent because of visual or motor impairments, or literacy
problems, oral informed consent was taken in the presence of an independent witness, who initialled,
signed and dated the consent form on the participant’s behalf.
We did not anticipate that any potential study participants would lack capacity to consent on initial
recruitment to the study or at the point of reconfirming consent at the time a donor lung became
available. It was, however, possible, although unlikely, that they could lose capacity over the follow-up
period. For example, if as a result of transplant surgery, any participant were to lose capacity temporarily or
permanently, such as by requiring prolonged ventilation in the ITU or by suffering a stroke, we planned to
continue to collect outcome measures in relation to such patients, working with personal or nominated
consultees and in line with the requirements of the Mental Capacity Act.44
We did not seek separate written consent from nominated consultees in the event of loss of capacity, as
this scenario was included in the initial participant consent form and patients were specifically asked to
give consent for continued collection of observational data as part of the study if they lost capacity after
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transplantation. As many of the data in the follow-up period were observational, their collection did not
impact on the standard care that any participant who has lost capacity would expect to receive.
The original signed consent form and reconsent form were retained in the investigator site file, with a copy in
the clinical notes and a copy provided to the participant. Participants were asked to consent explicitly to their
general practitioner (GP) being informed of their participation in the trial element of the DEVELOP-UK study.
The right to refuse to participate without giving reasons was respected. Owing to the small subject
population, the information sheet and consent form for the study were available only in English.
Interpreters were available for all visits of patients who required them either for verbal translation to
another language or for deaf subjects wishing to take part in the study, via local NHS arrangements.
Protocol compliance
The protocols determining the selection of donor lungs to undergo EVLP and indices that determine whether
or not the lungs were suitable for transplant after EVLP were clearly described in the study protocol and are
presented in an appendix to this report (see Appendix 2). To ensure compliance with the protocol, data were
collected about the donor assessment and EVLP procedure. This allowed confirmation that the donor lung
was appropriately allocated to undergo EVLP and that the decision on its suitability was correctly determined.
If any instances were identified when the protocol was not followed, this was recorded as a protocol
deviation and the site PI was asked to document why the protocol deviation occurred.
Ethics and regulatory issues
The conduct of this study was in accordance with the recommendations for physicians involved in research
on human subjects adopted by the 18th World Medical Assembly, Helsinki, 1964, and later revisions.45
All members of the research team, the investigators and supporting staff at each of the participating sites
received training in those aspects of good clinical practice appropriate to their role in the trial, in particular
the processes for obtaining informed consent, including the requirements of the Mental Capacity Act,44
and were expected to operate to principles of good clinical practice.
A favourable ethical opinion from the National Research Ethics Service (reference number 11/NE/0342) and
NHS research and development (R&D) approval was secured prior to commencement of the study. Local
NHS approvals were secured before recruitment commenced at each site. The Newcastle Clinical Trials
Unit, in its capacity as study co-ordination centre, obtained a written copy of local approval documentation
before initiating each centre and accepting participants into the study.
Information sheets were provided to all eligible subjects, and written informed consent was obtained prior
to any study procedures. Patients on the transplant waiting list who lived a significant distance from the
transplant centre were given the opportunity to sign an EOI form that allowed them to subsequently
consent when next attending the transplant centre (which might be on the day of transplant). Signing of
the EOI form permitted completion of the first SF-36 questionnaire and collection of waiting list survival
data. Copies of the patient information sheet and consent forms are included in Appendix 4.
We obtained informed and voluntary consent via an iterative process, providing adequate time (i.e. a
period of not < 24 hours) for consideration and discussion of the clinical and research aspects of the study.
For incident cases, initial consent was taken at the time a patient was listed for lung transplant. For those
patients already on the transplant list at the time of study initiation, consent was sought when the study
opened at their transplant centre. Reconsent on the day of transplant was sought only from patients
initially consenting to the study prior to the day of lung transplant.
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Assessments and data collection
All study-specific follow-up data were collected during the time of the clinical admission to hospital for the
lung transplantation procedure and, subsequently, at study visits that were co-ordinated to coincide with
routine post-lung transplantation clinic visits. The study research nurse ensured that routine clinic visits
were mapped to the study visit requirements by liaison with study participants and the transplant
outpatient facilities in each centre.
The scheduled outpatient study visits were at 1, 3, 6 and 12 months post transplant. A window of
± 10 days around each timetabled study visit was allowed. If a participant was unable to attend a study
visit within the allowable window, for example because he or she was an inpatient at an external hospital
that was not the study centre, then every effort was made to acquire the same study-specific information
from the non-study hospital. The HRQoL questionnaire (SF-36) was self-completed by each study participant
(or in conjunction with their nominated proxy).
Patients’ views and perceptions of EVLP were explored through qualitative interviews conducted by a
trained researcher. When possible, these interviews were performed face to face at study visits after
transplantation. Those interviewed prior to transplant were interviewed either in their own home or, more
usually because of the large geographic spread of individuals, by telephone.
All clinical tests required to determine the success of EVLP assessment and reconditioning of donor lungs,
including ABG analysis, glucose and lactate concentration measurement, and microbiological cultures,
were performed in each study centre using local laboratories and equipment.
Standard blood profiles during follow-up were performed as part of the recipients’ routine clinic care in
each participating centre’s certified NHS laboratories, and results were obtained from hospital data systems.
Data were collected by direct clinical observation, by clinical interpretation and from source patient records
or NHS documentation by the study clinical research fellow and the study research nurse, and the required
data fields were completed on the case report form (CRF) by the research nurse or a designated data
manager in each centre under the supervision of the local PI. A paper CRF was initially used in the study,
but in early 2014 an electronic CRF (MACRO; InferMed, Elsevier, London, UK) began to be used, in line
with regulations at the sponsoring trust. The donor data required for the study (such as age, comorbidities
and oxygenation, among others) were collected routinely by the SNODs, and were then captured
electronically by linking to the core data data set collected by NHSBT centrally.
Serious adverse event reporting
Guidance on adverse event (AE) and serious adverse event (SAE) reporting, as well as determining the
degree of relatedness and assessment of causality for SAEs that may be related to study participation,
was provided in the study protocol.
As lung transplant recipients experience a significant number of AEs as part of their normal recovery from
transplant surgery, the study protocol provided clear guidance on what constituted a SAE that required
expedited reporting. This was to avoid a huge burden of reporting that had no relevance to this
observational study (no CTIMP involved to monitor). Hospitalisations for elective treatment of a pre-existing
condition, and hospitalisations as part of routine post-transplant surveillance did not need reporting as
SAEs. Unrelated hospitalisations were elicited at the scheduled follow-up appointments and at all
emergency appointments.
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Serious adverse events requiring expedited reporting included death within 90 days of lung
transplantation, severe PGD requiring ECMO/iLA support, bronchial anastomotic dehiscence or any
unexpected SAE felt to be probably or definitely causally related to EVLP.
Some SAEs were excluded from expedited reporting to reduce the burden of reporting of events that are
common in the transplant journey. These were death on the waiting list prior to transplant or later than
90 days after lung transplantation; PGD grades 1–3 not requiring ECMO/iLA support or severe sepsis
associated with consolidation, necrosis or cavitation of lung tissue within 30 days of transplant; renal
failure necessitating renal replacement therapy, gastrointestinal complications, central nervous system
complications; and infections requiring an addition or change in antimicrobial therapy.
Medium- and longer-term outcomes that did not require reporting as urgent SAEs were bronchial strictures
(whether or not they required bronchial stenting), acute rejection requiring augmented immunosuppression,
development of post-transplant lymphoproliferative disease or obliterative bronchiolitis. Finally, deterioration
of any pre-existing medical conditions both before and after transplantation did not require urgent reporting.
Public and patient involvement and engagement
The DEVELOP-UK investigators were committed to ensuring appropriate public and patient engagement
throughout the study.
The CF Trust was approached to provide patient and service user expertise in the design of the study.
Oli Lewington, who has previously undergone lung transplantation, agreed to join the study team in order
to help prepare the application for funding, and to contribute to the study design and to the writing of
the Plain English summary. The chief investigator presented the study proposal to the board of directors
of the trust, and the concept of the study to the annual public meeting of the CF Trust. Following award of
the funding, Mr Lewington assisted in producing the participant documentation and the final study report.
Lay members were appointed to the Trial Steering Committee to regularly review study progress and to
provide valuable public input into key decision-making during the study.
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Chapter 3 Main study objectives
Study objectives
The DEVELOP-UK study is the first prospective multicentre study to be performed involving all of the adult
cardiopulmonary transplant units across the UK. The objective was to assess the clinical effectiveness and
cost-effectiveness of EVLP, a technology allowing objective assessment and reconditioning of unusable
donor lungs, in increasing UK lung transplantation activity. Its strategic importance was recognised by the
British Transplantation Society, the NHSBT, NHS specialist commissioners and by patient groups during
the study design and funding application process.
The DEVELOP-UK study was designed as a non-randomised, non-inferiority observational study with an
adaptive design, with two interim analyses planned for when one-third and two-thirds of total enrolment
was reached. The planned interim analyses provided the opportunity to determine if the primary end point
had been achieved, but also to calculate if any change in sample size was required. The original primary
objective was to determine if the 12-month survival of recipients of ex vivo assessed and reconditioned donor
lungs (EVLP intervention group) is non-inferior to 12-month survival in recipients of standard donor lungs
(control group). The secondary objective was to measure key early clinical outcomes in recipients and
changes in their HRQoL in the treatment and control groups in their first post-transplant year. These data
were planned to be used in a within-study cost–utility analysis and a Markov model-based evaluation. The
former comparison was to be a direct head-to-head comparison of outcomes over 12 months, and the latter
was to model the change in availability of lungs as well as extrapolating over the expected lifetime of those
needing a lung transplant. In addition, patients’ perceptions and understandings of EVLP-reconditioned
donor lungs were evaluated in a qualitative substudy.
Timelines and targets
The official start date for the study was 1 January 2012 based on release of NIHR funds to the study team.
To allow for local R&D approvals, research staff recruitment and subcontractor contracts with sites to be
secured, a 3-month run-in period was proposed, anticipating that recruitment would have started in all
sites by 1 April 2012. The actual start date of the study was therefore 1 April 2012. Study recruitment and
enrolment was scheduled to run for 36 months, with data collection ending by 42 months, and the final
study report was scheduled at 45 months in October 2015. The recruitment targets for the study were set
based on official waiting list numbers across the UK in the five adult lung transplant centres. The aim was
for a total of 600 patients from the lung transplant waiting list to consent to participate. As this was a
non-randomised study, enrolment into the two arms of the study, as defined by undergoing lung
transplantation (standard and EVLP transplant), occurred independently, and the study was powered on a
predicted 3 : 1 (standard arm to EVLP arm) enrolment ratio. The target for enrolment as lung transplant
recipients was 408 patients (306 in standard arm and 102 in EVLP arm).
Trial hypothesis
Had the study run to its planned duration in terms of recruitment, the tested hypothesis was to have been
that survival during the first 12 months after transplantation in recipients of EVLP-assessed and
-reconditioned donor lungs is non-inferior to that in recipients of standard donor lungs. The primary
outcome measure was survival during the first 12 months after lung transplantation.
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Consequences for the study analyses of the early closure of the study
The study was powered on survival during the first year post transplant and the target recruitment as
306 patients in the standard transplant arm and 102 in the EVLP transplant arm. This chapter reflects the
analysis possible following the early closure of the study, with recruitment of patients stopping in early July
2014 on the advice of the Trial Steering Committee because of a combination of poor recruitment rates into
the EVLP arm of the study, and also a safety signal from a higher than expected SAE rate resulting from the
need for ECMO support in the EVLP arm. The analyses described below are appropriate to the achieved sample
size and differ from that intended and described in the original protocol. The analysis to compare standard
with EVLP transplant groups, as well as the analysis of overall survival of patients awaiting transplantation,
are descriptive in nature and, as such, do not reflect the initial intention of testing for non-inferiority of EVLP to
standard transplants. The originally planned interim analyses, intended to test for the possibility of stoping the
study early if non-inferiority was achieved and to re-examine the sample size, did not take place, as the
recruitment threshold to trigger the first of these (34 EVLP transplants) was never reached.
Planned timelines for study analysis
In light of the change of circumstances of the analysis, the intent has changed from one of conducting
interim analyses to inform the continuation of the study while it was in progress, to one of a single main
report of outcome data to the funder. The plan was that data should be available for this analysis from the
end of May 2015. In practice, the collection and validation of data were delayed because of the large
number of missing data and data queries to sites, meaning that the analysis started in October 2015 and
continued into early 2016.
Longer-term analysis plans
It is important to recognise that, despite the early closure of the study, there remains a rich data set,
particularly in respect of information on standard transplants and on the total cohort of donor lungs
exposed to EVLP. Consideration of this alone was not part of the original comparative analysis plans and,
as a result, this is outside the scope of the main study analysis.
Following completion of the main study analyses, and outside the scope of the report to the funder,
it will be possible to consider further analysis of the data from the standard transplant arm. This did not
form part of the trial statistical analysis plan, as it was not in scope of the originally planned study, but the
information from this large contemporary cohort of 200 transplants, including extensive follow-up data, is
likely to be useful to future study. Possible approaches include modelling of outcome variables using
baseline clinical covariates to identify possible predictors of successful outcome at baseline.
In addition, a comprehensive sampling protocol was in place to collect perfusate, lung tissue and BAL from
the donor lungs undergoing EVLP. This will provide a valuable assessment of events at a cellular and
molecular level that can be correlated with clinical information within the main study data set. The work
on the mechanistic understanding of EVLP falls outside this report (as it is not the subject of the NIHR HTA
programme funding), but the tissue sample data will contribute to this subsequent analysis.
Recruitment
The study officially commenced on 1 January 2012, opened to recruitment on 1 April 2012, and closed to
recruitment on 9 July 2014. There was a temporary halt in recruitment into the EVLP arm from 6 April
2013 until mid-July 2013, when the study activity in the EVLP arm recommenced with a modified protocol.
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The timings for study recruitment in each individual site are shown in Table 1. The data analysed and
presented in this report were downloaded from the MACRO database in October 2015. Additional data
were assembled in Microsoft Excel® 2010 (Microsoft Corporation, Redmond, WA, USA) files for some of
the outcome measures (e.g. SF-36 and some lung function measurements) not recorded on CRFs, and for
the donor characteristics, which were imported from the NHSBT database.
A total of 593 patients were screened (from records) for eligibility, of whom 98 did not meet eligibility
criteria and a further eight declined to participate. Reasons for not meeting the eligibility criteria included
age, need for pre-transplant cardiorespiratory support, and listed for heart–lung transplantation or
transplantion of lungs and another organ. The screening failure rate was, therefore, only 16.1%, and the
refusal rate for participation was just 1.3%.
A total of 487 patients consented to participate or completed an EOI form while on the transplant waiting
list, of whom 19 were subsequently removed from the waiting list because of a change in their transplant
eligibility, leaving 468 participants eligible to be included in the study. The breakdown of patients
consented per participating site is shown in Table 2, and the rate at which patient consents were accrued
is shown in Figure 4.
By the end of the study, 158 participants remained on the waiting list for transplant; 74 had died while
waiting, before transplant had occurred, and 34 were excluded after transplant as they did not reconfirm
their consent, died before giving consent or were erroneously included after the recruitment cut-off date.
TABLE 1 Approvals and study commencement by site. Dates of NHS R&D approval and first patient consented
across five study sites
Site R&D approval
Delay from
1 January 2012
(official start date)
Date of first
EOI/consent
Delay from
1 April 2012
(actual start date)
Newcastle 1 February 2012 1 month 13 April 2012 13 days
Manchester 15 May 2012 5 months 15 days 24 May 2012 1 month 24 days
Cambridge (Papworth) 11 June 2012 6 months 11 days 21 September 2012 6 months 21 days
Birmingham 30 August 2012 8 months 19 September 2012 6 months 19 days
London (Harefield) 9 October 2012 10 months 9 days 26 October 2012 7 months 26 days
Lost recruitment time 31 centre-months 23 centre-months
Note
A centre month is a unit of recruitment time in a multicentre study. 10 centre months might be a single centre recruiting
for 10 months or two centres recruiting for 5 months.
TABLE 2 Recruitment (EOI/consent obtained)
Site Date opened Number of signed EOI/consent forms
Birmingham 30 August 2012 50
Cambridge (Papworth) 11 June 2012 69
London (Harefield) 9 October 2012 104
Manchester 15 May 2012 84
Newcastle 1 February 2012 180
Total 487
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A total of 202 participants were included in the two transplant arms of the study, 184 in the standard
transplant arm [60.1% of the target recruitment of 306, 95% confidence interval (CI) 55.4% to 65.7%]
and 18 in the EVLP transplant arm (17.6% of target recruitment of 102, 95% CI 10.8% to 26.4%). A total
of 53 EVLP assessments were performed, leading to the 18 transplants, giving a conversion rate of 34.0%
(95% CI 26.6% to 42.0%). The transplant activity in the participating sites is shown in Table 3. It is the
small number in the EVLP transplant arm that drives the need to restrict the comparative analysis to the
use of descriptive statistics. A Consolidated Standards of Reporting Trials (CONSORT) diagram showing
study activity is shown in Figure 5.
The main delay to commencing recruitment to the study resulted from obtaining NHS R&D approvals
across the study sites, which equated to 31 centre-months lost.
Two groups of patients were approached: patients already on a transplant waiting list and patients added
to the waiting list during the study. As a result, some patients signed an EOI form only, some signed both
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FIGURE 4 Cumulative recruitment numbers across all five centres defined as signing EOI or consent forms.
TABLE 3 Number of patients transplanted by centre
Centre
Number of transplants (% of total for type)
Number of EVLP
assessments (% of total)
Study group
TotalStandard EVLP
Birmingham 16 (8.7) 1 (5.6) 17 (8.4) 6 (11.3)
Cambridge (Papworth) 27 (14.7) 2 (11.1) 29 (14.4) 4 (7.5)
London (Harefield) 37 (20.0) 2 (11.1) 39 (19.3) 9 (17.0)
Manchester 22 (12.0) 4 (22.2) 26 (12.9) 7 (13.2)
Newcastle 82 (44.6) 9 (50.0) 91 (45.0) 27 (60.0)
Total 184 18 202 53
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3-month follow-up (n = 14)
• Lost to follow-up, n = 0
• Deaths, n = 4
• Data missing, n = 0
12-month follow-up (n = 12)
• Lost to follow-up, n = 0
• Deaths, n = 6
• Data missing, n = 0
Primary analysis (n = 18)
• Excluded from primary 
   analysis, n = 0
Control lung transplant
group standard donors
(n = 184)
FIGURE 5 The CONSORT diagram: withdrawals.
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(an EOI form followed by a consent form during a subsequent routine visit to the transplant centre or on
the day of transplant), and some signed only a consent form on the day of transplant, having received
study information previously.
No patients requested to be withdrawn from the study after transplantation, and none was withdrawn
by study staff on safety grounds. All withdrawals were due to changes in patients’ eligibility for lung
transplantation or to issues with completion of all necessary consent documents.
Analysis groups
Patients were analysed in groups defined by the type of transplant received [i.e. standard (control) or EVLP
(intervention)]. Allocation was not random, and it was not possible to switch between groups. All donors
who provided lungs assessed by EVLP (n = 53) were included in the descriptive analyses described in
Identifying clinical predictors of successful ex vivo lung perfusion reconditioning. Table 4 summarises the
times at which the various data were collected for each patient.
Study population
Baseline patient characteristics
There are a number of donor-, recipient- and procedure-related variables that mean that lung transplant
recipients constitute a heterogeneous group. The recipient or donor characteristics listed in Tables 5 and 6
have been identified from the ISHLT registry as those potentially influencing outcomes. Table 5 summarises
characteristics of the lung transplant recipients, split according to the type of transplant. The percentage
of recipients who were male and the median age were higher in the EVLP group {72.2% and 56 years
[interquartile range (IQR) 46–59 years], respectively} than in the standard transplant group [57.6% and
51 years (IQR 38–58 years), respectively]. About half of the patients in each group had been diagnosed
with chronic obstructive pulmonary disease or CF; interstitial lung disease (in the EVLP group) or a
combination of interstitial lung disease and emphysema (in the standard group) constituted a further 40%
of the diagnoses. The 18 EVLP recipients did possess indicators to suggest that they may have been a
higher-risk group, such as significant secondary pulmonary hypertension and requirement for non-invasive
ventilation prior to transplant. No lung allocation score is used in the UK and so Lung Allocation Scores or
other indicators of clinical urgency were not routinely recorded and cannot be reported.
The percentage of recipients who were diabetic was similar in the EVLP (22.1%) and standard groups
(18.1%), as were the median body mass index values, namely 21.6 kg/m2 (IQR 18.4–26.3 kg/m2) and
23.8 kg/m2 (IQR 20.5–26.5 kg/m2), respectively. The median FEV1 at baseline was 1.2 l (IQR 0.7–1.9 l) for
the EVLP group and 0.9 l (IQR 0.6–1.4 l) for the standard group; the corresponding FEV1 percentage
predicted was 29% (IQR 22–50%) in the EVLP group and 26% (IQR 20–44%) in the standard group.
In both groups, > 80% of the lung transplants performed were bilateral. However, the observed
percentage of transplants performed with the use of cardiopulmonary bypass was higher in the EVLP
group than in the standard group (88.9% vs. 63.0%), although cardiopulmonary bypass status was
missing for 12% of patients in the standard group.
The characteristics of the donors, again split between the EVLP and standard transplant groups, are shown
in Table 6. The percentage of donors who were male was slightly higher in the EVLP group than in the
standard group (55.6% vs. 46.7%) and donors in the former group were slightly older (median age
50.5 years and 44 years, respectively). DCD donor type was more common in the EVLP group (27.8% of
donors) than in the standard group (16.9%). The numbers of left and right lungs were similar, reflecting –
as indicated earlier – the high proportion of transplants that were bilateral. Within each transplant group,
ischaemic times were similar for left and right donor lungs. However, total ischaemic times were much
higher for EVLP transplants than for standard transplants, which reflects the nature of the procedure.
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TABLE 5 Recipient characteristics in the EVLP and standard lung transplant groups
Recipient characteristic
Study group
Total (N= 202)EVLP (N= 18) Standard (N= 184)
Sex, n (%)
Male 13 (72.2) 106 (57.6) 119 (58.9)
Female 5 (27.8) 78 (42.4) 83 (41.1)
Age (years)
n 18 183 201
Missing 0 1 1
Median 56 51 52
IQR 46–59 38–58 38–58
Rangea 20–64 18–70 18–70
Diagnosis, n (%)
COPD 5 (27.8) 40 (21.7) 45 (22.3)
CF 4 (22.2) 47 (25.5) 51 (25.2)
Interstitial lung disease 7 (38.9) 47 (25.5) 54 (26.7)
Emphysema 0 (0) 26 (14.1) 26 (12.8)
Non-CF bronchiectasis 1 (5.6) 8 (4.3) 9 (4.5)
Obliterative bronchiolitis 0 (0) 2 (1.1) 2 (1.0)
Pulmonary hypertension 1 (5.6) 3 (1.6) 4 (2.0)
Other 0 (0) 9 (4.9) 9 (4.5)
Missing 0 (0) 2 (1.1) 2 (1.0)
Diabetes, n (%)
Yes 4 (22.2) 33 (18.1) 37 (18.3)
No 13 (72.2) 142 (78.0) 155 (76.7)
Missing 1 (5.6) 9 (3.9) 10 (5.0)
BMI (kg/m2)
n 17 182 199
Missing 1 2 3
Median 21.6 23.8 23.7
IQR 18.4–26.3 20.5–26.5 20.4–26.5
Rangea 17.6–32.5 15.4–34.2 15.4–34.2
FEV1 (l)
n 15 176 191
Missing 3 8 11
Median 1.2 0.9 0.9
IQR 0.7–1.9 0.6–1.4 0.6–1.5
Rangea 0.5–2.5 0.3–3.6 0.3–3.6
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TABLE 5 Recipient characteristics in the EVLP and standard lung transplant groups (continued )
Recipient characteristic
Study group
Total (N= 202)EVLP (N= 18) Standard (N= 184)
FEV1 (%)
n 15 171 186
Missing 3 13 16
Median 29 26 27
IQR 22–50 20–45 20–45
Rangea 15–67 11–105 11–105
Type of transplant, n (%)
Single 2 (11.1)b 24 (13.0)c 26 (13)
Bilateral 16 (88.9) 152 (82.6) 168 (83)
Missing 0 (0) 8 (4.4) 8 (4)
Cardiopulmonary bypass use, n (%)
No 2 (11.1) 46 (25.0) 48 (24)
Yes 16 (88.9) 116 (63.0) 132 (65)
Not known 0 (0) 22 (12.0) 22 (11)
BMI, body mass index; COPD, chronic obstructive pulmonary disease.
a Range: minimum–maximum.
b One left and one right.
c Nine left, 13 right and two not known.
TABLE 6 Donor characteristics
Donor characteristics
Study group
Total (N= 202)EVLP (N= 18) Standard (N= 184)
Sex, n (%)
Male 10 (55.6) 86 (46.7) 96 (47)
Female 8 (44.4) 96 (52.2) 104 (52)
Missing 0 2 (1.1) 2 (1)
Age
n 18 181 199
Missing, n 0 3 3
Median (years) 50.5 44 46
IQR (years) 47–54 35–54 35–54
Rangea (years) 22–61 10–68 10–68
Donor type
n 18 183 201
DBD, n (%) 13 (72.2) 152 (82.6) 165 (81)
DCD, n (%) 5 (27.8) 31 (16.9) 36 (18)
Missing, n (%) 0 1 (0.5) 1 (1)
continued
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Compliance
Seventeen protocol violations were reported in 15 separate patients (7.4% of the total of 202 patients
consented and transplanted). Five were major and were due to patients being transplanted with donor
lungs that did not fully meet protocol criteria for transplant after EVLP assessment and reconditioning.
In all these cases the decision to proceed to transplant was made by the supervising transplant surgeon
on the basis of the balance of risks to the patient.
Twelve violations were minor, including approaching patients to give consent for retrospective data
collection post standard transplant even though they had not returned an EOI form; failure to obtain full
informed consent as the wrong consent form was signed; failure to obtain reconsent to continue on the
night of transplant; and, on nine occasions, a > 24-hour delay in the submission of a SAE to the clinical
trials unit. Seven of the protocol violations (all minor) were in standard transplant patients, whereas
10 (five major and five minor) were in EVLP transplant patients.
Serious adverse events
There were 42 SAEs affecting 38 patients (16 patients in Newcastle, four patients in London, four patients
in Manchester, 11 patients in Cambridge and three patients in Birmingham). Fifteen (35.7%) of these SAEs
(affecting 12 patients) occurred in EVLP transplant patients. Details of the SAEs reported are shown in
Table 7.
Of the 42 SAEs, 18 (42.9%) were a result of death within 90 days of transplant; 14 (77.8% of all fatal
SAEs) of these were in standard transplant patients and four (22.2%) were in EVLP patients. Of the total of
TABLE 6 Donor characteristics (continued )
Donor characteristics
Study group
Total (N= 202)EVLP (N= 18) Standard (N= 184)
Side transplanted (n)
Left 17 161 178
Right 17 165 182
Total ischaemic time
n
Left 11 136 147
Right 12 141 153
Median (hours)
Left 12.98 5.8 5.93
Right 13.26 5.45 5.6
IQR (hours)
Left 10.85–14.35 4.56–6.89 4.65–7.15
Right 10.35–14.49 4.43–6.62 4.5–6.95
Rangea (hours)
Left 7.92–19.13 1.12–14.22 1.12–19.13
Right 8.58–17.12 0.82–14.22 0.82–17.12
a Range: minimum–maximum.
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42 SAEs, four of these events (9.5%) arising in four patients were judged to be possibly causally related to
study procedures; all of these serious adverse reactions were initially considered by the site PI to be possibly
unexpected AEs. However, after review by the chief investigator, it was decided that all were in fact events
that could be expected to occur after lung transplantation, such as PGD or infection.
Activity in the EVLP arm was halted temporarily on 9 April 2013 for just over 3 months to allow an
independent review of the early study outcomes as part of a due diligence process. Before this point, four
out of eight transplant recipients in the EVLP arm required ECMO support post-operatively; following
resumption of EVLP transplants with a revised protocol, 3 out of 10 transplant recipients required ECMO,
but in all cases ECMO duration was limited, all patients were successfully weaned from ECMO, and all
except one were successfully discharged from the ITU.
Outcomes analyses
The original intention was that the statistical analysis be conducted in a number of parts: first, a
comparison of outcomes between recipients of standard and EVLP transplants to establish non-inferiority;
and, second, modelling of the effect of EVLP transplants on the overall survival of patients accepted for
lung transplantation in the UK, in order to assess the impact on the service. Furthermore, additional
analyses were also to be undertaken to identify clinical predictors with respect to donor characteristics of
successful EVLP reconditioning.
The early closure of the study and low numbers in the EVLP arm mean that the analysis methods originally
described in the protocol are no longer appropriate. Consequently, the comparative analysis of standard
and EVLP transplant groups, as well as the analysis of overall survival of patients awaiting transplantation,
reported in Primary outcome analysis, are descriptive in nature and, as such, do not reflect the initial
intention of testing for non-inferiority of EVLP to standard transplants.
Missing data
From clinical experience of this patient group, it had not been anticipated that there would be significant
numbers of dropouts or loss to follow-up of patients with respect to the primary outcome measure. Loss to
follow-up or missing data on the secondary outcome measures was assessed but, because of the low
numbers in the EVLP group, no imputation was performed for any outcome data. However, a significant
number of data were missing because they were not collected at the study sites. Most sites worked very
hard to keep data collection as complete as possible, but in one site the proportion of missing data was
> 20%. The missing data included, but were not limited to, SF-36 questionnaires, detail from outpatient
follow-up visits and some information collected during the EVLP procedure.
Primary outcome analysis
Survival in the 12 months following transplantation
The primary outcome of survival in the first 12 months post transplantation was compared in the EVLP and
standard transplant groups. Figure 6 shows the Kaplan–Meier plot of the survival (in days) during the first
12 months post transplantation, split by study group. This analysis takes account of censoring; specifically,
one patient (in the standard arm) emigrated during the follow-up, and has been included in the analysis
up to the time of the last visit (at 30 days post transplantation).
The numbers of patients who died, survived or were censored during the 12-month follow-up are shown
in Table 8. The median follow-up was 365 days for both the EVLP and standard transplant groups.
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The Kaplan–Meier estimate of survival at 12 months was 0.67 (95% CI 0.40 to 0.83) for the EVLP arm and
0.80 (95% CI 0.74 to 0.85) for the standard arm. Based on Cox regression, the hazard ratio for all-cause
mortality in the EVLP arm relative to the standard arm over the 12-month follow-up was 1.96 (95% CI
0.83 to 4.67). This equates to roughly a doubling of the risk of death in the EVLP arm relative to the
standard arm, although with a wide CI that encompasses the possibility that mortality might be lower in
the EVLP arm than in the standard arm. The width of this CI is influenced greatly by the small number of
patients who received an EVLP transplant.
Of the 18 patients who received an EVLP transplant, eight received a transplant based on the hybrid
protocol, and 10 received a transplant based on the Lund protocol (see Table 8). Survival was then
assessed by considering the EVLP protocol groups separately, and Figure 7 shows the Kaplan–Meier plot of
survival separately for patients in the standard, EVLP-Lund and EVLP-hybrid groups.
The Kaplan–Meier estimate of survival at 12 months was 0.80 (95% CI 0.41 to 0.95) for the Lund protocol
patients and 0.50 (85% CI 0.15 to 0.77) for the hybrid protocol patients. Based on Cox regression,
the hazard ratio for all-cause mortality in the EVLP-hybrid group relative to the EVLP-Lund group over the
12-month follow-up was 2.92 (95% CI 0.53 to 15.95). This wide CI reflects the small numbers of patients
in these two EVLP protocol groups.
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FIGURE 6 Kaplan–Meier survival estimates post transplantation, by study group.
TABLE 8 Numbers of patients who died, survived or were censored during the first 12 months following
transplantation
Study group Died Survived Censored Total
EVLP 6 12 0 18
Hybrid protocol 4 4 0 8
Lund protocol 2 8 0 10
Standard 36 147 1 184
Total of standard and EVLP groups 42 159 1 202
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Secondary outcome measures
Survival at 30 and 90 days
Survival in the early post-operative period after lung transplantation is an important indicator of early
complications and is widely used in audit and national and international registries of outcomes. The 30-day
survival rates for the EVLP and standard transplant groups are shown in Table 9 and the 90-day survival
rates in Table 10.
The Kaplan–Meier estimate of survival at 30 days is 0.94 (95% CI 0.67 to 0.99) for the EVLP arm and 0.97
(95% CI 0.93 to 0.98) for the standard arm. In other words, survival at 30 days was similar for the two
transplant groups. The Kaplan–Meier estimate of survival at 90 days was 0.78 (95% CI 0.51 to 0.91) for
the EVLP arm and 0.94 (95% CI 0.89 to 0.97) for the standard arm.
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FIGURE 7 Kaplan–Meier survival estimates post transplantation for the standard, EVLP-hybrid and EVLP-Lund
study groups.
TABLE 9 Numbers of patients who died, survived or were censored during the first 30 days following transplantation
Study group Died Survived Censored Total
EVLP 1 17 0 18
Standard 6 178 0 184
Total 7 195 0 202
TABLE 10 Numbers of patients who died, survived or were censored during the first 90 days following transplantation
Study group Died Survived Censored Total
EVLP 4 14 0 18
Standard 11 172 1 184
Total 15 186 1 202
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
35
Primary graft dysfunction
Primary graft dysfunction is the clinical syndrome of chest radiographic changes and poor oxygenation that
represents early acute injury to the transplanted lung. The PGD scores used in the study were as defined in
the ISHLT consensus definition.39 The distribution of the PGD score by study group, measured at baseline
and 24, 48 and 72 hours after the transplant, is shown in Table 11. A score of 0 represents no evidence of
PGD and a score of 3 represents the most severe form of PGD.
The same information, but with the results for grades 0 and 1 combined, is shown in graph format in
Figure 8. The percentage of patients with PGD grade 3 at baseline was much higher in the EVLP group
TABLE 11 Primary graft dysfunction score by trial arm and time since transplant
Score
Time point
Baseline 24 hours 48 hours 72 hours
EVLP,
n (%)
Standard,
n (%)
EVLP,
n (%)
Standard,
n (%)
EVLP,
n (%)
Standard,
n (%)
EVLP,
n (%)
Standard,
n (%)
Grade 0 1 (5.6) 42 (26.4) 1 (5.6) 43 (27.4) 1 (5.6) 34 (22.5) 1 (5.6) 34 (23.9)
Grade 1 0 (0) 27 (17.0) 3 (16.7) 43 (27.4) 7 (38.9) 51 (33.8) 7 (38.9) 52 (36.6)
Grade 2 1 (5.6) 42 (26.4) 6 (33.3) 43 (27.4) 3 (16.7) 33 (21.9) 5 (27.8) 24 (16.9)
Grade 3 16 (88.9) 48 (30.2) 8 (44.4) 28 (17.8) 7 (38.9) 33 (21.9) 5 (27.8) 32 (22.5)
Total 18 159 18 157 18 151 18 142
Note
Excluding patients with missing data.
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FIGURE 8 Primary graft dysfunction score by trial arm and time since transplant.
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than in the standard group (88.9% vs. 30.2%). However, this difference narrowed as time passed, with
27.8% of patients in the EVLP group and 22.5% of those receiving a standard transplant having PGD
grade 3 at 72 hours after transplant. Nevertheless, the percentages of patients with grade 0 remained
fairly static over time and were higher in the standard group than in the EVLP group (22.5–27.4% and
5.6%, respectively).
Early intensive therapy unit management and duration of hospital stay
Data on several key aspects of the ITU management and hospital stay were collected for all patients
transplanted and are presented in Table 12. The duration of invasive ventilation tended to be longer for
patients receiving an EVLP transplant (median 72 hours, IQR 38–624 hours) than for those receiving a
standard transplant (median 38 hours, IQR 19–140 hours). Similarly, ITU stay was longer for EVLP patients
(median 14.5 days, IQR 5.4–20.6 days) than for patients with a standard transplant (median 4.3 days,
IQR 2.1–10.8 days). However, the overall length of hospital stay was similar for both groups of patients
(median of 28 days in both groups) and, among those patients readmitted to ITU, length of stay in ITU
was similar in both groups [median 6 days (IQR 3–6 days) in the EVLP arm and 8 days (IQR 3–20.5 days) in
the standard arm].
TABLE 12 Summary statistics for duration of invasive ventilation, ITU stay, hospital stay before first discharge in
days and (where relevant) ITU readmission
ITU management and hospital stay
Study group
Total (N= 202)EVLP (N= 18) Standard (N= 184)
Invasive ventilation
n 18 174 192
Median (hours) 72 38 43
IQR (hours) 38–624 19–140 20–180.5
Rangea (hours) 8–2400 0–2208 0–2400
ITU stay
n 18 160 178
Median (days) 14.5 4.3 4.8
IQR (days) 5.4–20.6 2.1–10.8 2.6–15
Rangea (days) 1.7–98 0.4–100.6 0.4–100.6
Hospital stay
n 18 163 181
Median (days) 28 28 28
IQR (days) 21–46 18–43 18–44
Rangea (days) 16–100 2–99 2–100
ITU readmission
n 3 28 31
Median (days) 6 8 6
IQR (days) 3–6 3–20.5 3–18
Rangea (days) 3–6 1–80 1–80
a Range: minimum–maximum.
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Post-operative infection
The number of patients with at least one post-operative infection, both at baseline and during subsequent
follow-up periods, is shown in Table 13. The associated percentages are displayed graphically in Figure 9.
At baseline, just under half of patients in both the EVLP group and the standard group had at least one
post-operative infection. In both groups, the percentage of patients with at least one post-operative
infection dropped subsequently, as shown in Figure 6. This percentage tended to be lower in the EVLP
TABLE 13 Numbers of patients with at least one post-operative infection, at baseline and during
subsequent periods
Category
Time period
Baseline, n (%)
Baseline–1 month,
n (%) 1–3 months, n (%) 3–6 months, n (%)
6–12 months,
n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Number of
patients with
at least one
episode
7 (46.7) 81 (45.5) 2 (15.4) 37 (23.9) 2 (15.4) 38 (21.5) 3 (23.1) 38 (24.5) 2 (18.2) 39 (29.1)
Number at
risk
18 184 18 184 17 178 14 172 13 165
Notes
Percentages are given relative to the total.
The number at risk is based on those at risk at the start of the relevant period.
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FIGURE 9 Percentage of patients with at least one post-operative infection, at baseline and during subsequent
periods, by study group. Note that the number at risk is based on those at risk at the start of the relevant period.
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group than in the standard group. However, inferences are limited by the small numbers of patients with
infections in the EVLP group.
The number of episodes and number of organisms involved in specific post-operative infections are
detailed in Table 14. The most common organisms involved were Pseudomonas, Staphylococcus,
Escherichia coli and Candida species. Owing to small numbers, it is difficult to compare any differences in
the spectra of infections in the EVLP and standard groups.
TABLE 14 Numbers of episodes and organisms involved in specific post-operative infections, at baseline and during
subsequent follow-up periods
Organism
Time period
Baseline, n (%)
Baseline–1 month,
n (%)
1–3 months,
n (%)
3–6 months,
n (%)
6–12 months,
n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Pseudomonas 5 (29.4) 19 (12.8) 1 (33.3) 6 (15.0) 1 (50.0) 4 (7.7) 0 (0) 5 (12.2) 0 (0) 5 (11.1)
Staphylococcus 4 (23.5) 27 (18.1) 0 (0) 6 (15.0) 0 (0) 3 (5.8) 0 (0) 2 (4.9) 0 (0) 2 (4.4)
Coliforms 0 (0) 7 (4.7) 0 (0) 1 (2.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Escherichia coli 1 (5.9) 11 (7.4) 1 (33.3) 0 (0) 0 (0) 1 (1.9) 0 (0) 1 (2.4) 0 (0) 1 (2.2)
Clostridium difficile 0 (0) 4 (2.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Klebsiella 0 (0) 5 (3.4) 0 (0) 1 (2.5) 0 (0) 1 (1.9) 2 (50.0) 2 (4.9) 0 (0) 1 (2.2)
Haemophilus 1 (5.9) 5 (3.4) 0 (0) 1 (2.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Aspergillus 0 (0) 5 (3.4) 0 (0) 2 (5.0) 0 (0) 3 (5.8) 0 (0) 2 (4.9) 1 (25.0) 5 (11.1)
Candida 1 (5.9) 14 (9.4) 0 (0) 2 (5.0) 0 (0) 3 (5.8) 0 (0) 0 (0) 0 (0) 1 (2.2)
Influenza virus 1 (5.9) 1 (0.7) 0 (0) 1 (2.5) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4.4)
Adenovirus 0 (0) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Rhinovirus 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 3 (5.8) 0 (0) 0 (0) 1 (25.0) 0 (0)
Herpesvirus 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (2.4) 0 (0) 3 (6.7)
Streptococcus 0 (0) 2 (1.3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mycobacterium 0 (0) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Scedosporium 0 (0) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Stenotrophomonas 1 (5.9) 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 2 (4.4)
Other specified 3 (17.6) 34 (22.8) 1 (33.3) 12 (30.0) 0 (0) 21 (40.4) 1 (25.0) 14 (34.1) 1 (25.0) 10 (22.2)
Organism not
specified
0 (0) 11 (7.4) 0 (0) 8 (20.0) 1 (50.0) 13 (25.0) 1 (25.0) 14 (34.1) 1 (25.0) 13 (28.9)
Total number of
organisms
17 149 3 40 2 52 4 41 4 45
Total number of
episodes
16 144 3 38 2 52 4 41 4 44
Notes
Percentages are given relative to the total number of organisms. Each episode may have involved more than one organism.
Patients may have had more than one episode. Anastomotic complications.
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It is recognised that ischaemic injury to the donor lung could adversely affect the bronchus and lead to
bronchial complications. It was therefore important to consider if there was any difference in rates of
anastomotic complications between the study groups. In Table 15, the numbers of patients with anastomotic
complications are presented by study group and time since transplant. None of the patients in the EVLP group
had such complications at any of the follow-up times. In the standard group, the percentage of patients with
these complications varied between 4.4% and 9.6% over the follow-up period.
The Couraud Classification of anastomotic healing provides a means to quantify the degree of healing that
may be an indicator of low-level ischaemic injury.40 These scores are presented numerically by study group
and time since transplant in Table 16, and as percentages in graphical format in Figure 10. Among both
EVLP and standard transplant patients, the percentage with grade 1 healing tended to increase over the
period of the follow-up, from around 40% between baseline and 1 month to just over 80% between
6 and 12 months. Over the same period, the percentage of patients with grade 2 healing decreased,
from around 50% between baseline and 1 month to roughly 16% between 6 and 12 months.
TABLE 15 Numbers of patients with anastomotic complications, by study group and time since transplant
Category
Time period
Baseline–1 month,
n (%) 1–3 months, n (%) 3–6 months, n (%) 6–12 months, n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Number of patients
with anastomotic
complications
0 (0) 12 (6.7) 0 (0) 7 (4.4) 0 (0) 12 (8.0) 0 (0) 14 (9.6)
Total 18 179 14 160 13 150 12 146
Number at risk 18 184 17 178 14 172 13 165
Note
Percentages are given relative to the total.
TABLE 16 Anastomotic healing among patients (based on the Couraud Classification), by study group and time
since transplant
Score
Time period
Baseline–1 month, n (%) 1–3 months, n (%) 3–6 months, n (%) 6–12 months, n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Grade 1 4 (36.4) 38 (41.3) 2 (25.0) 51 (47.2) 6 (85.7) 68 (68.7) 5 (83.3) 67 (82.7)
Grade 2A 5 (45.5) 30 (32.6) 6 (75.0) 39 (36.1) 1 (14.3) 24 (24.2) 1 (16.7) 12 (14.8)
Grade 2B 1 (9.1) 17 (18.5) 0 (0) 13 (12.0) 0 (0) 2 (2.0) 0 (0) 1 (1.2)
Grade 3A 1 (9.1) 4 (4.3) 0 (0) 4 (3.7) 0 (0) 5 (5.1) 0 (0) 1 (1.2)
Grade 3B 0 (0) 3 (3.3) 0 (0) 1 (0.9) 0 (0) 0 (0) 0 (0) 0 (0)
Total 11 92 8 108 7 99 6 81
Number at risk 18 184 17 178 14 172 13 165
Note
Percentages are given relative to the total.
MAIN STUDY OBJECTIVES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
40
Lung function measurements
Measurement of FEV1 in both absolute volume in litres and as a percentage of the patient’s predicted values
based on age, sex, height and measurement of forced vital capacity (FVC) in litres is routinely performed as
part of post-lung transplant follow-up. This information is presented in Table 17 and also displayed in box
plots in Figures 11–13. Each of these measures tended to increase with increasing length of follow-up.
In addition, median values for the EVLP and standard transplant groups were generally similar.
Abnormalities on chest radiographs
The number of patients with abnormalities on chest radiographs, both at baseline and at subsequent
follow-up visits over the 12 months after transplant, is shown in Table 18. The associated percentages are
also displayed graphically in Figure 14. These percentages were lower at 6 and 12 months than at earlier
times. There is also some suggestion that abnormalities were slightly less common in the EVLP group than
in the standard group, although inferences are limited because of the small numbers of EVLP patients
with abnormalities.
The nature of the specific abnormalities on chest radiographs is shown in Table 19. Overall, effusion was
the most common abnormality, followed by pneumothorax, consolidation, atelectasis and shadowing.
Owing to the small numbers in EVLP group, it is not possible to compare the spectra of abnormalities
between the EVLP and standard groups.
The number of episodes of allograft alloimmune injury was collected in both study groups. Data on acute
vascular rejection by ISHLT score, presence of antibody-mediated rejection and lymphocytic bronchiolitis
are presented in Table 20 as numbers of rejection episodes by rejection type, study group and time period.
Overall, these episodes were less frequent > 3 months after transplant than at earlier times. This decrease
was particularly notable for A2+ episodes. The percentage of patients with at least one rejection episode
was generally similar for the EVLP and standard groups.
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FIGURE 10 Anastomotic healing among patients (based on the Couraud Classification), by study group and time
since transplant.
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TABLE 17 Lung function measurements by study group and time since transplant
Lung function
parameter
Time point
1 month 3 months 6 months 12 months
EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Number at risk 17 178 14 172 13 165 12 147
FEV1
na 10 124 13 150 13 149 11 129
Median (l) 2.26 2.07 2.26 2.29 2.53 2.38 2.82 2.44
IQR (l) 1.87–3.15 1.68–2.60 1.89–2.68 1.79–2.70 2.23–3.65 1.85–2.83 2.12–3.37 1.95–2.93
Rangeb (l) 1.54–3.89 0.77–3.85 1.17–4.46 0.80–4.53 1.53–4.83 0.74–4.75 1.88–4.30 0.78–4.90
FEV1
na 9 111 12 138 13 129 9 116
Median (% predicted) 58 69 71 71 85 78 93 77.5
IQR (% predicted) 45–74 55–81 51–84 57–87 65–106 63–91 62–97 65.5–91.5
Rangeb (% predicted) 44–97 25–100 34–131 29–135 44–142 23–143 51–99 30–143
FVC
na 10 123 13 150 12 149 11 128
Median (l) 2.70 2.49 2.80 2.70 3.23 3.03 3.35 3.53
IQR (l) 2.60–3.15 1.91–3.08 2.48–3.71 2.25–3.27 2.67–4.28 2.41–3.60 2.66–3.89 2.75–4.34
Rangeb (l) 1.90–4.10 1.16–4.80 1.82–4.53 0.92–5.35 1.82–5.88 0.85–5.84 1.98–5.56 1.14–5.96
a Number from which data are available.
b Range: minimum–maximum.
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FIGURE 11 Box plot of FEV1 by time since transplant.
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Short Form questionnaire-36 items health-related quality-of-life measure
The assessment of HRQoL in the DEVELOP-UK study was done using a well-validated questionnaire, the
SF-36. The SF-36 is a measure of general health that generates eight dimensions and two summary scores
from 36 different questions.46 In order to do so, each one of the 36 questions of the survey relates to a
different pre-coded numeric value. In order to interpret the SF-36 data, the raw scores should be translated
into a value from 0 (lowest or worst possible level of HRQoL) to 100 (highest or best possible level of
HRQoL). These translated scores are then used to calculate the mean for each one of the following eight
domains: physical functioning, role limitations due to physical health, bodily pain, general health
perceptions, vitality, social functioning, role limitations due to emotional problems and general mental
health. From these eight concepts, two summary measures of norm-based mental component score (MCS)
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FIGURE 12 Box plot of FEV1% by time since transplant.
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FIGURE 13 Box plot of FVC by time since transplant.
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and physical component score (PCS), with a mean of 50 and a standard deviation (SD) of 10 in a general
population, can be constructed from all the emotionally and physically relevant items, respectively.47
The higher the value of the summary scores the higher the level of functionality of the patient.
Short Form questionnaire-36 items data analysis
The SF-36 questionnaires were completed while the recipients were still on the waiting list, as well as at
3 and 12 months post transplant, and their mean scores were converted into health-state utilities using the
TABLE 18 Numbers of patients with abnormalities on chest radiographs, by study group and time since transplant
Category
Time point
Baseline, n (%) 1 month, n (%) 3 months, n (%) 6 months, n (%) 12 months, n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Number of
patients with
abnormality on
chest radiographs
7 (46.7) 105 (61.8) 7 (53.8) 96 (60.0) 7 (58.3) 66 (42.9) 2 (18.2) 48 (33.3) 2 (22.2) 28 (24.6)
Total 15 170 13 160 12 154 11 144 9 114
Number at risk 18 184 17 178 14 172 13 165 12 147
Note
Percentages are given relative to the total.
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FIGURE 14 Percentage of patients with abnormalities on chest radiographs, by study group and time
since transplant.
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TABLE 19 Numbers of specific abnormalities on chest radiographs, by study group and time since transplant
Type of
abnormality
Time point
Baseline, n (%) 1 month, n (%) 3 months, n (%) 6 months, n (%) 12 months, n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard EVLP Standard
Pneumothorax 0 (0) 21 (15.9) 1 (8.3) 12 (9.3) 0 (0) 6 (9.0) 0 (0) 3 (6.7) 0 (0) 2 (6.9)
Effusion 3 (37.5) 55 (41.7) 4 (33.3) 57 (44.2) 4 (50.0) 29 (43.3) 1 (100.0) 15 (33.3) 1 (50.0) 7 (24.1)
Consolidation 3 (37.5) 20 (15.2) 3 (25.0) 22 (17.1) 0 (0) 3 (4.5) 0 (0) 4 (8.9) 0 (0) 3 (10.3)
Atelectasis 1 (12.5) 16 (12.1) 2 (16.7) 17 (13.2) 3 (37.5) 9 (13.4) 0 (0) 8 (17.8) 1 (50.0) 7 (24.1)
Collection 0 (0) 5 (3.8) 1 (8.3) 4 (3.1) 0 (0) 2 (3.0) 0 (0) 0 (0) 0 (0) 0 (0)
Shadowing 0 (0) 13 (9.8) 1 (8.3) 16 (12.4) 1 (12.5) 12 (17.9) 0 (0) 11 (24.4) 0 (0) 5 (17.2)
Elevated
hemidiaphragm
1 (12.5) 0 (0) 0 (0) 0 (0) 0 (0) 4 (6.0) 0 (0) 3 (6.7) 0 (0) 1 (3.4)
No valid
description
0 (0) 2 (1.5) 0 (0) 1 (0.8) 0 (0) 2 (3.0) 0 (0) 1 (2.2) 0 (0) 4 (13.8)
Total number of
abnormalities
8 132 12 129 8 67 1 45 2 29
Notes
Percentages are expressed relative to the total number of abnormalities.
Acute rejection and associated alloimmune injury.
TABLE 20 Number of rejection episodes by rejection type, study group and time period
Category
Time period
Baseline–1 month,
n (%)
1–3 months,
n (%) 3–6 months, n (%) 6–12 months, n (%)
EVLP Standard EVLP Standard EVLP Standard EVLP Standard
A1 0 (0) 11 (22.9) 1 (16.7) 13 (26.5) 0 (0) 5 (19.2) 0 (0) 12 (57.1)
A2+ 4 (100.0) 30 (62.5) 4 (66.7) 25 (51.0) 1 (50.0) 11 (42.3) 1 (50.0) 8 (38.1)
Antibody-mediated
rejection
0 (0) 0 (0) 0 (0) 1 (2.0) 0 (0) 0 (0) 0 (0) 0 (0)
Clinical rejection without
biopsy
0 (0) 1 (2.1) 0 (0) 2 (4.1) 0 (0) 0 (0) 0 (0) 0 (0)
Lymphocytic bronchiolitis 0 (0) 1 (2.1) 0 (0) 2 (4.1) 0 (0) 1 (3.8) 0 (0) 0 (0)
Not classified 0 (0) 5 (10.4) 1 (16.7) 6 (12.2) 1 (50.0) 9 (34.6) 1 (50.0) 1 (4.8)
Total number of episodes 4 48 6 49 2 26 2 21
Number of patients with
at least one rejection
episodea
4 (22.2) 48 (26.1) 6 (35.3) 46 (27.0) 2 (14.3) 26 (15.1) 2 (15.4) 20 (12.1)
Number of patients at
riskb
18 184 17 178 14 172 13 165
a The percentage of patients with at least one rejection episode is given relative to the number of patients at risk.
b Based on those at risk at the start of the period.
Note
Precentages are expressed relative to the total number of episodes.
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SF-6D algorithm48 described in Chapter 4. In the SF-36 data analysis, the mean (SD) and median (IQR) score
for each of the eight domain scores were estimated for each one of the two study groups and for each
time point. The SF-36 data were also used to estimate the mean, SD, median and IQR for MCS and PCS
scores by study group. No hypothesis testing or modelling was undertaken and no imputation was
performed other than that which forms part of the standard scoring system for the SF-36.
The SF-36 data, available at each time point of the study, as well as the number of participants with missing
data for both the standard and EVLP trial arms, are summarised in Table 21. A significant number of participants
did not complete the SF-36 at each of the three time points identified in the study protocol. The absolute
number of patients for whom SF-36 data were collected at different stages of the study is shown in Table 22.
The detailed scores of the SF-36 questionnaires are presented in Tables 23 and 24. The mean, SD, median,
IQR and range of the eight domain scores and the two summary scores, respectively, at each data
collection point for each of the two transplant procedures are presented. These two tables also report the
number of responses at each time point, together with the number of patients at risk (i.e. the number that
would have been eligible to complete the SF-36).
TABLE 21 Number of SF-36 measurements at each time point of the study and by study group
Time point
Study group
Total, n (%)EVLP, n (%)a Standard, n (%)
Waiting list 8 (38.1) 67 (40.1) 75 (39.9)
3 months post transplant 7 (33.3) 52 (31.1) 59 (31.4)
12 months post transplant 6 (28.6) 48 (28.7) 54 (28.7)
Total number of measurements 21 167 188
Number of patients with no SF-36 data 6 83 89
a To aid interpretation, six participants in the EVLP arm did not complete the SF-36 at any data collection time points and
eight completed the questionnaire while on the waiting list.
TABLE 22 Numbers of patients with SF-36 data available for each stage of the study
Category
Time point
Baseline 3 months 12 months
Baseline and
3 months
Baseline and
12 months
3 and
12 months
Baseline, 3 and
12 months
EVLP
Number of
patients (%)a
8 (44.4) 7 (50.0) 6 (50.0) 4 (28.6) 2 (16.7) 4 (33.3) 1 (8.3)
Number at risk 18 14 12 14 12 12 12
Standard
Number of
patients (%)
67 (36.4) 52 (30.2) 48 (32.7) 31 (18.0) 27 (18.4) 26 (17.7) 18 (12.2)
Number at risk 184 172 147 172 147 147 147
Total
Number of
patients (%)
75 (37.1) 59 (31.7) 54 (34.0) 35 (18.8) 29 (18.2) 30 (18.9) 19 (11.9)
Number at risk 202 186 159 186 159 159 159
a Percentages are given relative to the number of patients at risk at the latest of the times considered.
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TABLE 23 Short Form questionnaire-36 items domain scores at each data collection point of the study, by study group
Domain
Study group
Standard EVLP
Baseline
(n= 67)
3 months
(n= 52)
12 months
(n= 48)
Baseline
(n= 8)
3 months
(n= 7)
12 months
(n= 6)
Number at risk 184 172 147 18 14 12
Bodily pain
Median (IQR) 46.68
(38.21–55.55)
49.10
(40.63–55.55)
55.55
(46.68–62.00)
53.53
(46.68–62.00)
51.51
(51.51–62.00)
62.00
(55.55–62.00)
95% CI 42.61 to 48.36 45.35 to 51.00 48.55 to 54.85 43.02 to 61.22 42.29 to 61.89 56.36 to 63.35
General health
Median (IQR) 23.71
(21.33–30.84)
48.43
(38.92–55.56)
48.43
(42.02–55.56)
28.46
(22.52–29.65)
57.94
(50.81–62.70)
55.56
(54.61–55.56)
95% CI 24.41 to 28.25 43.87 to 49.67 45.19 to 51.28 22.95 to 32.19 52.62 to 62.60 50.53 to 62.02
General mental
health
Median (IQR) 45.64
(37.79–53.48)
53.48
(44.33–58.72)
53.48
(45.64–58.72)
44.33
(41.71–49.56)
58.72
(53.48–61.33)
60.03
(53.48–63.95)
95% CI 42.06 to 47.33 48.38 to 54.07 50.81 to 55.40 39.18 to 50.13 54.35 to 61.59 48.95 to 65.87
Physical
functioning
Median (IQR) 23.09
(19.26–26.92)
46.06
(37.45–51.80)
46.06
(34.58–53.71)
24.05
(22.14–31.71)
53.71
(46.06–57.54)
48.93
(46.06–55.63)
95% CI 23.57 to 27.18 40.55 to 46.71 40.65 to 47.25 20.91 to 31.97 46.72 to 57.42 31.41 to 60.71
Role limitations
owing to
emotional health
Median (IQR) 38.76
(28.31–56.17)
56.17
(35.28–56.17)
56.17
(43.98–56.17)
40.50
(35.28–54.43)
56.17
(49.20–56.17)
54.43
(49.20–56.17)
95% CI 36.46 to 43.66 42.30 to 49.82 45.66 to 52.02 30.87 to 52.75 49.64 to 57.72 36.34 to 62.07
Role limitations
owing to physical
health
Median (IQR) 25.72
(21.23–32.46)
43.68
(33.58–52.66)
47.05
(35.83–54.91)
30.21
(25.72–39.20)
57.16
(41.44–57.16)
49.30
(41.44–57.16)
95% CI 25.87 to 29.79 39.06 to 45.37 41.79 to 48.01 24.62 to 40.29 42.65 to 58.19 31.79 to 60.07
Social functioning
Median (IQR) 27.26
(22.25–37.29)
52.33
(37.29–57.34)
47.31
(39.80–57.34)
37.29
(24.76–39.80)
57.34
(52.33–57.34)
52.33
(47.31–57.34)
95% CI 27.83 to 33.73 43.24 to 50.04 44.77 to 50.48 25.00 to 40.80 50.83 to 58.12 33.87 to 62.43
Vitality
Median (IQR) 31.80
(28.83–40.72)
55.57
(40.72–61.51)
52.60
(46.66–58.54)
36.26
(34.77–42.20)
55.57
(46.66–61.51)
60.03
(55.57–70.42)
95% CI 32.29 to 36.37 48.25 to 55.23 49.67 to 55.28 31.29 to 44.94 48.16 to 63.83 41.45 to 73.65
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The results show a general increase in the mean scores of the eight SF-36 domains from baseline to 12 months
post transplant (see Table 23). The two domains that show the biggest increase in their scores are general
health and vitality. Furthermore, although the physical functioning, role limitations owing to physical health and
social functioning domains appear to show the same increase after 3 and 12 months from the day of the
surgery in the standard arm of the study, they appear to increase at 3 months and then decrease at 12 months
for the EVLP arm. The data are, however, too few for the relevance of this change to be sensibly interpreted.
Similarly, the same pattern is seen for the general mental health and role limitations owing to emotional health
dimensions. For the bodily pain domain there was a slight drop, on average, at 3 months and then an increase
at 12 months for the EVLP arm. Nevertheless, the fact that few data are available for these three domains
means that further interpretation must be done with caution.
The values of both the SF-36 summary measures, namely MCS and PCS, increase after transplant no matter
which transplant procedure was performed. These data are presented in Table 24, and graphically in the box
plots in Figures 15 and 16. In other words, the HRQoL of the patients improves throughout the follow-up of
the lung recipients. In the standard procedure, the mean MCS score of the lung recipients increases from
43.5 at baseline to 51.0 at 3 months post transplant and 52.8 at 12 months post transplant, whereas the
mean PCS score increases from 27.2 at baseline to 43.7 and 45.4 at 3 and 12 months, respectively. As far as
the EVLP group is concerned, the mean MCS score changes from 44.2 at baseline to 57.2 at 3 months post
TABLE 24 Short Form questionnaire-36 items measurements by study group at each time point
Time and
category
Number at
risk
Number of
patients
measured
in group Minimum Maximum Median IQR 95% CI
Baseline
EVLP 18
SF-36 MCS 8 31.49 57.42 43.46 41.49–47.31 37.96 to 50.40
SF-36 PCS 8 22.70 45.68 29.50 24.98–37.19 24.55 to 38.38
Standard 184
SF-36 MCS 67 18.93 69.36 40.96 33.73–54.05 40.52 to 46.40
SF-36 PCS 67 13.19 51.12 27.61 22.30–30.94 25.39 to 29.02
3 months
EVLP 14
SF-36 MCS 7 50.05 59.45 58.18 57.30–59.43 54.21 to 60.25
SF-36 PCS 7 41.16 59.50 48.68 47.17–59.19 44.92 to 57.60
Standard 172
SF-36 MCS 52 23.58 65.62 55.70 42.4–60.08 47.73 to 54.35
SF-36 PCS 52 25.82 59.45 45.47 38.36–50.07 41.22 to 46.26
12 months
EVLP 12
SF-36 MCS 6 33.32 62.80 58.96 53.06–62.19 43.19 to 66.57
SF-36 PCS 6 34.56 59.91 52.41 46.39–56.37 40.94 to 59.74
Standard 147
SF-36 MCS 48 33.79 68.47 54.92 45.79–59.51 50.24 to 55.42
SF-36 PCS 48 24.22 60.40 47.69 36.18–54.08 42.47 to 48.27
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transplant and 54.9 at 12 months post transplant, whereas the mean PCS score increases from 31.5 to 51.3
at 3 months after the transplant and drops slightly to 50.3 at 12 months’ follow-up. This slight decrease in
the mean 12-month MCS and PCS scores in the EVLP arm of the study is consistent with the decrease in
the scores for most of the eight domains at this time point. As mentioned above, any results regarding the
effectiveness of the EVLP based on these scores given would not be reliable because of the very limited
number of data available.
Baseline 3 months
Time point
12 months
18 184 14 172 12 147Number at risk:
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FIGURE 15 Box plot of SF-36 MCS scores, by study group and time point.
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Time point
12 months
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FIGURE 16 Box plot of SF-36 PCS scores, by study group and time point.
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Examining the effect of ex vivo lung perfusion on the overall
survival of patients awaiting transplantation
To capture the effects that an increased availability of donor organs due to EVLP might have on the survival of
patients awaiting lung transplantation, waiting time in each of the two treatment groups was compared, and
then waiting time in each group was compared with survival of those remaining on the waiting list. Waiting
time is defined as the time from the date the participant is placed on the waiting list until the date transplant
is performed. The waiting times until transplantation in the two study groups is shown in Table 25.
The median waiting time for standard transplant was 197 days (IQR 95–373 days), whereas the median
waiting time for a transplant using an EVLP donor was 142 days (IQR 60–199 days), as shown in Table 25.
There was a median difference of 55 days between transplant groups, showing a reduction in waiting time
if having a transplant using an EVLP-assessed donor organ. This is also illustrated by Figure 17, which
shows a maximum waiting time of 551 days for transplant using a EVLP donor compared with a maximum
waiting time of 2143 days for a standard transplant. A log-rank test for difference in waiting times
between transplant type using the Kaplan–Meier estimates gave a p-value of 0.042, which shows a
significant difference in waiting times between the two groups. However, these findings should be
interpreted with caution, in view of the small numbers of patients in the EVLP group.
Survival from listing
To assess overall survival between transplant groups and those remaining on the waiting list, the time from
being placed on the waiting list until 12 months post transplant or 1 May 2015, with censoring for death
or loss to follow-up, is presented in Table 26. Waiting list dates were collated for all participants during
recruitment to the study; however, for those remaining on the waiting list, some of this information was
not collated. For these participants, waiting list dates were obtained from the NHSBT registry.
TABLE 25 Summary of waiting time until transplant
Transplant type
Waiting time (days)
Mean SD Median IQR Minimum Maximum
Standard (n = 184) 307 348 197 95–373 6 2143
EVLP (n= 18) 178 156 142 60–199 9 551
Total (N = 202) 296 337 184 93–367 6 2143
2000
Standard
EVLP
1.00
0.75
0.50
Pr
o
p
o
rt
io
n
 s
u
rv
iv
in
g
0.25
0.00
15001000500
Waiting time (days)
0
FIGURE 17 Kaplan–Meier graph of waiting time until transplant by transplant type (each event in this graph
indicates a transplant performed).
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For the purpose of this analysis, 1 May 2015 was chosen as the end date for those who did not have
a transplant, since this is approximately 12 months after the last transplant was performed. Of the
232 participants remaining on the waiting list, 20 have been excluded from the analysis. Thirteen
were excluded because they were recruited to another study in which they had a transplant, four were
excluded because they no longer wanted to be part of the study and three were excluded because
there is no record of the date they were removed from the waiting list. Thirty-nine participants who
were included in the analysis have been censored: 11 of these were censored by the date they were
removed from the waiting list or were lost to follow-up and 28 were censored by the date on which
they had a transplant outside of this trial. There were 41 participants for whom we had been unable to
confirm their status as of 1 May 2015. Since we have not received information regarding their death
(which we would have expected), we have assumed these participants remained on the waiting list on
1 May 2015.
The Kaplan–Meier estimates of survival from being placed on the transplant list to transplant or death/
censoring are shown in Figure 18 for the three study groups. The median survival time from listing was
536 days (IQR 429–703 days), 479 days (IQR 412–543 days) and 543 days (IQR 324–830 days) for standard
transplant, EVLP transplant and waiting list groups, respectively (see Table 26). The log-rank test of difference
in survival times was significant (p = 0.007), implying that those having a standard lung transplant had better
survival than those who remained on the waiting list and those having an EVLP transplant. However, these
findings should be interpreted with caution in view of possible selection bias and the small number of
patients in the EVLP group.
TABLE 26 Summary of survival time from listing
Group
Survival time (days)
Mean SD Media IQR Minimum Maximum
Standard (n = 184) 631 362 536 429–703 46 2508
EVLP (n = 18) 453 197 479 412–543 73 916
No transplant (n= 212) 621 438 543 324–830 18 2867
Total (N = 414) 618 399 535 394–741 18 2867
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FIGURE 18 Kaplan–Meier graph of survival time from being placed on the transplant waiting list.
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Identifying clinical predictors of successful ex vivo lung perfusion
reconditioning
Between 1 April 2012 and 9 July 2014, lungs from 53 UK multiorgan donors were identified as unsuitable
for immediate standard transplantation despite extensive donor management. These donors all satisfied
the strict entry criteria for inclusion in the EVLP arm of the study (Boxes 1 and 2).
BOX 1 Criteria for EVLP assessment and reconditioning: using DBD or DCD lungs
Any one or more of the following
l Warm ischaemic time > 30 minutes for DCD donors.
l Withdrawal of life support between 60 and 90 minutes for DCD donors.
l Chest radiograph findings prohibitive of standard transplantation.
l Systemic arterial PaO2 < 300 mmHg and/or selective pulmonary vein gas < 225 mmHg on 100% FiO2 and
8 cmH2O PEEP.
l History of aspiration with bronchoscopic inflammation/soiling of the airway, or recurrent but not prohibitive
secretions in the distal airway after adequate bronchial toilet.
l Difficult to recruit atelectasis.
l Sustained peak airway pressure > 30 cmH2O.
l Unsatisfactory deflation test on disconnecting endotracheal tube.
l Unsatisfactory palpation of the lungs identifying undetermined masses, nodules or gross oedema.
l Deterioration or cardiac arrest in the donor prior to retrieval such that uncertainty over assessment remains.
l Unsatisfactory inspection of the lung after administration of the preservation flush and procurement.
l Logistical reasons that will extend donor lung ischaemic time > 10–12 hours and prevent donor organ use,
such as:
¢ viral studies awaited
¢ HLA compatibility studies
¢ pathology assessment of indeterminate mass in any donor
¢ awaiting recipient admission.
PaO2, partial pressure of oxygen; PEEP, positive end-expiratory pressure.
BOX 2 Absolute contraindications to donor lung use for standard transplant or for EVLP
Any one of the following
l Donor aged > 65 years.
l Donor HIV positive or other contraindicated infection risk (e.g. hepatitis B or C unless being used for a HIV-,
hepatitis B- or C-positive recipient).
l Chest trauma with extensive bilateral lung contusions.
l Convincing evidence of bilateral pneumonic consolidation on inspection.
l Pre-existing structural lung changes (e.g. emphysematous or multiple large bullae).
l Previous complex intrapleural thoracic surgery or dense adhesions prohibiting safe lung procurement.
l Confirmation of malignancy within 5 years (excluding central nervous system malignancies).
HIV, human immunodeficiency virus.
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Of these 53 donors, 35 died from spontaneous intracranial haemorrhage (66%), eight from hypoxic brain
injury (15%), five from traumatic brain injury (9%), three from thrombotic stroke (6%), one from an
expansive brain tumour (2%) and one from meningitis (2%). The donor lungs were procured in a routine
fashion and transported on ice to the accepting institution. A total of 27 (51%) were assessed in
Newcastle, nine in Harefield (17%), seven in Manchester (13%), six in Birmingham (11%) and four in
Papworth (8%). Fourteen donor lungs were from donors without a circulation (DCD) (Maastricht category III,
26%) and 39 were from brain-dead donors (DBD) (Maastricht category IV, 74%). The EVLP assessments
were evenly distributed between donor sexes [26 female (49%) and 27 male (51%)] and the median
donor age was 50 years (range 16–65 years). If one lung did not meet entry criteria and was deemed
unusable because of severe consolidation or extensive contusion on inspection, or if the intended recipient
was for a specific side (i.e. single-lung transplant), only one lung was procured. Fifty lungs (94%) were
perfused as double lungs and three (6%) as singles (two right lungs and one left lung). They were assessed
for a median time of 175 minutes (range 73–383 minutes) while being normothermically perfused on the
Vivoline LS1 EVLP circuit.
The study protocol allowed for lungs that satisfied certain criteria, as outlined in Box 1, to be assessed
using EVLP. The primary indications for EVLP assessment were grouped into three general categories:
35 donor lungs (66%) were found unsuitable for standard transplantation because of poor lung function
with an optimised donor ratio of arterial partial pressure of oxygen (PaO2) – shown throughout the report
as kPa (mmHg) – to FiO2 < 40 (300) and/or a selective pulmonary vein gas < 30 (225) with a FiO2 of 1.0
(100%) at procurement; 13 lungs (25%) were turned down as a result of abnormalities during inspection
(pulmonary oedema, abnormal bronchoscopy, extensive atelectasis, etc.); and three lungs (6%) were
turned down for standard transplantation for logistical reasons. Some lungs were excluded from EVLP as
they had absolute contraindications to transplant (see Box 2).
Of the donor lungs turned down for logistic purposes, two had a suspicious mass in need of urgent
histological evaluation before a decision on transplant was made. One was revealed to be cancerous and
the lungs were discarded after an otherwise successful EVLP perfusion, and the other was confirmed
benign and the lungs were transplanted. In one case, no theatre team was available as they had just
started another transplantation. In this case, the lungs also remained stable or improved measurable
physiological parameters during preservation on the EVLP circuit, but were in the end turned down for
transplantation because of deteriorating oedema formation on inspection.
Of the 53 donors, 24 (45%) were current smokers, 18 (34%) had abnormal chest radiographs at the time
of procurement and 22 (42%) had airway secretions deemed prohibitive of standard transplantation,
predominantly purulent secretions. The median ventilation time for the EVLP donors before procurement
was 2 days (range < 1–10.3 days) and 27 donors (51%) had positive microbiology cultures from sputum,
BAL fluid or cerebrospinal fluid. The median optimised PaO2 : FiO2 ratio for the 53 EVLP donors at the
time of procurement was 39.9 [299 (range 95–535 mmHg)] and after EVLP was 50.9 [381.5 (range
74–638 mmHg)]. The EVLP assessments followed one of two standardised perfusion protocols depending
on when the lungs were entered into the study. Initially, between 1 April 2012 and 31 March 2013, a
hybrid protocol combining elements of the Toronto and Lund protocols was used with an open left atrium,
an acellular perfusate and a reduced perfusate flow to 40–60% of the donor’s calculated cardiac output.
After a pause midway through the study because of concerns over the rate of ECMO use in transplants
performed after assessment using the hybrid EVLP protocol, the perfusion strategy was altered and the
study was restarted in August 2013 and the hybrid protocol replaced by the Lund protocol.
The Lund protocol uses a cellular perfusate (haematocrit 10–15%) and a full-flow perfusion strategy
(100% of cardiac output), but is otherwise identical to the hybrid protocol. The assessment and ventilation
strategies, airway and vascular pressure limits, and perfusate composition was otherwise unaltered
(Table 27).
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Lung performance during ex vivo lung perfusion assessment
Transplant suitability was assessed as soon as the lungs had stabilised, at 37 °C and perfusing at full flow,
and thereafter hourly until the end of perfusion. Lungs meeting transplant suitability at any time point
were cooled and transplanted (Boxes 3 and 4). Lungs deemed to have futile prospects for improvement
were taken off the circuit and discarded.
TABLE 27 The DEVELOP-UK study EVLP protocols
Parameter
Protocol
Hybrid (1 April 2012–31 March 2013) Lund (1 August 2013–9 July 2014)
Perfusion
Target flow 40–60% of cardiac output 100% of cardiac output (70 ml/kg/minute)
Pulmonary arterial pressure < 20 mmHg < 20mmHg
Left atrial pressure 0 mmHg (open left atrium) 0 mmHg (open left atrium)
Pump Roller Roller
Perfusate 2 l of Steen Solution 2 l of Steen Solution with red cell
concentrates (haematocrit 10–15%)
Ventilation
Mode Volume controlled Volume controlled
Tidal volume 6–8ml/kg 6–8 ml/kg
Frequency 10–15 b.p.m. 10–15 b.p.m.
Positive end-expiratory pressure 5 cmH2O 5 cmH2O
FiO2 50% 50%
Temperature
Start of ventilation 32 °C 32 °C
Start of perfusion 15 °C 15 °C
Start of evaluation 37 °C 37 °C
b.p.m., beats per minute.
BOX 3 Criteria for transplant after successful EVLP assessment and reconditioning
All of the following
l Any DBD or DCD donor lungs meeting previously stated criteria for standard transplant.
l Pulmonary artery pressure < 20mmHg, while achieving target perfusate flow.
l Oxygen capacity shown by ΔPaO2 of > 300 mmHg (perfusate left atrium PaO2– perfusate pulmonary artery
PaO2)/FiO2.
l Selective pulmonary vein gas > 225 mmHg on 100% FiO2 and 5 cmH2O PEEP.
l Stable or improving lung compliance and stable or falling lung resistance.
l No pulmonary oedema build-up in the endotracheal tube.
l Satisfactory assessment on inspection and palpation.
l Confirmed reconsent of potential matched recipient to receive an EVLP-reconditioned lung.
PEEP, positive end-expiratory pressure.
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The performance of the 53 donor lungs undergoing EVLP assessment in the study is reported in two
different ways to give as robust a description as possible of this cohort.
First, clinical EVLP success was defined as any EVLP-assessed donor lung deemed clinically suitable for
transplantation at the end of perfusion by the surgical team performing the assessment (n = 22). This
included all EVLP lungs that were transplanted within the study (n = 18) and all lungs that were accepted
for transplantation on the basis of EVLP performance, but had to be turned down due to unforeseen
logistical reasons (n = 4) (Figure 19).
Of these four cases, one pair of lungs accepted for double lung transplant had to be discarded as the
recipient presented with an active airway infection and was found to be at too high risk for the operation on
arrival at the hospital. The lungs were offered on urgently, but turned down by all UK centres owing to
logistics. One lung had an unreported irreparable left pulmonary artery laceration with haematoma formation
from the retrieval surgery. The right lung was selectively perfused and deemed suitable for transplantation.
There was, at this point, no available matching single lung recipient and the lung had to be discarded after
having been offered on to all other UK centres. One left single lung accepted for transplantation for a
matched recipient had to be aborted due to an emergency in theatres and lack of additional surgical capacity
at the site. One lung was put on EVLP for logistical reasons while awaiting histology of suspicious masses
found during the organ procurement. Evaluation of a liver nodule showed chronic lymphatic lymphoma.
Although the lung biopsy was found benign, the transplant was aborted because of the elevated risk of
tumour transmission to the recipient. The lungs were meanwhile successfully reconditioned on the circuit and
deemed to be in a suitable condition for transplant had it not been for the histological liver findings.
BOX 4 Criteria for failed EVLP assessment and reconditioning: transplant will not proceed
Any of the following
l Any DBD or DCD donor lungs not meeting stated criteria for standard transplant.
l Not satisfying criteria for transplant after successful EVLP assessment and reconditioning.
DEVELOP-UK EVLP 
assessments, n = 53
Lund protocol
(n = 31, 58%)
Non-successful
(n = 17, 55%)
Transplanted
(n = 10, 71%)
Non-transplanted
(n = 4, 29%)
Hybrid protocol
(n = 22, 42%)
Non-successful
(n = 14, 64%)
Transplanted
(n = 8, 100%)
Non-transplanted
(n = 0, 0%)
Successful
(n = 14, 45%)
Successful
(n = 8, 36%)
FIGURE 19 Flow chart for clinical EVLP success (n= 22).
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Second, per-protocol success was defined as all perfused donor lungs meeting the complete set of
predefined study criteria for EVLP success, regardless of clinical transplant result (n = 17). This included all
EVLP lungs that were transplanted in the study while meeting all predefined transplant criteria (n = 13) and
all non-transplanted EVLP lungs that met all transplant criteria but were discarded purely on logistical
grounds (n = 4) (Figure 20).
Of the 18 EVLP lungs that were transplanted in the study, five had to be defined as per-protocol
non-successful perfusions as, although deemed clinically suitable for transplantation, they failed to meet
all predefined transplant criteria and were transplanted as a result of a protocol violation.
Two of these five lungs were transplanted even though their mixed pulmonary vein PaO2 : FiO2 ratio was
40.0 (< 300) during the assessment. One of these almost doubled its optimised retrieval PaO2 : FiO2 ratio
during the perfusion, increasing from 22.0 (166) to 38.6 (290), and the other had a recorded mixed
pulmonary vein PaO2 : FiO2 ratio of 35 (262), while all selective pulmonary vein gases were well above the
study cut-off point [range 46.0–72.0 (345–540)]. Three EVLP lungs were transplanted while having one or
two selective lower lobe pulmonary vein gases < 30 (225); however, their mixed pulmonary vein PaO2 : FiO2
met the study transplant criterion of > 40 (300). All five of these lungs were subsequently transplanted into
recipients with satisfying post-transplant outcomes and a 100% 1-year survival. Of the 13 recipients
receiving lungs that met all study criteria for transplantation, only seven (54%) remained alive 12 months
post transplant.
Logistic regression analyses
A logistic regression approach was used to examine the association between successful reconditioning
(defined on either of the bases explained above) and a number of potential predictors based on donor
characteristics and indices measured during EVLP. As a result of the lower than planned numbers in the
EVLP arm, the work here must be regarded as exploratory in nature rather than definitive.
In terms of the variables to be considered for the examination of potential predictors of successful EVLP,
univariate exact logistic regression models were fitted with successful EVLP as the dependent variable, and
each of the following in turn as the independent variable. These models were fitted using the exlogistic
option in Stata® 13.1 (StataCorp LP, TX, USA):
l donor {age, sex, cause of death, smoking history, ischaemic time, duration of ventilation, oxygenation,
donor type [after brain death (DBD) or after circulatory death (DCD)]}
l EVLP physiology (oxygenation, lung compliance and resistance, airway pressure, perfusion time).
The original intent was also to use similar approaches to examine EVLP donor lungs used in transplantation
and the association between early clinical outcome measures in recipients and physiological indices
measured during EVLP. However, having only 18 patients in the EVLP transplant group meant that such an
analysis would not be statistically meaningful.
Table 28 gives the results of the univariate analyses of predictors of clinical EVLP success. Here odds ratios
are presented for different categories or, in the case of continuous variables, based on a unit increase in
the variable. Although some of the point estimates for odds ratios varied somewhat from one, in all
instances the associated 95% CI included one.
Table 29 shows the results from the corresponding analyses, based on per-protocol success. The odds
ratios and CIs are very similar to those based on clinical EVLP success.
In conclusion, there was no strong evidence to indicate specific predictors of successful EVLP
reconditioning. However, the analyses were restricted by the relatively small numbers.
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Archiving
The trial data were stored on the Newcastle Clinical Trials Unit’s MACRO database system, provided by
Infermed’s MACRO software as a service system. The hardware was located at their hosting partner
Rackspace’s secure premises in London, UK, and is managed and supported by the Rackspace team.
All data were stored and transmitted securely. Data were hosted and backed up only in the UK and were
never transferred overseas. Only authorised staff can grant and have control of access. Any snapshots of
the database taken will be kept on the Newcastle University server, which is backed up daily.
Once all trial-related analysis and activities are completed, the database will remain on MACRO, with
permissions removed. The data will be archived onto disk for each site file and also centrally in accordance
with the Newcastle Clinical Trials Unit’s standard operating procedures (SOPs).
TABLE 28 Univariate exact logistic regression analysis of predictors of successful EVLP reconditioning
(clinical EVLP success)
Variable Category or units
Number of
patients in
category
Number of
successes OR (95% CI)
EVLP protocol Lund 31 14 1
Hybrid 22 8 0.70 (0.19 to 2.43)
Donor age (years) Based on a 10-year increase 53 22 1.46 (0.90 to 2.50)
Sex (reference category: males) Females 26 9 0.58 (0.16 to 1.97)
Males 27 13 1
Smoking (reference category:
non-smokers)
Non-smokers 29 13 1
Smokers 24 9 0.74 (0.21 to 2.54)
Ischaemic time (hours) Based on a 1-hour increase 48 21 1.00 (0.61 to 1.64)
Duration of ventilation (days) Based on a 1-day increase 53 22 1.17 (0.87 to 1.63)
Optimised donor PaO2 : FiO2 ratio
before EVLP
Based on a 100-mmHg increase 53 22 0.81 (0.50 to 1.27)
Donor type (reference category:
DBD)
DBD 39 17 1
DCD 14 5 0.72 (0.16 to 2.96)
PaO2 : FiO2 after EVLP Based on a 100-mmHg increase 48 22 1.34 (0.86 to 2.15)
Compliance start (ml/mbar) Based on a 10 ml/mbar increase 28 15 1.25 (0.94 to 1.72)
Change in compliance (ml/mbar)a Based on a 10 ml/mbar increase 15 7 0.98 (0.52 to 1.88)
Airway resistance start Based on a 1 mbar/l/second
increase
24 11 0.93 (0.77 to 1.00)
Change in airway resistancea Based on a 1 mbar/l/second
increase
12 4 2.11 (0.95 to 19.99)
Peak airway pressure start Based on a 1-cmH2O increase 41 18 0.88 (0.73 to 1.05)
Change in peak airway pressurea Based on a 1-cmH2O increase 24 9 1.06 (0.85 to 1.35)
EVLP time Based on a 1-hour increase 49 20 0.95 (0.54 to 1.65)
OR, odds ratio.
a Changes defined as start–end.
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TABLE 29 Univariate exact logistic regression analysis of predictors of successful EVLP reconditioning
(per-protocol success)
Variable Category or units
Number of
patients in
category
Number of
successes OR (95% CI)
EVLP type Lund 31 6 1
Hybrid 22 11 0.69 (0.17 to 2.58)
Donor age (years) Based on a 10-year increase 53 17 1.58 (0.92 to 2.93)
Sex (reference category: males) Females 26 8 0.89 (0.24 to 3.28)
Males 27 9 1
Smoking (reference category:
non-smokers)
Non-smokers 29 10 1
Smokers 24 7 0.79 (0.20 to 2.90)
Ischaemic time (hours) Based on a 1-hour increase 48 17 0.80 (0.45 to 1.33)
Duration of ventilation (days) Based on a 1-day increase 53 17 0.97 (0.68 to 1.32)
Optimised donor P/F before EVLP Based on a 100-mmHg increase 53 17 0.86 (0.52 to 1.39)
Donor type (reference category:
DBD)
DBD 39 14 1
DCD 14 3 0.49 (0.08 to 2.32)
PF after EVLP Based on a 100-mmHg increase 48 17 1.59 (0.97 to 2.77)
Compliance start (ml/mbar) Based on a 10 ml/mbar increase 28 13 1.10 (0.84 to 1.47)
Change in compliance (ml/mbar)a Based on a 10 ml/mbar increase 15 6 1.02 (0.54 to 2.00)
Airway resistance start Based on a 1 mbar/l/second
increase
24 9 0.98 (0.82 to 1.01)
Change in airway resistancea Based on a 1 mbar/l/second
increase
12 3 2.70 (0.95 to 58.58)
Peak airway pressure start Based on a 1-cmH2O increase 41 14 0.83 (0.66 to 1.01)
Change in peak airway pressurea Based on a 1-cmH2O increase 24 7 1.07 (0.84 to 1.36)
EVLP time (hours) Based on a 1-hour increase 49 17 0.93 (0.51 to 1.65)
OR, odds ratio.
a Changes defined as start–end.
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Chapter 4 Economic evaluation
Overall aims of the economic evaluation
The original aim of the economic analysis of the DEVELOP-UK study was to estimate the cost-effectiveness
of EVLP compared with standard donor lung transplantation. Cost-effectiveness was to be estimated in
terms of the incremental cost per quality-adjusted life-year (QALY) gained and compared with the current
National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold (£20,000 per QALY).
This analysis was to take the form of a within-study economic evaluation and a model to extrapolate
findings over patients’ lifetime. As previously described, the DEVELOP-UK study was terminated before the
target participant recruitment was reached. Therefore, the originally planned economic evaluation of the
study was conducted with a few changes within its initial design.
Given the smaller than planned recruitment numbers in the EVLP arm of the study, the aims of the
economic section were recast to:
1. provide a descriptive ‘within-study’ analysis of the available data in terms of costs and QALYs for both
EVLP and standard donor lung transplantation, without directly comparing the two procedures
2. estimate a regression model to explore predictors of NHS costs for transplants that may aid future
modelling studies involving a lung transplant as one of the events of interest
3. report an exploratory economic model populated for both types of lung transplantation (standard and
EVLP) with data obtained from the relevant literature and from the DEVELOP-UK study.
Within-study descriptive analysis of costs and quality-adjusted life-years
There are five parts of analysis that were proposed to be presented in this element of the study. First, the
unit costs and the sources of these costs for standard donor and EVLP lung transplantation were to be
described. Second, an analysis of the resource use was to be conducted to estimate the mean (SD) and the
median (IQR) use of each type of resource. In the third part of the analysis, resource use and unit cost data
were to be combined in order to estimate the average cost for each area of resource use and in total for
each one of the two types of transplantation. The fourth part of the analysis that gives information on
HRQoL was to be used to estimate QALYs for each type of transplantation based on the responses of the
participants to the SF-36. Fifth, and finally, the net benefits of standard and EVLP lung transplantation
were to be calculated based on the costs and QALYs of the two different approaches to achieving a
lung transplant.
As the study was terminated early because of a lack of patient recruitment in one of its two arms, it was
agreed that no direct within-study comparison would be drawn in terms of cost-effectiveness, and that the
presentation of results would be limited to descriptive data. These descriptive data were, however, used to
populate an exploratory economic model.
Methods
Outline of the lung transplant procedure
First of all, one of the most important parts of any economic evaluation is to understand the process of
care, so as to fully understand what costs and outcomes should be included in the analysis. The first stage
of the process is the notification of potential organ donors. In other words, it is necessary for every NHS
hospital to identify any potential donors that might exist within its patient population. In this case, the
donation of a lung might be after circulatory death (DCD) or brain death (DBD) of the donor. The donor’s
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hospital is also responsible for informing its local SNOD from NHSBT about the existence of a single- or a
multiple-organ donor on its premises. NHSBT would then assess the donor and contact the local transplant
centre for them to check its waiting list records in order to find the most suitable organ recipients for that
donor. Once a transplant centre is contacted by NHSBT about a possible donor, it should investigate
whether or not there are any patients on its lung transplant waiting list that have the necessary size and
tissue characteristics that match those of the donor. Here, it is important to mention that the patients who
are included in a hospital’s waiting list are frequently monitored in order to ensure that the most
appropriate patient will be chosen in case a lung transplant becomes available in the future.
After contacting the SNOD in order to receive more information regarding the condition and the
characteristics of the donor, the transplant centre may send a scout – if the donor hospital is less than
2 hours away – and, subsequently, a retrieval team to potentially collect the donor lung(s). Following the
initial assessment of the lung by the retrieval team, and assuming that it is in a suitable condition to
proceed to transplant, the retrieval team sends the organ back to the transplant site. For the purposes of
the study, during the period of time that the study was under way, the retrieval team should have also
considered whether or not an unusable lung (i.e. a lung that would not be retrieved otherwise based on
standard tests and the subjective assessment of the retrieval surgeon) could be assessed and reconditioned
by EVLP in order to be used as a transplant in the EVLP arm of the study. If so, retrieval was performed
with the intention that this lung would be transplanted using EVLP. In addition, during the same period of
time, more retrieval teams were sent out than normal because there was a higher probability that a lung
would be accepted for a transplant.
Here, it should be mentioned that during a usual retrieval, several organs might be retrieved (e.g. heart,
kidney, pancreas and liver). It should also be noted that at times no retrieval might be performed if the
team decides differently. During this study, 53 lungs were retrieved in order to undergo an EVLP
procedure. Of these lungs, only 18 were reconditioned successfully and transplanted at the end.
The remainder were not considered appropriate for transplantation at the transplant site. Therefore, in
the analysis of this study, the ratio of EVLP transplant per retrieval was considered to be equal to 18 EVLP
lungs out of 53 attempts. On the other hand, for the standard arm of the study, it was difficult to calculate
the number of lungs assessed but not retrieved given the parameters described above. However, expert
opinion from the study team advised that each time a lung is assessed as suitable for transplant, this lung
is always transplanted. Consequently, it was assumed that each time a retrieval team was sent to a donor’s
hospital a lung was retrieved and sent back to the transplant site in order to be assessed and transplanted.
At the same time as a retrieval team has been dispatched to the donor hospital, the transplant centre
should contact the potential recipient in order to inform them about the possibility of a transplant
happening. Sometimes, more than one patient is contacted in order to ensure that the lung will be
transplanted in the event that one of them has a current infection and cannot be transplanted. Once the
intended recipient(s) arrives at the transplant site, the recipient meets with the transplant co-ordinator to
receive more information about the transplant, and is prepared for the transplant. In the case of an EVLP
lung transplant, the EVLP procedure may be started before the recipient arrives at the hospital and
continue while the patient is being prepared for the surgery.
Afterwards, the lung transplant operation is under way, where exactly the same procedure for both
standard and EVLP transplants is followed. After the operation, the lung recipient is admitted to the ITU
and then onto the transplant ward in order to receive the necessary post-operative care and manage any
complications that might occur. Following hospital discharge, and assuming there are no complications,
infections or rejection episodes necessitating readmission, the recipient returns to the hospital every month
(or less depending on the clinicians’ recommendations) for routine tests (i.e. blood test, bronchoscopy, etc.)
and in order to report any complications. In between, the lung recipient might also visit a GP to report any
new symptoms or AEs from the medications given.
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Study perspective
The perspective of the study (i.e. which costs and outcomes were considered in the analysis) was the
national health-care provider (the UK NHS). The duration of follow-up was 12 months following transplant,
with outpatient visits planned at 1, 3, 6 and 12 months post transplant.
Cost and use of resources
The data collected on costs were categorised into the following areas based on when the resources were
used during the study: donor’s hospital, lung retrieval, transplant preparation, EVLP procedure, lung
transplant, post-operative care, outpatient care and concomitant medications.
Donor’s hospital
As mentioned above, the donor’s hospital is responsible for contacting the NHSBT to report any potential
lung donors. Before the retrieval team arrives, the SNOD should have performed an initial assessment to
provide the patient’s history to the transplant team. This assessment consists of several routine tests,
such as a full blood count (FBC) and chest radiography, as well as, sometimes, a bronchoscopy procedure.
The cost of the initial assessment was derived from the costing tool of Newcastle upon Tyne Hospitals
(NuTH; obtained from: www.newcastlejro.org.uk) or the NHS Reference Costs 2013/2014,49 while the
information regarding the use of each test was obtained from the CRFs of the study or the hospital staff
(personal communications: Mr Tanveer Butt, NuTH, June 2015; Ms Alison Davison, NuTH, June 2015;
Mr Paul Henderson, NuTH, September 2014; and Ms Katie Morley, NuTH, October 2014). The hospital
staff should also administer a single dose of methylprednisolone (500 mg, 1 g or 2 g, with the dose
decided based on the donor’s weight) to modulate the pulmonary inflammatory activity of the donor.
The use of methylprednisolone was reported on the CRF, while its cost was collected from the British
National Formulary (BNF) for each dose that was administered.50
Lung retrieval
Lung retrieval begins when the scout team and/or the retrieval team arrives at the donor’s hospital. Normally,
a scout team is sent out if the donor’s hospital is within a 2-hour range from the transplant site in order to
make an initial examination of the organ. According to the retrieval team of NuTH (Mr Tanveer Butt, NuTH,
September 2014, personal communication), around one-fifth of lung retrievals are scouted first. The scout
team consists of a retrieval surgeon (clinical fellow) and a scrub nurse (band 7), while in the retrieval team a
perfusionist (band 7) is also included. The retrieval process was estimated, based on clinical advice, to last
for approximately 9 hours, with a further 4 hours added if a scouting is performed (one in five cases).
All the costs of the staff were obtained from the Personal Social Services Research Unit (PSSRU)’s Unit
Costs of Health and Social Care 2014,51 while the resource information came from the NuTH retrieval team
(personal communications: Mr Tanveer Butt, NuTH, September 2014; and Mr Paul Henderson, NuTH,
September 2014).
As far as the travelling of the two teams is concerned, this is variable and depends on the distance of the
donor’s hospital from the transplant site. According to the NuTH NHS staff (Mr Brian Leadbitter, NuTH NHS,
June 2015, personal communication), a scout team always travels by road while a retrieval team travels by
road in 74% of the cases, and by road and air in 26% of the cases. Once the lung is retrieved, it might be
returned to the transplant centre either by road (50%), or by road and air (50%). The usage and costs of
travel were based on the cardiothoracic organ retrieval invoices given by the NHS staff of NuTH.
During the lung retrieval, the team requests the donor’s medical history and the screening tests provided
by the hospital staff [i.e. ABG, electrocardiography (ECG), etc.]. Then the team performs an initial
assessment of the patient in order to examine whether or not the lung can be transplanted. There are
three diagnostic tests that are normally performed by the retrieval team: chest radiography, an ABG test
and a bronchoscopy. Here, it should be mentioned that an ABG test is provided only when the lung comes
from a DBD donor; in cases of a DCD this test cannot be performed as the heart has already stopped
(Mr Tanveer Butt, NuTH, September 2014, personal communication).
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
Chest radiography is performed with the donor hospital’s equipment and, for the purposes of the analysis,
its cost was derived from the NuTH costing tool (obtained from: www.newcastlejro.org.uk) while its use
was reported on the CRF. For the ABG test and the bronchoscopy procedure, the retrieval team takes the
necessary equipment with them. According to the NuTH retrieval team’s checklist (personal communications:
Mr Tanveer Butt, NuTH, September 2014; and Mr Paul Henderson, NuTH, September 2014), the team always
brings a bronchoscope, strapple tape and 0.5% chlorhexidine spray to the donor’s hospital. In addition to
these pieces of equipment, a different number of 0.9% sodium chloride solutions might be needed during
the retrieval, and these are usually provided by the donor’s hospital. In the case of a DBD donor, the donor’s
hospital also provides the necessary equipment for the ABG test (i.e. vacutainers, syringes, portable clinical
analyser, etc.).
The costs of most of this equipment used by the retrieval team were obtained from the official websites of
the resective medical suppliers. In the case of the bronchoscope and the clinical analyser for blood analysis
(i-STAT® device, Abbott Laboratories, Dallas, TX, USA), their equivalent annual costs were estimated based
on the life expectancy of the equipment, assuming a 3.5% discount rate.52 The equivalent annual cost was
then divided by the expected annual usage to get a cost per recipient. The cost of the i-STAT test cartridges,
which are the testing cartridges used during a diagnostic test with an i-STAT clinical analyser, was obtained
from the retrieval team, and the cost of sodium bicarbonate was obtained from the BNF 2014.50
The perfusionist member of the team is responsible for measuring the breathing (ventilation) and
circulation (perfusion) in all areas of the lung retrieved, as well as ensuring the proper maintenance of the
organ. In order to increase the cooling, preservation and storage of the lungs, a colloid preservation
solution (PERFADEX) is needed. To be more precise, 2.8 l of PERFADEX solution is needed antegrade for
lung preservation, whereas 1 l is given retrograde on the back table just after the harvest procedure
(250 ml into each of the four veins of the lung). To each litre of this solution, a sterile sodium salt,
epoprostenol sodium (FLOLAN®, GlaxoSmithKline), THAM, CaCl2 and heparin sodium are added. The use
of the first three was reported by the retrieval team (personal communications: Mr Tanveer Butt, NuTH,
September 2014; and Mr Paul Henderson, NuTH, September 2014), whereas for heparin sodium and
CaCl2 it was collected from the BNF 2014.50 The costs of FLOLAN, THAM, heparin sodium and CaCl2 were
obtained from the BNF 2014,50 whereas the price of the different dosages of PERFADEX solutions was
given by its producer company, XVIVO Perfusion AB.
Transplant preparation
After the retrieval, the lung is delivered back to the transplant site in order to be prepared for the transplant.
In case the lung needs to be reconditioned before the transplant, the EVLP procedure is also followed in
parallel (see Ex vivo lung perfusion procedure). Meanwhile, the transplant co-ordinator is responsible for
contacting the potential recipient(s) – this normally lasts for 1 hour. The potential recipient is selected from
the transplant waiting list by the transplant surgeon on duty. The transplant surgeon on duty is ultimately
responsible for deciding which patient meets the necessary criteria and has the appropriate characteristics
that match with the donor’s tissue in order to be transplanted (Professor Andrew Fisher, NuTH, November
2015, personal communication). It should also be noted that each patient on the waiting list receives
frequent diagnostic tests, such as FBC and ECG, to monitor their condition. For the purposes of this study,
the costs of these tests were not considered as part of the transplant cost.
Once the appropriate patient(s) are selected, they are transferred to the transplant centre by road or air
depending on the accessibility to, and the distance from, the site. There are different ways that a patient
might be transferred to the hospital, including ambulance, aeroplane (air ambulance) or private car.
Nevertheless, during the analysis of the study, it was difficult to obtain more details regarding the
resources used for the patient travelling to the transplant centres. As a result, this information was omitted
from the estimation of costs.
At the transplant centre, the potential recipient(s) meets with the transplant co-ordinator for approximately
2 hours in order to receive more information regarding the transplant. Following this, a tissue typing
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procedure is performed by NHSBT in order to test the compatibility between the tissue of the prospective
donor and that of the potential recipient. The potential recipients will also receive the following tests
to monitor their health status: ABG test, chest radiography and ECG. After these tests, the patient
stays in the transplant centre ward until the operation (usually for 1 hour) or until sent home because
the transplant has not progressed. During this time, medications tailored to the patient’s health state
are administered (e.g. specific antibiotic cocktail). Azathioprine (200 mg) is also given orally before
the beginning of the transplant as part of the standard procedure (Professor Andrew Fisher, NuTH,
June 2015, personal communication).
The time needed for the contact and meeting with the potential recipients(s), as well as the average waiting
time, was sourced by the NuTH staff (personal communications: Ms Alison Davison, NuTH, June 2015;
and Ms Katie Morley, NuTH, October 2014). The hospital staff also reported that a tissue typing test is
performed after the meeting with the transplant co-ordinator, while an ECG is also provided before the
transplant. The CRF reported that an ABG, a FBC and chest radiography are conducted as well. The PSSRU’s
Unit Costs of Health and Social Care 201451 gave the costs per hour for the transplant co-ordinator, while
the cost of the hospital ward time was derived from the NHS Reference Costs 2013/2014.49 The unit costs of
all the diagnostic tests were obtained from the NuTH costing tool (obtained from www.newcastlejro.org.uk),
apart from the cost of the tissue typing test that is provided by the Information Services Division (ISD)’s ISD
Scotland Theatre Services.53 In addition, the cost of azathioprine was collected from the BNF 2014.50
Ex vivo lung perfusion procedure
The EVLP is a procedure that needs, on average, 6 hours in order to be completed. For the EVLP, an operating
theatre is required in which the whole procedure takes place. The cost per hour of an operating theatre came
from ISD’s ISD Scotland Theatre Services.53 As far as the staff is concerned, a consultant surgeon, a surgical
fellow, a scrub nurse (band 5), a perfusionist (band 7) and an anaesthetic registrar are needed for various
amounts of time during the EVLP. The salary calculations for all the members of the staff were based on the
PSSRU’s Unit Costs of Health and Social Care 2014,51 whereas the information regarding the staff time was
given by the hospital staff and Vivoline Medical AB company (personal communications: Anders Andreasson,
NuTH, September 2014; Anna Söderlund, Vivoline Medical AB, July 2014; Mr Paul Henderson, NuTH,
September 2014; and Ms Katie Morley, NuTH, October 2014).
According to Vivoline Medical AB and the NuTH hospital staff (personal communications: Mr Anders Andreasson,
NuTH, September 2014; Ms Anna Söderlund, Vivoline Medical AB, July 2014; and Mr Paul Henderson, NuTH,
September 2014), there are several pieces of equipment and consumables needed during the EVLP procedure.
The main equipment needed is a Vivoline system, which is the ‘rig’ unit, and a Vivoline disposable lung set, in
which the lung is inserted in order to be reconditioned before the transplant. Other surgical equipment is also
needed for the procedure (e.g. tissue forceps, surgical tape and sutures), while equipment for blood gases
tests (e.g. syringes for blood gases and blood gases samples) and a bronchoscope are necessary for the
screening of the lung. The costs of all the equipment and consumables used during an EVLP run were
collected from the official websites of the respective suppliers and the hospital or Vivoline Medical staff.
Where equipment is reusable, its equivalent annual costs were estimated based on its expected life
expectancy, assuming a 3.5% discount rate.52 The equivalent annual cost was then divided by the expected
annual usage to get a cost per recipient.
There are several drugs that are also administered to the lung during the EVLP procedure. These include
heparin sodium and methylprednisolone, as well as insulin and THAM. The CRF (p. 34) and the NuTH
clinical staff (Mr Anders Andreasson, NuTH, September 2014, personal communication) provided the
details of the medications used. The unit costs of the medications were obtained from the BNF 2014 based
on the doses recorded on the patients’ data set.50
Lung transplant
The procedure followed during the lung transplant is identical for both standard donor and EVLP lung
transplantation. Before lung transplant, the patient is transferred in the anaesthetic room of the operating
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theatre in order to receive the necessary anaesthesia. In this room, a consultant anaesthetist and an anaesthetic
nurse (band 5) are required in order to provide the anaesthetic management of the patient. As described in
Post-operative care, the anaesthetic staff move to the surgical room afterwards in order to oversee the level of
anaesthesia of the patient during the operation. The anaesthetic preparation needs 45 minutes, on average, in
order to be completed based on the NuTH transplant co-ordinators (Ms Alison Davison, NuTH, June 2015,
personal communication). As before, the cost of the anaesthetic room, as well as the operating theatre in
general, was obtained from ISD Scotland Theatre Services,53 while the costs of the staff were collected from the
PSSRU’s Unit Costs of Health and Social Care 2014.51
Once the anaesthetic preparation is finished, the patient is moved from the anaesthetic room into the
operating theatre. In addition to the anaesthetic staff (with the addition of an anaesthetic fellow),
a consultant surgeon, a surgical fellow, two scrub nurses (bands 5 and 7) and a perfusionist (band 7)
are required for the surgery (personal communications: A Fisher, NuTH, November 2015; and Mr Paul
Henderson, NuTH, September 2014). Depending on whether a single or a double lung is transplanted,
the surgery might last, on average, 4–7 hours. More information regarding the staff members needed was
provided by the hospital staff that took part in the study [Qualtrics® survey, 2014 (Qualtrics, Provo, UT,
USA); see Appendix 5], while their costs per hour were calculated from the PSSRU’s Unit Costs of Health
and Social Care 2014.51
As far as the equipment and consumables used during lung transplant are concerned, during the analysis
of this study, it was difficult to obtain more details from the different members of the hospital staff and
conduct the relevant microcosting. As a result, this information was omitted from the estimation of costs.
Post-operative care
After the operation is completed, the lung recipient is initially transferred to the ITU in order to be closely
observed by the anaesthetic team and the transplant physicians. On average, the patient stays for 10 days
in the ITU/high-dependency unit (HDU) before being discharged to the transplant ward. After being
discharged from the ITU/HDU, some recipients might require to stay for longer (> 1 month, on average) in
the hospital so they remain at the level 1 ward. Others might experience complications and may need to
be readmitted to ITU/HDU. The time spent in the different hospital wards after the operation was reported
on the CRF of the study. The unit costs of the wards were measured per bed-day and were calculated in
accordance with the NHS Reference Costs 2013/2014.49 The costs of the wards included the costs of the
ward, equipment and nursing needed during the patient’s hospital stay.
In the ITU/HDU, the patient is observed daily by a consultant surgeon (15 minutes), a surgical fellow
(15 minutes), a consultant physician (10 minutes), a consultant anaesthetist (30 minutes) and an anaesthetic
fellow (90 minutes). In the hospital ward, there are no visits from the consultant surgeon, the consultant
anaesthetist and the anaesthetic fellow, but the consultant physician time increases to 20 minutes, and a
transplant specialist registrar is now needed, who will spend approximately 30–40 minutes with each
patient every day. During their visits, the clinicians perform several diagnostic tests in order to monitor the
progress of the patient’s health (e.g. ABG, FBC, lung function test, etc.). Depending on the patient’s
condition, a tracheostomy and a bronchoscopy may be required. The CRF gave more details regarding the
use of these tests and procedures, while the staff time needed per day was estimated based on the
responses of the clinicians on the Qualtrics survey (see Appendix 5). The costs per hour for all the members
of the staff were collected from the PSSRU’s Unit Costs of Health and Social Care 2014,51 while the unit
costs of the tests and procedures performed were calculated using the NuTH costing tool (obtained from
www.newcastlejro.org.uk) or NHS Reference Costs 2013/2014.49
During post-operative care, some patients might require both cardiac and respiratory support if their heart
and/or lungs are unable to provide adequate amount of gas exchange to sustain life. This can be solved by
using either an ECMO machine, which artificially removes carbon dioxide from the person’s blood and
oxygenates red blood cells, or an iLA device, which is an artificial membrane that replaces the lung and its
functions. In addition, normally haemodynamic support is provided to the patient by using inotrope drugs
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(e.g. adrenaline hydrochloride, vasopressin, dobutamine, etc.). In some cases, some plasma volume
expanders, such as colloid (e.g. normal saline solution) and crystalloid (e.g. albumin, dextran, etc.) fluids,
might be required in order to restore the vascular volume and stabilise the circulatory haemodynamics.
When needed, red blood cells, plasma and platelets might also be given in order to change the levels of
the main blood components.
The use and amount of all the equipment and consumables described above were recorded on the
patient’s CRF (p. 45), while their costs were retrieved from different sources. The costs of ECMO and the
blood components were given by the hospital staff (personal communications: Mr Tanveer Butt, NuTH,
September 2014; and, Mr Paul Henderson and Ms Yvonne Scott, NuTH, July 2015) or the NHSBT. Using
the same methods as described before for reusable equipment (e.g. ECMO machine) a cost per recipient
was calculated.52 The unit costs of colloid and crystalloid fluids, as well as that of the inotrope drugs used,
were collected from the BNF.50
As mentioned above, the patient might be readmitted to ITU/HDU or hospital if any serious complications
develop after the operation. The type of management provided is linked to the type of complication
experienced. The CRF (pp. 52–58) gave all the information on the type of complications and management
received. The unit costs of the procedures came from the NHS Reference Costs 2013/2014,49 whereas all
the medications given as a result of rejection or infection episodes were obtained from the BNF.50
Outpatient care
According to the recommendations of the hospital staff, a lung recipient will need to visit the transplant clinic
every few weeks or months in the first year after the operation. During every outpatient visit, the patient is
seen for half an hour by a consultant physician and a clinic nurse (band 5). The clinic staff also arrange
a FBC, a urea and electrolytes and a liver function test, chest radiography, a pulmonary function test and a
bronchoscopy at 1, 3, 6 and 12 months, routinely or at other times if indicated by the recipients’ condition.
The information about the use of the tests provided was reported on the CRF, while the outpatient
hospital staff gave more information regarding the time spent with the patient (Ms Lyndsey Forrest, NuTH,
September 2014, personal communication). The costs of the tests were calculated using the NuTH costing
tool (obtained from: www.newcastlejro.org.uk) or the NHS Reference Costs 2013/2014,49 whereas the cost of
the staff was measured per hour based on the PSSRU’s Unit Costs of Health and Social Care 2014.51
Immunosuppressive medications are prescribed from immediately after the transplant operation and are
dispensed when a lung recipient is discharged from the hospital in order to reduce the risk of rejection of
the donor lungs. If the patient shows any AEs, rejection or infection episodes, these can be reported either
at an outpatient hospital and GP visit, where a clinical diagnosis/biopsy is performed, or the patient can call
the transplant centre for further advice. Depending on the complications reported, there might be some
new medications or current treatment may be changed. In some cases, a readmission to the ITU/HDU
or the level 1 hospital ward might be required. Information on changes in medications was included on
the CRF for every outpatient visit. The costs of the diagnostic and treatment procedures provided by
the hospital were collected from the NHS Reference Costs 2013/2014,49 whereas the unit costs of the
medications were obtained from the BNF.50 For the GP visits, the costs were calculated per hour based on
the costs of the GP per hour from the PSSRU’s Unit Costs of Health and Social Care 2014.51
Concomitant medications
There were some additional medications given to the lung recipients depending on their health condition
while the study was under way. As it is always difficult to define whether these drugs are required as a
result of the transplant or because of other medical conditions, they were reported and costed separately.
The doses and duration of treatment for these medications were defined by the CRF of the study or the
BNF50 in case the information was missing. The BNF50 was also used in order to provide the unit costs
of the concomitant medications used throughout the study.
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Cost data analysis
As described previously, the cost analysis of the study data was divided in eight different stages (e.g. donor’s
hospital, lung retrieval, etc.) based on the sequence of events of each one of the two transplant procedures
that were examined. Each stage was also subdivided into groups in accordance with the point of time that
the respective resources were used (e.g. initial assessment, tests, staff time, etc.). The unit costs of each
resource were obtained from different sources (e.g. BNF,50 PSSRU51) and they were then multiplied by the
mean usage of each resource as reported on the CRF or from the hospital staff (see Appendices 6 and 7).
The total costs of each resource were added in order to give the total cost of each group of resources, which
were further added in order to provide the total cost of each stage of the transplant process. At the end, the
total cost of the transplant was calculated for each lung recipient, and the average cost per recipient was
estimated. As noted above, in order to cost the two transplant procedures, a bottom-up methodology was
used instead of using the Reference Costs 2013/201449 for lung transplantation. This is because the EVLP
procedure is a new procedure and so not adequately captured in routine data sources. It is also essential to
mention that for the EVLP arm of the study, the resource costs of the first four stages (i.e. donor’s hospital,
lung retrieval, transplant preparation and EVLP procedure) were multiplied by 53/18 in order to consider the
additional costs of the lungs that were retrieved and not transplanted for each EVLP recipient. In other
words, for every 2.9 set of lungs retrieved only one transplant was performed. Therefore, the cost of a
transplant included the cost of the 2.9 retrievals.
The mean and median costs per recipient for each stage of each one of the two transplant procedures are
presented together with the relevant SD and IQR (see Tables 30–37). All costs are rounded to their nearest
pound sterling. Although this is a descriptive analysis with no intention to directly compare the two transplant
procedures in terms of their costs, the mean difference in cost per recipient – with its standard error – is
indicated in each table (the minus symbol in the mean difference in cost per recipient between the two arms
of the study indicates that the mean cost of the respective resources is lower in the standard donor arm than
in the EVLP lung transplant arm). A 95% CI of the mean difference in the cost of the two procedures per
recipient is also estimated based on statistical bootstrapping of the available data, which is used to simulate
a CI and is useful when data are not parametrically distributed and conventional (parametric) statistical
approaches may be inappropriate. Both mean cost differences and 95% CIs are presented for descriptive
purposes, with no intention to directly compare the two transplant procedures. The analysis of the costs of
the study was conducted using the statistical and decision analysis software Stata 13.1.
Quality of life
In order to examine the changes in HRQoL for each patient, QALYs were measured using the participant
responses on the SF-3654 questionnaire administered at the start of the study (baseline), when the
participant was added into the waiting list, 90 days and 12 months after lung transplant. In order to
measure QALYs, participant responses were then mapped onto the SF-6D using a validated algorithm48 to
determine utility values. These utility values had a range from 0 (death) to 1 (perfect health), with the
utility value of lung transplant ranking within these two boundaries. The SF-6D score was taken as 0 from
the date of death to the end of follow-up, the date of death was recorded as part of the data collection.
QALYs were then to be estimated for each study participant using the trapezoid rule. The SF-36 was
preferred in this context, as it was felt to be more sensitive over the range of likely health states
experienced by an individual than alternative preference-based quality-of-life tools.
Health outcome data analysis
The low rate of questionnaire completion at each stage of the study (see Table 22) meant that
assumptions needed to be made in order to follow the procedure described in Cost and use of resources,
and this would limit the robustness and increase the bias of the results. Methods, such as multiple
imputation, would be useful in these cases; however, given the limited overall sample size and the quality
of missing data, it was felt that imputed data might be potentially misleading. For this reason, it was
decided that the mean (SD) and median (IQR) SF-6D scores would be calculated for each data collection
time point (i.e. baseline, 3 and 12 months post transplant) based on the number of observations (n)
available at those time points. The means were then used as point estimates in order to measure the area
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under the curve, using the trapezoid rule, to give the mean QALYs per transplant type. As in the analysis
of costs, no direct comparison between the total numbers of QALYs for each transplant procedure was
conducted. This was, again, because of the limited number of data available. The analysis of the SF-36
data of the study was conducted using Stata 13.1.
Net benefits
Based on the values of total costs and QALYs that were measured from the standard donor and EVLP lung
transplants, the net benefit of each one of the two procedures was proposed to be calculated using the
following equation:
Net benefit = QALY × λ−cost, (1)
where λ is the current NHS cost-effectiveness threshold (£20,000 per QALY).52 However, owing to the
limitations of the quality-of-life data, which were mentioned above, the calculation of the study net
benefits was not performed, as it would not produce any accurate or meaningful results.
Missing data
As already mentioned, the data available for comparative purposes were very limited, and there were
missing data for study participants. Therefore, the nature and extent of missing data were reported, and
no imputation was attempted. The exceptions to this were that if the missing data were related to
standard resources that are normally used during the treatment pathway, it was assumed that these
resources were used and, therefore, costs were added.
Results
Cost analysis
The total average cost per recipient, by each area of resource use for each one of the eight stages of the
study, is listed in Economic evaluation methods (see Tables 30–37).
Table 30 shows that there were no large variations in the costs of the screening and testing of the donor
before the lung retrieval in either of the two types of transplantation. This is because the hospital staff
always perform the same type and number of tests in order to examine the person’s health condition
before requesting a retrieval team to arrive at the hospital. Any small variations observed in the donor’s
initial assessment costs (standard transplant, SD £6; EVLP transplant, SD £18) might be caused by the fact
that some of the tests might not be needed in some cases or had been provided recently to the donor.
In this stage, medication costs constitute a small component of the total costs, as only methylprednisolone
was given as a single dose, whereas the main component of costs for both standard and EVLP lung
transplants are the diagnostic tests. In addition, the large differences in mean costs between the two
transplant procedures (CostSTD = £403; CostEVLP = £1182) are because in the EVLP arm only 18 lungs were
transplanted out of 53 that were retrieved, while in the standard arm all retrieved lungs were transplanted.
The retrieval of the lung involves very similar resources regardless of the subsequent procedure. As can be
seen from Table 31, there is some variability in the costs of the equipment used for a DCD and a DBD
donor. This is because, during a DBD, the heart is still working and, therefore, an ABG test can also be
performed. This also explains the small differences observed in the cost of the tests provided by the
retrieval team (standard, SD £9; EVLP, SD £36). Moreover, some variation is observed in the cost of the
lung perfusion. This might mean that some of the medications that are normally used during the perfusion
of the organ were not needed in practice or that there were several missing patient data items that caused
these differences in costs. In this stage, the main components of costs are the staff time and the team’s
travelling costs, which would be expected given the potential distances that the scout and retrieval teams
have to travel and the time needed to complete the organ retrieval. As mentioned before, the large
increase in the costs of the EVLP compared with the standard transplant was mainly caused by the
different retrieval-to-transplant ratio of the two transplant procedures.
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Table 32 describes the costs of the preparation of the patient before lung transplant. As with the previous two
stages of the analysis, there is some variation in the use of the screening tests performed, which might mean
either that the test was performed but these data were missing, or that or no test was required during the
preparation of the patient. The table also indicates that the most costly resource used during this stage of the
transplant process was the time spent in the hospital ward before surgery (£265 per hour). Obviously, the
retrieval-to-transplant EVLP ratio (53/18) results in the higher costs for the EVLP arm of the study. Furthermore,
as mentioned above in the description of the lung transplant procedure, in this study it was difficult to obtain
detailed information about the resources used for the patient transportation to the transplant site. As a result,
these costs are missing from Table 31. Given the difference in retrieval-to-transplant ratios between the two
arms of the study and the nature of these costs, it might be expected that the costs of travelling would increase
the cost of the patient preparation and, subsequently, the cost of the total transplant procedure.
Table 33 describes the costs for the EVLP procedure. Obviously, because the EVLP procedure is performed
only during EVLP lung transplant, no costs are presented for the standard arm of the study. This process
includes the assessment and reconditioning of the lung in order to make it suitable for transplant, and it is
a stage that occurs between the transplant preparation and the transplant surgery. As expected, the most
costly resources used in this stage are the consumables needed for the procedure. These include the lung
set in which the lung is reconditioned (Vivoline disposable lung set, £6963). The medications used for the
reconditioning of the organ add to the costs of the procedure, as do the cost of staff time and theatre
time, because the EVLP procedure lasts for approximately 6 hours. As described in the stages above,
the retrieval-to-transplant ratio causes an additional increase in the costs of the EVLP procedure by 53/18.
The cost of the single lung transplant procedure or a double lung transplant procedure does not vary
according to whether it is a standard or EVLP lung transplantation. In this study, only 26 transplants were
reported as single, of which two were in the EVLP arm. The rest of the transplants were either reported
as double or assumed to be double in this analysis given that more double transplants were performed.
A double lung transplant increases the time needed for the surgery by approximately 3 hours, which leads
to a significant increase in the mean transplant costs (single transplant cost £4177; double transplant cost
£6934), because of increased theatre usage and staff time costs. The variability within the total costs of
the transplant (standard, SD £931; EVLP, SD £892) is mainly caused by the difference in the proportion of
single or double lung transplants performed in the standard and EVLP arms of the study. As indicated in
Table 34, the total cost of the equipment/consumables used during the operation is missing. This is
because every surgeon and clinic may differ in how the surgery is performed and, hence, may use different
equipment. In this study it was difficult to collect more details about the resources used in order to retrieve
their respective costs.
The post-operative and outpatient care of the patients shows the largest variability in total costs (see
Tables 35 and 36) because it is dictated by the nature and severity of any complications and AEs that
might occur, which vary markedly between patients. Given the nature of events that might occur and the
cost of their management, it would be expected that these costs would be highly skewed, and the mean
cost, especially for the EVLP arm, would be greatly affected by the very high costs incurred by a small
number of patients. As indicated in Table 35, the highest costs in this stage are the ward use (standard
arm, £20,064; EVLP arm, £21,276) and staff time costs (standard arm, £4828; EVLP arm, £5265). This is
because the length of hospital stay (especially in the ITU/HDU) varies between different patients and,
consequently, different amounts of staff time are required. Table 35 also shows a large variation in the
costs of the equipment used. In this case, the variation is mainly caused by the use of the ECMO machine
(ECMO cost, £34,000). In addition, variation is also observed in the costs caused by complications and
infection episodes. This is to be expected given the fact that each recipient responds differently to their
transplanted organ, and thus some patients become more prone to infections than others. (It should be
mentioned that the infection episodes and airway complication costs presented in Table 35 include the
costs from infections that occur either straight after the transplant or during the subsequent outpatient
care of the patient.)
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The data in Table 36 demonstrate that the outpatient care of a lung recipient varies markedly between
participants. Some patients might require more outpatient or GP visits, whereas others might need several
unplanned hospital admissions and longer duration of treatment with immunosuppressive medications. The
last two resources constitute almost the 70% of the outpatient care costs. As expected, the unplanned hospital
admissions of the recipients show a large variation, as their occurrence varies between different patients.
Concomitant medications can be considered as an additional part of the analysis of this study. A recipient
might need an additional treatment or a change in the current treatment as a result of complications.
The duration of treatment is also variable and depends on the condition of the patient. Therefore, the
medications given vary between patients, and this explains why such a large variation in the total cost of
concomitant medications exists (standard, SD £4505; EVLP, SD £3614) in Table 37.
Table 38 presents the total average cost per recipient for the standard donor and the EVLP lung
transplantation. These costs were calculated by adding the total costs of each stage of the transplant
procedure for each patient and calculating the average cost for each lung recipient. As can be seen from
Table 38, the mean and median cost of EVLP per recipient is substantially greater than for standard lung
transplant. This is partially because of the different retrieval-to-transplant ratio between the two lung
transplants, which leads to higher costs in the early stages of the analysis and, partially, as a result of the
actual cost of the EVLP procedure (£14,479 per lung assessed). Also presented in Table 38 is the mean
difference and bootstrapped 95% CI. The CI suggests that EVLP recipients are, on average, at least
£57,910 more costly and may be as much as £101,036. These data are only suggestive given the very
small number of participants in the EVLP arm (n = 18).
In Figure 21, the costs of each stage of both standard and EVLP lung transplant procedures are presented
as a bar chart. This reveals the significant difference in costs for certain parts of the procedure pathways
between standard and EVLP transplants.
Analysis of the quality of life
As indicated in Table 39, there were only a small number of lung recipients who contributed SF-6D data
(22/202) at all expected time points. These patients were those who completed the SF-36 questionnaire at
all three time points, or were known to have died by a given time point, in which case SF-6D scores for
that and any subsequent time points were given as zero. As a result, Table 40 presents the mean and
median SF-6D utility scores for each stage that a questionnaire was completed or a patient was reported as
being dead (i.e. at baseline, 3 and 12 months post transplant). It also presents the number of observations
(n) based on which the means and the medians were calculated at each time point. At the bottom of the
table, the total mean QALYs of each transplant type are shown, which were estimated by measuring the
area under the curve created from the mean utility scores of each one of the three time points.
Figure 22 presents the differences between the mean SF-6D scores between the two lung transplant
procedures. As was expected from the numbers provided in Table 40, the differences are negligible.
However, because these are the mean SF-6D scores reported, a comparison between the numbers of
QALYs gained from each one of the two procedures would be meaningless.
Predicting NHS expenditure costs for UK patients receiving a lung
transplant: a regression-based analysis
Rationale
The aim of this part of the economic analysis was to identify the key determinants of costs to the NHS of a
lung transplant. This aim was met by using information and data collected from the DEVELOP-UK study
in a regression model, where the dependent variable was the NHS costs for a lung transplant and the
independent (explanatory) variables were potential determinants of these costs. The purpose of the analysis
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
75
TA
B
LE
36
To
ta
l
av
er
ag
e
co
st
p
er
re
ci
p
ie
n
t
b
y
ea
ch
ar
ea
o
f
re
so
u
rc
e
u
se
:
o
u
tp
at
ie
n
t
ca
re
to
ta
la
ve
ra
g
e
co
st
p
er
re
ci
p
ie
n
t
R
es
o
u
rc
e
u
se
Pa
ti
en
t
d
et
ai
ls
St
u
d
y
g
ro
u
p
M
ea
n
(S
E)
d
if
fe
re
n
ce
in
co
st
p
er
re
ci
p
ie
n
t
95
%
C
Ib
as
ed
o
n
b
o
o
ts
tr
ap
p
in
g
St
an
d
ar
d
(n
=
18
4)
EV
LP
(n
=
18
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
To
ta
lo
ut
pa
tie
nt
re
vi
ew
co
st
s
Re
ci
pi
en
t
£1
42
0
(£
69
9)
£1
51
5
(£
89
5–
21
70
)
£9
94
(£
84
2)
£7
66
(£
20
9–
18
55
)
£4
26
(£
17
6)
To
ta
ls
ta
ff
tim
e
co
st
s
Re
ci
pi
en
t
£1
30
(£
50
)
£1
59
(£
12
0–
15
9)
£1
00
(£
70
)
£1
39
(£
40
–
15
9)
£3
1
(£
13
)
To
ta
lr
ej
ec
tio
n
ep
is
od
e
co
st
s
Re
ci
pi
en
t
£7
50
(£
34
43
)
£0
(0
–
65
3)
£2
90
(£
46
3)
£0
(£
0–
37
9)
£4
60
(£
81
4)
To
ta
lG
P
vi
si
t
co
st
s
Re
ci
pi
en
t
£9
(£
22
)
£0
(£
0–
0)
£1
8
(£
29
)
£0
(£
0–
34
)
–
£9
(£
6)
To
ta
lu
np
la
nn
ed
ho
sp
ita
l
ad
m
is
si
on
co
st
s
Re
ci
pi
en
t
£2
74
8
(£
10
,8
64
)
£0
(£
0–
55
9)
£6
89
(£
23
95
)
£0
(£
0–
39
2)
£2
05
9
(£
25
72
)
To
ta
li
m
m
un
os
up
pr
es
si
ve
m
ed
ic
at
io
n
co
st
s
Re
ci
pi
en
t
£2
92
3
(£
10
49
)
£3
18
7
(£
26
80
–
35
22
)
£2
47
5
(£
15
22
)
£3
22
2
(£
10
03
–
34
75
)
£4
47
(£
27
1)
To
ta
lo
ut
pa
tie
nt
ca
re
co
st
s
Re
ci
pi
en
t
£7
98
1
(£
12
,2
63
)
£5
74
6
(£
45
52
–
70
25
)
£4
56
7
(£
39
31
)
£4
96
9
(£
14
23
–
58
05
)
£3
41
4
(£
29
11
)
–
£2
32
6
to
£9
15
3
SE
,
st
an
da
rd
er
ro
r.
TA
B
LE
37
To
ta
l
av
er
ag
e
co
st
p
er
re
ci
p
ie
n
t
b
y
ea
ch
ar
ea
o
f
re
so
u
rc
e
u
se
:
co
n
co
m
it
an
t
m
ed
ic
at
io
n
to
ta
la
ve
ra
g
e
co
st
p
er
re
ci
p
ie
n
t
R
es
o
u
rc
e
u
se
Pa
ti
en
t
d
et
ai
ls
St
u
d
y
g
ro
u
p
M
ea
n
(S
E)
d
if
fe
re
n
ce
in
co
st
p
er
re
ci
p
ie
n
t
95
%
C
Ib
as
ed
o
n
b
o
o
ts
tr
ap
p
in
g
St
an
d
ar
d
(n
=
18
4)
EV
LP
(n
=
18
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
To
ta
lc
on
co
m
ita
nt
m
ed
ic
at
io
n
co
st
s
Re
ci
pi
en
t
£1
42
4
(£
45
05
)
£0
(£
0–
32
8)
£1
17
2
(£
36
14
)
£0
(£
0–
0)
£2
52
(£
10
96
)
–
£1
90
8
to
£2
41
2
SE
,
st
an
da
rd
er
ro
r.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
TA
B
LE
38
To
ta
l
av
er
ag
e
co
st
p
er
re
ci
p
ie
n
t
p
er
p
ro
ce
d
u
re
R
es
o
u
rc
e
u
se
Pa
ti
en
t
d
et
ai
ls
St
u
d
y
g
ro
u
p
M
ea
n
(S
E)
d
if
fe
re
n
ce
in
co
st
p
er
re
ci
p
ie
n
t
95
%
C
Ib
as
ed
o
n
b
o
o
ts
tr
ap
p
in
g
St
an
d
ar
d
(n
=
18
4)
EV
LP
(n
=
18
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
M
ea
n
(S
D
)
M
ed
ia
n
(I
Q
R
)
To
ta
ld
on
or
’s
ho
sp
ita
lc
os
ts
D
on
or
£4
03
(£
12
)
£4
08
(£
39
5–
41
2)
£1
18
2
(£
35
)
£1
18
2
(£
11
63
–
12
14
)
–
£7
79
(£
4)
–
£7
86
to
–
£7
71
To
ta
ll
un
g
re
tr
ie
va
lc
os
ts
D
on
or
£8
65
1
(£
17
0)
£8
72
9
(£
86
95
–
87
29
)
£2
5,
39
8
(£
52
4)
£2
5,
68
8
(£
24
,9
57
–
25
,7
00
)
–
£1
6,
74
7
(£
55
)
–
£1
6,
85
6
to
–
£1
6,
63
9
To
ta
lt
ra
ns
pl
an
t
pr
ep
ar
at
io
n
co
st
s
Re
ci
pi
en
t
£4
66
(£
8)
£4
67
(£
46
7–
47
1)
£1
36
5
(£
28
)
£1
37
5
(£
13
75
–
13
75
)
–
£8
99
(£
3)
–
£9
05
to
–
£8
94
To
ta
lE
V
LP
pr
oc
ed
ur
e
co
st
s
EV
LP
re
ci
pi
en
t
–
–
£4
2,
63
3
(£
21
72
)
£4
2,
67
5
(£
41
,1
67
–
43
,4
14
)
–
–
To
ta
ll
un
g
tr
an
sp
la
nt
co
st
s
Re
ci
pi
en
t
£6
57
4
(£
93
1)
£6
93
4
(£
69
34
–
69
34
)
£6
62
7
(£
89
2)
£6
93
4
(£
69
34
–
69
34
)
–
£5
3
(£
22
9)
–
£5
05
to
£3
99
To
ta
lp
os
t-
op
er
at
iv
e
ca
re
co
st
s
Re
ci
pi
en
t
£3
4,
10
9
(£
39
,5
61
)
£2
0,
11
2
(£
11
,6
39
–
42
,3
40
)
£5
6,
13
6
(£
57
,3
45
)
£2
1,
93
1
(£
12
,7
13
–
86
,4
64
)
–
£2
2,
02
7
(£
10
,2
17
)
–
£4
2,
17
4
to
–
£1
87
9
To
ta
lo
ut
pa
tie
nt
ca
re
co
st
s
Re
ci
pi
en
t
£7
98
1
(£
12
,2
63
)
£5
74
6
(£
45
52
–
70
25
)
£4
56
7
(£
39
31
)
£4
96
9
(£
14
23
–
58
05
)
£3
41
4
(£
29
11
)
–
£2
32
6
to
£9
15
3
To
ta
lc
on
co
m
ita
nt
m
ed
ic
at
io
n
co
st
s
Re
ci
pi
en
t
£1
42
4
(£
45
05
)
£0
(£
0–
32
8)
£1
17
2
(£
36
14
)
£0
(£
0–
0)
£2
52
(£
10
96
)
–
£1
90
8
to
£2
41
2
To
ta
lc
os
t
pe
r
pr
oc
ed
ur
e
–
£5
9,
60
8
(£
42
,6
64
)
£4
3,
63
0
(£
33
,8
33
–
68
,7
48
)
£1
39
,0
81
(£
58
,9
16
)
£1
08
,2
55
(£
93
,4
92
–
17
1,
76
8)
–
£7
9,
47
3
(£
10
,9
35
)
–
£1
01
,0
36
to
–
£5
7,
91
0
SE
,
st
an
da
rd
er
ro
r.
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
020
40
60
80
100
120
140
160
Standard EVLP
C
o
st
 (
£0
00
)
Lung transplant procedure
Donor's hospital
Lung retrieval
Transplant preparation
EVLP procedure
Lung transplant
Post operative
Outpatient
Concomitant medication
FIGURE 21 Total average cost per recipient per procedure.
TABLE 39 Percentage of SF-6D data available for each arm and stage of the study
Study
group
Time point
Baseline
only,
% (n)
3 months
only,
% (n)
12 months
only
Baseline and
3 months,
% (n)
Baseline and
12 months,
% (n)
3 and
12 months,
% (n)
Baseline, 3 and
12 months,
% (n)
Standard
(N = 184)
36.41 (67) 33.15 (61) 41.30 (76) 17.94 (33) 18.48 (34) 23.37 (43) 11.41 (21)
EVLP
(N = 18)
44.44 (8) 55.56 (10) 55.56 (10) 22.22 (4) 16.67 (3) 38.89 (7) 5.56 (1)
Total
(N = 202)
37.13 (75) 35.15 (71) 42.57 (86) 18.32 (37) 18.32 (37) 24.75 (50) 10.89 (22)
TABLE 40 Health-related quality of life (QALYs): SF-6D scores
Questionnaires
Study group
Standard (n= 184) EVLP (n= 18)
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
At baseline 0.5510 (0.0846) 0.5450
(0.5010–0.5970)
0.5880 (0.0382) 0.6000
(0.5590–0.6125)
Number of observations 67 8
3 months post-transplant 0.5884 (0.2766) 0.6660
(0.5540–0.7570)
0.5551 (0.3942) 0.7345
(0.0000–0.7990)
Number of observations 61 10
12 months post-transplant 0.4527 (0.3709) 0.6125
(0.0000–0.7550)
0.4689 (0.4267) 0.6010
(0.0000–0.8410)
Number of observations 76 10
QALYs (from SF-6D mean scores)a 0.5328 0.5269
a The QALYs presented in this table were calculated from the area under the curve created by the mean SF-6D scores of
each time point by using the trapezoid rule.
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was to help policy-makers understand what the main determinants of costs are, and also to provide a
resource for future modelling where lung transplant is a component of the care pathway modelled.
Methods
Planning the analysis
The first step was to examine the distribution of total transplant costs estimated in order to help decide
which type of statistical model would best suit the observed distribution of the data. For example, if the
costs were normally distributed, then a linear regression model (ordinary least squares) could be used.
On the other hand, if the costs were highly skewed, as was anticipated, a log-linear or a log-gamma
generalised linear model would be needed, with the choice between the two dependent on the explanatory
variables that would be selected for the model. Based on the observed distribution, the log-transformation
of the total NHS costs was considered to be the most appropriate approach to handle the impact of any
outlier observations on the predictions of the total expenditure.
The next step in this analysis was to identify all the explanatory variables that could potentially be included
in a regression model and define a cogent reason of their selection. From this long list of variables, the
most useful variables (i.e. the ones that were thought to make the most significant contribution to the
total NHS costs) were selected for the model, while the rest were removed as not being adequate to
explain the magnitude or direction of costs. It was expected that there would be some variables that are
strongly correlated with other variables selected for the model. These variables were omitted if they
provided little additional explanatory power.
After the selection of the most important likely parameters, a preliminary analysis of the relationship
between each variable and the total transplant costs was conducted, and this was further illustrated by
developing the corresponding scatterplots for each regressor. Once the relationship was understood,
the selected variables were introduced in the model in the most appropriate form using the step-wise
regression (forward selection) technique. More precisely, the most commonly used variables in this type of
economic regression analysis (e.g. demographic characteristics, such as age and sex) were used in order to
build a basic econometric model. Once this was done, a new potential variable was added each time in
order to check if it would be statistically significant and provide a more accurate prediction of costs. In
addition, this model contained a dummy variable that took values 0 or 1 depending on whether or not an
EVLP procedure was performed.
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Possible explanatory variables and model structure
Table 41 presents the explanatory variables that were tested in order to build the regression model, as well
as the reason for their selection. These variables were based on initial assumptions about the factors that
might have an impact on the total NHS cost of lung transplant and were divided into three main categories
based on the information that they provided: (1) recipient characteristics, (2) donor characteristics and
(3) resource use.
According to the assumptions made above, the cost model was expected to have the following form at
the beginning of the analysis, but its precise form would depend on which model fitted the data and
provided robust predictions of costs (i.e. would be calibrated with the observed data):
COSTS = β0 + β1AGE + β2SEX + β3TIME + β4IND + β5COM + β6SF-6D + β7COD + β8TEST
+ β9DIST + β10PROC + β11LUN + u,
(2)
where COSTS is NHS expenditure costs; AGE is the recipient age; SEX is the recipient sex; TIME is the
potential recipient’s time on the waiting list; IND is the transplant indication; COM is the patient’s
comorbidities and medications while on the waiting list; SF-6D is the SF-6D score of the patient while on
the waiting list based on their response to the SF-36 questionnaire; COD is the donor’s cause of death;
TEST is the donor–patient tissue compatibility test; DIST is the distance between the donor’s hospital
and the transplant site; PROC is the type of transplant (standard or EVLP); and LUN is the number of
lungs transplanted.
TABLE 41 Possible explanatory variables for the regression model
Variable number Explanatory variable Reason of selection
Recipient characteristics
1 Age (> 18 years) The age of the recipient can affect the health-care services
needed. It is common that older people are more susceptible
to diseases, especially chronic diseases, and might not
respond well to several treatments. Apart from the fact that
there might be some compatibility issues, which might be
related to age, age might lead easier to GVHD. Age is always
included as a variable in this type of analysis
2 Sex There might be differences in the resources needed
depending on the sex of the recipient. This is because there
are several biological differences between men and women
that normally lead to different health outcomes. Sex is always
included as a variable in this type of analysis
3 Time on the waiting list (i.e. time
between the date added on the
waiting list and the date of
transplant)
The time from diagnosis and inclusion in the waiting list until
lung transplantation might affect the condition of the
potential recipient. Obviously here, the time that is needed to
find a perfect organ match for the recipient plays the most
important role. However, normally the longer the patient
stays on the waiting list, the worse their condition will get
and, therefore, they might be more susceptible to diseases
after the operation
4 Transplant indication (reason of
transplant)
The reason why a lung transplant is needed is important,
as this might affect the total condition of the patient as
well as the body response of the recipient to the transplant.
If possible, different conditions should be grouped in wider
categories in order to have more robust results at the end
5 Number of other diseases
(comorbidities) and medications
while on the waiting list
Other diseases might have an impact on the overall health of
the potential recipient, which might mean additional costs for
the NHS. If possible, these conditions should be grouped in
bigger categories (e.g. cardiovascular diseases) in order to
generalise the values of the variable
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
TABLE 41 Possible explanatory variables for the regression model (continued )
Variable number Explanatory variable Reason of selection
6 SF-6D baseline scores (i.e. on entry
on to the waiting list)
These scores can provide information on the HRQoL of the
potential recipient while they are on the waiting list. This
information could possibly capture the condition of the
patient while on the waiting list, which might affect the need
for additional health-care services post transplant. The only
problem with the SF-6D scores in this study was that there
was only a limited number of SF-36 questionnaires completed
(73/202 at baseline), which might affect the accuracy of the
results. In other words, the result of the analysis would be
restricted to a smaller number of observations that could lead
to a systematic error in the final results
Donor characteristics
7 Cause of death or donor type
(i.e. after brain or circulatory death)
The cause of the donor’s death could affect the type of the
transplant and may lead to a higher possibility for GVHD.
A case might be that a transplant after circulatory death
might be more likely to need reconditioning before being
used in a surgery (i.e. EVLP). The donor’s previous condition
might also affect the quality of the organ donated. However,
this might be difficult to capture from the available data set
8 Donor–patient compatibility test Instead of including all the different characteristics of the
donor (e.g. age, sex, tissue characteristics), which might not
have a meaningful relationship to the total transplant costs,
the data from the donor–patient compatibility test (perhaps
tissue typing test) could be used. In other words, there might
be a scale and score with how well the tissues match that
may predict any AEs or GVHD
Resource use
9 Distance between the donor’s
hospital and the transplant site
The distance between the donor’s hospital and the transplant
site can have an impact on the cost of the retrieval/scout
team. In other words, a longer distance means a higher
travelling cost for the retrieval team and, consequently, higher
costs for the retrieval of the lung
10 Type of transplant (i.e. standard vs.
EVLP)
One of the main differences between standard and EVLP lung
transplant is the occurrence of the EVLP procedure before the
operation. This includes several costs, such as the cost of the
disposable lung set, the Steen Solution and the operating
theatre usage, which increase the cost of the transplant by
almost £43,000, on average. In addition, the fact that only
18 EVLP transplants were performed compared with 53 lungs
that were retrieved means that there is an extra cost
associated with the reconditioning of the lung in different
stages of the lung transplant procedure (i.e. donor’s hospital,
lung retrieval, transplant preparation). The type of the
transplant might also affect the post-operative and outpatient
care needed. It would, therefore, be reasonable to introduce
the type of the transplant in the form of a dummy variable
with value 0 if standard is performed and 1 if EVLP is followed
11 Number of lungs transplanted
(i.e. single or double lung surgery)
The number of lungs that are transplanted is associated with
different costs during the operation. This is because the time
needed for the surgery changes and as a result, the staff time
and usage time of the operating theatre changes. The number
of lungs needed might also affect the post-operative and
outpatient care. This variable could also take the form of a
dummy variable depending on whether a single or a double
lung transplant is performed
GVHD, graft-versus-host disease.
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This regression was planned to generate a β0 value and beta values for all of the independent variables in
the equation. β0 would be the intersection of the regression line with the y-axis (intercept). This value was
not expected to have a meaningful interpretation, especially if this was a negative value, because β0 would
be anticipated to represent the minimum or average cost for the NHS. The rest of the beta values would
describe the direction and magnitude of the relationship between each variable and the NHS cost of
transplant. A p-value of < 0.05 was taken as evidence of a real difference between the expected and
actual impact of each variable on the total costs.
The analysis of costs was conducted using the statistical software Stata 13.1.
Results
Base-case analysis
Figure 23 shows the distribution of costs based on the DEVELOP-UK study data. As expected, the costs
were highly skewed (i.e. several patients needed additional or more expensive health-care resources),
which meant that a simple linear model would not give robust results. As a consequence, the total cost
variable was log-transformed. This transformation had the effect of diminishing the impact of the outlier
observations on the total lung transplant costs per recipient.
Table 42 presents the variables that were finally selected for the model as well as their marginal effect on
arithmetic costs. As shown in Table 42, the regression model was a log-linear model. In other words, there
was a linear (additive) relationship between each one of the explanatory variables and the log-form of the
total lung transplant costs, which is reasonable when considering that the explanatory variables were
mainly qualitative (e.g. age, sex) or categorical (e.g. type of transplant procedure, number of lungs
transplanted). Obviously, Table 42 presents the exponential results of this regression model (i.e. the results
of the analysis in a normal arithmetic scale).
As indicated in Table 42, there were nine variables that were included in the model instead of the 11 that
were initially considered. The reasons for this reduction are listed below. First, the condition of the patient
due to comorbidities or medications taken was found to be captured by the SF-6D score of the patient
while on the waiting list. Second, the data for the donor–patient compatibility test were difficult to identify,
and were possibly not recorded by the transplant sites. Third, the distance between the donor’s hospital and
the transplant site was difficult to calculate based on the available data, and the total costs calculated in the
descriptive analysis of the study were based on estimates given by the NHS staff. Finally, it was decided that
rather than using the SF-6D, the SF-36 should be used with the scores reported as the two main SF-36
summary components (i.e. MCS and PCS), where MCS and PCS are reported on a 0–100 scale, with higher
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FIGURE 23 Distribution of total transplant costs based on the DEVELOP-UK study data.
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scores indicating better health, in order to have a more accurate understanding of the factors that affect
the patient.
In Table 42, four variables are shown to be significant (p < 0.05) when predicting the total cost of a lung
transplant for the NHS. These are the two subcomponents of the SF-36 scores (p = 0.018 and p = 0.035
for the MCS and the PCS scores, respectively), the type of the transplant procedure (p < 0.001) and the
number of lungs transplanted (p = 0.003). The final two parameters were expected to be statistically
significant because an EVLP transplant leads to higher costs because of the addition of the EVLP procedure
before the operation (βPROC = 58,097, which means that moving from a standard to an EVLP transplant will
cost at least £58,097 more to the NHS), whereas if a double lung surgery is conducted, then more time is
needed for the operation, resulting in higher staff and theatre costs. As far as the two subcomponents of
the SF-36 scores are concerned, both were significant and both had a coefficient of similar magnitude
(βMCS = 656 and βPCS = 784). This suggests that, in addition to the physical health driving lung transplant
cost, the mental health of the recipient also increases the cost. Nevertheless, these effects were relatively
small when compared with the total cost of transplant.
TABLE 42 Explanatory variables used in the regression and their impact on total lung transplant costs
Explanatory variables dy/dx (£)a SE z-score p> zb 95% CI
Recipient age (years) 246 274 0.900 0.368 –290 to 782
Recipient sex (male as reference sex)
Female 4214 5945 0.710 0.478 –7437 to 15,866
Time on the waiting list (days) –1 9 –0.100 0.924 –19 to 17
Transplant indication (CF as reference indication)
Non-CF bronchiectasis 36,051 24,816 1.450 0.146 –12,587 to 84,690
Interstitial lung disease 11,415 9447 1.210 0.227 –7101 to 29,931
Chronic obstructive pulmonary disease 559 7459 0.070 0.940 –14,061 to 15,179
Emphysema –9506 7777 –1.220 0.222 –24,748 to 5736
Obliterative bronchiolitis –11,629 9578 –1.210 0.225 –30,402 to 7144
Pulmonary hypertension 19,404 6380 3.040 0.002 6899 to 31,910
Other and missing indication 24,850 15,737 1.580 0.114 –5995 to 55,695
SF-36 score (MCS) while on the waiting list
(score units, i.e. 0–100)
656 277 2.370 0.018 112 to 1199
SF-36 score (PCS) while on the waiting list
(score units, i.e. 0–100)
784 372 2.110 0.035 56 to 1513
Donor type (DBD as reference type)
DCD 5078 7639 0.660 0.506 –9894 to 20,050
Transplant procedure (standard transplant as
reference procedure)
EVLP 58,097 13,041 4.450 0.000 32,537 to 83,658
Number of lungs transplanted 30,401 10,205 2.980 0.003 10,400 to 50,403
SE, standard error.
a dy/dx is the marginal effect of the independent variable.
b When p> z, the probability is higher than the z-score (p-value).
Note
Values in bold represent p< 0.05 and are, therefore, statistically significant.
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One interesting issue when looking at the impact of the SF-36 scores on the total transplant costs is the
positive symbol of their coefficients. That is, the healthier a person is, the higher the costs are. There
are a number of potential explanations for this. First, it could reflect the limited numbers of the SF-36
questionnaire completed at baseline (73/202 participants). This may mean that estimates derived were not
very robust and were biased due to missing data, especially if those who did not complete the SF-36 were
less well at baseline. Second, and related to the first reason, recipients that had lower scores were more
likely to die or had a shorter time to death between the 12-month follow-up of the study than patients
with higher scores, which therefore means they had less time to accrue costs. It is also interesting to
mention that when the two scores were excluded from the regression model, the impact of EVLP on the
total costs was higher (see Sensitivity Analysis).
Regarding the reason for the transplant, Table 42 indicates that pulmonary hypertension is a predictor of
cost (p = 0.002), whereas the rest of the indications are not. In order to examine further the significance of
the indication variable and compare the different indications, an F-test was performed. The F-test is
normally used when comparing two different populations of different sizes in order to examine if the
variance between the two groups is bigger than the variance within each group. If the groups are
significantly different, the variation in group will be bigger than the variation because of differences
among individuals in each group. This test proved that the reason of transplant is a significant predictor for
the model as a total (p = 0.006), so it would be wrong to remove it from the model, as this would lead to
inaccurate coefficients for the rest of the variables of the model. Based on this test, it was also understood
that there is a big difference in costs when the reason for transplant is pulmonary hypertension instead of
CF, which was the reference indication during the analysis.
The demographic characteristics of the potential recipient (i.e. age and sex) seem to have a limited effect,
that is, almost entirely captured by the two SF-36 subcomponent scores. This was expected since the
condition of the patient, as well as the tissue compatibility between the donor and the recipient, would be
the main reasons for any complications or AEs. However, age and sex should always be in this type of
regression model to represent the characteristics of the patient. The same argument can be also used
when examining the low impact of the donor type on the total costs. Perhaps the donor’s cause of death
does not influence the cost of the transplant directly, and it is the tissue compatibility that plays the most
important role here. Additionally, the time on the waiting list has the smallest impact (βTIME = –1) of all
variables. In other words, for every additional day on the waiting list, transplant costs reduce by £1.
Again, the longer the time on the waiting list the worse the condition of the patient gets and potentially
the less likely they will survive to accrue costs. However, it is worth noting that the impact is very small
and, although statistically significant, may not be of any practical significance.
Finally, based on the analysis of the DEVELOP-UK study data, it was calculated that the constant (β0) of the
regression model is equal to 3898. In this regression, this number is the minimum or average cost for a
lung transplant for a reference participant who is male, was referred for transplant as a result of CF,
received a standard single lung transplant, where the organ retrieved was from DBD. The intercept was
also calculated by controlling for age, time on the waiting list and SF-36 subcomponent summary scores.
Sensitivity analysis
Given the limited number of responses to the SF-36 questionnaire, a sensitivity analysis was performed
where both subscores were omitted from the model and all the observations were tested. This approach
would reduce the fit of the statistical model, but would allow more of the sample available for the analysis.
The new model contained seven variables, but did not fit the data as well as the base-case analysis (R2 was
equal to 0.338 compared with 0.539 before). This suggests that the loss of model fit when using the
larger data set makes the result unreliable. The transplant procedure, as well as the number of lungs that
were transplanted, remained significant (p < 0.001 and p = 0.004, respectively), as was the reason for the
transplant (probability > F = 0.002), but this time other and/or missing indications were the predictors of
cost instead of the pulmonary hypertension that was in the base-case analysis.
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Conclusion
In conclusion, the base-case regression model described above was the best possible model that could fit
the data that were available from the DEVELOP-UK study. Based on this model, there were four variables
that were significant when predicting the cost of a lung transplant for the NHS: the two components of
the SF-36 scores (i.e. mental and physical component summary), the type of the transplant procedure and
the number of lungs that are transplanted. Although this model can be used in further research in this
area, it should be considered that it was constrained by the limited number of data from the study. Of
course, the fact that this model was based on only 73 observations (owing to the small number of SF-36
questionnaires completed) further limits its robustness and estimation power. However, given the results of
the sensitivity analysis that was performed where the two SF-36 summary components were omitted and
where all the observations were tested, it was confirmed that the type of transplant and the number of
lungs remain significant when trying to predict the total transplant costs for the NHS. Furthermore, the fact
that it was not possible to collect the data from the donor–patient tissue compatibility test and the
distance between the donor’s hospital and the transplant site is an issue that should be considered when
conducting a future analysis. It is anticipated that these two parameters would have an impact on the total
lung transplant costs for the NHS.
Exploratory model-based economic evaluation
Aim
The aim of this element of the analysis was to conduct an exploratory model-based economic evaluation of
a UK adult lung transplant service that includes both EVLP and standard lung transplant compared with a
service that only includes standard lung transplant. As was noted before, the data for this model came
from the descriptive analysis described above and the available literature on lung transplantation.
Objectives
The objectives of this work were to:
l construct a decision-analytic model
l populate the model, as much as possible, with the DEVELOP-UK study data
l estimate the incremental costs per additional life-year gained (cost-effectiveness analysis) and per QALY
gained (cost–utility analysis) comparing a lung transplant service including both EVLP and standard lung
transplants with a service including only standard lung transplants.
Model structure
A decision-analytic model (Figure 24) was built in Microsoft Excel following the International Society for
Pharmacoeconomics and Outcomes Research (ISPOR) guidelines on conceptualising models.55 The model
represents the UK adult lung transplant service care pathway; beginning on the waiting list (state A) and
progressing to being removed from the waiting list (state G); dying (state F); or receiving a standard (state B),
or EVLP lung transplant (state D). From the lung transplant state, recipients progress either to death or,
if they survive 1 year post lung transplant, to a post-lung transplant state; either states C or E depending on
the type of lung transplant received.
The post-lung transplant states were split into first year post lung transplant (including the cost of the lung
transplant), and from year 2 onwards. This method was chosen as existing evidence suggested that the
first year post lung transplant is key and should be modelled separately.56,57
An area-under-the-curve Markov-type model was developed for post-lung transplant progression, where
the length of time a lung transplant recipient survived from year 2 post lung transplant onwards was
determined from a survival curve and allocated (as a fixed number of years) to each recipient in states C
and E. To calculate the area under the curve, UK Cardiothoracic Transplant Audit survival data for 1,
3, 5 and 10 years post lung transplant were used and information on maximum life expectancy was
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sought.58 More precisely, the ISHLT data for adults receiving a lung transplant between January 1990
and June 2012 report that survival of 19 years post lung transplant is 12%.
Half-cycle corrections were used for life-years gained in line with ISPOR guidelines,59 which are useful when
the timing of the transition within the cycle is not known. On the other hand, no adjustment was made
for QALY and cost calculations and, therefore, the QALY incremental cost-effectiveness ratio (ICER) would
not be affected by the adjustment. A cohort of 1000 patients start in the waiting list state in the same
year, and their progression was modelled over a lifetime horizon. The cycle length was 1 year, reflecting
waiting list transitions and survival data.
Target population/location
The target population was adults on the UK lung transplant waiting list.
Study perspective
The perspective was the UK NHS using direct health-care costs only.
Comparators
The comparators are a UK adult lung transplant service that includes the use of both EVLP and standard
lung transplants as the intervention (EVLP service) and a UK adult lung transplant service that includes only
standard lung transplant as the control (standard service).
Time horizon
The time horizon used was lifetime, enabling consideration of costs and effects over the cohort’s lifetime.
Discount rate
The base-case analysis used a 3.5% discount rate for both costs and effects following NICE guidelines.52,60
Outcomes
The principal outcome measure used was the QALY. Life-years gained was also measured, for the
cost-effectiveness analysis, along with the number of lung transplants carried out.
Measurement of effectiveness/transitions
Lung transplant activity witnessed at the Newcastle centre during the study was used to inform the
transition from waiting list to lung transplant in order to replicate within trial transitions. The Newcastle
Removed from
waiting list
(state G)
Death
(state F)
Waiting list
(state A)
Year 1 EVLP 
lung transplant
(state D)
EVLP
transplant
Year 1 standard
lung transplant
(state B)
Standard
transplant
> 1 year
post EVLP lung
transplant
(state E)
> 1 year
post standard 
lung transplant
(state C)
FIGURE 24 Model structure.
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centre was chosen as it was the largest study centre. During the trial, standard lung transplants increased
by 25% at the Newcastle centre, and this increase was applied to the pre-study transition from waiting list
to lung transplant to calculate a within-study transition. A 10% increase in lung transplant activity because
of EVLP lung transplant, also witnessed during the study overall by all centres, was used to calculate the
transition to EVLP lung transplant. The pre-trial transition was taken from NHSBT data.61 For transitions
from waiting list to removal from waiting list and to death, NHSBT transitions were used from a cohort
added to the waiting list in 2010/11 and followed for 3 years (to 2013/14), 2 of which were during the
DEVELOP-UK study, reflecting in-trial waiting list transitions.62
Post-transplant survival during the DEVELOP-UK study was not used to inform the model because of the small
number of EVLP transplants carried out during the trial. In the absence of conclusive data from the literature,
survival following EVLP and standard lung transplant were taken to be the same. Survival data were taken
from the UK Cardiothoracic Transplant Audit, 1-year survival includes surgical mortality.58 Area-under-the-curve
methods were used to calculate a survival estimate that was applied to all recipients of a lung transplant who
survived 1 year post transplant. The transitions used in the model are presented in Table 43.
Health state utilities
During the DEVELOP-UK study, SF-36 questionnaires were administered to participants while on the
waiting list, and again at 3 and 12 months post surgery. The conversion of SF-36 data to utilities is
described in Analysis of quality of life. For this exploratory analysis, average utility means were calculated
for baseline/waiting list, 3 and 12 months post transplant. Post-transplant, separate utilities were allocated
to the standard and EVLP transplant groups, and only survivor’s utilities were included. Separate utilities for
standard and EVLP were not allocated in the waiting list state, as some of the cohort patients will die or
be removed from the waiting list, and it is important to capture these utilities as well as the transplant
recipient utilities. The utilities used in the model are presented in Table 44.
Resources and costs
Costs were derived as described earlier in this chapter (see Within-study descriptive analysis of costs and
quality-adjusted life-years) and used to populate the model with the exception of waiting list costs that
were not available using the DEVELOP-UK study data. In this case, waiting list costs from Anyanwu et al.65
were used to populate the model. These costs were the results of a published economic evaluation of
adult lung transplantation in the UK. The costs for double lung transplantation waiting list were assigned
to the model and inflated to 2013/2014 prices using the Hospital and Community Health Services’s 2007/
2008 and Index 2013/14.51
Costs in the transplant states B and D (year 1 standard/EVLP lung transplant) include the costs of donor
hospital tests, lung retrieval, recipient preparation, EVLP procedure (if appropriate), lung transplant,
inpatient post-operative care, and medication and outpatient costs for 1 year following transplant. Costs in
states C and E (> 1 year post standard/EVLP lung transplant) are year 1 annual costs from the DEVELOP-UK
study data, extrapolated forward using the data annual costs reported in Anyanwu et al.65 The costs used
in the model are presented in Table 44.
Assumptions
l It was assumed that patients removed from the waiting list no longer accrue costs or utilities, and so
do not contribute further to model outcomes following removal.
l In line with survival rates reported by the ISHLT, it was assumed that no lung transplant recipients
survive beyond 25 years.
l Waiting list transitions were available for only 3 years post registration and, as only 6% of the cohort was
still on the waiting list after 3 years, it was assumed that all transitions remain linear from year 3 onwards,
and would have little effect on the overall results of the model after year 3. For example, mortality for year 1
is 17% of the cohort, in year 2 it was 18%, and by year 3 it had only increased to 19% of the original
cohort. The year 3 onwards transition to death is 0.02, and the remaining cohort is also small.
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l As no evidence of a difference in survival outcomes was found from a search of clinical trials comparing
standard and EVLP lung transplants, it was assumed that survival post lung transplant is the same for
standard lung transplant and EVLP lung transplant recipients.
Uncertainty in model parameters
The assumptions used in identifying and calculating parameters can introduce uncertainty into the model;
this uncertainty can be explored using sensitivity analysis. In this analysis, two types of sensitivity analysis
were used: scenario analysis and probabilistic sensitivity analysis.
Scenario analysis
Scenario analysis explores uncertainty in parameters by analysing results using plausible alternative
parameters. Four scenario analyses were carried out, variations in parameter values from the base case are
presented in Tables 43 and 44.
TABLE 44 Model utilities and costs: base case and scenario analysis
Parameters Base case Source
Joint
utilities Source
Utilities
Waiting list 0.563 DEVELOP-UK study data 0.563 DEVELOP-UK study data
Standard lung transplant 0.702 DEVELOP-UK study data
1 year post lung transplant 0.690 DEVELOP-UK study data 0.734 DEVELOP-UK study data
Year 2 onwards post lung transplant 0.728 DEVELOP-UK study data
EVLP lung transplant
1 year post lung transplant 0.793 DEVELOP-UK study data
Year 2 onwards post lung transplant 0.782 DEVELOP-UK study data
Costs
Waiting list cost per year £23,104 Anyanwu et al.65
Transplantation costs: standard £50,203 DEVELOP-UK study data
Transplantation costs: EVLP £133,342 DEVELOP-UK study data
Post transplantation
Standard lung transplant
Year 1 £9405 DEVELOP-UK study data
Year 2 £3696 DEVELOP-UK study data
Year 3 onwards £3400 DEVELOP-UK study data
Area-under-the-curve cost: year 2
onwards
£24,693 DEVELOP-UK study data
EVLP lung transplant
Year 1 £5739 DEVELOP-UK study data
Year 2 £2255 DEVELOP-UK study data
Year 3 onwards £2075 DEVELOP-UK study data
Area-under-the-curve cost: year 2
onwards
£15,068 DEVELOP-UK study data
Discount rate 0.035 NICE60
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NHS Blood and Transplant 2013/14 transitions
In order to explore the choice of transition from waiting list to transplant, the transitions from the
waiting list witnessed by all trial centres during the DEVELOP-UK study were used in a scenario analysis.
The waiting list transition to lung transplant used in the scenario analysis was the waiting list transition
published by NHSBT, plus an EVLP activity increase. To adjust for EVLP lung transplants carried out during
the DEVELOP-UK study and included in the NHSBT figures, the transition to lung transplant was decreased
by 5%. Leaving an estimated transition to standard lung transplant, an EVLP increase of 20% was used,
reflecting levels reported in the literature.30,63,64
Joint utilities
The utilities used post transplant are separate for EVLP and standard lung transplant. However, the number
of SF-36 questionnaires completed by EVLP recipients was low (seven at 3 months compared with 52
standard recipients, and six at 12 months compared with 48 standard recipients). An analysis was run
using a joint mean utility for both EVLP and standard lung transplant recipients at 3 and 12 months post
transplant calculated from the DEVELOP-UK study data.
NHS Blood and Transplant 2013/14 transitions and joint utilities
A separate scenario analysis was run, combining both of the above scenarios to reflect transitions
witnessed by all trial centres, and using the more robust joint utilities.
Increase in standard lung transplant activity
This scenario analysis compared pre-trial NHSBT standard lung transplant transitions61 to the within-trial
Newcastle transitions without any EVLP procedures. In other words, it purely compared a standard lung
transplant service using pre-trial transitions with a standard lung transplant service using the transitions
witnessed at Newcastle during the trial.
Probabilistic sensitivity analysis
Point estimates were used in the model, which do not represent the statistical variability surrounding
estimates of costs, effects and cost-effectiveness. For this reason, a probabilistic sensitivity analysis was
conducted. Probabilistic sensitivity analysis assigns suitable distributions to each parameter and simulations
are carried out, each of which select a possible value across all parameters at once. In this analysis,
1000 simulations were carried out, and results are presented as a cost-effectiveness plane, an incremental
cost-effectiveness plane and a cost-effectiveness acceptability curve. Parameters used in the probabilistic
sensitivity analysis are presented in Table 45 and distributions used are described below.
l Waiting list transitions: a beta distribution was chosen to fit to binomial data from the NHSBT service
for waiting list removal and death. For transition to lung transplant, a beta distribution was chosen
using figures reported by the DEVELOP-UK study.
l Survival rates post lung transplant: a beta distribution was fitted using the ‘methods of moments’
technique described by Briggs et al.66
l Costs: a gamma distribution was fitted to costs using the methods of moments technique. Briggs et al.66
report that a gamma distribution is constrained by zero and positive infinity, as are costs, making a
gamma distribution a good representation for uncertainty of costs.
l Utilities: a beta distribution was chosen for utility values using the methods of moments technique as
described above. Using a beta distribution is a practical approach when utilities are not near zero.
Model results
Cost-effectiveness results
The base-case cost-effectiveness results are presented in Table 46. The mean undiscounted lifetime cost of
a lung transplant in the standard service was £66,208, whereas the discounted lifetime cost was £64,861.
The mean undiscounted lifetime cost of a lung transplant in the EVLP service was £70,562, whereas the
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TABLE 45 Parameters used in the probabilistic sensitivity analysis
Parameters Alpha, beta Distribution Source/reference
Waiting list transitions
Removal from waiting list
Year 1 38, 184 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Year 2 3, 50 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Year 3 onwards 1, 19 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Transition to death
Year 1 9, 213 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Year 2 2, 51 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Year 3 onwards 5, 15 Beta NHSBT’s Organ Donation and Transplantation
Activity Report 2011–201261
Transition to standard lung
transplant
Year 1 111, 111 Beta DEVELOP-UK study data
Year 2 30, 23 Beta DEVELOP-UK study data
Year 3 onwards 12, 8 Beta DEVELOP-UK study data
Increase in lung transplant activity
because of EVLP
4.3, 39 Beta DEVELOP-UK study data
Post-lung transplant survival
1-year survival standard and EVLP 1694.3, 517.6 Beta NHSBT’s Annual Report on Cardiothoracic
Transplantation 2013–1462
Area under the curve
1-year survival 1694.3, 517.6 Beta NHSBT’s Annual Report on Cardiothoracic
Transplantation 2013–1462
3-year survival 1278.1, 770,2 Beta NHSBT’s Annual Report on Cardiothoracic
Transplantation 2013–1462
5-year survival 947.0, 863.7 Beta NHSBT’s Annual Report on Cardiothoracic
Transplantation 2013–1462
10-year survival 388.1, 777.3 Beta NHSBT’s Annual Report on Cardiothoracic
Transplantation 2013–1462
Utilities
Waiting list 2292.2, 1782.4 Beta DEVELOP-UK study data
1 year post standard lung
transplant
418.2, 187.6 Beta DEVELOP-UK study data
2 years onwards post standard
lung transplant
436.9, 163.2 Beta DEVELOP-UK study data
1 year post EVLP lung transplant 69.6, 18.2 Beta DEVELOP-UK study data
2 years onwards post EVLP lung
transplant
22.4, 6.3 Beta DEVELOP-UK study data
Costs
Waiting list cost per year 100.0, 232.0 Gamma DEVELOP-UK study data
Standard lung transplant 294.89, 170.24 Gamma DEVELOP-UK study data
EVLP lung transplant 95.43, 1397.21 Gamma DEVELOP-UK study data
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TABLE 45 Parameters used in the probabilistic sensitivity analysis (continued )
Parameters Alpha, beta Distribution Source/reference
Post-lung transplant costs – standard
Year 1 90.61, 103.8 Gamma DEVELOP-UK study data
Year 2 90.61, 40.79 Gamma DEVELOP-UK study data
Year 3 onwards 90.61, 37.53 Gamma DEVELOP-UK study data
Post-lung transplant costs – EVLP
Year 1 19.55, 293.48 Gamma DEVELOP-UK study data
Year 2 19.55, 115.34 Gamma DEVELOP-UK study data
Year 3 onwards 19.55, 106.11 Gamma DEVELOP-UK study data
TABLE 46 Base-case cost-effectiveness results
Without EVLP With EVLP
Costs (%)
Waiting list £9223 (14) £7157 (10)
Year 1 post lung transplant £43,259 (65) £49,861 (71)
Year 2 onwards post lung transplant £13,727 (21) £13,544 (19)
Total
Undiscounted £66,208 £70,562
Discounted £64,861 £69,358
Outcomes
Life-years gained
Undiscounted 5.61 5.63
Discounted 5.38 5.41
QALYs
Undiscounted 3.63 3.68
Discounted 3.48 3.54
Incremental
Costs £4496
Life-years gained 0.03
QALY 0.06
ICER
Life-years gained £147,000
QALY £73,000
Number of lung transplants
Standard lung transplant 726 675
EVLP lung transplant 67
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discounted cost was £69,358. In both services, the largest proportion of cost was the year in which the
transplant took place, accounting for 65% of total lifetime cost in the standard service and 71% of total
lifetime costs in the EVLP service. The incremental cost of the EVLP service was £4496, while the number
of incremental life-years gained and number of QALYs gained was 0.03 and 0.06, respectively. The life-year
ICER was £147,000, and the QALY ICER was £73,000.
In the standard service, the number of standard lung transplants carried out from a cohort of 1000 was
726. In the EVLP service, the number of standard lung transplants was 675 and the number of EVLP lung
transplants 67, a total of 742; 16 (2%) more than the standard service.
Scenario analysis results
The scenario results are presented in Table 47.
2013/2014 NHS Blood and Transplant transitions
This scenario resulted in an incremental cost per QALY gained of £40,000. The number of lung transplants
carried out was 644 in the standard service, and 709 in the EVLP service; thus, there was an increase of
65 lung transplants (10%).
Joint utilities
This scenario resulted in a QALY ICER of £124,000. The number of lung transplants carried out was 726 in
the standard service and 742 in the EVLP service, as in the base-case analysis.
Combining NHS Blood and Transplant 2013/14 transitions and joint utilities
This joint scenario resulted in a QALY ICER of £51,000. The number of lung transplants carried out was
644 in the standard service and 709 in the EVLP service, as in the NHSBT 2013/14 transitions scenario.
Standard lung transplant only
This scenario resulted in a QALY ICER of £7000. The number of lung transplants carried out was 620 in
the pre-trial standard service and 726 in the ‘Newcastle experience’ service, an increase of 106 lung
transplants (17%).
Probabilistic sensitivity analysis results
The results of this analysis are presented for the cost–utility analysis only. The ICER was £72,000, similar to
the base case. Figure 25 shows the predicted cost and QALY plots for each intervention, whereas Figure 26
shows the predicted plots for the difference in costs and QALYs between the two interventions, with a
threshold of £30,000 per QALY. Figure 25 indicates that the EVLP service is marginally more effective and
costly than the standard lung transplant service. Figure 26 indicates that the majority of the simulations fall
in the north-east quadrant, where the EVLP service is more costly and more effective than the standard
service, but several simulations fall into the north-west quadrant of the figure, where the EVLP service is less
effective and more costly than standard service. The incremental effectiveness in QALYs varies between
–0.05 and 0.3, with a mean of 0.061 (95% CI –0.006 to 0.152), and the incremental costs vary between
£680 and £16,180 with a mean of £4349 (95% CI £1167 to £9742).
The data from the Monte Carlo simulation were used to plot a cost-effectiveness acceptability curve (Figure 27).
The results indicate that at the typical ceiling ratio adopted by NICE of £20,000, the standard service has a
99.9% chance of being considered cost-effective compared with the EVLP service.
The conclusions of the economic evaluation are discussed in Chapter 6.
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Chapter 5 Qualitative study results
Introduction
There is currently no published literature examining patients’ views of EVLP, and research related to
people’s experiences of receiving donor organs is also limited.67–72 It is imperative that if new heath-care
technologies, such as EVLP, are to be implemented successfully and achieve real benefits for patients, the
views of those receiving them are taken into account. This substudy critically examined patients’ attitudes
towards, and understanding of, EVLP; their reasons for participation in the DEVELOP-UK study; and their
experiences of waiting for and receiving a transplant.
Research objectives
The aim of this 24-month qualitative substudy was to identify, describe and understand patients’ pre- and
post-operative perceptions of EVLP, and to explore how these are mediated by individual, social, physical
and clinical factors.
Methods
This qualitative study used focused interviews to explore patients’ views and experiences of consenting to
be part of DEVELOP-UK study and their views of EVLP both before and after transplantation. Focused
interviews are particularly useful when researching a new area about which relatively little is known.73
This substudy was conducted with patients from two study sites: the Freeman Hospital, Newcastle, and
Harefield Hospital, London. These two sites were chosen as they both provide care to diverse populations
across large geographical areas, and they were expected to recruit the largest number of patients to the
DEVELOP-UK study.
Prior to commencing data collection, an outline interview topic guide was developed that covered the
following key areas:
l pre transplantation
¢ patients’ understandings of EVLP and the perceived acceptability of this procedure in comparison
with other donor lungs
¢ patients’ hopes and expectations for EVLP
¢ patients’ accounts of their own health and experience of living with their condition
¢ patients’ experiences of waiting for lung transplantation
l post transplantation
¢ patients’ retrospective accounts of their pre-operative health and experiences
¢ patients’ accounts of waiting for a transplant
¢ patients’ views and experiences of receiving and living with an EVLP or standard transplant.
Sampling
The aim of this substudy was to sample a smaller group of patients from the DEVELOP-UK study to explore
their views and experiences in more detail. Initially the plan was to recruit between 20 and 30 adult
patients waiting for lung transplantation and between 20 and 30 patients 3–6 months post-operatively
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from across both sites. Maximum variation purposive sampling74 was used to ensure that a range of
different experiences was included; specifically, we sampled for: sex, age, location (distance from hospital),
diagnosis and length of time on the transplant list.
On consenting to take part in the DEVELOP-UK study, pre transplantation patients were given some brief
information about the qualitative substudy and, if they were willing to consider taking part, they were asked
to sign an EOI form. On completing an EOI form, patients were then given further detailed information
about the qualitative substudy by a research nurse. After this, if patients were still willing to take part, they
completed a consent to contact form, which was passed to the qualitative research team. The patients were
subsequently contacted by a qualitative researcher and were again given another opportunity to ask further
questions. If they were still interested in taking part, a date for interview was organised and a consent
form was mailed out for the patient to complete and return. It was made clear to patients at all times that
participation in any interviews was optional. During recruitment the team used purposive sampling, as
outlined above, and reviewed the sample regularly to ensure that a range of different views and experiences
was included, and actively targeted under-represented groups (e.g. patients with CF, younger patients, etc.).
At the end of their first interview, patients were asked if they were willing to be interviewed again and all
agreed, although only seven of the 26 patients interviewed pre transplantation were able to be interviewed
again, as the remainder either had not received a transplant within the timescale for the fieldwork or were
not well enough to be interviewed again.
Owing to the nature of the sampling for the study, not everyone who returned a consent to contact form
was actually invited to interview before their transplantation. However, following transplantation, a number
of patients who had previously returned consent to contact forms to the team but had not already been
interviewed were contacted again 3 months post transplantation by a researcher and invited to take part in
an interview at this stage. Upon receipt of consent to contact forms, an additional 11 individuals were
invited to take part in an interview 3–6 months post-operatively.
As only a small number of EVLP transplantations were undertaken there were only a few people who
could be interviewed about this experience. A targeted effort was made to identify and recruit all EVLP
patients to the qualitative substudy. However, some patients, although they had expressed an initial
interest in being interviewed, did not return a consent to contact form.
Interviews
Individual interviews were conducted either face to face or by telephone by JL. The first three
pre-transplantation interviews were carried out in participants’ homes. Subsequent interviews were
conducted either face to face in a room at the hospital when the patient attended for outpatient review
or by telephone at a time that was convenient to the participant. All except two post-transplantation
interviews were conducted by telephone. Telephone interviews were particularly useful in this study as
they allowed the team to interview people who lived across a wide geographic area. Transcripts of early
face-to-face interviews were carefully compared with initial telephone interviews and there appeared to be
little difference in the quality or detail of the data collected.
Data analysis
Following a long tradition in qualitative research,75,76 data collection and analysis occurred concurrently
to allow for issues or themes that were identified in earlier interviews to be explored in more depth in
subsequent interviews. All interviews were digitally audio-recorded and transcribed verbatim. Initially,
interview transcripts were checked against the audio-recording and, in line with Data Protection Legislation
and Research Governance stipulations,77 all potentially identifiable information pertaining to individuals
was anonymised. After this, transcripts were read; open, then focused, coding was undertaken; and
emergent codes from the analysis of this stage were presented to the wider research team for checking
and validity. The validity of data interpretation was ensured by independent coding and cross-checking by
the qualitative research team (JL and CE). Data collection stopped when no new themes were being
identified in the data. NVivo version 10 (QSR International, Warrington, UK) was used to facilitate data
analysis management.78
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Results
In total, interviews were conducted with 44 participants (24 men and 20 women) aged 21–69 years.
Of these, only 19 were interviewed before transplantation, seven both before and after transplantation
and 11 after transplantation.
Patients were located across a wide geographic area across the UK, Ireland and the Channel Islands.
The patients interviewed had been diagnosed with a range of conditions: pulmonary fibrosis (n = 7),
emphysema (n = 9), CF (n = 8), α1-antitrypsin deficiency (n = 5), idiopathic fibrosis (n = 2) and others
(n = 6). Twenty-six interviews (14 Newcastle; 12 Harefield) were conducted before transplantation with
12 women (aged 23–61 years) and 14 were with men (aged 25–69 years). Eighteen interviews were
conducted post transplantation (13 Newcastle; 5 Harefield) with eight women (aged 21–62 years) and
10 men (aged 25–69 years). Two patients interviewed had received an EVLP transplantation, the rest a
standard transplantation. Seven people (two women and five men) were interviewed both before and after
transplantation, and, as outlined above, a further 11 (six women and five men) were interviewed only
after transplantation.
Patients’ views and understandings of ex vivo lung perfusion
One of the main foci of the qualitative substudy was to explore patients’ views and understandings of EVLP
and their expectations and hopes regarding the use of this new transplantation technology. Patients were
asked to explain their understandings of EVLP. When asked specifically to explain EVLP, most people identified
the perfusion process and the effect it had on the lungs as the major difference between an EVLP transplant
and a standard transplant. Reference to a ‘cleaning out’, ‘improving’ the quality of the lungs was frequently
mentioned, and some patients demonstrated a good understanding of the processes involved in EVLP:
I understand to be the sort of passing of some magic liquid through the lungs while they are ex vivo,
i.e. after they have been removed from the donor to (a) deal with any bugs and whatever but also as
I understand it to potentially improve their quality or bring them up to what they, you know for
reasons of bugs.
Dominic, pre transplant, centre 1
They are pumped through with various different gases and a fluid to clean out and sort of recondition
these lungs into a better condition so that they are suitable for transplantation.
Mark, pre transplant, centre 2
When describing EVLP, participants tended not to use technical language or give detailed information
about the perfusion process. Rather, their explanations focused on what they appeared to regard as the
essential information, that EVLP can enhance the quality of lungs, which previously would not have been
suitable for transplantation so they could now be used:
They take somebody’s lungs that may have been a smoker and they basically recondition them.
Clean them on the machine and then pass them onto the patient that’s needing them.
Adrian, pre transplant, centre 2
It’s retrieving a pair of donor’s lungs that you’re not sure if they’re 100%, so they’re put on like a heart
lung by-pass machine and cleansed out given fluids and taken all the muck out, and replenishing as
soon as they then can be used as a donors [and] transferred to somebody waiting for them.
Amanda, pre transplant, centre 1
Patients were asked how they would explain the process of EVLP to family and friends, and some used
analogies to help explain EVLP to their families in everyday terms:
Well, I think I explained it as being like a washing machine where they take, put the lungs in, give
them a clean, give them, fix them up and then just let them dry out a little bit.
Angela, pre transplant, centre 2
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A service that’s basically what is was, you’re putting them in basically, donor lungs going for a service
or an MOT [Ministry of Transport test] you know just like your car.
Tom, post transplant, centre 2
Although most patients were able to articulate a clear and accurate explanation of EVLP, a small number
of people at both sites gave less accurate or confused explanations of EVLP:
My understanding of it is that it’s organs taken from long-term ill patients that perhaps have been on
a life-support machine for several months and died very slowly and as the organs, you know as the
body dies so the organs you know they lose their selves and they just get weaker and sort of die along
with the patient and you know they’ve found that they’re able to revive these lungs and bring them
back into working order.
Christine, pre transplant, centre 1
Pickled lungs, pickled lungs. I keep saying to everybody that they pickle the lungs. A set of lungs out
of a donor; something wrong with them; they put them in whatever, hoover them out, give them
antibiotics, clean them and everything, and hopefully get them up to a standard where they can
be transplanted.
Sarah, pre transplant, centre 2
When patients consented to take part in the DEVELOP-UK study they were given a lot of information
about the study, and were given several opportunities to ask questions and to clarify anything that was
unclear to them. However, some patients still felt the need to seek out additional information about EVLP,
often from the internet to supplement their knowledge. Patients in the DEVELOP-UK study also referred to
having also consented to participate in other studies. They were willing to do this, however, consenting to
several studies with large amounts of complex information sometimes led to some confusion about the
details of individual studies:
Oh basically a pair of live lungs isn’t it, they’re not put on ice as it were. They’re kept pumping using
the donor’s blood, yeah? I think I’ve got the gist of it.
Joseph, pre transplant, centre 1
Consenting to be part of the DEVELOP-UK study
During the interviews, participants were asked why they had made the decision to take part in the
DEVELOP-UK study to explore the motivations of people consenting to be part of a trial of a new
technology. Unsurprisingly, the most common reasons patients gave for consenting were the hope of
receiving a transplant quicker and the possibility of helping others in the future:
Well my mum like said to me right ‘You would have a better chance of getting a transplant if you go
with that’. But I had already made my mind up that it is something that – you’ve got to really give it a
go because you can double your chances really, can’t you?
Jack, pre transplant, centre 2
I’m interested in the greater good not just my own good [OK] and I think you know I don’t see how
we’ll ever make leaps forward in this stuff unless people are prepared to take a few chances.
Ali, pre transplant, centre 1
For a few, consenting to be part of a trial involving a new intervention was a difficult decision and required
considerable time and thought:
No like at first I, I’m sort of thinking oh, oh my goodness, know what I mean? What about I mean
what, who it was, he’s [donor] got AIDS [acquired immunodeficiency syndrome], somebody’s got this.
Know what I mean, and somebody that like smokes you know a 100 fags a day sort of thing and that
so I was initially, I thought at first until I read into, looked into it I thought I was getting the rough end
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of the deal to be honest. You know whereas now, you know I’ve spoke to Karen [transplant
co-ordinator] about it and she just says . . . we wouldn’t go with them unless we’re 100% sure,
they’ve got to be as good as the other ones they would have used in the first place.
Connie, pre transplant, centre 2
Others expressed some reservations about the technology or limited understanding, but were willing to
put their trust in the medical team who they believed would make the best decisions for them:
I wasn’t really sure at first but then the more I was thinking about it, basically the doctors are always
going to do their best for you so they are not going to give you something they think isn’t going to
work or anything like that so I wasn’t really phased. To be honest I wasn’t going to really think too
much into it. Like even the [standard] transplant I didn’t want to think too much into it I just wanted
the doctors to do their job and just not really think about it.
Brenda, post transplant, centre 1
I put my faith in the people that are doing the operation. And, I mean, if they decide that lung’s good
enough for me, that’s basically, good enough for me.
Adam, pre transplant, centre 2
However, patients’ accounts demonstrate that, regardless of any fears, concerns or limited understanding
of receiving EVLP lungs, they were aware that the lungs they received would function better than the ones
they currently had.
What are my, well I’m hoping that the lungs will just be good enough, I get called up, get
transplanted, and that even if its 80% better than what I’ve got now you know, I just know I’ve got
faith in the system that you just wouldn’t give me a crap pair of lungs really.
Amanda, pre transplant, centre 1
Going on the transplant list
Understanding of EVLP and motivation to take part in the DEVELOP-UK study were of interest to the
research team. For patients themselves, being asked to take part in a study employing a new technique to
increase the number of lungs available for transplantation appeared to be less significant than actually
accepting the need to be placed on the transplant list in the first place. During the interviews, patients
spoke in detail about what happened when they were accepted onto the transplant list, what they
expected the transplant process to be like and what they were fearful of. Many of the views in this
following section relate to transplant generally rather than EVLP specifically, but provide an insight into
patients’ broader experiences of waiting for a transplant.
During interviews, patients spoke about their condition needing to deteriorate to a point where the
transplant team would consider them to be at a stage where a transplant would be the best option:
I was too fit to go on the transplant list then I think. So it well I wasn’t overly disappointed, I was
disappointed slightly but I wasn’t overly disappointed if you know what I mean because I knew that I
was still fit enough I was still breathing not too badly I am saying not too bad I was absolutely
atrocious but you know what I mean compared to near the end.
Paul, post transplant, centre 2
On being accepted on to transplant waiting list all patients interviewed expressed feelings of hope, relief
or joy:
[I] absolutely burst into tears when they told me that I was going on the transplant register, it was like
you were getting some form of a lifeline.
Mark, post transplant, centre 2
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However, they were aware that if their health deteriorated too much they might be removed from the
transplant list:
Well what it is you see it’s like a window, it’s you’ve not got to be too ill but you’ve not got to be too
well, you can’t be either side of it you’ve got to be right.
Connie, pre transplant, centre 2
The only thing that I’m really scared of is because each time I get a chest infection now it comes worse
each time and the last time I had one well I thought, either, you know, I think I should have been in
hospital really but I couldn’t even walk to the toilet but we just got another load of antibiotics so I’ve
learnt by that mistake or experience and next time I’ll get the doctor in or get my husband to take me
to hospital but and so the only thing that worries me is that I’ll die of a chest infection so that’s the
scary bit.
Amanda, pre transplant, centre 1
Several patients spoke about their fear regarding the transplant operation, but acknowledged this had to
be balanced by the fact that transplantation was their only hope of survival:
I’d be lying if I said I wasn’t frightened, because I think everybody who’s facing any kind of surgery is
worried, apprehensive about it. But it was a choice of sitting in a chair, or having a chance. And I
chose the chance. I don’t want to be sitting in this chair.
Sarah, pre transplant, centre 1
Well dying more than owt [anything]. It’s just all going wrong and the first thing you hear like the first
thing you hear is like the rates that’s successful and then not successful and it were just like – I think it
was an 80% chance of it being successful and 20% that it been not be successful. That is all you can
think about really, is that 20% really if its. That’s all I kept thinking about. But now I’ve like kind of
thought if you don’t have it done you are going to be that 20% anyway, if so I could as well just
take risk.
Jack, pre transplant, centre 2
Being on the list
One of the main topics discussed in detail by patients during their interviews was their experience of living
their life while waiting on the transplant list. Although not specifically related to EVLP, it demonstrates the
ways in which people adapt to a life waiting for a transplant. However, some of the everyday difficulties
encountered may offer some insight into why people were willing to consent to be part of a study
involving a new technology that could increase their chances of receiving a transplant sooner. Although
patients’ experiences varied, the data suggest that waiting for a transplant had a significant impact on all
of their lives. Some people continued to try to do many of their normal activities, whereas others worked
hard to become fitter and more active to enhance their chances of a successful transplant:
As I got put on transplant list like I just knew I’d got to make sure I was fit enough and healthy
enough to get through this operation if and when it happened. Well just tried to, well I went on
exercise bike, you know do as much as I could on exercise bike, walking up and down us [our] drive
and obviously not in bad weather but I just do a bit more walking around the house and just doing
general housework you know what I mean trying to keep on top of everything.
Adrian, pre transplant, centre 2
Once accepted onto the transplant waiting list patients must adjust to a different way of living; many
patients referred to feeling constantly on the alert waiting for a telephone call about a potential donor and
needing to be ready to leave for the hospital when the call came:
I can’t go here, I can’t go there without thinking am I going to get a call. I always have my phone with
me, my phone is always on loud, it’s always in my hand. I’m constantly staring at it, every time it goes,
QUALITATIVE STUDY RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
102
makes a noise, my heart stops and it’s just crazy and it’s really annoying cos I can’t go on holiday . . .
I can’t even leave the county . . . so I basically I am trapped, it’s literally like being in a cage.
Angela, pre transplant, centre 2
As well as affecting their lives, participants also spoke of the impact of waiting on the lives of their families
and significant others:
Yeah it’s horrible, because you can’t relax, no you, I know it sounds, phone rings and your hearts in
your mouth you know, is it that, is it this? My husband I mean he, he doesn’t want much but now
and again he goes out. He can’t go out, all over Christmas week we couldn’t make arrangements to
go anywhere or, you know you can’t go out and have a drink . . . You know so it, it’s like you’re sort
of waiting with bated breath sort of thing.
Connie, pre transplant, centre 2
On being accepted onto the waiting list after their assessment, all participants spoke of going home to
pack their bags in preparation for being called in for a transplant. For many their initial feeling of anxiety
and/or expectation of a rapid transplant was replaced by the reality of being on the waiting list and
sometimes despondency:
I packed a suitcase. Bought new pyjamas and everything, and it’s been packed for a year. Packed and
unpacked and washed and put there. But it’s there.
Sarah, pre transplant, centre 2
Some participants spoke of being called into the hospital several times for potential transplants that failed
to progress. These ‘false alarms’, as the patients called them, raise expectations and can be very disruptive,
particularly for those travelling long distances to the hospital. However, false alarms could also be
reassuring, either because this appeared to convey that they were at the ‘top’ of the list, or because it
helped to orientate them towards the process:
I got the stockings on this time. Got the shower, got the gown on . . . Got the white stockings on.
Had the heart trace and the X-ray and all the bloods taken. So this was the farthest we’ve getting this
this time. I have actually been in the gown the last time, but that’s as far as it’s gone. But this time
was a little bit further, and I keep thinking, ‘Getting a little bit. She’s putting stockings on; I’ve never
had them on before’. You know, ‘Yes!’ A step closer, but it wasn’t to be. It just wasn’t to be.
Sarah, pre transplant, centre 2
Sarah saw the fact that she had different things done each time as a sign that she was getting further along
the line, nearer to her transplant: these may not have the significance that patients assigned to them.
Waiting for a suitable donor organ to become available could take many months or years, and, although
patients were waiting, they were conscious that their condition was deteriorating and that they could die
while waiting for a transplant. Connie spoke about treating each significant life event such as Christmas
and birthdays as her last, although she did not share this with her family:
I don’t know you see it’s like having like, how do I explain it? . . . this Christmas well I’ve seen that as
my last Christmas that’s on your mind all of the time. Do you understand what I mean? And that’s
there every day. It’s the only thing I haven’t said [to my family] . . . you just feel that everything’s your
last Christmas, your last New Year, it’s your last, every hurdle you can’t see beyond it and I still can’t.
You can’t dwell on it but it’s there, it’s like a dark shadow on you all the time, that’s the best way,
it’s so hard to explain.
Connie, pre transplant, centre 2
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Waiting for a transplant means waiting for someone else to die for their chance of survival, something that
was not discussed in detail by many people. One exception was Annie who spoke about it being a circle,
a link between the patient, the donor and the donor’s family:
And it’s not just a donor’s lung; you know, somebody’s got to die for you to have their lungs. And I
mean, that must be horrendous for their family as well, so it’s not just you; it’s a proper little circle.
It’s just amazing.
Annie, pre transplant, centre 2
Perhaps to counter or cope with the anxiety and stresses of being on the transplant list, many of those
interviewed made extensive plans for their lives post transplantation. These hopes ranged from the
mundane to new challenges. Some patients saw their goal as undertaking new physical challenges, others
just want to get back to ‘normal’, look after their grandchildren, go on holiday; the majority were happy to
be able to do the mundane everyday activities they have missed:
I’ve got a walk planned with a friend and a dog on a beach! And then I just hope to get back to
riding again.
Christine, pre transplant, centre 1
I look after my 4-year-old granddaughter quite a lot and sort of, although I’m fine with her because
we do a lot of sitting down things, it would be nice to go back to sort of going out with her and
things you know and just generally getting back to normal.
Julia, pre transplant, centre 1
Post-transplant experiences and hopes
Of the 18 patients interviewed post transplantation, seven had been interviewed before their transplantation
as well, and 11 were interviewed only after receiving their transplant. Two people had received an EVLP
transplantation. All the data from post-transplantation interviews are presented together for two reasons:
first, to protect the anonymity of the small number of EVLP patients; and, second, from these two
interviews it is not possible to ascertain any obvious differences in the reported experiences.
When participants described the events leading up to their transplant, they were often very specific about
events, timings and how they felt. Some details they could recall themselves, and other aspects they had
been told by relatives after the operation:
It was 1.30 in the morning, no sorry it was 9.30 on the Thursday night the phone rang again, it was
Karen [transplant co-ordinator] and she said guess what I’ve been made an offer she said but
someone else has also been offered the organs so start making your way to the hospital. I started
getting prepped yet again and about quarter to five in the morning Karen got a call from the retrieval
team to say, the organs are good it’s a go ahead. So I was then wheeled down to theatre at about
5.30 that was the last time I saw my wife then. Surgery commenced around 5.30 in the morning,
5.30/6.00 in the morning and I believe it took about 10/10.5 hours.
Mark, post transplant, centre 1
A key factor in the transplant process is the need for a donor. Those patients who mentioned the donor
referred to the emotion and grief that they felt for the donor’s family and the effect it had on them, which
varied between individuals:
Yeah it was definitely emotional time, there’s no doubt about that, thinking about the donor, donor
family all the time. Quite a lot of tears, emotional having to you know, them to pass away for me to
live like you know. And it’s not an easy thing to digest you know . . . I suppose the whole emotional
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thing was that I was alive and that someone had lost a brother, a dad, a husband you know a friend
it was very raw for a long time and I just couldn’t, I’d be walking down the corridor and just fall out
crying you know any little small thing at all emotionally would set me off so actually recently we sent a
letter to the donor’s family which helped a lot like and hope to God helps them as well, like you know
I wanted to show that I was up and about and achieving stuff before I sent the letter rather than send
it at the saying thanks kind of gave them hope what I was beforehand and what my life is today yeah,
so it was mentally tough and anything at all, even a song or something on the telly would set you off
like you know you ended up watching cookery programmes.
Barry, post transplant, centre 2
Several participants spoke of wanting to make contact with the donor family to thank them and show
how well they were doing, but were uncertain as to how this would be received:
What can you do that has any impact on anyone to say thank you? I mean you can write a letter and
say thank you and if they get it, even better, but it’s . . . might be a crumb comfort I suppose. If you
say who you are in terms of middle-aged or you know, whatever – do they say ‘Christ, what a waste,
why didn’t it go to a younger patient?’ – All those conflicts, you know.
Tim, post transplant, centre 1
In addition to talking about their donors, participants spoke of their physical recovery post transplantation
and their plans for the future. For all patients the first thing they recalled was the sensation of being able
to breathe without struggling. For some this new way of breathing took a while to get used to:
I found the breathing quite hard because I didn’t understand what was going on and I had to kind of
make myself do it [right] I didn’t trust it to do it on its own. It was a very strange experience [right]
especially at night I was frightened to go to sleep in case it stopped because it felt so different.
It’s very eh and the fact that the even now the breath is such a long breath in I think I’m going to
stop breathing because it’s such a long time. Yeah I think it is you think oh god it can’t really be that
slow a breath surely but then you think well it’s 3 litres instead of 0.5.
Beth, post transplant, centre 2
Some participants also experienced new health problems that they believed were in some way related to
the transplant or post-transplant medication. However, the majority felt that living with their new health
problem was not a significant issue compared with their condition pre transplant.
After receiving a transplant many patients expected to return to ‘normal’ life, restart work, go on holiday,
start running. However, this was not always straightforward or at the rate hoped for, leaving some
feeling disappointed:
It’s been ok since I’ll still be out, I’ll still be out of breath, I’m not, I’m not 100% there’s a lot of things
I still can’t do I can’t like, I can walk into town but there, I got, I got to rest and I get out of breath
very quickly there’re certain jobs I do I get dizzy quickly but other than that, no, I’m fine it’s good.
Keith, post transplant, centre 2
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Chapter 6 Summary of study findings
and discussion
Lung transplantation is the only therapeutic option for many patients with life-threatening chronic lungdisease. The main factor limiting access to this life-saving therapy is the availability of suitable donor
lungs. The consequences of this are a significant risk of death while on the waiting list for lung
transplantation that, in the UK, for some disease categories, reaches > 30%. The development of EVLP to
allow more objective assessment of organ suitability and potentially for reconditioning them has been
heralded as a major breakthrough and represents the current frontier in advancing the impact of solid
organ transplantation.
In the DEVELOP-UK study, all five UK adult lung transplant centres came together to investigate the
possible impact that access to EVLP assessment and reconditioning of donor lungs might have on lung
transplantation activity in the UK. Our hope was that EVLP would safely increase lung transplant activity by
using more of the donor lungs that are already available, but that are currently felt to be unsuitable. The
original hypothesis under investigation was that EVLP assessment and reconditioning of unsuitable donor
lungs would produce survival in the first year after lung transplant that was non-inferior to that after
standard lung transplantation.
The trial aimed to evaluate the clinical effectiveness of EVLP in increasing UK lung transplantation activity
and, specifically, to demonstrate comparable outcomes for patients who received donor lungs exposed to
EVLP compared with patients who received standard donor lungs. A within-study economic assessment
aimed to evaluate the cost-effectiveness of generating more lung transplants by using EVLP, including
modelling what sort of activity levels and costs would make it an intervention that could be adopted into
standard use. Finally, the investigators were keen to know how patients waiting for lung transplantation
felt about EVLP and use of donor lungs that might not otherwise have been deemed suitable.
The primary outcome measure of survival in the first year after transplant was chosen as a clinically
meaningful unequivocal end point. The known historical frequency of mortality events in the first year after
standard transplant from the Royal College of Surgeons UK audit58 meant that there were solid data that
could be used to calculate a sample size for the study to ensure that it was adequately powered.
Our main finding showed that survival in patients receiving a lung transplant after EVLP was not as good
as in those who received a standard lung transplant. The Kaplan–Meier estimate of survival at 12 months
was 0.67 (95% CI 0.40 to 0.83) for the EVLP arm and 0.80 (95% CI 0.74 to 0.85) for the standard arm,
and the Cox hazard ratio of 1.96 (95% CI 0.83 to 4.67) equated to just less than twice the risk of death in
first year in the EVLP arm.
The study was, however, terminated early because of slow recruitment and a concern about high levels
of ECMO use, and the sample size of 18 in the EVLP arm is too small to allow firm conclusions to be
drawn. There are a number of small studies published that include data on 1-year survival rates after lung
transplantation with EVLP-assessed donor lungs, these ranged from 67% to 95%.24,79 In the only larger
study looking at longer-term outcomes including the risk of developing chronic lung allograft dysfunction,
the group in Toronto showed 1-year survival of 79% in their EVLP group (n = 63) and 85% in their
standard group (n = 408) with no statistical difference.80 These data come from a single-centre experience
performed outside a clinical trial and, therefore, are not directly comparable with the results of the
DEVELOP-UK study.
When mortality events were compared by the EVLP protocol used, the hazard ratio for the hybrid protocol
relative to the Lund protocol was 2.92 (95% CI 0.53 to 15.95). The outcomes for the 10 EVLP patients in
the Lund protocol group were actually very similar to those in the standard transplant group with a
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Kaplan–Meier estimate of survival at 12 months of 0.80 (95% CI 0.41 to 0.95). This raises the possibility
that, had the study continued longer using the Lund protocol, robust conclusions could have been
achieved. When examining the causes of death in the SAE reports, it became clear that they were not
causally related to EVLP but as result of other complications that can occur after any lung transplantation.
It is therefore possible that the higher risk of death seen with the hybrid protocol was as a consequence of
small numbers in the study at that time rather than the protocol itself. There is a risk in overinterpreting
the higher death rate in the EVLP arm as a whole because of the small numbers and the change in the
EVLP protocol used.
The secondary outcomes used in the study were all key clinically relevant measures that indicate success of
lung transplantation. Several of these, such as duration of ventilation or length of ITU stay, can be subject to
variation that may not be due directly to the effectiveness of lung transplantation, as they can be influenced
by factors outside the lungs. We showed that those in the EVLP arm of the study spent longer intubated
(median 72 hours vs. 38 hours) and longer in the ITU, by a median of 10 days, than recipients of standard
lung transplants. However, the time to discharge from hospital after the transplant was very similar.
These observations fit well with our cautious finding (given the limited sample size) that there was more
severe early PGD in the EVLP group and a much higher rate of ECMO use for severe graft dysfunction, but
that once the patients recovered from this early graft dysfunction, they made a good recovery to match
the time to hospital discharge of the standard group. The largest difference in rates of severe PGD grade 3
was seen at baseline, which relates to that recorded on immediate return from theatre to the ITU, where
88.9% of the EVLP group had PGD grade 3. However, over the next 72 hours the rates of PGD grade 3
equalised between the EVLP and standard transplant group (27.8% vs. 22.5%, respectively). It is worthy of
note that the rate of PGD grade 3 at 72 hours was higher than expected in the standard group at > 20%.
The PGD grade 3 rates in published studies in the first 72 hours after transplant range from 0% to
14%.29,81 In a smaller recent study of eight EVLP transplants, the PGD grade 3 rate at baseline was 37%,
but this dropped to 0% at 72 hours; two of these eight (25%) EVLP patients required ECMO support.82
There was a 10-fold increased use of ECMO in the EVLP arm, with 7 of the 18 patients requiring ECMO.
Interestingly, there was no association between use of ECMO and early death as a result of graft failure,
as six of the seven patients needing ECMO were successfully discharged from ITU. The duration of ECMO
support was short, with the majority weaned off within 72 hours. The exact reason for very high levels
of early severe PGD and ECMO use in the EVLP group is not clear, but one possibility is that the use of
cardiopulmonary bypass during the transplant surgery might have caused a second hit to donor lungs that
already had some degree of vascular endothelial injury after undergoing EVLP. Participants in the EVLP
group had an 88.9% rate of cardiopulmonary bypass use during surgery compared with 63% in the
standard transplant arm. The use of ECMO to support patients after EVLP transplant in published studies
ranges from 0% to 33%.29
The medium-term outcomes – such as number of clinical infections, lung function as measured by FEV1
and FVC, chest radiograph appearance and numbers of rejection episodes – were comparable between the
two groups. This suggests that, despite a higher rate of early PGD in the EVLP group and high rates of
ECMO use, there do not appear to be other consequences of lung allograft health during the first year.
Strengths and weaknesses of the main DEVELOP-UK study
The DEVELOP-UK study has a number of strengths. It was the first study that brought together all five lung
transplant centres in the UK to investigate a new technology for the benefit of patients waiting for lung
transplantation. By involving all centres, the opportunity to demonstrate impact was maximised, and UK-wide
policies could take account of the study. All centres were following the same protocols and using the same
EVLP system to perform their assessments; this ensured the highest possible level of standardisation of the use
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of the technology across the study. The level of engagement of the population of patients waiting for lung
transplant surgery was an additional strength, as this enabled the opportunities to perform EVLP assessments
to be maximised.
Nonetheless, there are a number of weaknesses in the study that affect our ability to draw robust
conclusions. The major limitation is the fact that – due to early study termination – the small sample size in
the EVLP arm limited the analyses to descriptive statistics and exploratory modelling. The other significant
limitation is that the EVLP protocol used changed mid-way through the study from a hybrid protocol to
the Lund protocol. This change came about following an analysis of the early safety data by the Data
Monitoring Committee and based on advice received after independent safety reviews.
Challenges to study enrolment activity
As each donor lungs offer was made to a transplant centre, the lungs were assessed for suitability for
standard transplantation. If they failed to satisfy criteria for standard transplantation, they were considered
for EVLP assessment and reconditioning. This was possible only if there was an appropriate potential
recipient for that donor organ (based on blood group, tissue typing and size matching) who had signed at
least an EOI form for the study. The criteria by which the decisions to perform EVLP were made were
clearly defined in the study protocol. If there was no matching recipient or no consented recipient
available, then the opportunity to perform an EVLP assessment was lost to the study.
The predicted activity for EVLP assessments of 240 over the 3.5 years of the study was based on the need
to enrol 102 EVLP transplants and the expected conversion rate of EVLP assessment to transplantation of
approximately 40–50%. The predicted EVLP assessment rate across the study was 6.6 per month. The
actual number of EVLP assessments performed in the study was, however, lower across the study sites at
< 3 per month, even when allowing for R&D delays to sites opening.
There were five potential reasons for the lower level of EVLP assessment activity seen in the study. There
was a learning curve for the teams in each site both with the EVLP technique and with confidence in
decision-making in the first few months of performing EVLP assessments. The delays in securing R&D approvals
impacted on this during the first 11 months of the study, meaning that many centres did not hit the ground
running. Difficulty in recruiting appropriately skilled clinical fellows to support the study in sites meant that no
dedicated clinical fellow time was available to support study activities initially. Overcautious interpretation of
EVLP inclusion/exclusion criteria by on-call transplant surgeons in sites led to missed opportunities to perform
EVLP on donor lungs offered but not accepted for transplant. At one centre, technical issues with the EVLP
system led to a delay in recruitment because of a change of equipment and a lack of confidence by the local
team, which needed to be overcome. Finally, on numerous occasions, the organ retrieval team were sent out
to evaluate donor lungs for EVLP that were not initially suitable for standard transplant to discover that with
some simple management the donor lungs improved to satisfy criteria for standard transplant. These were
then used in the standard arm of the study. Although a limitation of the study, this does suggest that
consideration could be given in future to optimising methods of retrieval of lungs for standard transplantation.
All sites performed audits of donor offer suitability for EVLP over a 1- to 2-month period in November and
December 2012 and this revealed at least three missed opportunities for EVLP assessment at each site.
This suggested that donor lungs suitable for EVLP were regularly available, but that the opportunities to
perform EVLP were not always taken.
Low conversion rate from ex vivo lung perfusion assessment to transplant
Once EVLP assessment and reconditioning of a donor lung was performed, the decision of whether or not
the lungs were used in transplantation was determined by the criteria outlined in the study protocol and
listed in Appendix 2. The conversion rate in moving from EVLP assessment and reconditioning to EVLP
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transplant was below our predicted rate of 40–50%, with 18 EVLP transplants performed from 53 EVLP
assessments (34%). The number of EVLP transplants in the treatment arm of the study therefore fell
behind predicted targets. The lower conversion rate was compounded by the lower than expected
numbers of EVLP assessment activity. Previous single-centre publications have suggested that much higher
conversion rates can be achieved, with levels of 82% reported in one large series.32
However, these single-centre reports can be very selective as to which donor lungs are placed on EVLP and
were not driven by a study protocol that defined the lungs that should be exposed to EVLP. It is interesting
that in the multicentre NOVEL study, in which selection of lungs to undergo EVLP is protocol driven,
a conversion rate of 55% was reported. Furthermore, in the NOVEL study the rate of PGD grade 3 was
21% in the 42 EVLP transplants.83
Actions performed to increase study enrolment activity
Amendment of consent procedures
In order to reduce missed opportunities to enrol patients receiving standard lung transplants into the
control group, the consent requirements of the study were changed. The investigators believed that, as the
study was simply collecting clinical outcome data in this group and there were no study interventions or
changes to routine care, reconsent on the day of transplant was unnecessary and dispensable. In addition,
it was felt that patients who had signed the EOI form but did not sign either a consent form or consent to
continue form on the night of standard transplant could be approached when conscious and fully
competent post transplant to sign their consent form retrospectively and be included in the study.
A substantial amendment to the study protocol was approved by the sponsor and the Research Ethics
Committee to make this change to the consent arrangements.
Communication
In an attempt to increase communication between the study management team, PIs and staff in the
participating sites, the following changes were made:
l The monthly investigators’ teleconference was also attended by the research nurse/study co-ordinators
and clinical fellows from each site, in addition to the site PIs. This allowed the wider study team to
contribute to discussions on study performance, and to highlight any specific difficulties at sites to the
study management team.
l The study newsletter was sent out monthly (previously was every 2 months) to update on study
progress against targets. The trial managers ensured that the newsletter was passed to the wider
transplant team in each site and to the donor management teams to improve engagement and also
use it as a means of reminding them of communal responsibility to the study through increasing EVLP
assessments of donor lungs.
Research nurses and fellows workshop
In order to support the research nurses/study co-ordinators and clinical fellows in each site, the trial
management team organised a face-to-face meeting in Newcastle in March 2013 to review the study protocol,
consent process, EVLP protocol and data collection. The fellows and nurses also set up a web-based discussion
group to support each other with queries and comments about study-related activities.
Missed ex vivo lung perfusion opportunity audit
Initial audits of donor lung offers in the study sites after 6 months of study activity identified a number of
missed opportunities to perform EVLP assessment and reconditioning of donor lungs that were not suitable
for standard transplantation. The failure to perform sufficient EVLP assessments represented the greatest
threat to the successful completion of the study in an acceptable time frame. The audit results provided
evidence that there was a clear potential to increase EVLP assessment activity if the study EVLP inclusion
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criteria were followed more carefully. A laminated, easy-to-follow sheet outlining the EVLP criteria and
a flow chart for decision-making was circulated to the on-call transplant surgeons and co-ordinators.
Each site was asked to prospectively audit donor offers on a regular basis and report the results of the
audit back to the investigator meeting to show improvement by reducing missed opportunities.
Study site visits
Although all sites were visited by the chief investigator and trial managers as part of site initiation, another
round of site visits was arranged by the chief investigator and trial manager prior to recommencement of
the study with the Lund protocol to provide support to local PIs, and to allow a meeting for questions and
answers about the study. This provided the opportunity to inform the wider transplant team (surgeons,
physicians, co-ordinators and perfusionists) at each site about the study progress and the importance of
their role in the process, as well as to address any misconceptions or misinterpretations in study criteria for
EVLP assessment and reconditioning.
The role of external agency support
The DEVELOP-UK study was fortunate to receive support from a number of groups who believed this to be
a very important study. The NHS commissioners provided NHS excess treatment costs and took a keen
interest in the progress of the study. The study management team ensured that the commissioners were
kept informed of progress in the study through newsletters, and they did get involved to stress the
importance of the study to NHS trusts from whom they commission lung transplant services. In addition,
NHSBT also provided support with donor data and highlighted the importance of the study in official
documents. The support offered by these agencies is testimony to the importance placed on the work by
the professional NHS community.
Modifications to the ex vivo lung perfusion standard operating procedure
The DEVELOP-UK study investigators recognised that the conversion rate from EVLP assessment to EVLP
transplantation of just 36% was significantly lower than that reported in other small series in single centres
worldwide.29 This might reflect the nature of the donor organs being used in the DEVELOP-UK study, but
could also reflect the SOP for EVLP used in the study initially. When the study protocol was first designed,
the decision of the investigators was to adopt a hybrid approach containing elements of both the Toronto
and Lund approaches. The use of the Vivoline system at all sites in the study did mean fixing some aspects
of the SOP, such as having an open left atrium, but the consensus among the investigators was to adopt
some aspects of the Toronto protocol as well with a limited flow and acellular perfusate. At the time the
initial SOP was agreed, worldwide experience was substantially higher with the acellular and limited-flow
approach than with a blood-based perfusion and full-flow approach.
However, after the study commenced, experience with the Vivoline EVLP system had grown worldwide
and several groups (Gothenburg, Copenhagen and Brisbane) generated single-centre series with the Lund
approach of full flow and red blood cell-supplemented perfusate and an open left atrium. The conversion
rate from EVLP assessments to EVLP transplants using the full Lund protocol and the Vivoline system has
been reported as being significantly higher, at > 80% than that which was experienced in the first stage of
the DEVELOP-UK study.
In an attempt to increase EVLP transplant activity in the DEVELOP-UK study, and following advice from the
independent expert review, the investigators agreed to amend the EVLP SOP to follow the Lund approach
in its entirety. This was hoped to have a significant impact in converting EVLP assessments to transplants
and boosting enrolment to the treatment arm of the study. The impact of such a change on patients
already enrolled into the EVLP arm was discussed with the Trial Steering Committee independent
statisticians. It was felt that any effect of change of SOP could be considered at the end of the study in an
appropriate subanalysis. This subanalysis was performed and the findings were discussed earlier in
this chapter.
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Health economic analysis
The study included both a within-study assessment of costs and HRQoL, and an exploratory economic
model. For the within-study data, it is obvious from the large SDs of Tables 30–37 that there is significant
variation in the cost associated with the transplant of each individual, no matter which one of the two
procedures was followed. This means that there is a large variability between the lung recipients regarding
the resources required in each stage of the study.
Based on the calculations made, the average total cost per recipient for the standard donor lung
transplantation is equal to £59,608 (SD £42,664). Almost half of this cost (£34,109) consists of the cost
of the post-operative care, which also shows the biggest variability between the patients (SD £39,561).
This large difference mainly lies on the need for ECMO and the length of stay in the ITU. In the standard
arm, the mean total QALYs gained per recipient were estimated to be 0.533.
As far as the EVLP lung transplant is concerned, the total cost of the transplant was estimated to be
around £139,081 (SD £58,916). This high cost is partially a result of the cost of the EVLP procedure
(mean cost £42,633) and partly because of the cost of the post-operative care (mean cost £56,136).
The variability in the total EVLP cost is similarly high, showing that the cost of the EVLP transplant might
vary up to £58,916 from the average cost per recipient. This variability is, again, because of the use of
ECMO and the length of hospital stay that the recipient might require after the transplant. Finally, the total
QALYs gained per EVLP recipient were estimated to be 0.527.
A regression model on cost identified three statistically significant predictors of increased total cost: higher
quality of life when the person joined the waiting list; use of EVLP procedure; and transplanting two lungs
rather than one lung. A sensitivity analysis excluding quality of life on joining the waiting list (because
relatively few respondents completed the SF-36 at this point) gave broadly similar results, but was a much
poorer fit for the model data. One value of the regression model results is that information is now available
to assist researchers involved in modelling events that include lung transplantation. They now have an
additional data source that can be used and tailored to the characteristics of the patients modelled.
The exploratory model-based analysis estimated an incremental cost per QALY was £73,000, well over the
typical ceiling ratio adopted by NICE.
The average discounted lifetime cost for a standard lung transplant was £64,861 and £69,358 for when
EVLP available. The number of discounted life-years was 5.38 for standard transplant and 5.41 in the EVLP
service, the increased life-years in the EVLP service reflect the increased number of lung transplants in the
EVLP service: 726 transplants in the standard service and 742 in the EVLP service. The discounted QALYs
are 3.48 and 3.54 in the standard and EVLP services, respectively. The higher level of QALYs in the EVLP
service reflected both the increased life-years in this service and the higher utilities in the EVLP recipients.
The conclusion was broadly consistent across the range of scenarios considered. Given the novel nature of
the therapy, it is not possible to put these findings into the context of other research. A comprehensive
literature review identified no other cost-effectiveness studies comparing EVLP lung transplantation with
standard lung transplantation.
As far as the exploratory model-based analysis is concerned, the analysis suggests that non-technical
solutions to increasing the availability of lungs for transplant may be worthwhile investigating. At present,
the Newcastle and Birmingham lung transplant teams are carrying out EVLP lung transplant again as part
of a service evaluation. This will provide a valuable opportunity to assess whether or not the increase in
standard lung transplant witnessed during the DEVELOP-UK study is replicated when EVLP is again
available as a back-up for substandard lungs.
Strengths and limitations of the within-trial descriptive analysis
The economic evaluation and regression model within the DEVELOP-UK study draws upon the strengths
described above. It also suffers many of the same limitations; primarily caused by the limited number of
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data available on EVLP. Therefore, the within-study economic component was limited to a descriptive
analysis of the available data; any comparative data are presented primarily for illustrative purposes,
and thus should be treated cautiously.
In addition to the limited sample size, there was also a considerable degree of missing data in some parts
of the CRF sent by certain sites, which meant that assumptions based on the data collected from the rest
of the sites needed to be made. Similarly, responses were sought on the SF-36 for all participants while
they were still on the waiting list, as well as after 90 days and 12 months from the date of the transplant.
However, there were a considerable number of missing responses from the SF-36, which meant that
robust estimates of QALYs could not be made. This same issue limited the regression model on costs.
However, a model excluding quality of life that therefore included data from more study participants was a
much poorer fit for the data, although it did provide similar results.
Although considerable efforts were made to capture costs over the entire patient pathway, the different
administration and organisation systems between the transplant sites meant that data were not readily
available to estimate the patient’s travelling to the transplant centre before surgery. Consequently, these
costs were considered as missing. This means that total costs were underestimated, although it was
believed that these costs would make up only a small proportion of total costs.
Strengths and limitations of the exploratory analysis model
Model strengths include the following: the parameters used in the model were all based on the UK adult
lung transplant population, so were generalisable to this population; ISPOR guidelines55 were followed
when designing the model, so as to reflect best practice; and uncertainty was evaluated using sensitivity
analysis. Nevertheless, the limited number of data available from the DEVELOP-UK study imposes
limitations on the model.
In addition to the generally limited data, a further key model limitation is that, in the model, it was assumed
that when a patient in the waiting list state was removed from that state to a state ‘removed from waiting
list’ (state G), they no longer accrued any costs or utilities. This assumption is in line with assumptions
made in a Dutch economic evaluation of a lung transplant service.84 Although the reason for removal from
the waiting list is unknown, it is reasonable to assume that most patients will be removed as a result of
worsening health. The impact of this is to increase average total QALYs and reduce average total costs.
This in turn would improve the cost-effectiveness of the standard service relative to the service including
EVLP, because for the standard service people are less likely to be transplanted in any given time period and
hence are more likely to be removed from the list before a transplant.
The qualitative interview substudy
Patients’ understanding and information needs regarding ex vivo lung perfusion
Generally, patients had a good understanding of what was involved in EVLP and were able to give clear
explanations of what was involved. However, some patients gave confused explanations or appeared to
have a limited understanding of EVLP. This may be explained by conclusions from other research, which
suggests that the severity of someone’s illness may affect the amount of information that they are able to
retain.85,86 Alternatively, it could be, as Lowton has argued,69 that simple definitions such as those offered by
the participants in this study may illustrate a limited understanding and lack of information. All patients
were provided with the same information when taking part in a study. Long et al.87 suggest that when
information is being given at a very emotional time, it is difficult for patients and their families to take in all
the detail, and thus that there is a need for better methods of communication to be employed. Information
giving in any study is always challenging and it may be, as Entwistle et al.88 have argued, that to improve
everyone’s understanding, key facts about the research should be given to everyone, with supplementary
information available for those who request it, including links to online resources.
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Reasons for participating in the DEVELOP-UK study
This qualitative substudy suggests a number of reasons why people consented to take part in the DEVELOP-UK
study. First, many people interviewed appeared to think that participating in the DEVELOP-UK study might
increase the likelihood of them receiving a transplantation sooner. Echoing the research of Bjørk et al.,89 one
of the concerns expressed by several patients was the increasing possibility that that the longer they waited
the greater their chance of dying while on the transplant list. Second, people gave altruistic reasons for taking
part, such as wanting to help other patients or the clinical team, in whom they had a great deal of trust. Other
studies have found that trust in the clinician90 or the notion for some that they will be the ‘first to [have a] go’
may be enough to override any uncertainties patients may have about a treatment.86 As noted earlier, it is
important to emphasise that, for many people, consenting to take part in the DEVELOP-UK study was not
considered as significant a decision or event as actually being placed on the transplant waiting list in the first
place. The emphasis placed by patients on decision to go on the transplant register ought to be reflected in
the information we give patients.
Impact on everyday life of waiting for a transplant
It is recognised that any chronic condition can have a potentially ‘disruptive’ effect on people’s lives and
their own biographies,91 and this would seem to be true for patients in this study. Waiting for a transplant
involves multiple ongoing disruptions to everyday life, and has an impact not just on patients themselves,
but also on others, usually their family.92,93 Patients have to continually adjust to new routines, restrictions
and, sometimes, new treatment regimes. When a patient experiences false alarms or hospital stays as a result
of deterioration of their condition, their lives are further disrupted.91 This waiting, for some, disrupts life to
the extent that life is on hold, in limbo; as Naef et al.93 have argued, the waiting rules their life.
Waiting for a transplant involves experiencing and balancing hope and despair, illness and good health,
survival and function. For example, patients need to be sick enough to be put on the list but stay well
enough for a transplant should this be offered. Initially, when they are placed on the transplant list they
are filled with hope,94 but this can often be replaced by feelings of disappointment as the wait continues
and they realise that they may not get a transplant in time.95 Patients must also manage being on the
waiting list and waiting for a transplant with continuing to try to live their everyday lives and function
within their families (and for some at work), all of which must be balanced alongside the deterioration of
their condition and the further limitations this imposes on them.96 The impact of deteriorating health, the
experience of waiting and the possibility of dying before a transplantation may provide some insight into
why people wanted to take part in the DEVELOP-UK study.
Strengths and weaknesses of interview substudy
One of the strengths of this qualitative study is that it gives a unique, detailed insight into patient views,
expectations and experiences regarding EVLP specifically, and lung transplantation more generally.
The use of telephone interviews in this study enabled us to interview a diverse group of patients spread
over a large geographical area. This approach to interviewing in this study appeared to be particularly
successful as, given the need for patients to avoid infection and remain well enough to be able to receive
a transplant, telephone interviews bore no additional risk to patients in terms of infection. Recruitment to
interviews may not have been as successful if patients were required to take part in face-to-face interviews.
This is something that may be of use when considering recruiting to future research with vulnerable and/or
very sick patient groups.
The weaknesses of this qualitative research are twofold. First, because of the limited number of patients
who underwent an EVLP transplant, there were few patients with this experience to recruit. This means
that it is difficult to infer anything from the findings specifically about EVLP post-transplantation
experiences. Second, the only patients available to be invited to participate in the qualitative study were
those who had agreed to be part of the main trial, thus we know nothing of the reasons why people did
not want to take part in the trial.
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The data from this qualitative substudy provide some insights into patients’ experiences, which can be
used to improve future practice development in the area of transplant research and EVLP research in
particular. This substudy suggests that patients had a good understanding of the need for, and processes
of, EVLP, although in the future clinicians may want to consider exploring different ways and modes of
providing information depending on patient preferences. Finally, this work appears to suggest that if EVLP
can increase the number of suitable donor lungs available, then it is likely to be regarded as an acceptable
technology to patients waiting for a lung transplant.
The DEVELOP-UK study implications for practice
The DEVELOP-UK study is the first to report poorer outcomes in a group of EVLP transplants than a
contemporaneous standard lung transplant group. It is, however, the first non-commercial multicentre
EVLP study performed and relied on a small number of centres (five) in a single country to aim to deliver a
substantial number of EVLP assessments and subsequent transplants. To date, two commercially funded
multicentre EVLP studies have been performed, but have not yet published their results other than in
abstract format.97,98
The slow enrolment into the EVLP arm of the study was because of a combination of the low number of
EVLP assessments performed, and the low conversion rate from EVLP assessment to transplant. This
demonstrates the challenge of running an EVLP assessment service alongside an active clinical transplant
programme, when logistics and staff availability because of competing transplant activity can significantly
affect units’ ability to perform EVLP assessments, even if resourced.
The higher rate of early PGD grade 3 and need for ECMO support in the EVLP arm has raised issues about
the selection of the best lungs on which to perform EVLP. Although there was a much higher ECMO rate
in the EVLP arm, it was not associated with a higher mortality risk in the recipients undergoing ECMO,
which in most cases was limited to a few days’ support. The almost uniform use of cardiopulmonary bypass
in recipients of EVLP donor lungs (89%) may have also contributed to the high early PGD 3 rates and the
frequent use of ECMO as a second hit to donor lungs, which already have a disrupted vascular integrity.
Finally, it appears that use of our hybrid EVLP protocol was not as effective in terms of conversion rate
and possibly 1-year survival after transplant as the Lund protocol, suggesting that mixing elements of
established protocols is not advisable and that matching the appropriate protocol to the appropriate EVLP
circuit is an important consideration.
Overall, our main conclusion is that EVLP using a Lund protocol has the potential to offer an increased
chance of achieving effective lung transplant in patients at high risk of death on the waiting list.
The DEVELOP-UK study implications for future research
After completing a study of the complexity of DEVELOP-UK, it is important that time is taken to reflect on
what lessons can be learnt and how these should guide future research in this area. Although the overall
findings of the DEVELOP-UK study were not what was hoped for, and did not allow the original research
question to be definitively answered, there are still a significant number of factors to consider that will help
to direct further research in the area of EVLP.
Study design
The decision to conduct an open, observational, non-inferiority study was made after careful consideration
by the investigator group, in consultation with the HTA programme commissioning brief. However, this
approach brought with it some significant challenges. The open nature of the study meant that bias was
introduced to the wider clinical teams when early complications occurred. This is likely to have contributed to
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poor recruitment of lungs for EVLP. It is unlikely to be possible in the future to blind investigators to which
organs have been exposed to EVLP assessment and reconditioning if EVLP is conducted at all investigating
sites. However, in the future, if EVLP activity was concentrated in a smaller number of more experienced sites
and then organs were transported after EVLP to remote sites, this could reduce the risk of bias.
There is also the issue of what is the best research question to evaluate in a future EVLP study. It has been
suggested that a better question than comparing EVLP with standard lung transplant outcomes is to
compare EVLP outcomes with the risk of waiting list mortality. The difficulty with this question is that not
everyone on the waiting list has access to organs in an equal way. Size, blood group and presence of
pre-formed HLA antibodies can limit access to transplant opportunity in some patients, and there is also
the issue that EVLP might be offered more readily to the more severely ill patients on the list to reduce
their waiting time on the transplant list. To compensate for these potential confounders, it might be
possible to consider a cluster-type study, with some sites acting as control centres, and others with specific
experience offering EVLP.
Study logistics
The model of having dedicated EVLP centres may also be important to consider if future multicentre EVLP
studies are to be successfully performed. Our experience was that one centre (Newcastle) did 50% of the
EVLP assessments and 50% of the EVLP transplants, and the other four centres did not achieve their targets
for recruitment of donor lungs to undergo EVLP. This suggests that expecting every transplant centre to be
able to provide an EVLP service is probably unrealistic, even if appropriate resource is provided. EVLP makes
an already challenging clinical situation with an emergency surgical procedure requiring huge manpower
resources even more complicated. Centres enrolled in EVLP studies in the future should have previously
demonstrated an ability to deliver a clinical EVLP service effectively and have performed at least 15–20 EVLP
procedures before being invited to enrol in an EVLP study.
Choice of ex vivo lung perfusion protocol
There is evidence that both the Toronto and the Lund protocols can be effective at assessing and
reconditioning donor lungs for transplantation. There is a different philosophy behind each protocol with
real physiological differences. In the future, work should be done to help determine which elements of the
protocols are critical. Our use of a hybrid approach at the start of the DEVELOP-UK study was associated
with a high rate of early severe PGD and need for ECMO. The reason for this requires further investigation,
particularly whether or not a combination of EVLP followed by performing transplant surgery on
cardiopulmonary bypass causes a second hit, which increases vascular leak and early reperfusion injury.
In addition, as all but one of the recipients who required ECMO was weaned from this support rapidly, it
raises the question if this should be considered a prophylactic intervention to any recipient receiving a
higher-risk donor lung after EVLP. The use of ECMO routinely intraoperatively in higher-risk recipients is
increasing internationally and maybe this approach should be considered for higher-risk donor organs
as well.
Identifying which donor lungs should undergo ex vivo lung perfusion
The conversion rate from EVLP assessment to transplant varies significantly in the published case series from
> 90% to 40%. In the DEVELOP-UK study, only 30–40% of the donor lungs perfused satisfied transplant
criteria. It is unclear if this was a problem with donor organ selection for EVLP or a result of the rigidity of
following a multicentre prospective study protocol, which imposes stricter decision-making than would
happen in a single centre outside a formal study setting. The conversion rate has a significant effect on
overall costs of offering an EVLP service, and a target conversion rate of > 50% would seem reasonable to
aim for. More work needs to be done to help identify which donor lungs can be effectively reconditioned
and for which EVLP should not be considered.
In conclusion, many lessons were learnt in conducting the DEVELOP-UK study, and a future study would
need to be designed differently, in order to have a better chance of hitting its recruitment targets, and of
fully addressing the research question.
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Appendix 1 Couraud et al.’s classification of
anastomotic healing
The grades corresponding to Couraud et al.’s classification40 of anastomotic healing are:
l grade 1 – complete circumferential primary mucosal healing
l grade 2A – complete circumferential primary healing of the airway wall without necrosis and partial
mucosal healing
l grade 2B – complete circumferential primary healing of the airway wall without necrosis but no primary
mucosal healing
l grade 3A – limited necrosis
l grade 3B – extensive necrosis.
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Appendix 2 Standard operating procedures
 Ex-Vivo Lung Perfusion (EVLP)
Standard Operating Procedure (Version 3.0: 5th July 2013) 
 Location:
EVLP is performed in a suitably designated clinical area that fulfils the necessary infection 
control precautions. In most cases this will be in an operating theatre but it could be in an air-
locked ICU cubicle with operating theatre standard positive pressure ventilation. 
 Equipment:
• Vivoline evaluation unit: An integrated roller pump (Jostra), heater cooler unit, gas 
system, monitor and control unit with associated software package. 
• Vivoline disposable lung set: Includes an oxygenator (Capiox), LDF leukocyte filter, 
pressure sensors and temperature probes. 
• 93% Nitrogen and 7% CO2 gas mixture cylinder on a trolley:  A full cylinder 
contains 10000 litres and each EVLP run requires at least 2000 litres of gas mixture (3 
hours). 
• Oxygen supply: From the wall outlet. 
• ICU standard ventilator: Model that measures minute and tidal volumes, lung 
compliance / resistance and airway pressure. 
• Arterial blood gas machine. 
• Standard thoracic surgical instrument tray. 
• Sterilised bronchoscope: With suction tubing and lavage traps, 5, 10 and 20ml syringes. 
• Sample collection disposables: Includes Duet-stapler devices for lung biopsies, specimen 
pots for tissue, test tubes for perfusate and ice bucket or refrigerator for sample storage 
(please refer to sample SOP). 
 
 Medications:
• Saline 0.9%: 240mls for 2xBAL and additional 100mls for flushing pressure transducers. 
• Steen Solution: At least 4 x 500ml bottles. 
• Packed Red Blood Cells: Request 3 packs of red blood cells from the blood bank, 
either universal donor (O negative) if >1 potential recipient identified or cross matched to 
the single known recipient. 
• THAM/TRIS solution: Use a preparation containing Trometamol 3.0mmol/ml in a 
quantity as directed by base deficit to a Base Excess +/- 3 and pH of 7.35 – 7.45 (see 
Appendix 1). 
• Heparin: 10,000IU unfractionated. 
• Methylprednisolone: 500mg. 
• Antibiotics: Meropenem 500mg is the default antibiotic if there is no documented 
recipient allergy to ß- lactams. If donor airway cultures known, other antibiotics can be 
used after discussion with microbiology. 
• Amphotericin B: 10 mg for injection (Amphocin, Fungizone or equivalent). 
• Actrapid Insulin and 10% Glucose Solution: Possible requirement for 10ml of 10% 
Glucose solution and 20 IU Actrapid Insulin but not routinely used. 
 Priming the Circuit:
• Connect the disposable kit to the evaluation unit according to user manual instructions. 
• Flush the pressure transducers. 
• Connect the water to the heater-cooler unit, open the water bag. 
• Start the priming phase on the screen. Check the oxygenator for leakage. 
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• Calibrate the pressure transducers. 
• Fill the system with 2.0L Steen solution (4 x 500ml bottles). 
• Calibrate the pump occlusion by following the screen instructions. 
• Recirculate perfusate at 15°C set flow to 2.0 L/minute and maximum perfusion pressure at 
10 mmHg. 
• Connect the gases. 
• Add 10,000IU of unfractionated Heparin to circulating Steen solution. 
• Add 1-2 units of Packed Red Blood Cells. 
• Prepare 500mg dose of Methylprednisolone. 
• Make up Antibiotics and Amphotericin B according to manufacturers’ instructions. 
• Add Methylprednisolone, Antibiotics and Amphotericin B to the circulating perfusate. 
• Do a perfusate blood gas analysis and correct the base deficit with THAM to a Base 
Excess +/- 3 and pH of 
7.35 – 7.45. Add 3 mmol THAM per minus unit in base deficit please see Appendix 1. 
The blood gas needs to be temperature corrected for 15oC. 
• Note haematocrit of perfusate on blood gas. Target is 10-15% so add more red cells if 
needed. 
• Check perfusate glucose and potassium concentration via blood gas analysis; if glucose 
<5 or >20 mmol or potassium >7mmol correct with Insulin as per Appendix 2. 
• Repeat the perfusate gas prior to connecting the lung for any further corrections. 
• The perfusate, pharmaceuticals and gases should be circulated for ≥15 minutes before 
connecting the lung. 
• If satisfactory, start the reconditioning phase. 
 
 Reconditioning Phase:
• Surgical dissection is performed to allow placement of the donor lung onto the Vivoline 
EVLP circuit in the covered organ bath to maintain humidity. 
• Before connecting the lung to the circuit, take Lung Biopsy #1 from the RML or Lingula 
and collect Perfusate Sample P0 (See separate Sample collection SOP). 
• Cannulate the main pulmonary artery with the quick-fix pre-fashioned cannula and open 
the shunt to the inflow cannula. 
• The left atrium is left open and visualised to ensure a smooth flow of perfusate. 
• The LA temperature probe and sampling line is secured in place equal distance from the 4 
pulmonary veins. 
• Where possible the trachea remains clamped with lungs partially inflated with 50% FiO2 
while the quick-fix ventilation tube is secured in place. This prevents collapse of the 
lungs and development of atelectasis prior to the ventilation. 
• Set the pulmonary artery (PA) pressure to a maximum of 15 mmHg. 
• Perform de-airing of the circuit with the shunt open at a flow of 0.5L / minute for 
approximately 2 minutes until fully de-aired. Leave the shunt open. 
• Set temperature to 32oC.  The  system  will  warm  up  the  lung  automatically  with  a  
maximum  delta temperature of less than 8°C. 
• If initial perfusion is uneventful, increase the PA pressure limit to 20 mmHg and flow to 
maximum. 
• The recommended max flow is 70 ml/kg IBW /minute (see Appendix 3). With a cold lung 
the pressure will limit the flow, when the resistance in the lung goes down the flow will 
increase over time. 
• When temperature has reached 25oC close the shunt. 
• At 32oC remove the clamp on the trachea and before commencing ventilation, perform a 
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bronchoscopy and collect BAL sample #1 from either RLL or LLL using 120 ml 0.9% 
NaCl with the bronchoscope in a wedged position (See separate Sample collection SOP). 
• Commence mechanical volume-controlled ventilation at 32oC with a protective ventilation 
strategy: 
• Set inspired oxygen (FiO2) to 0.5 (50%) 
• Set respiratory rate (RR) initially to 5 or 8 breaths/min according to donor IBW (see 
Appendix 4) 
• Set Minute volume (mV) initially to 1 L/min 
• Set PEEP at 5cmH2O 
• Set I:E ratio 1:2 and inspiratory pause at 10% 
• Keep peak airway pressure <20 cmH2O 
• Increase temperature from 32oC to 37oC. 
• Increase the mV in 1 L/min increments gradually as lung warms to 37oC; mV should 
not exceed 1.5X the flow. Continue to keep peak airway pressure (Paw) < 20 cmH2O. 
Increase the RR, as mV increases, up to a maximum of 15 breaths/min to keep tidal 
volume <7ml/kg IBW (see Appendix 4). 
• At 32°C the perfusate flow is usually lower than the set value, please note the flow as 
the lungs warm to 37°C as the minute volume should not exceed 1.5X the flow. 
• If uneventful and once 37°C reached, mV can be increased gradually up to a maximum 
of 100ml/kg IBW/ min but the tidal volume should not exceed 7ml/kg IBW (see Appendix 
4). 
• If persistent atelectasis present, perform a recruitment manoeuvre by transiently 
increasing PEEP from 5cmH2O in increments of 1cmH2O for a few breaths  to  a 
max of 12cmH2O while always keeping Paw <25cmH2O. Note flow will fall 
significantly during increase in PEEP. After recruitment return PEEP to 5cmH2O. 
• Flow, PVR, Lung Compliance and PA pressure to be documented once lungs reach 37°C 
and flow stabilised. 
• Once lungs are at 37°C with stable flow and ventilation settings and satisfactory 
appearance, shift to the evaluation phase. 
 Evaluation Phase:
• Once re-warming is complete and target perfusion established, the function of the donor 
lungs undergoing EVLP can be assessed as specified in the study protocol. 
• Disconnect the oxygen from the perfusion system prior to evaluation. 
• Once the perfusate is deoxygenated and confirmed on blood gas analysis, perform 
recruitment manoeuvres as above and set the ventilator for evaluation as below: 
• Increase FiO2 via the ventilator from 50% to 100%. 
• PEEP can be increased to 8cmH2O for a short period. 
• Maximum mV should not exceed 100mls/kg/min (donor IBW) 
• Keep peak airway pressure Paw <25cmH2O 
• RR can be adjusted between 12 and 15breaths/min to maintain VT  up to a maximum of 
7ml/kg (donor IBW) 
• Perform blood gas analysis 15 minutes after FiO2 is increased to 100% to assess 
venous and arterial pO2 values. Blood gas analyses should be performed from each 
pulmonary vein as well as a mixed LA sample. 
• Flow, PVR, Lung Compliance and PA pressure should be carefully documented on the data 
sheets. 
• Perform a lung deflation test by disconnecting the tracheal tube at the end of inspiration. 
Remember to first reduce perfusate flow to maximum of 1.5L/min to avoid alveolar 
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oedema. Recoil of the lungs is evaluated subjectively; global collapse of the lungs is 
defined as normal. 
• If  transplant  suitability  criteria  have  been  achieved,  move  immediately  to  cooling  
phase  for  organ preservation. 
• If transplant suitability criteria have not been achieved, return to the reconditioning phase. 
• Perform hourly clinical assessments as documented in the protocol until a decision on 
suitability of the lungs for transplantation or 240 minutes of EVLP perfusion has been 
reached (from the time of reaching 37°C). 
• During perfusion if pH <7.35 administer additional THAM to the Steen Solution™. 
• During perfusion do not automatically replace Steen Solution™. 
 
 Cooling Phase:
• Reduce mV by a 30% reduction in tidal volume and lowering respiratory rate to 8 
breaths/min 
• Set temperature to 32°C 
• Reconnect the oxygen to the perfusate. 
• Before discontinuing ventilation, perform a bronchoscopy and collect BAL sample #2 
from the same lobe, but from a different segment than BAL sample #1, using 120 ml 
0.9% NaCl with the bronchoscope in a wedged position (See separate Sample collection 
SOP). 
• Stop ventilation at 32°C, clamp trachea with lungs partially inflated with 50% FiO2. 
• Set temperature to 12°C and continue to cool lungs until perfusate temperature 12°C. 
• Collect Perfusate Sample PX. 
• Disconnect PA cannula and plug PA with special bung. 
• Once perfusion has stopped and the lung is disconnected, take Lung Biopsy #2 from the 
same lobe as Lung Biopsy #1 (See separate Sample collection SOP). 
• Commence topical cooling. 
• Place mat under lungs and wrap towels over lungs so that they touch the mat all around 
lungs. 
• Connect the Y shaped hose from the cooling assembly to the lung perfusion quick 
connection and cover the highest point of each lung. Connect the remaining hose from 
the cooling assembly to the shunt quick connection and place over the trachea and PA. 
• In the preservation phase set pump to 2.5 L/ min. Check fluid level and add more Steen 
Solution if necessary. 
• Maintain the lungs in topical Steen solution at 6 - 8 °C on the circuit (preservation 
phase) until ready for transplant. 
 
 Adaption for Single lung Reconditioning
• For cannulation, if feasible staple the contralateral PA (right PA if it is a left lung 
transplant or vice versa) at least 2 cm above its first branch to facilitate as much length as 
possible. If the pulmonary artery is too short and/or the surgeon is unable to fit the 
quick-fix pre-fashioned cannula, use a part of the donor’s aorta to augment the cuff. 
• For connection of the bronchus, please note there are 3 sizes of connection available in the 
disposable kit to aid achieving an effective connection. If it is a right lung EVLP, staple 
the left main bronchus at the level of the carina and cannulate the trachea. If it is a left 
lung EVLP, the left main bronchus from the level of the carina should be long enough to 
facilitate attachment. Ensure a seal that prevents either ineffective ventilation of fluid 
entering the airway. 
• Set to 50% target flow i.e. 35 ml/kg body weight/minute. 
• When starting ventilation, start at a minute volume of 0.5 L/min and increase to a 
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maximum of 1.5 times the perfusate flow. 
 
 Appendices:
Appendix A 
Use of THAM/TRIS to buffer Steen Solution: THAM is available in various dilutions 
(ranging from 3.6% (Abbott, Köhler) to 36.5% (Braun) or 40% (Fresenius-Kabi or Addex-
THAM) so caution is advised in measuring the correct amount. PLEASE CHECK THE 
CONCENTRATION OF YOUR THAM PREPARATION! 
A 3.6% solution of THAM contains a concentration of Trometamol (active 
ingredient) of 0.33mmol/ml A 40% solution of THAM contains a concentration of 
Trometamol (active ingredient) of 3.0mmol/ml When buffering Steen solution in the 
circuit use 3mmol of THAM per minus unit in base deficit. 
This will be 1ml per minus unit base deficit for the 40% THAM preparations and 10ml per 
minus unit base deficit if the 3.6% THAM preparation is used. 
A THAM preparation of between 3.0 – 3.3 mmol/ml is strongly recommended and use of 
lower concentrations strongly  discouraged  due  to  the  dilutional  effects  on  Steen  Solution  
of  adding  large  volumes  of  a  lower concentration THAM. 
 
Appendix B 
During perfusion administer 10ml of 10% Glucose if the perfusate glucose concentration 
falls below 5mmol/L. If the glucose concentration is above 20mmol/L then add 10 IU 
Actrapid Insulin to perfusate. Recheck glucose 5 min after any intervention. If potassium is 
>7mmol then administer 10 IU Actrapid Insulin and recheck potassium and glucose 5 min 
after intervention. 
 
Appendix C 
The ideal body weight calculation formulae used to determine the tidal volumes in protective 
lung ventilation are:  
IBW (kg) for men = [(height (cm) -154) x 0.9] + 50 
IBW (kg) for women = [(height (cm) -154) x 0.9] + 45.5 
If you copy/paste below link you’ll get an online IBW calculator 
http://www.ukmicentral.nhs.uk/resource/calcs/ibw.asp?group=m 
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Appendix D - Ventilation strategy see chart below 
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Study Card Version 3.0, July 2013 
 
 
A Study of Donor Ex-vivo Lung Perfusion 
In United Kingdom Lung Transplantation 
RECIPIENT INCLUSION / EXCLUSION CRITERIA 
Inclusion Criteria 
•  Male or female patients 
•  Adult patients (aged over 18 years) 
•  Patients already on or added to the active waiting list for first lung transplant while the 
DEVELOP-UK study is in its recruitment phase 
•  Patients providing informed consent for participation in the DEVELOP-UK study at the time 
of study commencement or time of listing for transplant* 
•  Patients in EVLP treatment group re-confirming informed consent for the DEVELOP-UK 
study on the day of lung transplant* 
* If Informed Consent Form was signed on the day of transplant re-confirming consent is not required. 
Patients in standard control group are not required to re-confirm informed consent on the day of 
transplant if they have signed the Expression of Interest Form or the Informed Consent Form prior to the 
transplant. 
 
Exclusion Criteria 
•  Patients aged less than 18 years 
•  Patients listed for lung re-transplantation 
•  Patients listed for heart-lung transplantation 
•  Patients listed for live donor lobar transplant 
•  Patients not in possession of patient information sheets for the DEVELOP-UK study prior to 
the day of lung transplant 
•  Patients in EVLP treatment group not re-confirming consent for the DEVELOP-UK study on 
the day of lung transplant* 
•  Patients in the ITU requiring invasive ventilation, ECMO or Novalung support 
•  Patients enrolled in Trials within the preceding 12 months (please discuss with principal and 
chief investigators before exclusion on this basis).* If Informed Consent Form was signed on 
the day of transplant re-confirming consent is not required. 
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Study Card Version 3.0, July 2013 
 
ABSOLUTE CONTRA-INDICATIONS TO DONOR ORGAN USE  
FOR TRANSPLANT (BASED ON NHS BT GUIDELINES) 
 
Donation after Brain Death (DBD)  
•  Age >85 years 
•  Cancer with evidence of spread outside affected organ (including  
lymph nodes) within 3 years of donation (however, localised prostate, 
thyroid, in situ cervical cancer and non-melanotic skin 
cancer are acceptable) 
•  Active melanoma 
•  Choriocarcinoma 
•  Active haematological malignancy (myeloma, lymphoma, leukaemia) 
•  Definite, probable or possible case of human TSE, including CJD and vCJD, 
individuals whose blood relatives have had familial CJD, other neurodegenerative 
diseases associated with infectious agents 
•  TB: active or within 6 months of treatment* 
•  Malaria: if not fully treated* 
•  Meningoencephalitis for which no infection has been identified* 
•  HIV disease (but not HIV infection) 
* in exceptional cases 
 
Donation after Cardiac Death (DCD) (NHSBT Guidelines) 
• As above but age >80 years 
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Study Card Version 3.0, July 2013 
ABSOLUTE CONTRA-INDICATIONS TO DONOR LUNG USE FOR STANDARD 
TRANSPLANT OR FOR EVLP 
•  Donor age >65 years 
•  Donor HIV positive or other contra-indicated infection risk eg 
Hepatitis 
B or C unless being used for a HIV, Hepatitis B or C positive recipient 
•  Chest trauma with extensive bilateral lung contusions 
•  Convincing evidence of bilateral pneumonic consolidation on 
inspection  
•  Pre-existing structural lung changes (e.g. emphysematous or multiple large bullae) 
•  Previous complex intra-pleural thoracic surgery or dense adhesions prohibiting safe 
lung procurement 
•  Confirmation of malignancy within 5 years (excluding central nervous system 
malignancies) 
 
DONOR  LUNG  PROCUREMENT  FOR  ALL  LUNGS 
 
The standard lung procurement procedure will be followed for donor lungs 
to be used for EVLP.  
•  Flush the organs ante-gradely with supplemented (3.6% THAM 3.3 
mls, 0.6 ml CaCl +/- 2.5 mls Prostacyclin / litre) Perfadex®: 
 the first 1 litre at room temperature,  
 the rest at 4oC. Give a minimum volume of 60ml/Kg.  
•  After the antegrade dose, give 200 ml down each pulmonary vein as a final retrograde 
flush.  
•  An adequate portion of main pulmonary artery (PA), left atrial cuff and particularly at 
least 4cm of trachea will be taken by the retrieval surgeon.  
•  A piece of aorta will be required to extend a deficient main PA (divided in close 
proximity to the bifurcation) to allow for successful cannulation and bilateral 
perfusion. 
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Study Card Version 3.0, July 2013 
CRITERIA FOR STANDARD TRANSPLANT 
(DBD AND DCD DONOR LUNGS) 
  
Using Donation after Brain Death (DBD) donor lungs 
•  Satisfactory Chest X-ray reviewed by retrieval surgeon   
•  Systemic arterial PO2  > 35-40 kPa on 100% FiO2 and 8cm 
H2O PEEP 
•  Selective Pulmonary Vein (PV) Gases >30kPa on 100% FiO2 
and 8cm H2O PEEP 
•  Peak airway pressure < 30 cmH2O 
•  Bronchoscopy – no severe inflammation of the airway, or recurrent secretions in the 
distal airway after adequate bronchial toilet 
•  Easily recruited atelectasis 
•  Satisfactory deflation test on disconnecting endotracheal tube 
•  Satisfactory palpation of the lung to exclude undetermined masses, nodules or gross 
oedema 
•  Satisfactory inspection of the lung after administration of the preservation flush and 
procurement 
 
Using Donation after Circulatory Death (DCD) donor lungs 
•  Satisfies criteria  as for standard DBD donor lungs (if information available) 
•  DCD Donors from Maastrict Category 2, 3 or 4 
•  Systemic arterial PO2  > 40 kPa on 100% FiO2 and 8 cmH2O PEEP, or equivalent 
FiO2:PaO2 within 12 hours  
•  Warm ischaemic time (WIT) < 30 minutes 
(WIT starts when donor systolic BP < 50 mmHg and / or O2 sats < 70%)  
 
•  Withdrawal of life support (WLS) time < 120 minutes 
 
  
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
140
Study Card Version 3.0, July 2013 
 
CRITERIA FOR EVLP ASSESSMENT AND RECONDITIONING 
(DBD AND DCD LUNGS) 
 
 
Using DBD or DCD lungs 
Any one or more of the following: 
 
•  Warm Ischaemic Time (WIT) > 30 minutes for DCD donors 
but < 60 minutes 
•  Chest X-ray findings prohibitive to standard transplantation 
•  Systemic arterial PO2  < 35-40 kPa and / or selective PV gas 
< 30 kPa on 100% FiO2 and 8 cmH2O PEEP 
•  History of aspiration with bronchoscopic inflammation/soiling of the airway, or recurrent 
but not prohibitive secretions in the distal airway after adequate bronchial toilet 
•  Difficult to recruit atelectasis 
•  Sustained peak airway pressure  > 30 cmH2O 
•  Unsatisfactory deflation test on disconnecting ET tube 
•  Unsatisfactory palpation of the lungs identifying undetermined masses, nodules or gross 
oedema 
•  Deterioration or cardiac arrest in the donor prior to retrieval such that uncertainty over assessment 
remains 
•  Unsatisfactory inspection of the lung after administration of the preservation flush and 
procurement 
•  Logistical reasons that will extend donor lung ischaemic time >10-12 hrs and prevent 
donor organ use, such as: 
 Viral studies awaited 
 HLA compatibility studies  
 Pathology assessment of indeterminate mass in any donor 
 Awaiting recipient admission 
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CRITERIA FOR TRANSPLANT AFTER SUCCESSFUL EVLP ASSESSMENT AND 
RECONDITIONING 
 
•  Any DBD or DCD donor lungs meeting previously stated criteria for 
standard transplant 
•  Pulmonary artery pressure < or equal to 20 mmHg, whilst achieving 
stable perfusate flow of up to 70 ml/kg IBW /minute at 37oC.  
•  Peak airway pressure < 25 cms H2O while achieving adequate 
ventilation (tidal volumes up to a max 7 mls/kg IBW)  
•  Oxygen capacity shown by deltaPO2 of > 40 kPa (perfusate LA PO2 
– perfusate PA PO2) / FiO2  
•  Selective PV gas > 30 kPa on 100% FiO2 and 5 cm H2O PEEP 
•  Stable or improving lung compliance and stable or falling lung resistance 
•  No pulmonary oedema build-up in the ET tube 
•  Satisfactory assessment on inspection and palpation 
•  Confirmed re-consent of potential matched recipient to receive an EVLP 
reconditioned lung* 
 
* If Informed Consent Form was signed on the day of transplant re-confirming consent 
is not required 
 
CRITERIA FOR FAILED EVLP ASSESSMENT AND RECONDITIONING 
 
Transplant will not proceed if:  
•  Any DBD or DCD donor lungs not meeting stated criteria for standard transplant 
•  Not satisfying criteria for transplant after successful EVLP 
assessment and reconditioning 
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Study Card Version 3.0, July 2013 
REPORTING OF SERIOUS ADVERSE EVENTS 
PROTOCOL SPECIFICATIONS 
 
 
Serious adverse events requiring urgent reporting include: 
•  Death within 90 days of lung transplantation 
•  Severe Primary Graft Dysfunction requiring ECMO/Novalung support 
•  Bronchial anastomotic dehiscence 
•  Any unexpected SAE felt to be probably or definitely causally related to EVLP 
Serious adverse events excluded from urgent reporting: 
•  Death on the waiting list prior to transplant 
•  Death greater than 90 days after lung transplantation 
•  Primary Graft Dysfunction grade 1 to 3 not requiring ECMO/Novalung support 
•  Severe sepsis associated with consolidation, necrosis or cavitation of lung 
 tissue within 30 days of transplant 
•  Renal failure necessitating renal replacement therapy 
•  Gastrointestinal complications 
•  Central nervous system complications 
•  Infections requiring an addition or change in anti-microbial therapy 
•  Bronchial stricture whether or not requiring bronchial stenting 
•  Acute rejection requiring augmented immunosuppression 
•  Development of post-transplant lymphoproliferative disease 
•  Development of obliterative bronchiolitis 
•  Deterioration of pre-existing medical conditions both pre and post transplant 
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CHIEF INVESTIGATOR 
Professor Andrew Fisher 
Professor of Respiratory Transplant Medicine 
Institute of Cellular Medicine 
4th Floor William Leech Building 
The Medical School 
Newcastle University 
Newcastle upon Tyne NE2 4HH 
Tel:  
Email:  
 
TRIAL MANAGER 
Jessica Qian 
Newcastle Clinical Trials Unit (NCTU) 
4th Floor William Leech Building 
The Medical School 
Newcastle University 
Newcastle upon Tyne NE2 4HH 
Tel:  
Email:  
 
PARTICIPATING CENTRES and PRINCIPAL INVESTIGATORS 
 
Harefield Hospital (London) 
Mr Andre Simon 
Wythenshawe Hospital (Manchester) 
Prof Nizar Yonan 
Freeman Hospital (Newcastle) 
Prof John Dark 
Queen Elizabeth Hospital (Birmingham) 
Mr Jorge Mascaro 
Papworth Hospital (Cambridge) 
Mr Steven Tsui 
 
 
 Disclaimer: The purpose of this flyer is to act as an aid memoir and in no way replaces the 
trial protocol. Please refer to the main protocol for further information. The protocol may 
 be revised periodically. If so participating centres will be informed.  
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Study Card Version 3.0, July 2013 
Sample  col lec t ion,  process ing and s torage 
  
Standard Operating Procedure 
 
 
 
Collection and storage of biological samples from donor lungs is limited to those donor lungs 
exposed to EVLP assessment and reconditioning and no samples are collected from standard 
donor lungs. 
Give each sample a unique identifying code comprising the following: 
Centre / EVLP number / Type of Sample and number / Date 
(DDMMYY)  
 
Centre Codes   Sample Codes 
NCL  = Newcastle   BAL = Bronchoalveolar Lavage 
HAR  = Harefield   PERF = Perfusate 
PAP   = Papworth   BIO = Lung Biopsy 
BMH  = Birmingham 
MAN   = Manchester 
 
For example NCL/17/PERF3/030912 represents the code for perfusate 
sample 3 collected during EVLP run 17 performed in Newcastle on 3rd 
September 2012. 
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Equipment: 
 
Equipment and Reagents Procedure 
Sterile normal saline (0.9% NaCL solution) BAL, BIO 
Crushed Ice BAL, BIO 
Sterile universal containers BAL, PER 
Sterile gauze BAL, BIO 
Centrifuge (refrigerated if possible)  BAL, PER 
PBS (phosphate buffered saline) BAL 
Improved Neubauer Haemocytometer 0.1 mm depth BAL 
Cytospin  with Cytospin funnels and glass slides BAL 
1ml Storage tubes (NUNC) BAL, PER 
-20ºC freezer BAL, PER 
-80ºC freezer  
Covidien Duet (absorbable buttressed) endo-GIA 
stapler BIO 
Sample pots BIO 
Liquid nitrogen in Dewar storage flask BIO 
Formalin BIO 
Glutaraldehyde (see Appendix 1) BIO 
Dulbeccos Phosphate buffered sal ine. (Sigma 
D5773) 
BAL 
Acetone (VWR 20066.321) BAL 
Virkon (Du Pont ) BAL 
Trigene (Medichem) BAL 
RNA later BAL 
 
BAL- BAL collection and processing 
PER- Perfusate collection and processing 
BIO- Donor Lung Biopsy collection and processing 
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Bronchoalveolar Lavage (BAL) 
BAL Collection: 
•  Under flexible bronchoscopic guidance perform a standardised BAL using 120 mls of 
sterile normal saline (0.9% NaCl solution) from: Either the left or right lower lobe of 
the donor lung on two occasions (BAL1 and BAL2).  
•  Perform  BAL2  in a different segment from the same lobe as BAL1 
•  The timing of each BAL is detailed below: 
o BAL1: At the beginning of the EVLP process after perfusion has commenced and 
the lung temperature has reached at least 30oC but before ventilation of the lung is 
initiated 
o BAL 2: At the end of EVLP process once the final assessment is complete but 
before ventilation is discontinued 
•  For BAL1 and BAL2  record data on sample collection data sheet for: 
o the duration of perfusion before the sample is taken  
o the lobe and segment the BAL is performed in 
o the volume of saline administered 
o the volume retrieved  
o the volume after filtration 
•  Store BAL1 on ice until BAL 2 is performed and placed on ice. The 2 BAL samples can 
then be processed together at the end of the EVLP run. 
•  The samples after processing can be placed straight into a -80oC freezer if accessible. If 
not immediately accessible the samples can be placed at -20oC until transfer to the -80 
within the following 48 hours. 
BAL Processing: 
•  Place a minimum of 2mls to a maximum of 5mls of the total BAL sample into a sterile 
container and send to your hospital laboratory for gram stain and formal microbiological 
assessment. 
•  Keep the remaining BAL on ice until ready to process, this should be started as soon as is 
feasible and ideally within 6-8 hours of it being taken. 
•  Filter the BAL fluid through a single layer of gauze to remove excess mucus. The gauze 
can be moistened with sterile saline to aid adherence to the funnel. Measure and record 
the volume on the work sheet. 
•  Centrifuge to separate the cellular component from the acellular supernatant at 180g for 6 
minutes at 4oC 
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•  Decant the supernatant into a clean tube, taking care not to disturb the cell pellet. 
•  Centrifuge the supernatant at 700g for 6 minutes at 4oC.  
•  Divide the supernatant into 1ml aliquots (maximum 12 from each BAL sample) and 
freeze at -20oC before transfer to -80oC the next working day for long term storage. 
•  Add Dulbeccos Phosphate Buffered Saline* (D-PBS) to the cell pellet to produce an 
opaque suspension. Mix gently. 
(*The choice of the initial volume of D-PBS added to the pellet comes with experience 
and depends on the volume and visual characteristic of the starting BAL sample and the 
size of the cell pellet. For example a 10ml BAL sample which appears dense and opaque 
suggests a high cellularity sample, so in this scenario start with 10mls of Dulbeccos PBS 
added. If the BAL is 10ml but clear and translucent suggesting a lower cellularity sample, 
add just 5mls of D-PBS initially. In essence the initial volume added is a best guess and 
the final volume can then be adjusted to get the correct final cell concentration.) 
 
•  To find the total cell concentration, use an Improved Neubauer counting chamber (depth 
0.1mm). Count the cells in 4 large squares. (4 mm2).  
•  Divide this figure by 4 then adjust the volume to give a final cell concentration of 0.5 
million cells per ml. 
Total number of cells x 106                     = x ml  DPBS 
                                                      0.5 
•  Use the diluted cell suspension to prepare cytospins x 6, 100ul per cytospin at 300 rpm 
(9g) for 3 minutes. Check the quality of the cytospins microscopically. If they are too 
dense repeat using a more dilute cell suspension. If the cytospins are too sparse increase 
the volume to 150ul. 
•  Fix 1 cytospin in acetone at room temperature for 10 minutes then air dry. 
•  The remaining 5 cytospins should be air-dried and then wrapped in foil and placed in the 
freezer. These can be stored at -20oC before transfer to -80oC the next working day. 
•  Stain with Geimsa (or Diff Quick) and perform a differential count. (This can be done the 
next day if necessary). Perform differential cell count to determine the percentage of: 
o Neutrophils; macrophages; lymphocytes; eosinophils and epithelial cells 
•  Once the quality of the cytospins has been assessed the cell suspension is centrifuged at 
180g for 6 minutes at 4oC. Decant the supernatant from the cell pellet and resuspend in 
2mls of RNAlater. This concentrated cell suspension can then be divided to give approx 3 
x 106 cells per tube. Snap Freeze and store at -20oC before transfer to -80oC. 
•  Place used cytofunnels in 1% Virkon for sterilisation. Discard all pipettes, tubes etc to 
clinical waste. Sterilise work surfaces with 1:50 Trigene. 
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Perfusate  
 
Perfusate Collection: 
Collect samples of perfusate solution longitudinally during the EVLP process from the 
perfusate sampling port on the back of the Vivoline machine. 
Place collected perfusate samples in an ice filled insulated box to keep at 4oC. 
 
•  Collect 5mls from the perfusate sampling port at the following times: 
o Perfusate 0: Taken from the primed EVLP circuit before the donor lung perfusion 
is started 
o Perfusate 1: Taken 15 minutes after perfusion is started 
o Perfusate 2: Taken 30 minutes after perfusion is started 
o Perfusate 3 to a maximum of Perfusate 8:  Taken every 30 minutes during 
perfusion 
o Perfusate X: Taken at the end of the perfusion immediately before the perfusion 
is stopped 
 
Perfusate Processing: 
•  The perfusate samples can be stored on ice for the duration of the EVLP run and then 
placed in a fridge at 4oC until processed.  
•  The samples should be processed all together at the end of the EVLP run and ideally 
within 8 hours of collection.  
•  Centrifuge the perfusate samples at 180g for 6 minutes at 4oC to remove cellular debris 
•  If a refrigerated centrifuge is not available please keep the samples on ice immediately 
before and after centrifugation. 
•  Carefully remove the supernatant and aliquot equally into 5x1ml tubes for each time point 
sample before freezing at -20oC. 
•  Transfer them to -80oC as soon as feasible. The next working day ideally but within the 
following 48 hours for longer term storage. 
 
Donor Lung Biopsy 
 
Biopsy Collection 
Take small biopsies of lung tissue using a Covidien Duet (absorbable buttressed) endo-GIA 
stapler from either the right middle lobe or lingular at two time points: 
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o Biopsy 1: Taken prior to the commencement of the EVLP process at the recipient 
hospital 
o Biopsy 2: Taken at the end of the EVLP process once perfusion has stopped  
•  Place biopsies on sterile gauze.  
•  Dampen them with 0.9% Saline in a sample pot. 
•  Store the pot on ice until processing. 
•   It is understood that there will be different storage times on ice for the two biopsies. 
Once cooled to 4 degrees it is unlikely to affect the cellular processes in the tissue.  
•  At the end of the EVLP run both biopsies can be processed at the same time. It is 
important is to make sure the first biopsy is kept moist in the pot but not wet. 
 
Biopsy Processing  
From each of these biopsies: 
•  Fix a small amount of tissue in glutaraldehyde for electron microscopy studies. 
o See detailed protocol below 
•  Snap freeze small amount of tissue in liquid nitrogen for subsequent mechanistic studies. 
o See detailed protocol below 
•  Place the remaining tissue in Formalin fixative pots. 
•  Sterilise the work area with 1:50 Trigene. Dispose of gloves, apron etc to clinical waste. 
•  Transfer Formalin fixed blocks to Pathology for paraffin (FFPE) embedding as soon as 
possible. 
•  Subsequently cut FFPE sections for routine histological evaluation (Haematoxylin and 
Eosin staining). 
 
Snap freezing Procedure 
•  2-3 small pieces of tissue should be prepared for freezing. Each piece should be ideally 5-
10mm in diameter. 
•  Store biopsies / blocks at 4oC until ready to be quenched. 
•  In a Dewar flask collect 1litre of liquid nitrogen. 
•  Place approx 60ml isopentane* in a plastic beaker and gently suspend in the flask of 
nitrogen, leave until the isopentane is almost solid, approx 10 – 15 mins. 
•  Remove the beaker from the Dewar flask. 
•  The isopentane should now be a half liquid / half frozen slurry. Place the pieces of tissue 
on squares of tin foil approx 1.5 x 1.5 cms using medium forceps plunge the tin foil and 
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
150
Study Card Version 3.0, July 2013 
tissue into the isopentane moving it through the liquid phase for approx. 30 seconds until 
the tissue is solid. Repeat this for each piece of tissue. 
•  Remove the frozen block from the isopentane and drain off any liquid then securely wrap 
in a 5cm square of tin foil to exclude all air. Place the wrapped tissue in a labeled 
unicassette, seal and plunge into the liquid nitrogen. 
•  Using tongs transfer the unicassette to the –20oC freezer for later transfer to –80oC 
storage on the next working day. 
•  Place all instruments in 1:50 Trigene for sterilization.  
•  Transfer the Dewar flask containing the Liquid nitrogen to the fume hood. Attach the 
hazard label and allow the nitrogen to evaporate. 
(* Snap freezing in isopentane slurry is considered the best methods to avoid freezing 
artefact. As the frozen tissue will be used mainly for cell biology purposes. The isopentane 
step is not compulsory part of the protocol but is recommended.) 
Preparation of lung biopsy for Electronic Microscopy (EM) examination 
• 3-4 small pieces of approximately 4x4x10 mm are CAREFULLY (try not to squash) 
taken with a sharp scalpel or scissors from the removed lung tissue. Take these away 
from the stapled edges where there might be crush artefact.   
• Place IMMEDIATELY in glutaraldehyde fixative as delays will lead to artefact which 
can be interpreted as tissue injury.   
• Gently without squeezing the tissue push to the bottom of the fixative and agitate to try to 
get the air out of the lung.  Residual air will make the tissue float and not fix resulting in 
artefact.  
• Agitate the closed bottle to try to remove further air. 
• Once the sample is adequately placed in glutaraldehyde it can be stored in the fridge until 
posted away for processing in Birmingham on the next convenient working day. 
• See Appendix 1 for method to prepare glutaraldehyde stock solution. This is best done by 
an experienced pathology lab. 
Appendix 1:  Method for the preparation of a standard 2.5% glutaraldehyde fixative in 
0.1M sodium phosphate buffer - for electron microscopy. 
Contains a Hazardous chemical, read COSHH data sheet before preparing fixative for the 
first time. This is best done in an experienced pathology laboratory. 
Materials and Equipment: 
pH meter 
Balance  
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500ml measuring cylinder 
100ml measuring cylinder 
Gloves 
Clean 500ml bottles with well-fitting stoppers 
 
Chemical Suppliers: Glutaraldehyde EM grade (25%)  Catalogue no. R1011 
Agar Scientific Ltd 
Unit 7, M11 Business Link, Parsonage Lane, 
Stansted, Essex, CM24 8GF 
Tel:  
Email: 
 
di-Sodium hydrogen orthophosphate 
Sodium di-hydrogen orthophosphate 
VWR International Ltd. 
Hunter Boulevard 
Magna Park 
Lutterworth 
LE17 4XN 
Customer service centre:   
 
Procedure: 
Preparation of 0.2M sodium phosphate buffer 
To make up stock solutions 
31.2g/l sodium di-hydrogen orthophosphate is an 0.2M solution Acidic solution (A): 
Weigh out 15.6g of A; put powder in 500ml measuring cylinder, half fill with distilled water, 
shake until dissolved and top up to 500ml.  Transfer to a clean 500ml bottle and stopper 
tightly.  Label with 3 months expiry date. 
 28.4g/l di-Sodium hydrogen orthophosphate is an 0.2M solution Basic solution (B):
Weigh out 14.2g of B.  Prepare and label ‘Solution B’ as above. 
 
To make up 0.2M phosphate buffer 
To make 100ml of 0.2M sodium phosphate buffer measure out 23mls of solution A and 
77mls of solution B in to a beaker.  Mix thoroughly.  This should give a pH of 7.3. 
To check the pH 
Check pH. Bring solution to pH 7.3 using small quantities of A or B, measured out with a 
pipette.  Stir thoroughly. Keep in fridge until required. 
NOTE:  When making up buffer from older stock solutions. 
Ensure any crystals formed at the bottom of the stock bottles are dissolved thoroughly before 
making up the buffer.  Stand bottles in warm / hot water to speed the process.  
APPENDIX 2
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
Study Card Version 3.0, July 2013 
Preparation of fixative 
Work is conducted in a fume cupboard and wearing gloves. 
Add 10mls of 25% glutaraldehyde to 50mls 0.2M sodium phosphate buffer and dilute with 
40ml distilled water and mix well. 
Label with contents, date made up and expiry date (one month) and “Harmful” warning label 
Keep “PGP” well stoppered in fridge. 
Decant into specimen vials.  Ensure specimens are immersed in sufficient fixative – the 
volume of fixative should be at least 10 to 20 times the volume of the specimens. Ensure all 
lids are tightly closed. 
Cleaning up 
Rinse glassware in fume cupboard before transferring to lab sink for further washing.  Wash 
using detergent and rinse well, giving final rinse in distilled water. 
Label all vials with the appropriate ‘HAZARD’ label plus one which states the concentration 
of glutaraldehyde and ‘EM FIXATIVE’.   
Discard all unused fixative after 1 month and replace with fresh. 
Always discard down the sink in the fume cupboard with extraction on and plenty of running 
water. 
 
: For any further advice on EM preparation and processing contact
Dr Liz Curtis 
Clinical; Scientist 
Electron Microscopy Unit 
Queen Elizabeth Hospital Birmingham 
Birmingham   
 
Tel:  
 
Addresses for Dispatch of EM Samples 
EM samples in glutaraldehyde to be sent to: 
Dr Desley Neil 
DEVELOP-UK study 
Electron Microscopy Unit 
Department of Cellular Pathology 
Level -1 Queen Elizabeth Hospital Birmingham 
Edgbaston 
Birmingham 
B15 2WB 
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EVLP NUMBER  
DATE (dd/mm/yyyy)          /         / 
TIME (hh:mm)                    : 
TRANSPLANTED                       YES              NO 
Donor Consent  for 
Research 
 
           YES              NO               UNKNOWN 
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BAL 1 Pre-EVLP BAL 2 Post-EVLP 
The duration of perfusion before BAL 2 is taken 
 
The lobe and segment the BAL is 
performed in 
  
The volume of saline administered 
  
The volume of BAL retrieved 
  
Beginning of sample processing:  
Date (dd/mm/yyyy)          /         / 
Time (hh:min)                   : 
Volume of BAL after 
filtration (ml) A 
  
Volume D-PBS added to cell 
pellet (ml) B 
  
Total Cell Count C 
  
Total Cell Count / 4 x 104 D 
  
Cell Count x Volume D-PBS D x B = E 
  
Cell Count  / Volume of 
BAL E / A 
  
Number of 1 ml supernatants (max 12) 
  
Number of Cell pellets for RNA 
  
Number of Cytospins produced 
  
 
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
155
Study Card Version 3.0, July 2013 
Cell Differential 
 Pre Number of Cells % Post Number of cells % 
Macrophages 
    
Neutrophils 
    
Lymphocytes 
    
Eosinophils 
    
Total 
    
Ciliated Epithelia 
    
Metaplastic 
Epithelia 
    
Total 
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Perfusate Samples 
 P0 P1 P2 P3 P4 P5 P6 P7 P8 Px 
Number 
of 
Perfusate 
samples 
(stored at 
-80) 
          
 
Donor Lung Biopsy 
List numbers of lung tissue specimens stored 
 Formalin EM Snap Frozen 
Biopsy 1 prior to EVLP 
   
Biopsy 2 post EVLP 
   
 
 
List specimens transferred and 
centre to which moved 
 
 
 
 
 
 
 
 
EM  transfer date (dd/mm/yyyy) 
         /         / 
Frozen transfer date (dd/mm/yyyy) 
         /         / 
Paraffin transfer date 
(dd/mm/yyyy) 
         /         / 
Responsibility 
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Method for the preparation of a standard 2.5% glutaraldehyde fixative in 0.1M sodium 
phosphate buffer - for electron microscopy. 
 
 
Contains a Hazardous chemical, read COSHH data sheet before preparing fixative for the 
first time. 
 
 
1. Materials and Equipment 
1.1. Suppliers: 
Glutaraldehyde EM grade (25%)  Catalogue no. R1011 
Agar Scientific Ltd 
Unit 7, M11 Business Link, Parsonage Lane, 
Stansted, Essex, CM24 8GF 
Tel:  
Email: 
 
 
di-Sodium hydrogen orthophosphate 
Sodium di-hydrogen orthophosphate 
 
VWR International Ltd. 
Hunter Boulevard 
Magna Park 
Lutterworth 
LE17 4XN 
Customer service centre:   
 
 
balance  
500ml measuring cylinder 
100ml measuring cylinder 
gloves 
clean 500ml bottles with well fitting stoppers 
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Procedure 
 
2.1 Preparation of 0.2m sodium phosphate buffer 
1.1.1. To make up stock solutions 
Acidic solution (A): 31.2g/l sodium di-hydrogen orthophosphate is an 0.2M solution 
Weigh out 15.6g of A; put powder in 500ml measuring cylinder, half fill with distilled water, 
shake until dissolved and top up to 500ml.  Transfer to a clean 500ml bottle and stopper 
tightly.  Label with 3 months expiry date 
 
Basic solution (B): 28.4g/l di-Sodium hydrogen orthophosphate is an 0.2M solution 
Weigh out 14.2g of B.  Prepare and label ‘Solution B’ as above. 
 
1.1.2. To make up 0.2m buffer 
To make 100ml of 0.2m sodium phosphate buffer measure out 23mls of solution A and 
77mls of solution B in to a beaker.  Mix thoroughly.  This should give a pH of 7.3. 
1.1.3. To check the pH 
Check pH.  Bring solution to pH 7.3 using small quantities of A or B, measured out with a 
pipette.  Stir thoroughly. 
 
Keep in fridge until required. 
1.1.4. NOTE:  When making up buffer from older stock solutions. 
Ensure any crystals formed at the bottom of the stock bottles are dissolved thoroughly before 
making up the buffer.  Stand bottles in warm / hot water to speed the process.   
1.2. Preparation of fixative 
Work is conducted in fume cupboard 
Wear gloves 
Add 10mls of 25% glutaraldehyde to 50mls 0.2M sodium phosphate buffer and dilute with 
40ml distilled water. 
Mix well. 
Label with contents, date made up and expiry date (one month) and “Harmful” 
Keep “PGP” well stoppered in fridge. 
 
Decant into specimen vials.  Ensure specimens are immersed in sufficient fixative – the 
volume of fixative should be at least 10 to 20 times the volume of the specimens. Ensure 
all lids are tightly closed. 
2. Cleaning up 
Rinse glassware in fume cupboard before transferring to lab sink for further washing.  Wash 
using detergent and rinse well, giving final rinse in distilled water. 
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Label all vials with the appropriate ‘HAZARD’ label plus one which states the concentration 
of glutaraldehyde and ‘EM FIXATIVE’.   
 
Discard all unused fixative after 1 month and replace with fresh. 
 
Always discard down the sink in the fume cupboard with extraction on and plenty of running 
water. 
 
Dr Liz Curtis 
Clinical; Scientist 
 
EM Unit 
Level -1 
Cellular Pathology Department 
Queen Elizabeth Hospital Birmingham 
Mindelsohn Way 
Edgbaston 
Birmingham  B15 2WB 
 
 
 
Any other SOPs? 
 
There are: Donor offer pathway document 
  Sample collection data sheet 
  ex vivo Vivoline machine protocol 
  Guide to Primary Graft Dysfunction 
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To be printed on the local trust headed paper 
 
Date: 
 
Patient’s name and Address: 
 
Dear................................. 
 
RE:      DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
I am contacting you because you are on the active waiting list for a lung 
transplantation and would like to invite you to consider taking part in the DEVELOP-
UK study. This letter will be followed by a telephone call within one week by one of 
the research team to answer any questions you may have after reading the detailed 
patient information sheet and to ask about your willingness to take part. 
 
The DEVELOP-UK study is funded by the Department of Health and the UK Cystic 
Fibrosis Trust and is being performed in all 5 adult lung transplant centres in the UK. 
The study aims to examine how effective a new technique called Ex-Vivo Lung 
Perfusion (known as EVLP) is at assessing and improving the function of donor lungs 
before transplant.  
 
The shortage of donor lungs is made worse because many possible donor lungs are 
found to be unusable for transplant because their function is not good enough. EVLP 
is a new technique in which unusable donor lungs which have poor function or in 
which the function is uncertain, can be carefully assessed and often improved to allow 
their safe use in lung transplantation. 
 
However EVLP is not yet part of standard practice and the DEVELOP-UK study will 
test whether this new technology is effective at safely increasing the number of lung 
transplants performed in the UK and help decide if it should become standard 
practice. The study will observe how the condition of patients who have received 
EVLP assessed and improved donor lung(s) compares in the first 12 months after 
their transplant to patients that have received standard donor lung(s).  
 
Agreeing to take part in the study means you may be offered the chance of receiving 
EVLP assessed and improved donor lung(s) if they are found to be a good match for 
you. This will certainly increase the number of possible donor lungs available to you 
but may not necessarily mean you will get your transplant performed more quickly. 
You will not need any extra visits to the hospital for the study as all results will be 
collected at the time you attend for your usual hospital visits after transplant. 
 
The study also involves completing a short Quality of Life Questionnaire before 
your transplant surgery, and at 3 and 6 months after receiving a lung transplant. 
 
Some but not all patients taking part in the study will be invited to take part in a 
detailed interview with a researcher to identify, describe, and understand views of 
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EVLP before and after lung transplantation. Taking part in the interview is optional 
and does not affect your opportunity to participate in the DEVELOP-UK study. 
 
In order to provide you with more information about the study, I have enclosed a 
detailed patient information leaflet. Please read the leaflet and feel free to discuss the 
study with your family and/or friends.  
 
After you have had a telephone call from the research team we will ask you to 
complete the Expression of Interest Form that accompanies this letter. It will ask 
you to declare whether or not you are interested in taking part in the DEVELOP-UK 
study.  
 
When your completed Expression of Interest Form is received your response will be 
recorded on the transplant waiting list. If you declared an interest in participating in 
DEVELOP-UK you will be able to sign the Informed Consent Form when you attend 
a hospital appointment at the transplant centre or when called into the transplant 
centre for a potential lung transplant. When you are called for a potential lung 
transplant you will be told whether you are to receive a standard donor lung(s) or an 
EVLP assessed and improved donor lung(s). If you have been told that you are to 
receive an EVLP assessed and improved donor lung (s), then you will be asked 
whether you wish to continue with the study and confirm your consent.   
 
Thank you for taking the time to read the information sheet regarding this research 
study. Please tick the appropriate boxes on the form, and return it in the enclosed 
reply-paid envelope. If you do not wish to take part you don’t have to return the form, 
but it would be helpful for us if you could. 
 
If you have any questions please do not hesitate to contact me: 
(Name and signature of local PI and contact phone number) 
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
DEVELOP-UK Expression of Interest Form 
Name (capitals)  
Date  
Signature  
Telephone number and/or 
email address 
 
Best time to contact me  
 
       Please initial all boxes that apply 
 
Yes, I am interested in taking part in the DEVELOP-UK 
study.  
I understand that I can withdraw my interest at any time and 
that my  
current and future care will continue exactly as before. 
 
 
 
Initial in 
box 
No, I am not interested in taking part in this research 
study. 
I understand that my current and future care will continue 
exactly as  
Before but I understand I can change my mind in the future 
and contact the transplant team to express my interest. 
 
 
Initial in 
box 
 
If you answered YES to an interest in taking part in the DEVELOP-UK study, 
please complete the question below about the Interview study: 
 
 
Yes, I am willing to be contacted about a detailed 
interview with a researcher. I understand that I can 
withdraw my interest in this interview at any time and that 
my participation in DEVELOP-UK study will not be 
affected. 
 
 
 
Initial in 
box 
No, I do not wish to be contacted about a detailed 
interview with a researcher. I understand that my 
participation in the DEVELOP-UK study will not be 
affected. 
 
 
Initial in 
box 
 
Please return the completed Expression of Interest Form in the enclosed  
prepaid envelope to:  
Address of the relevant transplant centre 
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Appendix 4 Informed consent forms
Donor (in PDF form in eTMF) 
 
Consent Form Main Study Participant v 5.0, 24 May 2013 
 
To be printed on the local trust headed paper 
 
Centre Number: 
Study Number: 
Participant Identification Number: 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Participant Consent Form 
          Please initial box 
1. I confirm that I have read and understand the Participant Information 
Sheet dated 24 May 2013 (version 5.0) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Sponsor (The 
Newcastle upon Tyne Hospitals NHS Foundation Trust) or its 
representatives, or from regulatory or ethical authorities where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
4. I understand that small samples of lung tissue will be collected from donor 
lungs during ex-vivo lung perfusion (EVLP). I accept that these samples 
will be used by the research team and by academic or industry partners 
some of whom may be outside the United Kingdom.  
5. If as a result of transplant surgery I were to lose capacity temporarily or 
permanently I agree that the collection of observational data from my 
medical records can continue.  
6. I understand that if, for any reason, I withdrew from the study, the 
researchers will still be able to use any data collected during the time I 
have been taking part in the study.  
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7. I agree to my GP being informed of my participation in the study. 
 
8. I agree to take part in the above study.
 
 
___________________________ ____________ ____________________ 
Name of Participant   Date   Signature 
 
________________________ ____________ ____________________
Name of person  
taking consent    Date   Signature 
 
 
 
 
 
 
 
 
 
 
When completed: one copy to participant; one copy for hospital record; original copy to 
Site Investigator File. 
If a participant is able to give informed consent but unable to sign this consent 
form, consent should be confirmed orally in the presence of a witness. 
 
___________________________ 
Name of Participant  
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Consent Form Interview Study Participant v 1.0, 1 November 2011 
 
To be printed on the local trust headed paper 
 
Centre Number: 
Study Number: 
Participant Identification Number: 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Interview Study 
 
Participant Consent Form 
        Please initial box 
1. I confirm that I have read and understand the Participant Information Sheet dated 
01 November 2011 (version 1.0) for the above Interview study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I received enough information about the study and I understand what the 
study involves. 
 
3. I understand that the Interview study is purely optional and I can withdraw from 
this study at any time and do not have to give a reason for doing so. I understand 
I will not be contacted again with regards to the Interview study if I 
choose not to be involved.  
4. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Sponsor (The 
Newcastle upon Tyne Hospitals NHS Foundation Trust) or its 
representatives, or from regulatory or ethical authorities where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
5. I understand and agree to the interview being recorded. 
 
6. I understand that I can ask for the recording to be stopped at any time 
without giving a reason. 
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7. I understand that I will not be personally named in any report and that 
anything I say will be treated with confidence. 
 
8. I understand that any information collected will be kept in a secure way 
and that all data will be anonymised so that my name does not appear. 
9. I understand that information collected will be managed by the study team 
only and will be destroyed after a period of fifteen years. 
  
10. I agree to take part in an interview for the study. 
 
 
 
___________________________  ____________ ____________________ 
Name of participant      Date   Signature 
 
 
___________________________  ____________ ____________________ 
Name of person taking consent  Date   Signature 
(if different from PI)   
 
________________________  ____________ ____________________ 
Principal Investigator    Date   Signature 
 
When completed: one copy to participant; one copy for hospital record; original copy to 
Site Investigator File. 
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Consent Form Interview Study Nominated Carer v 1.0, 1 November 2011 
 
To be printed on the local trust headed paper 
 
Centre Number: 
Study Number: 
Participant Identification Number: 
 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Interview Study 
 
Nominated relative or Carer Consent Form 
        Please initial box 
1. I confirm that I have read and understand the Participant Information Sheet dated 
01 November 2011 (version 1.0) for the above interview study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I have received enough information about the study and I understand what 
the study involves. 
 
3. I understand that this part of the study is purely optional. I understand I will not 
be contacted again with regards to the interview study if the person I care 
for is not to be involved. 
 
4. I understand that data collected during the study, may be looked at by 
individuals from Sponsor (The Newcastle upon Tyne Hospitals NHS 
Foundation Trust) or its representatives, or from regulatory or ethical 
authorities where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my records. 
 
5. I understand and agree to the interview being recorded 
 
6. I understand that I can ask for the recording to be stopped at any time 
without giving a reason. 
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7. I understand that I will not be personally named in any report and that 
anything I say will be treated with confidence. 
 
8. I understand that any information collected will be kept in a secure way 
and that all data will be anonymised so that my name does not appear. 
9. I understand that information collected will be managed by the study team 
only and will be destroyed after a period of fifteen years. 
 
10. I agree to take part in an interview for the study. 
 
 
 
___________________________  ____________ ____________________ 
Name of Relative or Carer   Date   Signature 
 
 
___________________________  ____________ ____________________ 
Name of person taking consent  Date   Signature 
(if different from PI)   
 
________________________  ____________ ____________________ 
Principal Investigator    Date   Signature 
 
When completed: one copy to relative/carer; one copy for hospital record; original copy to 
Site Investigator File. 
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Consent Form Study Participant after standard lung transplant v 1.0, 24 May 2013 
 
To be printed on the local trust headed paper 
 
Centre Number: 
Study Number: 
Participant Identification Number: 
 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Participant Consent Form  
(After Standard Lung Transplant) 
Please initial box 
1. I confirm that I have read and understand the Participant Information 
Sheet dated 24 May 2013 (version 5.0) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that relevant sections of my medical notes and data collected 
during the study, may be looked at by individuals from Sponsor (The 
Newcastle upon Tyne Hospitals NHS Foundation Trust) or its 
representatives, or from regulatory or ethical authorities where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records. 
 
4. If as a result of transplant surgery I were to lose capacity temporarily or 
permanently I agree that the collection of observational data from my 
medical records can continue.  
5. I understand that if, for any reason, I withdrew from the study, the 
researchers will still be able to use any data collected during the time I 
have been taking part in the study.  
6. I agree to my GP being informed of my participation in the study. 
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7. I agree to take part in the above study. 
 
 
 
___________________________ ____________ ____________________ 
Name of Participant   Date   Signature 
 
 
________________________ ____________ ____________________ 
Name of person  
taking consent    Date   Signature 
 
 
 
 
 
 
 
 
 
 
 
When completed: one copy to participant; one copy for hospital record; original copy to 
Site Investigator File. 
If a participant is able to give informed consent but unable to sign this consent 
form, consent should be confirmed orally in the presence of a witness. 
 
___________________________ 
Name of Participant  
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Consent to continue Form Main Study Participant v 5.0, 24 May 2013 
 
To be printed on the local trust headed paper 
 
Centre Number: 
Study Number: 
Participant Identification Number: 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Participant Consent to Continue Form 
(FOR EVLP TRANSPLANTS ONLY) 
Please initial box 
1. I confirm that I have read and understand the Participant Information 
Sheet dated 24 May 2013 (version 5.0) for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Sponsor (The 
Newcastle upon Tyne Hospitals NHS Foundation Trust) or its 
representatives, or from regulatory or ethical authorities where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have  access to my records. 
 
4. I understand that small samples of lung tissue will be collected from donor 
lungs during ex-vivo lung perfusion (EVLP). I accept that these samples 
will be used by the research team and by academic or industry partners 
some of whom may be outside the United Kingdom.  
5. If as a result of transplant surgery I were to lose capacity temporarily or 
permanently I agree that the collection of observational data from my 
medical records can continue.  
6. I understand that if, for any reason, I withdrew from the study, the 
researchers will still be able to use any data collected during the time I 
have been taking part in the study.  
7. I agree to my GP being informed of my participation in the study. 
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8. I agree to take part in the above study. 
 
 
 
___________________________ ____________ ____________________ 
Name of Participant   Date   Signature 
 
 
________________________ ____________ ____________________ 
Name of person  
taking consent    Date   Signature 
 
 
 
 
 
 
 
 
 
 
When completed: one copy to participant; one copy for hospital record; original copy to 
Site Investigator File.
If a participant is able to give informed consent but unable to sign this consent 
form, consent should be confirmed orally in the presence of a witness. 
 
___________________________ 
Name of Participant  
 
 
APPENDIX 4
NIHR Journals Library www.journalslibrary.nihr.ac.uk
174
Appendix 5 Hospital staff resource use survey
Qualtrics survey
In September 2014, a survey was conducted in order to determine the hospital resource use and staff time
after lung transplant. In this survey, most of the hospital staff who took part in the DEVELOP-UK study
were involved. The survey was conducted using the online Qualtrics software.
Questions
The questions asked to each member of the hospital staff are presented below.
Consultant surgeon/surgical fellow/consultant physician
Question 1
On the day/night of lung transplantation how much time do you spend preparing for the surgery (i.e. on
the telephone or in discussion with other team members)?
Question 2
How long do you spend in theatre undertaking the lung transplant procedure?
Question 3
Post operation, how long is it before you leave the hospital/are ready to see another patient?
Question 4
How much time do you spend in ITU on a daily basis with a straightforward, uncomplicated lung
transplant patient who requires single organ support or remains in single organ failure?
Question 5
How much time do you spend in ITU on a daily basis with a lung transplant patient experiencing more
severe complications with multiorgan failure?
Question 6
In a more specific example, how much time do you spend each day with lung transplant patients on
ECMO (extracorporeal membrane oxygenation)?
Question 7
How much time do you spend on a daily basis with a lung transplant patient in level 1 ward-based care?
Additional comments
Any additional comments you have regarding the time you input into the care of lung transplant patients
would be greatly appreciated.
Consultant anaesthetist/anaesthetic fellow
Question 1
On the day/night of lung transplantation how much time do you spend preparing the patient
for anaesthesia?
Question 2
How much time do you spend preparing for the surgery (i.e. discussing with colleagues and transplant
co-ordinators)?
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Question 3
How much time do you spend in theatre supervising the patient during anaesthesia?
Question 4
How much time do you spend bringing the patient back to ITU to stabilise them?
Question 5
How much time do you spend in ITU on a daily basis with a straightforward, uncomplicated lung
transplant patient who requires single organ support or remains in single organ failure?
Question 6
How much time do you spend in ITU on a daily basis with a lung transplant patient experiencing more
severe complications with multiorgan failure?
Question 7
In a more specific example, how much time do you spend each day with lung transplant patients on
ECMO (extracorporeal membrane oxygenation)?
Question 9
How much time do you spend on a daily basis with a lung transplant patient in level 1 ward-based care?
Additional comments
Any additional comments you have regarding the time you input into the care of lung transplant patients
would be greatly appreciated.
Transplant co-ordinator
Question 1
How long do you spend in hospital once organs have arrived?
Question 2
How long do you spend in theatre on day/night of transplant?
Question 3
Do you spend time with the relatives of the patient post transplant?
Question 4
How long do you spend with the relatives of the patient post transplant (e.g. comforting them, helping to
sort out accommodation for the night if needed)?
Additional comments
Any additional comments you have regarding the time you input into the care of lung transplant patients
would be greatly appreciated.
Responses
Table 48 shows the number of responses from the hospital staff resource use survey.
Table 49 shows the number of complete responses per each member of the staff.
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TABLE 48 Responses to survey
Response details First draft New survey Total
Total number of responses 24 89 113
Completed responses 2 41 43
Blank responses: initial question not displayed 0 6 6
Blank responses: initial question not answered 2 9 11
Job role only: no questions displayed 6 8 14
Job role only: no questions answered 8 13 21
Job role only: mix of questions not displayed or answered 6 12 18
TABLE 49 Complete responses to survey per each member of staff
Member of staff Completed responses
Consultant surgeon 7
Surgical fellow 4
Consultant physician 8
Physician fellow 0
Consultant anaesthetist 8
Anaesthetic fellow 3
Transplant co-ordinator 13
Total 43
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Appendix 6 Unit costs of resources
and interventions
TABLE 50 Unit costs of resources and interventions: detailed
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Donor’s hospital
Fixed costs
Initial assessment
ABG Test Donor 4.37 4.37 NuTH’s costing tool99
Bronchoscopy Procedure Donor 340.00 340.00 Reference Costs
2013/201449
Chest X-ray (radiography) Test Donor 24.97 24.97 NuTH’s costing tool99
ECG Test Donor 20.81 20.81 NuTH’s costing tool99
FBC Test Donor 4.94 4.94 NuTH’s costing tool99
Drugs
Methylprednisolone
(as sodium succinate)
500-mg vial Donor 9.60 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Donor 17.30 17.30 BNF 201450
Methylprednisolone
(as sodium succinate)
2-g vial Donor 32.66 32.66 BNF 201450
Lung retrieval
Fixed costs
Equipment
DCD donor
Bronchoscope Instrument Donor 8.18 8.18 EAC
Pink spray 0.5%
chlorhexidine
Spray Donor 3.69 3.69 Medical supplies
2 l of 0.9% sodium
chloride solution
1-l solution Donor 0.97 0.97 NHSBSA’s
Amendments to the
Drug Tariff100
Strapple tape Roll Donor 2.00 2.00 Medical supplies
DBD donor
Blue 23-gauge 25-mm
(1-inch) needles
1-inch needle Donor 0.05 0.05 Medical supplies
Bronchoscope Instrument Donor 8.18 8.18 EAC
1-l cardioplegia bag
(green PLEGIVEX, Ivex
Pharmaceuticals Ltd,
Larne, UK)
1-l bag Donor 35.92 35.92 Medical supplies
Green vacutainers Vacutainer Donor 0.13 0.13 Medical supplies
i-STAT portable clinical
analyser
Device Donor 3.13 3.13 EAC
continued
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
179
TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
i-STAT cartridges Cartridge Donor 8.00 8.00 Paul Henderson,
NuTH, September
2014, personal
communication
Pink spray 0.5%
chlorhexidine
Spray Donor 3.69 3.69 Medical supplies
1-l pressure infusion bag 1-l bag Donor 49.99 49.99 Medical supplies
Red vacutainers Vacutainer Donor 0.12 0.12 Medical supplies
10 ml of 8.4% sodium
bicarbonate
10-ml ampoule Donor 11.03 11.03 BNF 201450
2 l of 0.9% sodium
chloride solution
1-l solution Donor 0.97 0.97 NHSBSA’s
Amendments to the
Drug Tariff100
Spleen pots Pot Donor 0.41 0.41 Medical supplies
Strapple tape Roll Donor 2.00 2.00 Medical supplies
1-ml syringes 1-ml syringe Donor 0.08 0.08 Medical supplies
Staff time
Scout team
Retrieval surgeon (fellow) Hour Donor 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 5) Hour Donor 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Retrieval team
Perfusionist (band 7) Hour Donor 28.09 28.09 PSSRU’s Unit Costs of
Health and Social
Care 201451
Retrieval surgeon (fellow) Hour Donor 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 5) Hour Donor 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Tests
Chest X-ray (radiography) Test Donor 24.97 24.97 NuTH’s costing tool99
Perfusion (dosage)
2.8 l of PERFADEX solution 2.8-l solution Donor 376.00 376.00 XVIVO101
1 l of PERFADEX solution 1-l solution Donor 134.24 134.24 XVIVO101
CaCl2 1 mmol/ml
(1.7 ml/2.8 l PERFADEX
and 0.6 ml/1 l PERFADEX)
10-ml ampoule Donor 14.94 14.94 BNF 201450
FLOLAN 0.5-mg vial
(7 ml/2.8 l PERFADEX)
0.5-mg vial Donor 22.22 22.22 BNF 201450
FLOLAN 0.5-mg vial
(2.5 ml/1 l PERFADEX)
0.5-mg vial Donor 22.22 22.22 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Heparin sodium
5000 units/5 ml
(15,000 units/2.8 l
PERFADEX)
5-ml ampoule Donor 7.58 7.58 BNF 201450
Heparin sodium
5000 units/5 ml
(5000 units/1 l
PERFADEX)
5-ml ampoule Donor 7.58 7.58 BNF 201450
THAM 1-ml ampoule
(7 ml/2.8 l PERFADEX)
1-ml ampoule Donor 1.07 1.07 BNF 201450
THAM 1-ml ampoule
(2.5 ml/1 l PERFADEX)
1-ml ampoule Donor 1.07 1.07 BNF 201450
Variable costs
Travelling
Scout team
Road Transport type Donor 225.00 225.00 Brian Leadbitter,
NuTH, June 2015,
personal
communication
Retrieval team
Road Transport type Donor 297.00 297.00 Brian Leadbitter,
NuTH, June 2015,
personal
communication
Road and air Transport type Donor 9791.00 9791.00 Brian Leadbitter,
NuTH, June 2015,
personal
communication
Organ (lung)
Road Transport type Donor 392.00 392.00 Brian Leadbitter,
NuTH, June 2015,
personal
communication
Road and air Transport type Donor 7527.00 7527.00 Brian Leadbitter,
NuTH, June 2015,
personal
communication
Transplant preparation
Fixed costs
Contacting potential
recipients
Transplant co-ordinator Hour Recipient 30.41 30.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Meeting potential recipients
Transplant co-ordinator Hour Recipient 30.41 30.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Tissue typing
Tissue typing test Test Recipient 59.87 59.87 ISD Scotland’s About
ISD102
Tests
ABG Test Recipient 4.37 4.37 NuTH’s costing tool99
Chest X-ray (radiography) Test Recipient 24.97 24.97 NuTH’s costing tool99
ECG Test Recipient 20.81 20.81 NuTH’s costing tool99
FBC Test Recipient 4.94 4.94 NuTH’s costing tool99
Ward time
Transplant centre ward Bed-day Recipient 265.00 265.00 Reference Costs
2013/201449
Drugs
Azathioprine, 50 mg 56-tablet pack Recipient 3.48 3.48 BNF 201450
Variable costs
Transfer to ward
Air Transport type Recipient Missing Missing Missing
Road Transport type Recipient Missing Missing Missing
EVLP procedure
Fixed costs
Staff time
Anaesthetic registrar Hour EVLP
recipient
– 22.84 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant surgeon Hour EVLP
recipient
– 60.11 PSSRU’s Unit Costs of
Health and Social
Care 201451
Perfusionist (band 7) Hour EVLP
recipient
– 28.09 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse/ODA (band 5) Hour EVLP
recipient
– 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgical fellow Hour EVLP
recipient
– 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Equipment
Bronchoscope Instrument EVLP
recipient
– 8.18 EAC
DeBakey tissue forceps Forceps EVLP
recipient
– 0.08 EAC
McIndoe scissors Scissors EVLP
recipient
– 1.65 Medical supplies
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Nebuliser circuit Item EVLP
recipient
– 1.32 Paul Henderson,
NuTH, September
2014, personal
communication
4–0 Prolene (No. 8935)
suture pack (Ethicon Inc.,
Somerville, NJ, USA)
Pack EVLP
recipient
– 2.87 Anna Soderlund,
Vivoline, July 2014,
personal
communication
10-fg suction catheter
(SHODS)
Catheter EVLP
recipient
– 0.45 Medical supplies
Suction connecting
tubing
Tubing EVLP
recipient
– 2.36 Paul Henderson,
NuTH, September
2014, personal
communication
Consumables
Nylon surgical tape Roll EVLP
recipient
– 1.56 Medical supplies
Gas (2000 l of N2/CO2) Cylinder EVLP
recipient
– 400.00 Anna Soderlund,
Vivoline, July 2014,
personal
communication
PERFADEX solution 1-l solution EVLP
recipient
– 134.24 XVIVO101
Packed red blood cells 274-ml bag EVLP
recipient
– 120.00 Paul Henderson,
NuTH, September
2014, personal
communication/
Yvonne Scott, NuTH,
July 2015, personal
communication
Syringes for blood gases Syringe EVLP
recipient
– 0.36 Medical supplies
Syringes (other) Syringe EVLP
recipient
– 0.08 Medical supplies
Vivoline disposable lung
set
Set EVLP
recipient
– 6962.87 Anna Soderlund,
Vivoline, July 2014,
personal
communication
Miscellaneous equipment
Blood gases samples Sample EVLP
recipient
– 1.77 Paul Henderson,
NuTH, September
2014, personal
communication
Vivoline system System EVLP
recipient
– 39.40 EAC
Theatre usage
Operating theatre Hour EVLP
recipient
– 587.66 ISD Scotland’s About
ISD102
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Drugs
2 l of Steen Solution 500-ml
solution
EVLP
recipient
– 528.36 XVIVO101
Heparin sodium,
1000 units/ml
1-ml ampoule EVLP
recipient
– 1.49 BNF 201450
Heparin sodium,
5000 units/ml
1-ml ampoule EVLP
recipient
– 7.58 BNF 201450
Insulin human [ACTRAPID®
HM (Novo Nordisk,
Bagsværd, Denmark)],
100 IU/ml
10-ml vial EVLP
recipient
– 7.48 BNF 201450
Methylprednisolone
(as sodium succinate)
500-mg vial EVLP
recipient
– 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial EVLP
recipient
– 17.30 BNF 201450
Methylprednisolone
(as sodium succinate)
2-g vial EVLP
recipient
– 32.66 BNF 201450
THAM, 30mg/ml
(3.0 mmol/ml)
1-ml ampoule EVLP
recipient
– 1.07 BNF 201450
Antibiotics
Meropenem
(as trihydrate)
500-mg vial EVLP
recipient
– 8.00 BNF 201450
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml
solution for
infusion bottle
(400 mg)
EVLP
recipient
– 12.43 BNF 201450
Antifungal
Amphotericin B 50-mg vial EVLP
recipient
– 3.88 BNF 201450
Lung transplant
Fixed costs
Anaesthetic preparation
Anaesthetic room Hour Recipient 587.66 587.66 ISD Scotland’s About
ISD102
Anaesthetic nurse (band 5) Hour Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant anaesthetist Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Staff time
Single lung surgery
Anaesthetic fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
184
TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Anaesthetic nurse (band 5) Hour Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant anaesthetist Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant surgeon Hour Recipient 60.11 60.11 PSSRU’s Unit Costs of
Health and Social
Care 201451
Perfusionist (band 7) Hour Recipient 28.09 28.09 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 7) Hour Recipient 30.34 30.34 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 5) Hour Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgical fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Double lung surgery
Anaesthetic fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Anaesthetic nurse (band 5) Hour Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant anaesthetist Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant surgeon Hour Recipient 60.11 60.11 PSSRU’s Unit Costs of
Health and Social
Care 201451
Perfusionist (band 7) Hour Recipient 28.09 28.09 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 7) Hour Recipient 30.34 30.34 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 5) Hour Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgical fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Theatre usage
Single lung surgery
Operating theatre Hour Recipient 587.66 587.66 ISD Scotland’s About
ISD102
Double lung surgery
Operating theatre Hour Recipient 587.66 587.66 ISD Scotland’s About
ISD102
Equipment/consumables
Usual surgical set Set Recipient Missing Missing Missing
Post-operative care
Fixed costs
Staff time in ITU/HDU
Anaesthetic fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant anaesthetist Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant physician Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Consultant surgeon Hour Recipient 60.11 60.11 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgical fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Staff time in hospital
Consultant physician Hour Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgical fellow Hour Recipient 56.41 56.41 PSSRU’s Unit Costs of
Health and Social
Care 201451
Transplant specialist
registrar
Hour Recipient 40.00 40.00 PSSRU’s Unit Costs of
Health and Social
Care 201451
Tests
ABG Test Recipient 4.37 4.37 NuTH’s costing tool99
Chest X-ray (radiography) Test Recipient 24.97 24.97 NuTH’s costing tool99
FBC Test Recipient 4.94 4.94 NuTH’s costing tool99
Pulmonary/lung function
test
Test Recipient 169.00 169.00 Reference Costs
2013/201449
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Variable costs
Ward usage (if needed)
HDU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU/HDU readmission Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
Level 1 ward care
(hospital stay)
Bed-day Recipient 265.00 265.00 Reference Costs
2013/201449
Procedures (if needed)
Bronchoscopy Procedure Recipient 340.00 340.00 Reference Costs
2013/201449
Tracheostomy Procedure Recipient 135.00 135.00 Reference Costs
2013/201449
Equipment (if needed)
ECMO Machine Recipient 34,000.00 34,000.00 Tanveer Butt, NuTH,
June 2015, personal
communication
iLA membrane ventilator Device Recipient 4.28 4.28 EAC
Consumables (if needed)
2 l colloid (plasma and
plasma substitutes)
500 ml Recipient 8.00 8.00 BNF 201450
1 l crystalloid (fluids
containing electrolytes)
500 ml Recipient 8.00 8.00 BNF 201450
Fresh-frozen plasma 271-ml bag Recipient 28.46 28.46 NHSBT
Packed red blood cells 274-ml bag Recipient 120.00 120.00 Paul Henderson,
NuTH, September
2014, personal
communication/
Yvonne Scott, NuTH,
July 2015, personal
communication
Platelets 250-ml bag Recipient 196.96 196.96 NHSBT
Inotropes (if needed)
Adrenaline (base),
1 mg/10 ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 6.99 6.99 BNF 201450
Dobutamine (as
hydrochloride), 12.5 mg/ml
20-ml ampoule Recipient 5.20 5.20 BNF 201450
Glyceryl trinitrate, 1 mg/ml 50-ml vial Recipient 15.90 15.90 BNF 201450
Milrinone, 1 mg/ml 10-ml ampoule Recipient 19.91 19.91 BNF 201450
Noradrenaline (as acid
tartrate), 1 mg/ml
4-ml ampoule Recipient 4.40 4.40 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Pitressin (argipressin –
synthetic vasopressin),
20 units/ml
1-ml ampoule Recipient 22.50 22.50 BNF 201450
Other
Dopamine hydrochloride,
40 mg/ml
5-ml ampoule Recipient 3.88 3.88 BNF 201450
Enoximone, 5 mg/ml 20-ml ampoule Recipient 15.02 15.02 BNF 201450
Isoprenaline – Recipient 5.20 5.20 –
Metaraminol – Recipient 4.40 4.40 –
Post-implantation haemodynamic support (if needed)
Adrenaline (base),
1 mg/10 ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 6.99 6.99 BNF 201450
Dobutamine
(as hydrochloride),
12.5 mg/ml
20-ml ampoule Recipient 5.20 5.20 BNF 201450
Glyceryl trinitrate, 1 mg/ml 50-ml vial Recipient 15.90 15.90 BNF 201450
Milrinone, 1 mg/ml 10-ml ampoule Recipient 19.91 19.91 BNF 201450
Noradrenaline (as acid
tartrate), 1 mg/ml
4-ml ampoule Recipient 4.40 4.40 BNF 201450
Pitressin (argipressin –
synthetic vasopressin),
20 units/ml
1-ml ampoule Recipient 22.50 22.50 BNF 201450
Complications (if reported)
Cerebrovascular accident Treatment Recipient 840.65 840.65 Reference Costs
2013/201449
Haemofiltration Procedure Recipient 139.00 139.00 Reference Costs
2013/201449
Haemodialysis Procedure
(days)
Recipient 139.00 139.00 Reference Costs
2013/201449
Re-exploration Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Airway complications (if reported)
Balloon dilatation Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Cryotherapy Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Diathermy Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Stenting Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Surgical intervention Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
ITU rejection episodes (if reported)
Ward usage
HDU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
Procedures
Clinical diagnosis/biopsy Procedure Recipient 851.00 851.00 Reference Costs
2013/201449
Treatment
Cefuroxime (as sodium) 750-mg vial Recipient 2.52 2.52 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Piperacillin (as sodium),
2 g; and tazobactam
(as sodium), 250 mg
(Tazocin®, Pfizer Ltd, New
York City, NY, USA)
2.25-g vial Recipient 7.65 7.65 BNF 201450
Changes in maintenance
therapy
Methylprednisolone,
100 mg
20-tablet pack Recipient 48.32 48.32 BNF 201450
Tacrolimus, 5 mg/ml 1-ml ampoule Recipient 58.45 58.45 BNF 201450
Ward rejection episodes (if reported)
Procedures
Clinical diagnosis/biopsy Procedure Recipient 851.00 851.00 Reference Costs
2013/201449
Treatment
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 9.60 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Methylprednisolone,
100 mg
20-tablet pack Recipient 48.32 48.32 BNF 201450
Prednisolone acetate,
25 mg/ml
1-ml ampoule Recipient 6.87 6.87 BNF 201450
Prednisolone, 25 mg 56-tablet pack Recipient 50.00 50.00 BNF 201450
Sulfamethoxazole,
400 mg; and
trimethoprim, 80 mg
(co-trimoxazole) 480 mg
28-tablet pack Recipient 3.34 3.34 BNF 201450
Tacrolimus, 5 mg/ml 1-ml ampoule Recipient 58.45 58.45 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Infection episodes (if reported)
Treatment
Aciclovir (as sodium),
25 mg/ml
20-ml vial
(500 mg)
Recipient 19.61 19.61 BNF 201450
Adefovir dipivoxil, 10 mg 30-tablet pack Recipient 252.22 252.22 BNF 201450
Amikacin (as sulfate),
250 mg/ml
2-ml vial Recipient 9.64 9.64 BNF 201450
Amoxicillin (as trihydrate),
500 mg
21-capsule
pack
Recipient 1.62 1.62 BNF 201450
Amoxicillin (as trihydrate),
500 mg; and clavulanic
acid (as potassium),
125 mg (co-amoxiclav)
21-tablet pack Recipient 4.23 4.23 BNF 201450
Amphotericin B liposomal
(AmBisome®)
50-mg vial Recipient 82.19 82.19 BNF 201450
Amphotericin B
(as sodium deoxycholate
complex)
50-mg vial Recipient 3.88 3.88 BNF 201450
Anidulafungin 100-mg vial Recipient 299.99 299.99 BNF 201450
Azithromycin
(as dihydrate), 250 mg
4-capsule pack Recipient 10.06 10.06 BNF 201450
Aztreonam 1-g vial Recipient 9.40 9.40 BNF 201450
BAL Procedure Recipient 340.00 340.00 Reference Costs
2013/201449
Budesonide, 100 µg; and
formoterol fumarate, 6 µg
[Symbicort Turbohaler®
(AstraZeneca, London, UK)]
120-dose
inhaler
Recipient 33.00 33.00 BNF 201450
Caspofungin (as acetate) 70-mg vial Recipient 416.78 416.78 BNF 201450
Ceftazidime
(as pentahydrate)
2-g vial Recipient 17.90 17.90 BNF 201450
Cefuroxime (as sodium) 750-mg vial Recipient 2.52 2.52 BNF 201450
Chloramphenicol
(as sodium succinate)
1-g vial Recipient 1.39 1.39 BNF 201450
Ciprofloxacin (as lactate)
2 mg/ml
200-ml
solution for
infusion bottle
Recipient 19.79 19.79 BNF 201450
Ciprofloxacin
(as hydrochloride),
500 mg
20-tablet pack Recipient 1.47 1.47 BNF 201450
Ciprofloxacin
(as hydrochloride),
3 mg/ml
5-ml 0.3% eye
drops
Recipient 4.70 4.70 BNF 201450
Clarithromycin 500-mg vial Recipient 9.45 9.45 BNF 201450
Clindamycin
(as phosphate),
150 mg/ml
4-ml ampoule Recipient 11.80 11.80 BNF 201450
Colistimethate sodium 2-million-unit
vial
Recipient 3.24 3.24 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Domperidone
(as maleate), 10 mg
100-tablet
pack
Recipient 5.83 5.83 BNF 201450
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.13 1.13 BNF 201450
Eradication therapy for
Helicobacter pylori
7-day course Recipient 4.30 4.30 BNF 201450
Ertapenem (as sodium) 1-g vial Recipient 31.65 31.65 BNF 201450
Ethambutol
hydrochloride, 100 mg
56-tablet pack Recipient 11.52 11.52 BNF 201450
Flucloxacillin (as sodium),
500 mg
28-capsule
pack
Recipient 2.60 2.60 BNF 201450
Flucloxacillin (as sodium) 1-g vial Recipient 4.90 4.90 BNF 201450
Fluconazole, 50 mg 7-capsule pack Recipient 1.02 1.02 BNF 201450
Fluconazole, 2 mg/ml 100-ml
solution for
infusion bottle
Recipient 27.45 27.45 BNF 201450
Fluconazole, 50 mg 7-capsule pack Recipient 1.02 1.02 BNF 201450
Foscarnet sodium,
24 mg/ml
250-ml
solution for
infusion bottle
Recipient 119.85 119.85 BNF 201450
Fosfomycin (as sodium) 2-g vial Recipient 15.00 15.00 BNF 201450
Furosemide, 10 mg/ml 5-ml ampoule Recipient 0.32 0.32 BNF 201450
Ganciclovir (as sodium) 500-mg vial Recipient 29.77 29.77 BNF 201450
Gentamicin (as sulfate),
40 mg/ml
2-ml vial Recipient 1.40 1.40 BNF 201450
Immunoglobulin 10-g vial Recipient 401.00 401.00 BNF 201450
Itraconazole, 10 mg/ml 25-ml ampoule Recipient 79.71 79.71 BNF 201450
Lamivudine, 150 mg 60-tablet pack Recipient 121.82 121.82 BNF 201450
Lesion excision Day case Recipient 2488.00 2488.00 Reference Costs
2013/201449
Linezolid, 2 mg/ml 300-ml
infusion bag
Recipient 44.50 44.50 BNF 201450
Meropenem (as trihydrate) 1-g vial Recipient 16.00 16.00 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Metoclopramide
hydrochloride, 5 mg/ml
2-ml ampoule Recipient 0.32 0.32 BNF 201450
Metronidazole, 200 mg 21-tablet pack Recipient 6.46 6.46 BNF 201450
Micafungin (as sodium) 100-mg vial Recipient 341.00 341.00 BNF 201450
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml
solution for
infusion bottle
Recipient 39.95 39.95 BNF 201450
Oseltamivir (as
phosphate), 75 mg
10-capsule
pack
Recipient 15.41 15.41 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Packed red blood cells 274-ml bag Recipient 120.00 120.00 Paul Henderson,
NuTH, September
2014, personal
communication/
Yvonne Scott, NuTH,
July 2015, personal
communication
Piperacillin (as sodium),
4 g; and tazobactam
(as sodium), 500 mg
(Tazocin)
4.5-g vial Recipient 12.90 12.90 BNF 201450
Posaconazole, 100 mg 96-tablet pack Recipient 2387.85 2387.85 BNF 201450
Prednisolone, 25 mg 56-tablet pack Recipient 50.00 50.00 BNF 201450
Respiratory failure
(inpatient)
Treatment Recipient 3445.00 3445.00 Reference Costs
2013/201449
Sirolimus, 2 mg 30-tablet pack Recipient 172.98 172.98 BNF 201450
Streptokinase 250,000-unit
powder vial
Recipient 13.52 13.52 BNF 201450
Sulfamethoxazole,
80 mg; and trimethoprim,
16 mg [Septrin® (Aspen
Pharmcare Holding Ltd,
Durban, South Africa)]
5-ml ampoule Recipient 1.78 1.78 BNF 201450
Surgical intervention or
VATS
Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Teicoplanin 200-mg vial Recipient 3.93 3.93 BNF 201450
Trimethoprim, 100 mg 28-tablet pack Recipient 7.55 7.55 BNF 201450
Tobramycin (as sulfate),
40 mg/ml
1-ml vial Recipient 3.70 3.70 BNF 201450
Tigecycline 50-mg vial Recipient 32.31 32.31 BNF 201450
Valaciclovir
(as hydrochloride),
500 mg
42-tablet pack Recipient 8.50 8.50 BNF 201450
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1081.46 1081.46 BNF 201450
Vancomycin
(as hydrochloride)
1-g vial Recipient 12.99 12.99 BNF 201450
Voriconazole 200-mg vial Recipient 77.14 77.14 BNF 201450
Ward usage
HDU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
Outpatient care
Fixed costs
Outpatient reviews
Bronchoscopy Procedure/visit
(4 visits)
Recipient 340.00 340.00 Reference Costs
2013/201449
Chest X-ray (radiography) Test/visit (4 visits) Recipient 24.97 24.97 NuTH’s costing tool99
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
FBC Test/visit
(4 visits)
Recipient 4.94 4.94 NuTH’s costing tool99
Liver function test Test/visit
(4 visits)
Recipient 6.80 6.80 NuTH’s costing tool99
Pulmonary/lung function
test
Test/visit
(4 visits)
Recipient 169.00 169.00 Reference Costs
2013/201449
Urea and electrolytes test Test/visit
(4 visits)
Recipient 2.96 2.96 NuTH’s costing tool99
Staff time
Consultant physician Hour/visit
(4 visits)
Recipient 59.37 59.37 PSSRU’s Unit Costs of
Health and Social
Care 201451
Scrub nurse (band 5) Hour/visit
(4 visits)
Recipient 20.31 20.31 PSSRU’s Unit Costs of
Health and Social
Care 201451
Variable costs
Rejection episodes (if reported)
Procedures
Clinical diagnosis/biopsy Procedure Recipient 295.00 295.00 Reference Costs
2013/201449
Ventilation–perfusion
scan
Test Recipient 203.00 203.00 Reference Costs
2013/201449
Treatment
Anti-thymocyte
immunoglobulin (rabbit),
25 mg
25-mg vial Recipient 158.77 158.77 BNF 201450
Azathioprine, 25 mg 28-tablet pack Recipient 3.24 3.24 BNF 201450
Azathioprine, 50 mg 56-tablet pack Recipient 3.48 3.48 BNF 201450
Ciclosporin, 25 mg 30-capsule
pack
Recipient 13.05 13.05 BNF 201450
Ciclosporin, 50 mg 30-capsule
pack
Recipient 25.50 25.50 BNF 201450
Ciclosporin, 100 mg 30-capsule
pack
Recipient 48.50 48.50 BNF 201450
Ciclosporin [NEORAL®
(Novartis International
AG, Basel, Switzerland)],
10 mg
60-capsule
pack
Recipient 16.68 16.68 BNF 201450
Ciclosporin (NEORAL),
25 mg
30-capsule
pack
Recipient 16.79 16.79 BNF 201450
Ciclosporin (NEORAL),
50 mg
30-capsule
pack
Recipient 32.88 32.88 BNF 201450
Ciclosporin (NEORAL),
100 mg
30-capsule
pack
Recipient 62.41 62.41 BNF 201450
Immunoglobulin 10-g vial Recipient 401.00 401.00 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Meropenem
(as trihydrate)
1-g vial Recipient 16.00 16.00 BNF 201450
Methylprednisolone
(as sodium succinate)
125-mg vial Recipient 4.75 4.75 BNF 201450
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 9.60 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Mycophenolate mofetil,
500 mg
50-tablet pack Recipient 10.15 10.15 BNF 201450
Mycophenolate mofetil
(MMF), 250 mg
100-capsule
pack
Recipient 82.26 82.26 BNF 201450
Prednisolone, 1 mg 28-tablet pack Recipient 1.08 1.08 BNF 201450
Prednisolone, 5 mg 28-tablet pack Recipient 1.29 1.29 BNF 201450
Prednisolone, 25 mg 56-tablet pack Recipient 50.00 50.00 BNF 201450
Rituximab, 100 mg/ml 10-ml vial Recipient 174.63 174.63 BNF 201450
Tacrolimus [Prograf®
(Astellas Pharma Inc.,
Tokyo, Japan)], 500 µg
50-capsule
pack
Recipient 61.88 61.88 BNF 201450
Tacrolimus (Prograf),
1 mg
50-capsule
pack
Recipient 80.28 80.28 BNF 201450
Tacrolimus (Prograf),
1 mg
100-capsule
pack
Recipient 160.54 160.54 BNF 201450
Tacrolimus (Prograf),
5 mg
50-capsule
pack
Recipient 296.58 296.58 BNF 201450
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1081.46 1081.46 BNF 201450
Ward usage
HDU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
GP visits (if needed)
Out-of-surgery visit Visit Recipient 85.00 85.00 PSSRU’s Unit Costs of
Health and Social
Care 201451
Surgery visit Visit Recipient 34.00 34.00 PSSRU’s Unit Costs of
Health and Social
Care 201451
Transplant centre advice Call Recipient 34.00 34.00 PSSRU’s Unit Costs of
Health and Social
Care 201451
Unplanned hospital admission (if needed)
Treatment
Aciclovir (as sodium),
25 mg/ml
20-ml vial Recipient 19.61 19.61 BNF 201450
Aciclovir, 400 mg 56-tablet pack Recipient 4.05 4.05 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Adrenaline (base),
100 µg/ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 6.99 6.99 BNF 201450
Amiodarone
hydrochloride, 30 mg/ml
10-ml pre-filled
disposable
injection
Recipient 13.50 13.50 BNF 201450
Amoxicillin (as sodium),
500 mg; and clavulanic
acid (as potassium),
125 mg (co-amoxiclav)
500-/100-mg
vial
Recipient 1.21 1.21 BNF 201450
Amphotericin B 50-mg vial Recipient 3.80 3.80 BNF 201450
Aspirin, 300 mg 32-tablet pack Recipient 3.35 3.35 BNF 201450
Azathioprine, 25 mg 28-tablet pack Recipient 3.24 3.24 BNF 201450
Azithromycin (as
dihydrate), 250 mg
4-capsule pack Recipient 10.06 10.06 BNF 201450
Aztreonam 1-g vial Recipient 9.40 9.40 BNF 201450
Balloon dilatation Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Basiliximab 20-mg vial Recipient 842.38 842.38 BNF 201450
Bisoprolol fumarate,
10 mg
28-tablet pack Recipient 1.02 1.02 BNF 201450
Bortezomib 3.5-mg vial Recipient 762.38 762.38 BNF 201450
Bronchoscopy Procedure Recipient 340.00 340.00 BNF 201450
Budesonide, 100 µg; and
formoterol fumarate
dihydrate, 6 µg
(Symbicort 100/6
Turbohaler)
120-dose unit
inhaler
Recipient 33.00 33.00 BNF 201450
Calcium gluconate, 1 g 28-tablet pack Recipient 15.68 15.68 BNF 201450
Calcium polystyrene
sulfonate [Calcium
Resonium® (Aventis
Pharma Ltd, Mumbai,
India)]
300-g powder Recipient 68.47 68.47 BNF 201450
Candesartan cilexetil,
4 mg
28-tablet pack Recipient 1.10 1.10 BNF 201450
Caspofungin (as acetate) 70-mg vial Recipient 416.78 416.78 BNF 201450
Ciclosporin, 100 mg 30-capsule pack Recipient 48.50 48.50 BNF 201450
Ciclosporin, 50 mg/ml 5-ml ampoule Recipient 9.16 9.16 BNF 201450
Ciprofloxacin
(as hydrochloride),
500 mg
20-tablet pack Recipient 1.47 1.47 BNF 201450
Clarithromycin 500-mg vial Recipient 9.45 9.45 BNF 201450
Clinical diagnosis/biopsy Procedure Recipient 295.00 295.00 Reference Costs
2013/201449
Colistimethate sodium 1-million-unit
vial
Recipient 5.60 5.60 BNF 201450
Colistimethate sodium 2-million-unit
vial
Recipient 3.24 3.24 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Computerised
tomography
Procedure Recipient 91.00 91.00 Reference Costs
2013/201449
DeBakey tissue forceps Forceps Recipient 0.08 0.08 EAC
Docusate sodium,
100 mg
30-capsule
pack
Recipient 2.09 2.09 BNF 201450
Doxazosin (as mesilate),
4 mg
28-tablet pack Recipient 1.04 1.04 BNF 201450
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.13 1.13 BNF 201450
ECG 24-hour test Recipient 20.81 20.81 NuTH’s costing tool99
Enoxaparin sodium
[Clexane® Forte (Sanofi
SA, Gentilly, France)],
150 mg
1-ml pre-filled
disposable
injection
Recipient 9.99 9.99 BNF 201450
ECMO Machine Recipient 34,000.00 34,000.00 Tanveer Butt, NuTH,
June 2015, personal
communication
Filgrastim, 30 million
units (300 µg /ml)
1-ml vial Recipient 52.70 52.70 BNF 201450
Flucloxacillin (as sodium) 1-g vial Recipient 4.90 4.90 BNF 201450
Fluticasone propionate,
250 µg; and salmeterol
xinafoate, 50 µg
[Seretide® 250 Accuhaler®
(GlaxoSmithKline,
Brentford, London, UK)]
120-unit dose
inhaler
Recipient 35.00 35.00 BNF 201450
Foscarnet sodium,
24 mg/ml
250-ml solution
for infusion
bottle
Recipient 119.85 119.85 BNF 201450
Furosemide, 10 mg/ml 5-ml ampoule Recipient 0.32 0.32 BNF 201450
Ganciclovir (as sodium) 500-mg vial Recipient 29.77 29.77 BNF 201450
Gastrograffin Solution Recipient 3.42 3.42 Medical supplies
Glucose anhydrous,
50 mg/ml
1000-ml bag Recipient 1.38 1.38 BNF 201450
iLA Device Recipient 4.28 4.28 EAC
Immunoglobulin 10-g vial Recipient 408.00 408.00 BNF 201450
Insulin, 3 ml 5 × 3-ml
pre-filled
disposable
injection
devices
Recipient 44.85 44.85 BNF 201450
Intubation Procedure Recipient 235.00 235.00 Reference Costs
2013/201449
Hydralazine
hydrochloride, 50 mg
56-tablet pack Recipient 18.30 18.30 BNF 201450
Hydrocortisone (as sodium
succinate)
100-mg vial Recipient 1.16 1.16 BNF 201450
Lansoprazole, 30 mg 28-capsule
pack
Recipient 1.52 1.52 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Level 1 ward care
(hospital stay)
Bed-day Recipient 265.00 265.00 Reference Costs
2013/201449
Macrogol compound oral
powder
50-sachet pack Recipient 11.13 11.13 BNF 201450
Magnesium hydroxide
with liquid paraffin
150-ml bottle Recipient 11.50 11.50 BNF 201450
Magnesium sulfate
heptahydrate, 100 mg
10-ml ampoule Recipient 51.93 51.93 BNF 201450
Magnetic resonance
imaging scan
Test Recipient 412.00 412.00 Reference Costs
2013/201449
Meropenem
(as trihydrate)
1-g vial Recipient 16.00 16.00 BNF 201450
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 9.60 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Metoclopramide
hydrochloride, 5 mg/ml
2-ml ampoule Recipient 0.32 0.32 BNF 201450
Midazolam
(as hydrochloride),
1 mg/ml
5-ml ampoule Recipient 0.65 0.65 BNF 201450
Minocycline
(as hydrochloride),
100 mg
28-tablet pack Recipient 13.09 13.09 BNF 201450
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml
solution for
infusion bottle
Recipient 39.95 39.95 BNF 201450
Nefopam hydrochloride,
30 mg
90-tablet pack Recipient 10.59 10.59 BNF 201450
Non-invasive ventilation Procedure Recipient 166.00 166.00 BNF 201450
Normal immunoglobulin,
10 g
200-ml
solution for
infusion bottle
Recipient 408.00 408.00 BNF 201450
Oxycodone
hydrochloride, 10 mg/ml
120-ml oral
solution
Recipient 46.63 46.63 BNF 201450
Packed red blood cells 274-ml bag Recipient 120.00 120.00 Paul Henderson,
NuTH, September
2014, personal
communication/
Yvonne Scott, NuTH,
July 2015, personal
communication
Phosphate enema 133-ml enema
pack
Recipient 0.68 0.68 BNF 201450
Piperacillin (as sodium),
4 g; and tazobactam
(as sodium), 500mg
(Tazocin)
4.5-g vial Recipient 15.17 15.17 BNF 201450
Posaconazole, 100 mg 96-tablet pack Recipient 2387.85 2387.85 BNF 201450
Prednisolone, 5 mg 28-tablet pack Recipient 1.29 1.29 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Pregabalin, 150 mg 56-capsule
pack
Recipient 65.40 65.40 BNF 201450
Redo lung
transplantation
Procedure Recipient 2702.00 2702.00 Reference Costs
2013/201449
Renal support Treatment Recipient 755.04 755.04 Reference Costs
2013/201449
Ribavirin, 200 mg 42-tablet pack Recipient 92.50 92.50 BNF 201450
Ribavirin, 400 mg 56-tablet pack Recipient 246.65 246.65 BNF 201450
Salbutamol (as sulfate),
5 mg/2.5 ml
20-unit dose
nebuliser liquid
vial
Recipient 3.82 3.82 BNF 201450
Sirolimus, 2 mg 30-tablet pack Recipient 172.98 172.98 BNF 201450
Sodium bicarbonate,
42 mg/ml
500-ml
intravenous
infusion bottle
Recipient 9.39 9.39 BNF 201450
2 l of 0.9% sodium
chloride solution
1-l solution Recipient 0.97 0.97 BNF 201450
Stenting Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Sulfamethoxazole, 80mg;
and trimethoprim, 16mg
(Septrin)
5-ml ampoule Recipient 1.78 1.78 BNF 201450
Sulfamethoxazole, 400mg;
and trimethoprim, 80mg
(co-trimoxazole)
5 ml ampoule Recipient 1.78 1.78 BNF 201450
Surgical intervention Procedure Recipient 4580.36 4580.36 Reference Costs
2013/201449
Tacrolimus (Prograf),
1 mg
50-capsule
pack
Recipient 80.28 80.28 BNF 201450
Tacrolimus (Prograf),
1 mg
100-capsule
pack
Recipient 160.54 160.54 BNF 201450
Tacrolimus (Prograf),
5 mg/ml
10 × 1-ml
ampoules
Recipient 58.45 58.45 BNF 201450
Tinzaparin sodium, 20,000
units/ml [Innohep® (Leo
Pharma A/S, Copenhagen,
Denmark)
0.5-ml vial Recipient 5.95 5.95 BNF 201450
Tracheostomy Procedure Recipient 135.00 135.00 Reference Costs
2013/201449
Tramadol hydrochloride,
150 mg
60-capsule
pack
Recipient 22.92 22.92 BNF 201450
Ultrasound scan Test Recipient 59.00 59.00 Reference Costs
2013/201449
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1081.46 1081.46 BNF 201450
Vancomycin
(as hydrochloride),
125 mg
28-capsule
pack
Recipient 140.08 140.08 BNF 201450
Voriconazole 200-mg vial Recipient 77.14 77.14 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Warfarin sodium, 3 mg 28-tablet pack Recipient 1.07 1.07 BNF 201450
Warfarin sodium,
1 mg/ml
150-ml oral
suspension
Recipient 107.98 107.98 BNF 201450
Ward usage
HDU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
ITU care Bed-day Recipient 852.00 852.00 Reference Costs
2013/201449
Immunosuppressive medications (if needed)
Azathioprine, 25 mg 28-tablet pack Recipient 3.24 3.24 BNF 201450
Azathioprine, 50 mg 56-tablet pack Recipient 3.48 3.48 BNF 201450
Ciclosporin, 25 mg 30-capsule
pack
Recipient 13.05 13.05 BNF 201450
Ciclosporin, 50 mg 30-capsule
pack
Recipient 25.50 25.50 BNF 201450
Ciclosporin, 100mg 30-capsule
pack
Recipient 48.50 48.50 BNF 201450
Mycophenolate mofetil,
500 mg
50-tablet pack Recipient 10.15 10.15 BNF 201450
Prednisolone, 1 mg 28-tablet pack Recipient 1.08 1.08 BNF 201450
Prednisolone, 5 mg 28-tablet pack Recipient 1.29 1.29 BNF 201450
Prednisolone, 25 mg 56-tablet pack Recipient 50.00 50.00 BNF 201450
Prednisolone acetate,
25 mg/ml
1 ml ampoule Recipient 6.87 6.87 BNF 201450
Sirolimus, 500 µg 30-tablet pack Recipient 69.00 69.00 BNF 201450
Sirolimus, 1 mg 30-tablet pack Recipient 86.49 86.49 BNF 201450
Sirolimus, 2 mg 30-tablet pack Recipient 172.98 172.98 BNF 201450
Tacrolimus, 500 µg 50-capsule
pack
Recipient 61.88 61.88 BNF 201450
Tacrolimus, 1 mg 50-capsule
pack
Recipient 80.28 80.28 BNF 201450
Tacrolimus, 1 mg 100-capsule
pack
Recipient 160.54 160.54 BNF 201450
Tacrolimus, 5 mg 50-capsule
pack
Recipient 296.58 296.58 BNF 201450
Other
Aciclovir, 200 mg 25-tablet pack Recipient 1.77 1.77 BNF 201450
Amoxicillin (as trihydrate),
500 mg
21-capsule
pack
Recipient 1.62 1.62 BNF 201450
Azithromycin
(as dihydrate), 250 mg
4-capsule pack Recipient 10.06 10.06 BNF 201450
Beclomethasone
dipropionate, 400 µg/dose
100-dose unit Recipient 19.61 19.61 BNF 201450
Calcium carbonate
(Adcal), 1.5 g
100-tablet
pack
Recipient 8.70 8.70 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Cetirizine hydrochloride,
10 mg
30-tablet pack Recipient 1.07 1.07 BNF 201450
Ciclosporin (NEORAL),
10 mg
60-capsule
pack
Recipient 16.68 16.68 BNF 201450
Ciclosporin (NEORAL),
25 mg
30-capsule
pack
Recipient 16.79 16.79 BNF 201450
Ciclosporin (NEORAL),
50 mg
50-capsule
pack
Recipient 32.88 32.88 BNF 201450
Ciclosporin, 100 mg 30-capsule
pack
Recipient 62.41 62.41 BNF 201450
Citalopram
(as hydrobromide), 20mg
28-tablet pack Recipient 1.09 1.09 BNF 201450
Dapsone, 100 mg 28-tablet pack Recipient 92.51 92.51 BNF 201450
Dexamethasone, 2 mg 50-tablet pack Recipient 52.41 52.41 BNF 201450
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.13 1.13 BNF 201450
Furosemide, 40 mg 28-tablet pack Recipient 0.88 0.88 BNF 201450
Hydrocortisone, 10 mg 30-tablet pack Recipient 65.78 65.78 BNF 201450
Hydrocortisone, 20 mg 30-tablet pack Recipient 86.63 86.63 BNF 201450
Lisinopril dihydrate,
2.5 mg
28-tablet pack Recipient 0.96 0.96 BNF 201450
Lisinopril dihydrate, 5 mg 28-tablet pack Recipient 0.98 0.98 BNF 201450
Methylprednisolone,
2 mg
30-tablet pack Recipient 3.88 3.88 BNF 201450
Methylprednisolone
(as sodium succinate)
40-mg vial Recipient 1.58 1.58 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.3 17.3 BNF 201450
Mycophenolic acid
(as sodium), 180 mg
120-tablet
pack
Recipient 96.72 96.72 BNF 201450
Mycophenolic acid
(as sodium), 360 mg
120-tablet
pack
Recipient 193.43 193.43 BNF 201450
N-acetylcysteine,
200 mg/ml
10-ml ampoule Recipient 1.96 1.96 BNF 201450
Perindopril erbumine,
2 mg
30-tablet pack Recipient 1.15 1.15 BNF 201450
Perindopril erbumine,
4 mg
30-tablet pack Recipient 1.56 1.56 BNF 201450
Sulfamethoxazole, 400mg;
and trimethoprim, 80mg
(co-trimoxazole)
28-tablet pack Recipient 3.34 3.34 BNF 201450
Tacrolimus (Prograf),
1 mg
50-capsule
pack
Recipient 80.28 80.28 BNF 201450
Tacrolimus (Prograf),
1 mg
100-capsule
pack
Recipient 160.54 160.54 BNF 201450
Tinzaparin sodium,
3500 units
0.35-ml
pre-filled
disposable
injection
Recipient 2.77 2.77 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Concomitant medications
Variable costs
Treatment
Aciclovir, 200 mg 25-tablet pack Recipient 1.77 1.77 BNF 201450
Adrenaline (base),
100 µg/ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 6.99 6.99 BNF 201450
Alendronic acid
(as sodium), 70 mg
28-tablet pack Recipient 1.03 1.03 BNF 201450
Alfentanil (as
hydrochloride), 500 µg/ml
2-ml ampoule Recipient 0.7 0.7 BNF 201450
Alfentanil (as
hydrochloride), 5 mg/ml
1-ml ampoule Recipient 2.5 2.5 BNF 201450
Allopurinol, 300 mg 28-tablet pack Recipient 1.18 1.18 BNF 201450
Amiloride hydrochloride,
5 mg; and furosemide,
40 mg (co-amilofruse)
56-tablet pack Recipient 2.50 2.50 BNF 201450
Amiodarone
hydrochloride, 30 mg/ml
10-ml pre-filled
disposable
syringe
Recipient 13.5 13.5 BNF 201450
Amiodarone
hydrochloride, 100 mg
28-tablet pack Recipient 1.08 1.08 BNF 201450
Amiodarone
hydrochloride, 200 mg
28-tablet pack Recipient 2.04 2.04 BNF 201450
Amitriptyline
hydrochloride, 10 mg
28-tablet pack Recipient 1.19 1.19 BNF 201450
Amlodipine, 5 mg 28-tablet pack Recipient 0.98 0.98 BNF 201450
Amlodipine, 10 mg 28-tablet pack Recipient 1.00 1.00 BNF 201450
Amoxicillin (as trihydrate),
500 mg
21-capsule
pack
Recipient 1.62 1.62 BNF 201450
Amoxicillin (as amoxicillin
trihydrate), 500 mg;
and clavulanic acid
(as potassium), 125 mg
21-tablet pack Recipient 9.60 9.60 BNF 201450
Amphotericin B, 5 mg/ml 20-lozenge
pack
Recipient 7.84 7.84 BNF 201450
Amphotericin B
(as phospholipid
complex), 5 mg/ml
20-ml vial Recipient 77.50 77.50 BNF 201450
Antiembolism socks Socks pack Recipient 12.99 12.99 Medical supplies
Anti-thymocyte
immunoglobulin (rabbit)
25-mg vial Recipient 158.77 158.77 BNF 201450
Aspirin, 75 mg 28-tablet pack Recipient 0.94 0.94 BNF 201450
Atracurium besilate,
10 mg/ml
5-ml ampoule Recipient 4.00 4.00 BNF 201450
Azathioprine, 25 mg 28-tablet pack Recipient 3.24 3.24 BNF 201450
Azathioprine, 50 mg 56-tablet pack Recipient 3.48 3.48 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Azithromycin
(as dihydrate), 250 mg
4-tablet pack Recipient 1.83 1.83 BNF 201450
Azithromycin
(as dihydrate), 250 mg
6-capsule pack Recipient 15.10 15.10 BNF 201450
Azithromycin, 500 mg 3-tablet pack Recipient 1.77 1.77 BNF 201450
Aztreonam 2-g vial Recipient 18.82 18.82 BNF 201450
Bisoprolol fumarate,
1.25 mg
28-tablet pack Recipient 2.35 2.35 BNF 201450
Bisoprolol fumarate,
2.5 mg
28-tablet pack Recipient 2.35 2.35 BNF 201450
Bisoprolol fumarate,
5 mg
28-tablet pack Recipient 0.98 0.98 BNF 201450
Bupivacaine
hydrochloride, 1 mg/ml
100-ml
infusion bag
Recipient 8.41 8.41 BNF 201450
Calcium carbonate
(Adcal), 1.5 g
100-tablet
pack
Recipient 8.70 8.70 BNF 201450
Calcium carbonate, 1.25 g;
and colecalciferol, 400
units (Calcichew D3 Forte)
60-tablet pack Recipient 4.24 4.24 BNF 201450
Calcium chloride
dihydrate, 10%
10-ml pre-filed
disposable
injection
Recipient 6.94 6.94 BNF 201450
Calogen® (Nutricia,
Danone, Paris, France)
emulsion
500-ml bottle Recipient 10.72 10.72 BNF 201450
Carbocisteine, 375 mg 120-capsule
pack
Recipient 17.11 17.11 BNF 201450
Caspofungin (as acetate) 50-mg vial Recipient 327.67 327.67 BNF 201450
Ceftazidime
(as pentahydrate)
2-g vial Recipient 17.90 17.90 BNF 201450
Chlordiazepoxide
hydrochloride, 5 mg
100-capsule
pack
Recipient 8.07 8.07 BNF 201450
Chlordiazepoxide
hydrochloride [Librium
Meda AB, Solna,
Sweden)], 10 mg
100-capsule
pack
Recipient 14.06 14.06 BNF 201450
Chlorhexidine gluconate,
4%
500-ml surgical
scrub
Recipient 3.59 3.59 BNF 201450
Chlorhexidine
hydrochloride
500-mg pump
pack
Recipient 6.04 6.04 BNF 201450
Chlorhexidine
hydrochloride, 1mg/g; and
neomycin sulfate, 5mg/g
[Naseptin® (Alliance
Pharma, Clippenham, UK)]
15-g nasal
cream
Recipient 1.90 1.90 BNF 201450
Chlorhexidine
hydrochloride, 10 mg/g;
and nystatin, 100,000
units/g [Nystaform®
(Typharm Ltd, Norwich,
UK)]
30-g cream Recipient 2.62 2.62 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Chlorphenamine
maleate, 10 mg/ml
1 ml ampoule Recipient 4.47 4.47 BNF 201450
Chlorpromazine
hydrochloride, 25 mg
28-tablet pack Recipient 2.31 2.31 BNF 201450
Ciclosporin (NEORAL),
25 mg
30-capsule
pack
Recipient 16.79 16.79 BNF 201450
Ciclosporin, 50 mg 30-capsule
pack
Recipient 25.50 25.50 BNF 201450
Ciclosporin, 100 mg 30-capsule
pack
Recipient 48.50 48.50 BNF 201450
Ciprofloxacin
(as hydrochloride),
500 mg (Ciproxin)
10-tablet pack Recipient 12.49 12.49 BNF 201450
Ciprofloxacin
(as hydrochloride),
750 mg
10-tablet pack Recipient 8.00 8.00 BNF 201450
Citalopram
(as hydrobromide), 20 mg
28-tablet pack Recipient 1.09 1.09 BNF 201450
Citalopram
(as hydrobromide), 40 mg
28-tablet pack Recipient 1.28 1.28 BNF 201450
Clonidine hydrochloride,
25 µg
112-tablet
pack
Recipient 5.02 5.02 BNF 201450
Codeine phosphate,
8 mg; and paracetamol,
500 mg
30-tablet pack Recipient 1.19 1.19 BNF 201450
Codeine phosphate,
30 mg; and paracetamol,
500 mg
100-tablet
pack
Recipient 5.80 5.80 BNF 201450
Codeine phosphate,
30 mg
28-tablet pack Recipient 1.52 1.52 BNF 201450
Codeine phosphate,
60 mg
28-tablet pack Recipient 2.70 2.70 BNF 201450
Colecalciferol, 500 µg
(20,000 units)
15-capsule
pack
Recipient 17.40 17.40 BNF 201450
Colistimethate sodium 1-million-unit
vial
Recipient 3.24 3.24 BNF 201450
Colistimethate sodium 2-million-unit
vial
Recipient 3.24 3.24 BNF 201450
CREON® (AbbVie Inc.,
North Chicago, IL, USA),
25,000 units
100-capsule
pack
Recipient 28.25 28.25 BNF 201450
CREON Micro
Pancreatine, 20 g
60.12-mg
granules
Recipient 31.50 31.50 BNF 201450
Cryoprecipitate 8 units Recipient 711.29 711.29 Medical supplies
Cyclizine hydrochloride,
50 mg
100-tablet
pack
Recipient 10.97 10.97 BNF 201450
Dapsone, 100 mg 28-tablet pack Recipient 92.51 92.51 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Diazepam, 2 mg 28-tablet pack Recipient 1.09 1.09 BNF 201450
Digoxin, 250 µg/ml 2-ml ampoule Recipient 0.70 0.70 BNF 201450
Diltiazem hydrochloride,
120 mg
28-capsule
pack
Recipient 6.27 6.27 BNF 201450
Diltiazem hydrochloride,
200 mg
7-capsule pack Recipient 6.27 6.27 BNF 201450
Docusate sodium,
100 mg
100-capsule
pack
Recipient 6.98 6.98 BNF 201450
Domperidone
(as maleate), 10 mg
100-tablet
pack
Recipient 4.83 4.83 BNF 201450
Dopamine hydrochloride,
40 mg/ml
5-ml ampoule Recipient 3.88 3.88 BNF 201450
Dosulepin hydrochloride,
25 mg
28-capsule
pack
Recipient 1.86 1.86 BNF 201450
Doxazosin (as mesilate),
4 mg
28-tablet pack Recipient 5.00 5.00 BNF 201450
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.13 1.13 BNF 201450
Enoxaparin sodium,
100 mg/ml
0.4-ml
pre-filled
disposable
injection
Recipient 3.03 3.03 BNF 201450
Ensure® (Abbott
Laboratories, Chicago, IL,
USA) liquid
250 ml Recipient 2.26 2.26 BNF 201450
Erythromycin
(as lactobionate)
1-g vial Recipient 10.98 10.98 BNF 201450
Esomeprazole
(as magnesium
dihydrate), 40 mg
28-capsule
pack
Recipient 3.96 3.96 BNF 201450
Ethambutol
hydrochloride, 400 mg
56-tablet pack Recipient 42.74 42.74 BNF 201450
Ezetimibe, 10 mg 28-tablet pack Recipient 26.31 26.31 BNF 201450
Ethinylestradiol, 30 µg;
and gestodene, 75 µg
21-day
preparation
Recipient 6.73 6.73 BNF 201450
Ferrous sulfate dried,
200 mg
28-tablet pack Recipient 1.11 1.11 BNF 201450
Flucloxacillin (as sodium),
500 mg
28-capsule
pack
Recipient 2.60 2.60 BNF 201450
Flucloxacillin (as sodium) 1-g vial Recipient 4.90 4.90 BNF 201450
Fluconazole, 50 mg 7-capsule pack Recipient 1.02 1.02 BNF 201450
Fluconazole, 200 mg 7-capsule pack Recipient 6.36 6.36 BNF 201450
Fluconazole, 2 mg/ml 100-ml
solution for
infusion bottle
Recipient 27.45 27.45 BNF 201450
Fluoxetine
(as hydrochloride), 20 mg
30-capsule
pack
Recipient 1.16 1.16 BNF 201450
Fluticasone propionate,
50 µg
150-unit dose
nasal spray
Recipient 11.01 11.01 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Fluticasone propionate,
250 µg (Flixotide 250
Accuhale)
60-dose
inhaler
Recipient 21.26 21.26 BNF 201450
Fluticasone propionate,
250 µg; and salmeterol
xinafoate, 50 µg (Seretide
250 Accuhaler)
60-dose
inhaler
Recipient 35.00 35.00 BNF 201450
Folic acid, 400 µg 90-tablet pack Recipient 2.71 2.71 BNF 201450
Foscarnet sodium,
24 mg/ml
250-ml
solution for
infusion bottle
Recipient 119.85 119.85 BNF 201450
Fosfomycin (as sodium) 2-g vial Recipient 15.00 15.00 BNF 201450
Fresh-frozen plasma 271-ml bag Recipient 28.46 28.46 NHSBT
Furosemide, 10 mg/ml 2-ml ampoule Recipient 0.35 0.35 BNF 201450
Furosemide, 20 mg 28-tablet pack Recipient 0.98 0.98 BNF 201450
Furosemide, 40 mg 28-tablet pack Recipient 0.88 0.88 BNF 201450
Ganciclovir (as sodium) 500-mg vial Recipient 29.77 29.77 BNF 201450
Gelatin (Gelofusine®) 1-l infusion
bag
Recipient 9.04 9.04 BNF 201450
Gelatin, 140 mg/g; and
glycerol, 700mg/g
4-g
supplementary
pack
Recipient 1.94 1.94 BNF 201450
Gliclazide (glycoside),
30 mg
56-tablet pack Recipient 4.10 4.10 BNF 201450
Gliclazide, 40 mg 28-tablet pack Recipient 3.36 3.36 BNF 201450
Glucose anhydrous,
500 mg/ml
50-ml vial Recipient 2.01 2.01 BNF 201450
Glyceryl trinitrate (GTN),
1 mg/ml
50-ml ampoule Recipient 15.90 15.90 BNF 201450
Haloperidol, 5 mg 28-tablet pack Recipient 3.30 3.30 BNF 201450
Haloperidol, 5 mg/ml 1-ml ampoule Recipient 0.87 0.87 BNF 201450
Heparin sodium,
5000 units/ml
1-ml ampoule Recipient 2.90 2.90 BNF 201450
Heparin sodium,
5000 units/ml
5-ml ampoule Recipient 7.58 7.58 BNF 201450
Hydroxocobalamin,
1 mg/ml
1-ml ampoule Recipient 1.75 1.75 BNF 201450
Hyoscine butylbromide
[Buscopan® (Boehringer
Ingelheim, Ingelheim,
Germany)], 10 mg
56-tablet pack Recipient 3.00 3.00 BNF 201450
Ibandronic acid
(as sodium monohydrate)
50 mg
28-tablet pack Recipient 10.76 10.76 BNF 201450
Iloprost (as THAM),
10 µg/ml
30 × 1-ml unit
dose vials
Recipient 400.19 400.19 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Insulin, 3 ml 5 × 3-ml
pre-filled
disposable
injection
devices
Recipient 44.85 44.85 BNF 201450
Insulin aspart,
100 units/ml
5 × 3-ml
pre-filled
disposable
injection
devices
Recipient 32.13 32.13 BNF 201450
Insulin human (as soluble
human) (ACTRAPID®),
100 units/ml
10-ml vial Recipient 7.48 7.48 BNF 201450
Insulin human
(as detemir), 100 units/ml
(LEMEVIR®, Novo
Nordisk, Bagsværd,
Denmark)
5 × 3-ml
pre-filled
disposable
injection device
Recipient 43.00 43.00 BNF 201450
Ipratropium bromide,
250 µg/ml
60 × 1-ml unit
dose vial
Recipient 12.44 12.44 BNF 201450
Ipratropium bromide 500-µg
nebuliser
solution
Recipient 23.75 23.75 BNF 201450
Ipratropium bromide,
2.5 mg/2.5 ml
60-unit dose
vial
Recipient 24.10 24.10 BNF 201450
Ipratropium bromide,
200 µg/ml; and
salbutamol (as sulfate),
1 mg/ml (Combivent)
60-unit dose
vials
Recipient 24.10 24.10 BNF 201450
Itraconazole, 100 mg 15-capsule
pack
Recipient 4.57 4.57 BNF 201450
Itraconazole, 10 mg/ml 150-ml oral
solution
Recipient 58.34 58.34 BNF 201450
Labetalol hydrochloride,
100 mg
56-tablet pack Recipient 6.99 6.99 BNF 201450
Labetalol hydrochloride,
200 mg
56-tablet pack Recipient 9.89 9.89 BNF 201450
Lactulose 300-ml
solution
Recipient 1.95 1.95 BNF 201450
Lansoprazole, 15 mg 28-capsule
pack
Recipient 1.17 1.17 BNF 201450
Lansoprazole, 30 mg 28-tablet pack Recipient 1.52 1.52 BNF 201450
Loratadine, 10 mg 30-tablet pack Recipient 1.11 1.11 BNF 201450
Levomepromazine
maleate, 25 mg
84-tablet pack Recipient 20.26 20.26 BNF 201450
Linezolid, 600 mg 10-tablet pack Recipient 445.00 445.00 BNF 201450
Loperamide
hydrochloride, 2 mg
30-tablet pack Recipient 2.15 2.15 BNF 201450
Lorazepam, 1 mg 28-tablet pack Recipient 2.67 2.67 BNF 201450
Lymecycline, 408 mg 28-capsule
pack
Recipient 9.18 9.18 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Magnesium oxide,
160 mg
28-capsule
pack
Recipient 17.50 17.50 Medical supplies
Magnesium sulfate
heptahydrate, 500 mg/ml
2-ml ampoule Recipient 1.18 1.18 BNF 201450
Magnesium sulfate
heptahydrate, 500 mg/ml
5-ml ampoule Recipient 5.56 5.56 BNF 201450
Magnesium sulfate
heptahydrate, 500 mg/ml
4-ml ampoule Recipient 10.23 10.23 BNF 201450
Menadiol phosphate
(as sodium phosphate),
10 mg
100-tablet
pack
Recipient 128.60 128.60 BNF 201450
Meropenem
(as trihydrate)
1-g vial Recipient 16.00 16.00 BNF 201450
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 9.60 9.60 BNF 201450
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 17.30 17.30 BNF 201450
Metformin hydrochloride,
500 mg
28-tablet pack Recipient 2.66 2.66 BNF 201450
Metoclopramide
hydrochloride, 10 mg
28-tablet pack Recipient 0.97 0.97 BNF 201450
Metronidazole, 400 mg 21-tablet pack Recipient 1.70 1.70 BNF 201450
Midazolam (as
hydrochloride), 1 mg/ml
5-ml ampoule Recipient 6.00 6.00 BNF 201450
Milrinone (as lactate),
1 mg/ml
10-ml ampoule Recipient 19.91 19.91 BNF 201450
Minocycline (as
hydrochloride), 100 mg
28-tablet pack Recipient 6.20 6.20 BNF 201450
Mirtazapine, 30 mg 28-tablet pack Recipient 1.60 1.60 BNF 201450
Montelukast (as sodium),
10 mg
28-tablet pack Recipient 26.97 26.97 BNF 201450
Mometasone furoate,
50 µg
140-unit dose
nasal spray
Recipient 7.68 7.68 BNF 201450
Morphine sulfate,
1 mg/ml
10-mg
disposable
syringe
Recipient 15.00 15.00 BNF 201450
Morphine sulfate
(Oramorph®), 10 mg/5 ml
300-ml oral
solution
Recipient 5.45 5.45 BNF 201450
Movicol® (Norgine
Pharmaceuticals Ltd,
Amsterdam,
the Netherlands)
30-sachet pack Recipient 6.68 6.68 BNF 201450
Moxifloxacin
(as hydrochloride),
400 mg
5-tablet pack Recipient 12.43 12.43 BNF 201450
Multivitamins 28-capsule
pack
Recipient 1.50 1.50 BNF 201450
Mupirocin, 20 mg/g 15-g ointment Recipient 5.35 5.35 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Micafungin (as sodium) 100-mg vial Recipient 341.00 341.00 BNF 201450
N-acetylcysteine, 600mg 100-tablet
pack
Recipient 23.45 23.45 Medical supplies
Naproxen, 500 mg 28-tablet pack Recipient 1.67 1.67 BNF 201450
Nebivolol (as
hydrochloride), 5 mg
28-tablet pack Recipient 1.81 1.81 BNF 201450
Nifedipine, 5 mg 84-capsule
pack
Recipient 15.20 15.20 BNF 201450
Nifedipine, 10 mg 84-capsule
pack
Recipient 6.53 6.53 BNF 201450
Noradrenaline base,
1 mg/ml (as
noradrenaline acid
tartrate, 2 mg/ml)
4-ml ampoule Recipient 4.40 4.40 BNF 201450
Nutrison energy
multifibre
1000-ml
solution
Recipient 11.74 11.74 BNF 201450
Nystatin, 100,000 units/ml 30-ml oral
suspension
Recipient 3.35 3.35 BNF 201450
Omeprazole
(as magnesium), 10 mg
28-tablet pack Recipient 1.25 1.25 BNF 201450
Omeprazole
(as magnesium), 20 mg
28-tablet pack Recipient 6.11 6.11 BNF 201450
Omeprazole
(as magnesium), 40 mg
28-capsule
pack
Recipient 4.98 4.98 BNF 201450
Omeprazole (as sodium) 40-mg vial Recipient 4.16 4.16 BNF 201450
Ondansetrol
(as hydrochloride),
2 mg/ml
1-ml ampoule Recipient 1.00 1.00 BNF 201450
Ondansetron
(as hydrochloride), 4 mg
30-tablet pack Recipient 5.37 5.37 BNF 201450
Oxycodone
hydrochloride, 5 mg
56-tablet pack Recipient 11.43 11.43 BNF 201450
Oxycodone
hydrochloride, 10 mg
56-capsule
pack
Recipient 22.86 22.86 BNF 201450
Pabrinex® (Archimedes
Pharma Ltd, Reading, UK)
vitamin B substances
with ascorbic acid,
250 mg/10 ml
2 × 5ml
ampoule
Recipient 2.25 2.25 BNF 201450
Packed red blood cells 274-ml bag Recipient 120.00 120.00 Paul Henderson,
NuTH, September
2014, personal
communication/
Yvonne Scott, NuTH,
July 2015, personal
communication
Paracetamol, 500 mg 32-tablet pack Recipient 0.96 0.96 BNF 201450
Paracetamol, 1 g 10mg/ml
100-ml vial
Recipient 1.20 1.20 BNF 201450
Peppermint water 100-ml
solution
Recipient 10.81 10.81 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Perindopril erbumine,
4 mg
30-tablet pack Recipient 1.56 1.56 BNF 201450
Phenoxymethylpenicillin
(as potassium), 250 mg
28-tablet pack Recipient 1.20 1.20 BNF 201450
Phosphate 500-ml bottle Recipient 5.15 5.15 BNF 201450
Piperacillin,(as sodium) 4 g;
and tazobactam
(as sodium), 500mg
(Tazocin)
4.5-g vial Recipient 15.17 15.17 BNF 201450
Platelets 250-ml bag Recipient 196.96 196.96 BNF 201450
Posaconazole, 100 mg 96-tablet pack Recipient 2387.85 2387.85 BNF 201450
Potassium bicarbonate,
400 mg; and potassium
chloride, 600 mg
[Sando-K® (HK Pharma
Ltd, Bedford, UK)]
20 tablets Recipient 1.53 1.53 BNF 201450
Potassium chloride,
150 mg/ml
10-ml ampoule Recipient 0.48 0.48 BNF 201450
Pravastatin sodium,
10 mg
28-tablet pack Recipient 1.31 1.31 BNF 201450
Pravastatin sodium,
20 mg
28-tablet pack Recipient 1.57 1.57 BNF 201450
Pravastatin sodium,
40 mg
28-tablet pack Recipient 1.93 1.93 BNF 201450
Prednisolone, 5 mg 28-tablet pack Recipient 1.29 1.29 BNF 201450
Pregabalin, 25 mg 56-capsule
pack
Recipient 64.40 64.40 BNF 201450
Pregabalin, 50 mg 84-capsule
pack
Recipient 96.60 96.60 BNF 201450
Pregabalin, 75 g 56-capsule
pack
Recipient 64.40 64.40 BNF 201450
Pregabalin, 100 mg 84-capsule
pack
Recipient 96.60 96.60 BNF 201450
Prochlorperazine
maleate, 3 mg
5 × 10-tablet
pack
Recipient 6.49 6.49 BNF 201450
Propofol, 5 mg/ml 20-ml ampoule Recipient 3.46 3.46 BNF 201450
Propofol, 10 mg/ml 20-ml ampoule Recipient 3.07 3.07 BNF 201450
Propofol, 10 mg/ml 50-ml pre-filled
disposable
injection
Recipient 10.10 10.10 BNF 201450
Ramipril, 2.5 mg 28-tablet pack Recipient 1.12 1.12 BNF 201450
Ramipril, 5 mg 28-capsule
pack
Recipient 1.24 1.24 BNF 201450
Ranitidine
(as hydrochloride),
25 mg/ml
2-ml ampoule Recipient 0.54 0.54 BNF 201450
Ranitidine
(as hydrochloride),
150 mg
60-tablet pack Recipient 1.57 1.57 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Ranitidine
(as hydrochloride),
300 mg
30-tablet pack Recipient 1.48 1.48 BNF 201450
Remifentanil
(as hydrochloride)
5-mg vial Recipient 25.40 25.40 BNF 201450
Risperidone, 500 µg 20-tablet pack Recipient 1.07 1.07 BNF 201450
Risperidone, 2 mg 60-tablet pack Recipient 1.68 1.68 BNF 201450
Salbutamol (as sulfate),
2.5 mg/2.5 ml
20-unit dose
nebuliser
Recipient 1.91 1.91 BNF 201450
Salbutamol (as sulfate),
200 µg
100-dose unit
inhaler
Recipient 4.85 4.85 BNF 201450
Sennoside B
(as sennosides), 7.5 mg
60-tablet pack Recipient 3.52 3.52 BNF 201450
Sildenafil (as citrate),
25 mg
4-tablet pack Recipient 1.09 1.09 BNF 201450
Sodium chloride, 0.9% 20 × 2.5 ml
spray
Recipient 20.60 20.60 BNF 201450
Sodium chloride, 600 mg 100-tablet
pack
Recipient 6.05 6.05 BNF 201450
Sodium cromoglycate,
5 mg/dose
112-unit dose
inhaler
Recipient 17.07 17.07 BNF 201450
Sodium dihydrogen
phosphate anhydrous,
1.936 g
100-tablet
pack
Recipient 3.29 3.29 BNF 201450
Sodium valproate,
200 mg
100-tablet
pack
Recipient 4.49 4.49 BNF 201450
Strepsils® (Reckitt
Benckiser Group, Slough,
UK)
24-lozenge
pack
Recipient 2.99 2.99 Medical supplies
Sulfamethoxazole,
400mg; and trimethoprim,
80mg (co-trimoxazole)
28-tablet pack Recipient 3.34 3.34 BNF 201450
Tadalafil, 20 mg 8-tablet pack Recipient 53.98 53.98 BNF 201450
Tamsulosin
hydrochloride, 400 µg
30-capsule
pack
Recipient 4.62 4.62 BNF 201450
T.E.D™ compression
socks/hose (Medtronic,
Minneapolis, MN, USA)
(knee length)
Stocking Recipient 8.12 8.12 Medical supplies
Teicoplanin 400-mg vial Recipient 7.32 7.32 BNF 201450
Theophylline [Uniphyllin®
(Napp Pharmaceuticals
Ltd, Cambridge, UK)],
200 mg
56-tablet pack Recipient 2.96 2.96 BNF 201450
Thiamine hydrochloride,
100 mg
100-tablet
pack
Recipient 9.18 9.18 BNF 201450
Tiotropium (as bromide),
18 µg
30-capsule
pack
Recipient 34.87 34.87 BNF 201450
Tobramycin, 60 mg/ml 56 × 5ml –
300-mg unit
Recipient 1305.92 1305.92 BNF 201450
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TABLE 50 Unit costs of resources and interventions: detailed (continued )
Resource or intervention Unit
Patient
details
Standard
donor lung
transplantation (£)
EVLP
transplantation (£) Cost source
Tobramycin, 75 mg/ml 56 × 4-ml
nebuliser
Recipient 1187.00 1187.00 BNF 201450
Tramadol hydrochloride,
50 mg
30-capsule
pack
Recipient 1.20 1.20 BNF 201450
Tramadol hydrochloride,
50 mg
60-capsule
pack
Recipient 6.56 6.56 BNF 201450
Tramadol hydrochloride,
100 mg
60-capsule
pack
Recipient 14.72 14.72 BNF 201450
Ursodeoxycholic acid,
150 mg
60-tablet pack Recipient 18.99 18.99 BNF 201450
Ursodeoxycholic acid,
300 mg
60-tablet pack Recipient 38.86 38.86 BNF 201450
Valaciclovir
(as hydrochloride),
500 mg
42-tablet pack Recipient 8.50 8.50 BNF 201450
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1081.46 1081.46 BNF 201450
Vancomycin
(as hydrochloride)
1-g vial Recipient 12.99 12.99 BNF 201450
Vitamin B compound
strong
28-tablet pack Recipient 1.95 1.95 BNF 201450
Vitamins A, D, E 30-capsule
pack
Recipient 5.93 5.93 BNF 201450
Multivitamins 100-tablet
pack
Recipient 9.21 9.21 BNF 201450
Voriconazole, 200 mg 28-tablet pack Recipient 1102.74 1102.74 BNF 201450
Warfarin sodium, 3 mg 28-tablet pack Recipient 1.07 1.07 BNF 201450
Water for injections 5-ml ampoule Recipient 0.24 0.24 BNF 201450
Zopiclone, 3.75 mg 28-tablet pack Recipient 1.68 1.68 BNF 201450
EAC, equivalent annual cost; N2, nitrogen gas; NHSBSA, NHS Business Service Authority; ODA, operating department
assistant; VATS, video-assisted thoracoscopic surgery.
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Appendix 7 NHS resource use
TABLE 51 NHS resource use: detailed table
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Donor’s hospital
Fixed costs
Initial assessment
ABG Test Donor 1.00 1.00 CRF p. 23/Anne Davison,
NuTH, June 2015,
personal communication
Bronchoscopy Procedure Donor 1.00 1.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Katharine Thornalley,
NuTH, June 2015,
personal communication
Chest X-ray (radiography) Test Donor 1.00 1.00 CRF p. 23/Anne Davison,
NuTH, June 2015,
personal communication
ECG Test Donor 1.00 1.00 Anne Davison, NuTH,
June 2015, personal
communication
FBC Test Donor 1.00 1.00 Anne Davison, NuTH,
June 2015, personal
communication
Drugs
Methylprednisolone
(as sodium succinate)
500-mg vial Donor 1.00 1.00 CRF p. 25
Methylprednisolone
(as sodium succinate)
1-g vial Donor 1.00 1.00 CRF p. 25/Tanveer Butt,
NuTH, June 2015,
personal communication
Methylprednisolone
(as sodium succinate)
2-g vial Donor 1.00 1.00 CRF p. 25
Lung retrieval
Fixed costs
Equipment
DCD donor
Bronchoscope Instrument Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Pink spray 0.5%
chlorhexidine
Spray Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
2 l of 0.9% sodium
chloride solution
1-l solution Donor 16.00 16.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Strapple tape Roll Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
DBD donor
Blue 23-gauge
25-mm (1-inch) needles
1-inch needle Donor 5.00 5.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Bronchoscope Instrument Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
1-l cardioplegia bag
(green PLEGIVEX)
1-l bag Donor 3.00 3.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Green vacutainers Vacutainer Donor 6.00 6.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
i-STAT portable clinical
analyser (Abbott
Laboratories, Chicago, IL,
USA)
Device Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
i-STAT cartridges Cartridge Donor 8.00 8.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Pink spray 0.5%
chlorhexidine
Spray Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
1-l pressure infusion bag 1-l bag Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Red vacutainers Vacutainer Donor 6.00 6.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Sodium bicarbonate
8.4%
10-ml ampoule Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
2 l of 0.9% sodium
chloride solution
1-l solution Donor 20.00 20.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Spleen pots Pot Donor 6.00 6.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Strapple tape Roll Donor 1.00 1.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
1-ml syringes 1-ml syringe Donor 5.00 5.00 Retrieval team/
Paul Henderson, NuTH,
September 2014,
personal communication
Staff time
Scout Team
Retrieval surgeon (fellow) Hour Donor 0.80 0.80 Tanveer Butt, NuTH,
June 2015, personal
communication
Scrub nurse (band 5) Hour Donor 0.80 0.80 Tanveer Butt, NuTH,
June 2015, personal
communication
Retrieval team
Perfusionist (band 7) Hour Donor 9.00 9.00 Tanveer Butt, NuTH,
June 2015, personal
communication/
Paul Henderson, NuTH,
September 2014,
personal communication
Retrieval surgeon (fellow) Hour Donor 9.00 9.00 Tanveer Butt, NuTH,
June 2015, personal
communication/
Paul Henderson, NuTH,
September 2014,
personal communication
Scrub nurse (band 5) Hour Donor 9.00 9.00 Tanveer Butt, NuTH,
June 2015, personal
communication/
Paul Henderson, NuTH,
September 2014,
personal communication
Tests
Chest X-ray (radiography) Test Donor 1.00 1.00 CRF p. 23/Anne Davison,
NuTH, June 2015,
personal communication
Perfusion (dosage)
2.8 l of PERFADEX solution 2.8-l solution Donor 1.00 1.00 CRF p. 27/
Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
1 l of PERFADEX solution 1-l solution Donor 1.00 1.00 CRF p. 27/
Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Calcium chloride 1 mmol/ml
(1.7 ml/2.8 l PERFADEX and
0.6 ml/1 l PERFADEX)
10-ml ampoule Donor 1.00 1.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
FLOLAN 0.5-mg vial
(7 ml/2.8 l PERFADEX)
0.5-mg vial Donor 3.00 3.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
FLOLAN 0.5-mg vial
(2.5 ml/1 l PERFADEX)
0.5-mg vial Donor 1.00 1.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Heparin sodium
5000 units/5 ml
(15,000 units/2.8 l PERFADEX)
5-ml ampoule Donor 3.00 3.00 BNF 201450
Heparin sodium
5000 units/5 ml
(5000 units/1 l PERFADEX)
5-ml ampoule Donor 1.00 1.00 BNF 201450
THAM 1-ml ampoule
(7 ml/2.8 l PERFADEX)
1-ml ampoule Donor 7.00 7.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
THAM 1-ml ampoule
(2.5 ml/1 l PERFADEX)
1-ml ampoule Donor 3.00 3.00 Paul Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Variable costs
Travelling
Scout team
Road Transport
type/case
Donor 0.20 0.20 Brian Leadbitter, NuTH,
June 2015, personal
communication
Retrieval team
Road Transport
type/case
Donor 0.74 0.74 Brian Leadbitter, NuTH,
June 2015, personal
communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Road and air Transport
type/case
Donor 0.26 0.26 Brian Leadbitter, NuTH,
June 2015, personal
communication
Organ (lung)
Road Transport
type/case
Donor 0.50 0.50 Brian Leadbitter, NuTH,
June 2015, personal
communication
Road and air Transport
type/case
Donor 0.50 0.50 Brian Leadbitter, NuTH,
June 2015, personal
communication
Transplant preparation
Fixed costs
Contacting potential
recipients
Transplant
co-ordinator
Hour Recipient 1.00 1.00 Katie Morley, NuTH,
October 2014, personal
communication
Meeting potential recipients
Transplant
co-ordinator
Hour Recipient 2.00 2.00 Katie Morley, NuTH,
October 2014, personal
communication
Tissue typing
Tissue typing test Test Recipient 1.00 1.00 Katie Morley, NuTH,
October 2014, personal
communication
Tests
ABG Test Recipient 1.00 1.00 CRF p. 20
Chest X-ray (radiography) Test Recipient 1.00 1.00 CRF p. 21
ECG Test Recipient 1.00 1.00 Katie Morley, NuTH,
October 2014, personal
communication/
Anne Davison, NuTH,
June 2015, personal
communication
FBC Test Recipient 1.00 1.00 CRF p. 20
Ward time
Transplant centre ward Bed-day Recipient 1.00 1.00 Care Pathway/
Katie Morley, NuTH,
October 2014, personal
communication
Drugs
Azathioprine 50 mg 56-tablet pack Recipient 0.02 0.02 Andrew Fisher, NuTH,
November 2015,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Variable costs
Transfer to ward
Air Transport type Recipient Missing Missing Missing
Road Transport type Recipient Missing Missing Missing
EVLP procedure
Fixed costs
Staff time
Anaesthetic registrar Hour EVLP
recipient
– 2.00 Katie Morley, NuTH,
October 2014, personal
communication/Paul
Henderson, NuTH,
September 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Consultant surgeon Hour EVLP
recipient
– 0.33 Paul Henderson, NuTH,
September 2014,
personal communication
Perfusionist (band 7) Hour EVLP
recipient
– 6.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Scrub nurse/ODA (band 5) Hour EVLP
recipient
– 3.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Surgical fellow Hour EVLP
recipient
– 4.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Equipment
Bronchoscope Instrument EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
DeBakey tissue forceps Forceps EVLP
recipient
– 3.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
McIndoe scissors Scissor EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Nebuliser circuit Item EVLP
recipient
– 1.00 Paul Henderson, NuTH,
September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
4–0 Prolene (no. 8935)
suture pack
Pack EVLP
recipient
– 2.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
10FG suction catheter
(SHODS)
Catheter EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Suction connecting tubing Tubing EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Consumables
Nylon surgical tape Roll EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Gas (2000 l of N2/CO2) Cylinder EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
PERFADEX solution 1-l solution EVLP
recipient
– 2.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Packed red blood cells 274-ml bag EVLP
recipient
– 2.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
Anders Andreasson,
NuTH, September 2014,
personal communication
Syringes for blood gases Syringe EVLP
recipient
– 9.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Syringes (other) Syringe EVLP
recipient
– 10.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Vivoline disposable lung set Set EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Miscellaneous equipment
Blood gases samples Sample EVLP
recipient
– 20.00 Anna Soderlund,
Vivoline, July 2014,
personal communication
Vivoline system System EVLP
recipient
– 1.00 Anna Soderlund,
Vivoline, July 2014,
personal communication/
protocol103
Theatre usage
Operating theatre Hour EVLP
recipient
– 6.00 Protocol p. 35/
Anders Andreasson,
NuTH, September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Drugs
2 l of Steen Solution 500-ml solution EVLP
recipient
– 4.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Heparin sodium,
1000 units/ml
1-ml ampoule EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Heparin sodium,
5000 units/ml
1-ml ampoule EVLP
recipient
– 2.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Insulin human (ACTRAPID
HM), 100 IU/ml
10-ml vial EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Methylprednisolone
(as sodium succinate)
500-mg vial EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Methylprednisolone
(as sodium succinate)
1-g vial EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Methylprednisolone
(as sodium succinate)
2-g vial EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
THAM, 30mg/ml
(3.0 mmol/ml)
1-ml ampoule EVLP
recipient
– 20.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication
Antibiotics
Meropenem
(as trihydrate)
500-mg vial EVLP
recipient
– 2.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication/
Andrew Fisher, NuTH,
November 2015,
personal communication
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml solution
for infusion bottle
(400mg)
EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication/
Andrew Fisher, NuTH,
November 2015,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Antifungal
Amphotericin B 50-mg vial EVLP
recipient
– 1.00 CRF p. 34/
Anders Andreasson,
NuTH, September 2014,
personal communication/
Andrew Fisher, NuTH,
November 2015,
personal communication
Lung transplant
Fixed costs
Anaesthetic preparation
Anaesthetic room Hour Recipient 0.75 0.75 Transplant co-ordinators
Anaesthetic nurse (band 5) Hour Recipient 0.75 0.75 Transplant co-ordinators
Consultant anaesthetist Hour Recipient 0.75 0.75 Transplant co-ordinators
Staff time
Single lung surgery
Anaesthetic fellow Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Anaesthetic nurse (band 5) Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Consultant anaesthetist Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Consultant surgeon Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Perfusionist (band 7) Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Scrub nurse (band 7) Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Scrub nurse (band 5) Hour Recipient 4.00 4.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Surgical fellow Hour Recipient 4.00 4.00 Qualtrics survey/
0Paul Henderson, NuTH,
September 2014,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Double lung surgery
Anaesthetic fellow Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Anaesthetic nurse (band 5) Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Consultant anaesthetist Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Consultant surgeon Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Perfusionist (band 7) Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Scrub nurse (band 7) Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Scrub nurse (band 5) Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Surgical fellow Hour Recipient 7.00 7.00 Qualtrics survey/
Paul Henderson, NuTH,
September 2014,
personal communication
Theatre usage
Single lung surgery
Operating theatre Hour Recipient 4.00 4.00 CRF p. 43/Qualtrics
survey
Double lung surgery
Operating theatre Hour Recipient 7.00 7.00 CRF p. 43/Qualtrics
survey
Equipment/consumables
Usual surgical set Set Recipient Missing Missing Missing
Post-operative care
Fixed costs
Staff time in ITU/HDU
Anaesthetic fellow Hour Recipient 1.50 1.50 Qualtrics survey/
Andrew Fisher, NuTH,
November 2015,
personal communication
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Consultant anaesthetist Hour Recipient 0.50 0.50 Qualtrics survey/
Andrew Fisher, NuTH,
November 2015,
personal communication
Consultant physician Hour Recipient 0.17 0.17 Qualtrics survey/
Andrew Fisher, NuTH,
November 2015,
personal communication
Consultant surgeon Hour Recipient 0.25 0.25 Qualtrics survey/
Andrew Fisher, NuTH,
November 2015,
personal communication
Surgical fellow Hour Recipient 0.25 0.25 Qualtrics survey/
Andrew Fisher, NuTH,
November 2015,
personal communication
Staff time in hospital
Consultant physician Hour Recipient 0.34 0.34 Andrew Fisher, NuTH,
November 2015,
personal communication
Surgical fellow Hour Recipient 0.25 0.25 Andrew Fisher, NuTH,
November 2015,
personal communication
Transplant specialist
registrar
Hour Recipient 0.67 0.67 Andrew Fisher, NuTH,
November 2015,
personal communication
Tests
ABG Test Recipient 1.00 1.00 CRF p. 47
Chest X-ray (radiography) Test Recipient 1.00 1.00 CRF p. 56
FBC Test Recipient 1.00 1.00 CRF p. 56
Pulmonary/lung function
test
Test Recipient 1.00 1.00 CRF p. 56
Variable costs
Ward usage (if needed)
HDU care Bed-day Recipient 10.00 10.00 CRF p. 51/52
ITU care Bed-day Recipient 11.00 11.00 CRF p. 51/52
ITU/HDU readmission Bed-day Recipient 15.00 15.00 CRF p. 52
Level 1 ward care
(hospital stay)
Bed-day Recipient 34.00 34.00 Andrew Fisher, NuTH,
November 2015,
personal communication/
CRF p. 51/52
Procedures (if needed)
Bronchoscopy Procedure Recipient 1.00 1.00 CRF p. 46
Tracheostomy Procedure Recipient 1.00 1.00 CRF p. 51
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Equipment (if needed)
ECMO Machine Recipient 1.00 1.00 CRF p. 45
iLA membrane ventilator Device Recipient 1.00 1.00 CRF p. 45
Consumables (if needed)
2 l of colloid (plasma and
plasma substitutes)
500ml Recipient 4.00 4.00 CRF p. 45
1 l of crystalloid (fluids
containing electrolytes)
500ml Recipient 2.00 2.00 CRF p. 45
Fresh-frozen plasma 271-ml bag Recipient 3.00 3.00 CRF p. 45
Packed red blood cells 274-ml bag Recipient 4.00 4.00 CRF p. 45
Platelets 250-ml bag Recipient 2.00 2.00 CRF p. 45
Inotropes (if needed)
Adrenaline (base),
1 mg/10 ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 1.00 1.00 CRF p. 45
Dobutamine
(as hydrochloride),
12.5 mg/ml
20-ml ampoule Recipient 1.00 1.00 CRF p. 45
Glyceryl trinitrate, 1 mg/ml 50-ml vial Recipient 1.00 1.00 CRF p. 45
Milrinone, 1 mg/ml 10-ml ampoule Recipient 1.00 1.00 CRF p. 45
Noradrenaline (as acid
tartrate), 1 mg/ml
4-ml ampoule Recipient 1.00 1.00 CRF p. 45
Pitressin (argipressin –
synthetic vasopressin),
20 units/ml
1-ml ampoule Recipient 1.00 1.00 CRF p. 45
Other
Dopamine hydrochloride,
40 mg/ml
5-ml ampoule Recipient 1.00 1.00 CRF p. 46
Enoximone, 5 mg/ml 20-ml ampoule Recipient 1.00 1.00 CRF p. 46
Isoprenaline – Recipient 1.00 1.00 CRF p. 46
Metaraminol – Recipient 1.00 1.00 CRF p. 46
Post implantation haemodynamic support (if needed)
Adrenaline (base),
1 mg/10 ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 1.00 1.00 CRF p. 50
Dobutamine
(as hydrochloride),
12.5mg/ml
20-ml ampoule Recipient 1.00 1.00 CRF p. 50
Glyceryl trinitrate, 1mg/ml 50-ml vial Recipient 1.00 1.00 CRF p. 50
Milrinone, 1 mg/ml 10-ml ampoule Recipient 1.00 1.00 CRF p. 50
Noradrenaline (as acid
tartrate), 1 mg/ml
4-ml ampoule Recipient 1.00 1.00 CRF p. 50
Pitressin (argipressin –
synthetic vasopressin),
20 units/ml
1-ml ampoule Recipient 1.00 1.00 CRF p. 50
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Complications (if reported)
Cerebrovascular accident Treatment Recipient 1.00 1.00 CRF p. 52
Hemofiltration Procedure Recipient 14.00 14.00 CRF p. 52
Haemodialysis Procedure (days) Recipient 9.00 9.00 CRF p. 52
Re-exploration Procedure Recipient 1.00 1.00 CRF p. 52
Airway complications (if reported)
Balloon dilatation Procedure Recipient 1.00 1.00 CRF p. 53
Cryotherapy Procedure Recipient 1.00 1.00 CRF p. 53
Diathermy Procedure Recipient 1.00 1.00 CRF p. 53
Stenting Procedure Recipient 1.00 1.00 CRF p. 53
Surgical intervention Procedure Recipient 1.00 1.00 CRF p. 53
ITU rejection episodes (if reported)
Ward usage
HDU care Bed-day Recipient 18.00 18.00 CRF p. 58
ITU care Bed-day Recipient 26.00 26.00 CRF p. 58
Procedures
Clinical diagnosis/biopsy Procedure Recipient 1.00 1.00 CRF p. 57
Treatment
Cefuroxime (as sodium),
750 mg
750-mg vial Recipient 1.00 1.00 CRF p. 54
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 1.00 1.00 CRF p. 54
Piperacillin (as sodium),
2 g; and tazobactam
(as sodium), 250 mg
(Tazocin)
2.25-g vial Recipient 1.00 1.00 CRF p. 54
Changes in maintenance
therapy
Methylprednisolone,
100 mg
20-tablet pack Recipient 0.50 0.50 CRF p. 54
Tacrolimus, 5 mg/ml 1-ml ampoule Recipient 1.00 1.00 CRF p. 54
Ward rejection episodes (if reported)
Procedures
Clinical diagnosis/biopsy Procedure Recipient 1.00 1.00 CRF p. 57
Treatment
Methylprednisolone
(as sodium succinate),
500 mg
500-mg vial Recipient 1.00 1.00 CRF p. 57
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 1.00 1.00 CRF p. 57
Methylprednisolone,
100 mg
20-tablet pack Recipient 1.00 1.00 CRF p. 57
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Prednisolone acetate,
25 mg/ml
1-ml ampoule Recipient 1.00 1.00 CRF p. 57
Prednisolone, 25 mg 56-tablet pack Recipient 1.00 1.00 CRF p. 57
Sulfamethoxazole,
400 mg; and
trimethoprim, 80 mg
(co-trimoxazole 480 mg)
28-tablet pack Recipient 1.00 1.00 CRF p. 57
Tacrolimus, 5 mg/ml 1-ml ampoule Recipient 1.00 1.00 CRF p. 57
Infection episodes (if reported)
Treatment
Aciclovir (as sodium),
25 mg/ml
20-ml vial
(500 mg)
Recipient 15.00 15.00 CRF p. 58
Adefovir dipivoxil, 10 mg 30-tablet pack Recipient 1.00 1.00 CRF p. 58
Amikacin (as sulfate),
250 mg/ml
2-ml vial Recipient 30.00 30.00 CRF p. 58
Amoxicillin (as trihydrate),
500 mg
21-capsule pack Recipient 1.00 1.00 CRF p. 58
Amoxicillin (as trihydrate),
500 mg; and clavulanic
acid (as potassium),
125 mg (co-amoxiclav)
21-tablet pack Recipient 1.00 1.00 CRF p. 58
Amphotericin B liposomal
(AmBisome)
50-mg vial Recipient 7.00 7.00 CRF p. 58
Amphotericin B
(as sodium deoxycholate
complex)
50-mg vial Recipient 14.00 14.00 CRF p. 58
Anidulafungin 100-mg vial Recipient 16.00 16.00 CRF p. 58
Azithromycin
(as dihydrate), 250 mg
4-capsule pack Recipient 1.00 1.00 CRF p. 58
Aztreonam 1-g vial Recipient 42.00 42.00 CRF p. 58
BAL Procedure Recipient 1.00 1.00 CRF p. 58
Budesonide, 100 µg; and
formoterol fumarate,
6 µg (Symbicort
Turbohaler)
120-dose inhaler Recipient 1.00 1.00 CRF p. 58
Caspofungin (as acetate) 70-mg vial Recipient 14.00 14.00 CRF p. 58
Ceftazidime
(as pentahydrate)
2-g vial Recipient 42.00 42.00 CRF p. 58
Cefuroxime (as sodium) 750-mg vial Recipient 21.00 21.00 CRF p. 58
Chloramphenicol
(as sodium succinate)
1-g vial Recipient 84.00 84.00 CRF p. 58
Ciprofloxacin (as lactate),
2 mg/ml
200-ml solution
for infusion bottle
Recipient 14.00 14.00 CRF p. 58
Ciprofloxacin
(as hydrochloride),
500 mg
20-tablet pack Recipient 1.00 1.00 CRF p. 58
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Ciprofloxacin
(as hydrochloride),
3mg/ml
5-ml 0.3% eye
drops
Recipient 2.00 2.00 CRF p. 58
Clarithromycin 500-mg vial Recipient 10.00 10.00 CRF p. 58
Clindamycin
(as phosphate),
150mg/ml
4-ml ampoule Recipient 20.00 20.00 CRF p. 58
Colistimethate sodium 2-million-unit vial Recipient 28.00 28.00 CRF p. 58
Domperidone
(as maleate), 10 mg
100-tablet pack Recipient 1.00 1.00 CRF p. 58
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.00 1.00 CRF p. 58
Eradication therapy for
H. pylori
7-day course Recipient 1.00 1.00 CRF p. 58
Ertapenem (as sodium) 1-g vial Recipient 14.00 14.00 CRF p. 58
Ethambutol
hydrochloride, 100 mg
56-tablet pack Recipient 1.00 1.00 CRF p. 58
Flucloxacillin (as sodium) 28-capsule pack Recipient 1.00 1.00 CRF p. 58
Flucloxacillin (as sodium) 1-g vial Recipient 12.00 12.00 CRF p. 58
Fluconazole, 50 mg 7-capsule pack Recipient 8.00 8.00 CRF p. 58
Fluconazole, 2 mg/ml 100-ml solution
for infusion bottle
Recipient 43.00 43.00 CRF p. 58
Fluconazole, 50 mg 7-capsule pack Recipient 8.00 8.00 CRF p. 58
Foscarnet sodium,
24 mg/ml
250-ml solution
for infusion bottle
Recipient 42.00 42.00 CRF p. 58
Fosfomycin (as sodium) 2-g vial Recipient 30.00 30.00 CRF p. 58
Furosemide, 10 mg/ml 5-ml ampoule Recipient 21.00 21.00 CRF p. 58
Ganciclovir (as sodium) 500-mg vial Recipient 42.00 42.00 CRF p. 58
Gentamycin (as sulfate),
40 mg/ml
2-ml vial Recipient 28.00 28.00 CRF p. 58
Immunoglobulin 10-g vial Recipient 1.00 1.00 CRF p. 58
Itraconazole,
10 mg/ml
25-ml ampoule Recipient 16.00 16.00 CRF p. 58
Lamivudine, 150 mg 60-tablet pack Recipient 1.00 1.00 CRF p. 58
Lesion excision Day case Recipient 1.00 1.00 CRF p. 58
Linezolid, 2 mg/ml 300-ml infusion
bag
Recipient 84.00 84.00 CRF p. 58
Meropenem
(as trihydrate)
1-g vial Recipient 12.25 12.25 CRF p. 58
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 3.00 3.00 CRF p. 58
Metochlopramide
hydrochloride, 5mg/ml
2-ml ampoule Recipient 15.00 15.00 CRF p. 58
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Metronidazole, 200 mg 21-tablet pack Recipient 2.00 2.00 CRF p. 58
Micafungin (as sodium) 100-mg vial Recipient 14.00 14.00 CRF p. 58
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml solution
for infusion bottle
Recipient 14.00 14.00 CRF p. 58
Oseltamivir
(as phosphate), 75 mg
10-capsule pack Recipient 1.00 1.00 CRF p. 58
Packed red blood cells 274-ml bag Recipient 1.00 1.00 CRF p. 58
Piperacillin (as sodium),
4 g; and tazobactam
(as sodium), 500 mg
(Tazocin)
4.5-g vial Recipient 43.00 43.00 CRF p. 58
Posaconazole, 100 mg 96-tablet pack Recipient 1.00 1.00 CRF p. 58
Prednisolone, 25 mg 56-tablet pack Recipient 1.00 1.00 CRF p. 58
Respiratory failure
(inpatient)
Treatment Recipient 1.00 1.00 CRF p. 58
Sirolimus, 2 mg 30-tablet pack Recipient 1.00 1.00 CRF p. 58
Streptokinase 250,000-unit
powder vial
Recipient 12.00 12.00 CRF p. 58
Sulfamethoxazole,
80 mg; and
trimethoprim, 16 mg
(Septrin)
5-ml ampoule Recipient 24.00 24.00 CRF p. 58
Surgical intervention or
VATS
Procedure Recipient 1.00 1.00 CRF p. 58
Teicoplanin 200-mg vial Recipient 10.00 10.00 CRF p. 58
Trimethoprim, 100 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 58
Tobramycin (as sulfate),
40 mg/ml
1-ml vial Recipient 12.25 12.25 CRF p. 58
Tigecycline 50-mg vial Recipient 30.00 30.00 CRF p. 58
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1.00 1.00 CRF p. 58
Vancomycin
(as hydrochloride)
1-g vial Recipient 14.00 14.00 CRF p. 58
Voriconazole 200-mg vial Recipient 34.00 34.00 CRF p. 58
Ward usage
HDU care Bed-day Recipient 18.00 18.00 CRF p. 58
ITU care Bed-day Recipient 26.00 26.00 CRF p. 58
Outpatient care
Fixed costs
Outpatient reviews
Bronchoscopy Procedure/visit
(4 visits)
Recipient 1.00 1.00 CRF
Chest X-ray (radiography) Test/visit (4 visits) Recipient 1.00 1.00 CRF
FBC Test/visit (4 visits) Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Liver function test Test/visit (4 visits) Recipient 1.00 1.00 Andrew Fisher, NuTH,
November 2015,
personal communication
Pulmonary/lung function
test
Test/visit (4 visits) Recipient 1.00 1.00 CRF
Urea and electrolytes test Test/visit (4 visits) Recipient 1.00 1.00 Andrew Fisher, NuTH,
November 2015,
personal communication
Staff time
Consultant physician Hour/visit (4 visits) Recipient 0.50 0.50 Care pathway/
Katie Morley, NuTH,
October 2014, personal
communication
Scrub nurse (band 5) Hour/visit (4 visits) Recipient 0.50 0.50 Care pathway/Katie
Morley, NuTH, October
2014, personal
communication
Variable costs
Rejection episodes (if reported)
Procedures
Clinical diagnosis/biopsy Procedure Recipient 1.00 1.00 CRF
Ventilation–perfusion
scan
Test Recipient 1.00 1.00 CRF
Treatment
Anti-thymocyte
immunoglobulin (rabbit),
25 mg
25-mg vial Recipient 40.00 40.00 CRF
Azathioprine, 25 mg 28-tablet pack Recipient 1.00 1.00 CRF
Azathioprine, 50 mg 56-tablet pack Recipient 2.00 2.00 CRF
Ciclosporin, 25 mg 30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin, 50 mg 30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin, 100 mg 30-capsule pack Recipient 3.00 3.00 CRF
Ciclosporin (NEORAL),
10 mg
60-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin (NEORAL),
25 mg
30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin (NEORAL),
50 mg
30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin (NEORAL),
100 mg
30-capsule pack Recipient 1.00 1.00 CRF
Immunoglobulin 10-g vial Recipient 1.00 1.00 CRF
Meropenem
(as trihydrate)
1-g vial Recipient 30.00 30.00 CRF
Methylprednisolone
(as sodium succinate)
125-mg vial Recipient 4.00 4.00 CRF
continued
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
229
TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 3.00 3.00 CRF
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 3.00 3.00 CRF
Mycophenolate mofetil,
500 mg
50-tablet pack Recipient 1.00 1.00 CRF
Mycophenolate mofetil,
250 mg
100-capsule pack Recipient 1.00 1.00 CRF
Prednisolone, 1 mg 28-tablet pack Recipient 1.00 1.00 CRF
Prednisolone, 5 mg 28-tablet pack Recipient 2.00 2.00 CRF
Prednisolone, 25 mg 56-tablet pack Recipient 1.00 1.00 CRF
Rituximab, 100 mg/ml 10-ml vial Recipient 4.00 4.00 CRF
Tacrolimus (Prograf),
500 µg
50-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus (Prograf),
1 mg
50-capsule pack Recipient 4.00 4.00 CRF
Tacrolimus (Prograf),
1 mg
100-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus (Prograf),
5 mg
50-capsule pack Recipient 1.00 1.00 CRF
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1.00 1.00 CRF
Ward usage
HDU care Bed-day Recipient 30.00 30.00 CRF
ITU care Bed-day Recipient 7.00 7.00 CRF
GP visits (if needed)
Out-of-surgery visit Visit Recipient 1.00 1.00 CRF
Surgery visit Visit Recipient 1.00 1.00 CRF
Transplant centre advice Call Recipient 1.00 1.00 CRF
Unplanned hospital admission (if needed)
Treatment
Aciclovir (as sodium),
25 mg/ml
20-ml vial Recipient 15.00 15.00 CRF
Aciclovir, 400 mg 56-tablet pack Recipient 1.00 1.00 CRF
Adrenaline (base),
100 µg/ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 1.00 1.00 CRF
Amiodarone
hydrochloride,
30 mg/ml
10-ml pre-filled
disposable
injection
Recipient 7.00 7.00 CRF
Amoxicillin (as sodium),
500 mg; and clavulanic
acid (as potassium),
125 mg (co-amoxiclav)
500/100-mg vial Recipient 15.00 15.00 CRF
Amphotericin B 50-mg vial Recipient 14.00 14.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Aspirin, 300 mg 32-tablet pack Recipient 1.00 1.00 CRF
Azathioprine, 25 mg 28-tablet pack Recipient 1.00 1.00 CRF
Azithromycin
(as dihydrate), 250 mg
4-capsule pack Recipient 1.00 1.00 CRF
Aztreonam 1-g vial Recipient 42.00 42.00 CRF
Balloon dilatation Procedure Recipient 1.00 1.00 CRF
Basiliximab 20-mg vial Recipient 2.00 2.00 CRF
Bisoprolol fumarate,
10 mg
28-tablet pack Recipient 1.00 1.00 CRF
Bortezomib 3.5-mg vial Recipient 1.00 1.00 CRF
Bronchoscopy Procedure Recipient 1.00 1.00 CRF
Budesonide, 100 µg; and
formoterol fumarate
dihydrate, 6 µg
(Symbicort 100/6
Turbohaler®)
120-dose unit
inhaler
Recipient 1.00 1.00 CRF
Calcium gluconate, 1 g 28-tablet pack Recipient 1.00 1.00 CRF
Calcium polystyrene
sulfonate (Calcium
Resonium)
300-g powder Recipient 1.00 1.00 CRF
Candesartan cilexetil,
4 mg
28-tablet pack Recipient 2.00 2.00 CRF
Caspofungin (as acetate) 70-mg vial Recipient 14.00 14.00 CRF
Ciclosporin, 100 mg 30-capsule pack Recipient 2.00 2.00 CRF
Ciclosporin, 50 mg/ml 5-ml ampoule Recipient 17.00 17.00 CRF
Ciprofloxacin (as
hydrochloride), 500 mg
20-tablet pack Recipient 2.00 2.00 CRF
Clarithromycin 500-mg vial Recipient 10.00 10.00 CRF
Clinical diagnosis/biopsy Procedure Recipient 1.00 1.00 CRF
Colistimethate sodium 1-million-unit vial Recipient 28.00 28.00 CRF
Colistimethate sodium 2-million-unit vial Recipient 28.00 28.00 CRF
Computerised
tomography
Procedure Recipient 1.00 1.00 CRF
DeBakey tissue forceps Forceps Recipient 1.00 1.00 CRF
Docusate sodium,
100 mg
30-capsule pack Recipient 4.00 4.00 CRF
Doxazosin (as mesilate),
4 mg
28-tablet pack Recipient 2.00 2.00 CRF
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.00 1.00 CRF
ECG 24-hour test Recipient 24.00 24.00 CRF
Enoxaparin sodium
(Clexane Forte), 150 mg
1-ml pre-filled
disposable
injection
Recipient 5.00 5.00 CRF
ECMO Machine Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Filgrastim, 30 million
units (300 µg/ml)
1-ml vial Recipient 14.00 14.00 CRF
Flucloxacillin (as sodium) 1-g vial Recipient 12.00 12.00 CRF
Fluticasone propionate,
250 µg; and salmeterol
xinafoate, 50 µg (Seretide
250 Accuhaler)
120-unit dose
inhaler
Recipient 1.00 1.00 CRF
Foscarnet sodium,
24 mg/ml
250-ml solution
for infusion bottle
Recipient 1.00 1.00 CRF
Furosemide, 10 mg/ml 5-ml ampoule Recipient 21.00 21.00 CRF
Ganciclovir (as sodium) 500-mg vial Recipient 42.00 42.00 CRF
Gastrograffin Solution Recipient 1.00 1.00 CRF
Glucose anhydrous,
50 mg/ml
1000-ml bag Recipient 7.00 7.00 CRF
iLA membrane ventilator Device Recipient 1.00 1.00 CRF
Immunoglobulin 10-g vial Recipient 1.00 1.00 CRF
Insulin, 3 ml 5 × 3-ml pre-filled
disposable
injection devices
Recipient 1.00 1.00 CRF
Intubation Procedure Recipient 1.00 1.00 CRF
Hydralazine
hydrochloride, 50 mg
56-tablet pack Recipient 1.00 1.00 CRF
Hydrocortisone
(as sodium succinate)
100-mg vial Recipient 28.00 28.00 CRF
Lansoprazole, 30 mg 28-capsule pack Recipient 1.00 1.00 CRF
Level 1 ward care
(hospital stay)
Bed-day Recipient 1.00 1.00 CRF
Macrogol compound
oral powder
50-sachet pack Recipient 1.00 1.00 CRF
Magnesium hydroxide
with liquid paraffin
150-ml bottle Recipient 1.00 1.00 CRF
Magnesium sulfate
heptahydrate, 100 mg
10-ml ampoule Recipient 1.00 1.00 CRF
Magnetic resonance
imaging scan
Test Recipient 1.00 1.00 CRF
Meropenem
(as trihydrate)
1-g vial Recipient 11.00 11.00 CRF
Methylprednisolone
(as sodium succinate),
500 mg
500-mg vial Recipient 3.00 3.00 CRF
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 3.00 3.00 CRF
Metoclopramide
hydrochloride, 5mg/ml
2-ml ampoule Recipient 4.00 4.00 CRF
Midazolam (as
hydrochloride), 1mg/ml
5-ml ampoule Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Minocycline
(as hydrochloride),
100 mg
28-tablet pack Recipient 1.00 1.00 CRF
Moxifloxacin
(as hydrochloride),
1.6 mg/ml
250-ml solution
for infusion bottle
Recipient 14.00 14.00 CRF
Nefopam hydrochloride,
30 mg
90-tablet pack Recipient 1.00 1.00 CRF
Non-invasive ventilation Procedure Recipient 1.00 1.00 CRF
Normal immunoglobulin,
10 g
200-ml solution
for infusion bottle
Recipient 1.00 1.00 CRF
Oxycodone hydrochloride,
10mg/ml
120-ml oral
solution
Recipient 1.00 1.00 CRF
Packed red blood cells 274-ml bag Recipient 2.00 2.00 CRF
Phosphate enema 133-ml enema
pack
Recipient 1.00 1.00 CRF
Piperacillin (as sodium),
4 g; and tazobactam
(as sodium), 500 mg
(Tazocin)
4.5-g vial Recipient 40.00 40.00 CRF
Posaconazole, 100 mg 96-tablet pack Recipient 1.00 1.00 CRF
Prednisolone, 5 mg 28-tablet pack Recipient 4.00 4.00 CRF
Pregabalin, 150 mg 56-capsule pack Recipient 1.00 1.00 CRF
Redo lung
transplantation
Procedure Recipient 1.00 1.00 CRF
Renal support Treatment Recipient 1.00 1.00 CRF
Ribavirin, 200mg 42-tablet pack Recipient 1.00 1.00 CRF
Ribavirin, 400mg 56-tablet pack Recipient 1.00 1.00 CRF
Salbutamol (as sulfate),
5 mg/2.5 ml
20-unit dose
nebuliser liquid
vial
Recipient 1.00 1.00 CRF
Sirolimus, 2 mg 30-tablet pack Recipient 2.00 2.00 CRF
Sodium bicarbonate,
42 mg/ml
500-ml
intravenous
infusion bottle
Recipient 1.00 1.00 CRF
2 l of 0.9% sodium
chloride solution
1-l solution Recipient 20.00 20.00 CRF
Stenting Procedure Recipient 1.00 1.00 CRF
Sulfamethoxazole,
80 mg; and
trimethoprim, 16 mg
(Septrin)
5-ml ampoule Recipient 18.00 18.00 CRF
Sulfamethoxazole,
400 mg; and
trimethoprim, 80 mg
(co-trimoxazole)
5-ml ampoule Recipient 12.00 12.00 CRF
Surgical intervention Procedure Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Tacrolimus (Prograf),
1 mg
50-capsule pack Recipient 4.00 4.00 CRF
Tacrolimus (Prograf),
1 mg
100-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus (Prograf),
5 mg/ml
10 × 1-ml
ampoules
Recipient 7.00 7.00 CRF
Tinzaparin sodium,
20,000 units/ml
(Innohep)
0.5-ml vial Recipient 630.00 630.00 CRF
Tracheostomy Procedure Recipient 1.00 1.00 CRF
Tramadol hydrochloride,
150 mg
60-capsule pack Recipient 1.00 1.00 CRF
Ultrasound scan Test Recipient 1.00 1.00 CRF
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 1.00 1.00 CRF
Vancomycin
(as hydrochloride),
125 mg
28-capsule pack Recipient 2.00 2.00 CRF
Voriconazole 200-mg vial Recipient 78.00 78.00 CRF
Warfarin sodium, 3 mg 28-tablet pack Recipient 1.00 1.00 CRF
Warfarin sodium,
1 mg/ml
150-ml oral
suspension
Recipient 3.00 3.00 CRF
Ward usage
HDU care Bed-day Recipient 14.00 14.00 CRF
ITU care Bed-day Recipient 14.00 14.00 CRF
Immunosuppressive medications (if needed)
Azathioprine, 25 mg 28-tablet pack Recipient 1.00 1.00 CRF
Azathioprine, 50 mg 56-tablet pack Recipient 3.00 3.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Ciclosporin, 25 mg 30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin, 50 mg 30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin, 100mg 30-capsule pack Recipient 4.00 4.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Mycophenolate mofetil,
500 mg
50-tablet pack Recipient 3.00 3.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Prednisolone, 1 mg 28-tablet pack Recipient 1.00 1.00 CRF
Prednisolone, 5 mg 28-tablet pack Recipient 3.00 3.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Prednisolone, 25 mg 56-tablet pack Recipient 1.00 1.00 CRF
Prednisolone acetate,
25 mg/ml
1-ml ampoule Recipient 26.00 26.00 CRF
Sirolimus, 500 µg 30-tablet pack Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Sirolimus, 1 mg 30-tablet pack Recipient 1.00 1.00 CRF
Sirolimus, 2 mg 30-tablet pack Recipient 2.00 2.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Tacrolimus, 500 µg 50-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus, 1 mg 50-capsule pack Recipient 4.00 4.00 CRF/Ruth Coxhead,
NuTH, March 2015,
personal communication
Tacrolimus, 1 mg 100-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus, 5 mg 50-capsule pack Recipient 1.00 1.00 CRF
Other
Aciclovir, 200 mg 25-tablet pack Recipient 28.00 28.00 CRF
Amoxicillin (as trihydrate),
500 mg
21-capsule pack Recipient 1.00 1.00 CRF
Azithromycin (as
dihydrate), 250 mg
4-capsule pack Recipient 1.00 1.00 CRF
Beclomethasone
dipropionate,
400 µg/dose
100-dose unit Recipient 1.00 1.00 CRF
Calcium carbonate
(Adcal), 1.5 g
100-tablet pack Recipient 1.00 1.00 CRF
Cetirizine hydrochloride,
10 mg
30-tablet pack Recipient 3.00 3.00 CRF
Ciclosporin (NEORAL),
10 mg
60-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin (NEORAL),
25 mg
30-capsule pack Recipient 1.00 1.00 CRF
Ciclosporin (NEORAL),
50 mg
50-capsule pack Recipient 2.00 2.00 CRF
Ciclosporin, 100 mg 30-capsule pack Recipient 1.00 1.00 CRF
Citalopram
(as hydrobromide),
20 mg
28-tablet pack Recipient 1.00 1.00 CRF
Dapsone, 100 mg 28-tablet pack Recipient 1.00 1.00 CRF
Dexamethasone, 2 mg 50-tablet pack Recipient 1.00 1.00 CRF
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 1.00 1.00 CRF
Furosemide, 40 mg 28-tablet pack Recipient 1.00 1.00 CRF
Hydrocortisone, 10 mg 30-tablet pack Recipient 5.00 5.00 CRF
Hydrocortisone, 20 mg 30-tablet pack Recipient 1.00 1.00 CRF
Lisinopril dihydrate,
2.5 mg
28-tablet pack Recipient 1.00 1.00 CRF
Lisinopril dihydrate, 5 mg 28-tablet pack Recipient 4.00 4.00 CRF
Methylprednisolone,
2 mg
30-tablet pack Recipient 1.00 1.00 CRF
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Methylprednisolone
(as sodium succinate)
40-mg vial Recipient 1.00 1.00 CRF
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 1.00 1.00 CRF
Mycophenolic acid
(as sodium), 180 mg
120-tablet pack Recipient 1.00 1.00 CRF
Mycophenolic acid
(as sodium), 360 mg
120-tablet pack Recipient 1.00 1.00 CRF
N-acetylcysteine,
200 mg/ml
10-ml ampoule Recipient 1.00 1.00 CRF
Perindopril erbumine,
2 mg
30-tablet pack Recipient 1.00 1.00 CRF
Perindopril erbumine,
4 mg
30-tablet pack Recipient 1.00 1.00 CRF
Sulfamethoxazole,
400 mg; and
trimethoprim, 80 mg
(co-trimoxazole)
28-tablet pack Recipient 1.00 1.00 CRF
Tacrolimus (Prograf),
1 mg
50-capsule pack Recipient 1.00 1.00 CRF
Tacrolimus (Prograf),
1 mg
100-capsule pack Recipient 1.00 1.00 CRF
Tinzaparin sodium,
3500 units
0.35-ml pre-filled
disposable
injection
Recipient 1.00 1.00 CRF
Concomitant medications
Variable costs
Treatment
Aciclovir, 200 mg 25-tablet pack Recipient 9.00 9.00 CRF p. 111
Adrenaline (base),
100 µg/ml (1 in 10,000)
10-ml pre-filled
disposable
injection
Recipient 15.00 15.00 CRF p. 111
Alendronic acid
(as sodium), 70 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Alfentanil
(as hydrochloride),
500 µg/ml
2-ml ampoule Recipient 2.00 2.00 CRF p. 111
Alfentanil
(as hydrochloride),
5mg/ml
1-ml ampoule Recipient 9.00 9.00 CRF p. 111
Allopurinol, 300 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Amiloride hydrochloride,
5 mg; and furosemide,
40 mg (co-amilofruse)
56-tablet pack Recipient 1.00 1.00 CRF p. 111
Amiodarone
hydrochloride,
30 mg/ml
10-ml pre-filled
disposable syringe
Recipient 60.00 60.00 CRF p. 111
Amiodarone
hydrochloride, 100 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Amiodarone
hydrochloride, 200 mg
28-tablet pack Recipient 6.00 6.00 CRF p. 111
Amitriptyline
hydrochloride, 10 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Amlodipine, 5 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Amlodipine, 10 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Amoxicillin (as trihydrate),
500 mg
21-capsule pack Recipient 1.00 1.00 CRF p. 111
Amoxicillin (as amoxicillin
trihydrate), 500 mg;
and clavulanic acid
(as potassium), 125 mg
21-tablet pack Recipient 2.00 2.00 CRF p. 111
Amphotericin B, 5 mg/ml 20-lozenge pack Recipient 2.00 2.00 CRF p. 111
Amphotericin B
(as phospholipid
complex, 5 mg/ml
20-ml vial Recipient 2.00 2.00 CRF p. 111
Antiembolism socks Socks pack Recipient 1.00 1.00 CRF p. 111
Anti-thymocyte
immunoglobulin (rabbit)
25-mg vial Recipient 20.00 20.00 CRF p. 111
Aspirin, 75 mg 28-tablet pack Recipient 2.00 2.00 CRF p. 111
Atracurium besilate,
10 mg/ml
5-ml ampoule Recipient 1.00 1.00 CRF p. 111
Azathioprine, 25 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Azathioprine, 50 mg 56-tablet pack Recipient 2.00 2.00 CRF p. 111
Azithromycin
(as dihydrate), 250 mg
4-tablet pack Recipient 1.00 1.00 CRF p. 111
Azithromycin
(as dihydrate), 250 mg
6-capsule pack Recipient 9.00 9.00 CRF p. 111
Azithromycin, 500 mg 3-tablet pack Recipient 1.00 1.00 CRF p. 111
Aztreonam 2-g vial Recipient 12.00 12.00 CRF p. 111
Bisoprolol fumarate,
1.25 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Bisoprolol fumarate,
2.5 mg
28-tablet pack Recipient 5.00 5.00 CRF p. 111
Bisoprolol fumarate,
5 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Bupivacaine hydrochloride,
1mg/ml
100-ml infusion
bag
Recipient 1.00 1.00 CRF p. 111
Calcium carbonate
(Adcal), 1.5 g
100-tablet pack Recipient 1.00 1.00 CRF p. 111
Calcium carbonate,
1.25 g; and colecalciferol,
400 units (Calcichew D3
Forte)
60-tablet pack Recipient 3.00 3.00 CRF p. 111
Calcium chloride
dihydrate, 10%
10-ml pre-filed
disposable
injection
Recipient 1.00 1.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Calogen emulsion 500-ml bottle Recipient 4.00 4.00 CRF p. 111
Carbocisteine, 375 mg 120-capsule pack Recipient 3.00 3.00 CRF p. 111
Caspofungin (as acetate) 50-mg vial Recipient 18.00 18.00 CRF p. 111
Ceftazidime
(as pentahydrate)
2-g vial Recipient 11.00 11.00 CRF p. 111
Chlordiazepoxide
hydrochloride, 5 mg
100-capsule pack Recipient 1.00 1.00 CRF p. 111
Chlordiazepoxide
hydrochloride (Librium),
10 mg
100-capsule pack Recipient 1.00 1.00 CRF p. 111
Chlorhexidine gluconate,
4%
500-ml surgical
scrub
Recipient 1.00 1.00 CRF p. 111
Chlorhexidine
hydrochloride, 500 mg
500-mg pump
pack
Recipient 1.00 1.00 CRF p. 111
Chlorhexidine
hydrochloride, 1 mg/g;
and neomycin sulfate,
5 mg/g (Naseptin)
15-g nasal cream Recipient 8.00 8.00 CRF p. 111
Chlorhexidine
hydrochloride, 10 mg/g;
and nystatin,
100,000 units/g
(Nystaform)
30-g cream Recipient 1.00 1.00 CRF p. 111
Chlorphenamine
maleate, 10 mg/ml
1-ml ampoule Recipient 3.00 3.00 CRF p. 111
Chlorpromazine
hydrochloride, 25 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Ciclosporin (NEORAL),
25 mg
30-capsule pack Recipient 1.00 1.00 CRF p. 111
Ciclosporin, 50 mg 30-capsule pack Recipient 2.00 2.00 CRF p. 111
Ciclosporin, 100 mg 30-capsule pack Recipient 2.00 2.00 CRF p. 111
Ciprofloxacin
(as hydrochloride),
500 mg (Ciproxin)
10-tablet pack Recipient 3.00 3.00 CRF p. 111
Ciprofloxacin
(as hydrochloride),
750 mg
10-tablet pack Recipient 1.00 1.00 CRF p. 111
Citalopram
(as hydrobromide), 20 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Citalopram
(as hydrobromide), 40 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Clonidine hydrochloride,
25 µg
112-tablet pack Recipient 1.00 1.00 CRF p. 111
Codeine phosphate,
8 mg; and paracetamol,
500 mg
30-tablet pack Recipient 3.00 3.00 CRF p. 111
Codeine phosphate
30 mg and paracetamol,
500 mg
100-tablet pack Recipient 1.00 1.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Codeine phosphate,
30 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Codeine phosphate,
60 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Colecalciferol, 500 µg
(20,000 units)
15-capsule pack Recipient 1.00 1.00 CRF p. 111
Colistimethate sodium 1-million-unit vial Recipient 56.00 56.00 CRF p. 111
Colistimethate sodium 2-million-unit vial Recipient 28.00 28.00 CRF p. 111
CREON, 25,000 units 100-capsule pack Recipient 2.00 2.00 CRF p. 111
CREON Micro
Pancreatine, 20 g
60.12-mg
granules
Recipient 1.00 1.00 CRF p. 111
Cryoprecipitate 8 units Recipient 1.00 1.00 CRF p. 111
Cyclizine hydrochloride,
50 mg
100-tablet pack Recipient 3.00 3.00 CRF p. 111
Dapsone, 100 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Diazepam, 2 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Digoxin, 250 µg/ml 2-ml ampoule Recipient 28.00 28.00 CRF p. 111
Diltiazem hydrochloride,
120 mg
28-capsule pack Recipient 1.00 1.00 CRF p. 111
Diltiazem hydrochloride,
200 mg
7-capsule pack Recipient 1.00 1.00 CRF p. 111
Docusate sodium 100-capsule pack Recipient 1.00 1.00 CRF p. 111
Domperidone
(as maleate), 10 mg
100-tablet pack Recipient 2.00 2.00 CRF p. 111
Dopamine hydrochloride,
40 mg/ml
5-ml ampoule Recipient 8.00 8.00 CRF p. 111
Dosulepin hydrochloride,
25 mg
28-capsule pack Recipient 2.00 2.00 CRF p. 111
Doxazosin (as mesilate),
4 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Doxycycline (as hyclate),
100 mg
8-capsule pack Recipient 3.00 3.00 CRF p. 111
Enoxaparin sodium,
100 mg/ml
0.4-ml pre-filled
disposable
injection
Recipient 19.00 19.00 CRF p. 111
Ensure liquid 250ml Recipient 1.00 1.00 CRF p. 111
Erythromycin
(as lactobionate)
1-g vial Recipient 18.00 18.00 CRF p. 111
Esomeprazole
(as magnesium
dihydrate), 40 mg
28-capsule pack Recipient 2.00 2.00 CRF p. 111
Ethambutol
hydrochloride, 400 mg
56-tablet pack Recipient 2.00 2.00 CRF p. 111
Ezetimibe, 10 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Ethinylestradiol, 30 µg;
and gestodene, 75 µg
21-day
preparation
Recipient 1.00 1.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Ferrous sulfate dried,
200 mg
28-tablet pack Recipient 3.00 3.00 CRF p. 111
Flucloxacillin (as sodium),
500 mg
28-capsule pack Recipient 8.00 8.00 CRF p. 111
Flucloxacillin (as sodium) 1-g vial Recipient 5.00 5.00 CRF p. 111
Fluconazole, 50 mg 7-capsule pack Recipient 7.00 7.00 CRF p. 111
Fluconazole, 200 mg 7-capsule pack Recipient 11.00 11.00 CRF p. 111
Fluconazole, 2 mg/ml 100-ml solution
for infusion bottle
Recipient 12.00 12.00 CRF p. 111
Fluoxetine
(as hydrochloride), 20 mg
30-capsule pack Recipient 1.00 1.00 CRF p. 111
Fluticasone propionate
50 µg
150-unit dose
nasal spray
Recipient 1.00 1.00 CRF p. 111
Fluticasone propionate,
250 µg (Flixotide 250
Accuhaler)
60-dose inhaler Recipient 1.00 1.00 CRF p. 111
Fluticasone propionate,
250 µg; and salmeterol
xinafoate, 50 µg
(Seretide 250 Accuhaler)
60-dose inhaler Recipient 1.00 1.00 CRF p. 111
Folic acid, 400 µg 90-tablet pack Recipient 1.00 1.00 CRF p. 111
Foscarnet sodium,
24 mg/ml
250-ml solution
for infusion bottle
Recipient 42.00 42.00 CRF p. 111
Fosfomycin (as sodium) 2-g vial Recipient 2.00 2.00 CRF p. 111
Fresh-frozen plasma 271-ml bag Recipient 7.00 7.00 CRF p. 111
Furosemide, 10 mg/ml 2-ml ampoule Recipient 14.00 14.00 CRF p. 111
Furosemide, 20 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Furosemide, 40 mg 28-tablet pack Recipient 2.00 2.00 CRF p. 111
Ganciclovir (as sodium) 500-mg vial Recipient 21.00 21.00 CRF p. 111
Gelatin (Gelofusine) 1-l infusion bag Recipient 2.00 2.00 CRF p. 111
Gelatin, 140mg/g; and
glycerol, 700mg/g
4-g supplement
pack
Recipient 72.00 72.00 CRF p. 111
Gliclazide (glycoside),
30 mg
56-tablet pack Recipient 1.00 1.00 CRF p. 111
Gliclazide, 40 mg 28-tablet pack Recipient 2.00 2.00 CRF p. 111
Glucose anhydrous,
500 mg/ml
50-ml vial Recipient 168.00 168.00 CRF p. 111
Glyceryl trinitrate,
1 mg/ml
50-ml ampoule Recipient 10.00 10.00 CRF p. 111
Haloperidol, 5 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Haloperidol, 5 mg/ml 1-ml ampoule Recipient 248.00 248.00 CRF p. 111
Heparin sodium,
5000 units/ml
1-ml ampoule Recipient 49.00 49.00 CRF p. 111
Heparin sodium,
5000 units/ml
5-ml ampoule Recipient 6.00 6.00 CRF p. 111
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Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Hydroxocobalamin,
1 mg/ml
1-ml ampoule Recipient 14.00 14.00 CRF p. 111
Hyoscine butylbromide
(Buscopan), 10 mg
56-tablet pack Recipient 3.00 3.00 CRF p. 111
Ibandronic acid
(as sodium
monohydrate), 50 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Iloprost (as THAM),
10 µg/ml
30 × 1-ml
unit-dose vials
Recipient 1.00 1.00 CRF p. 111
Insulin, 3 ml 5 × 3-ml pre-filled
disposable
injection devices
Recipient 1.00 1.00 CRF p. 111
Insulin aspart,
100 units/ml
5 × 3-ml pre-filled
disposable
injection devices
Recipient 2.00 2.00 CRF p. 111
Insulin human
(as soluble human)
(ACTRAPID), 100 units/ml
10-ml vial Recipient 27.00 27.00 CRF p. 111
Insulin human
(as detemir), 100 units/ml
(LEMEVIR)
5 × 3-ml pre-filled
disposable
injection device
Recipient 1.00 1.00 CRF p. 111
Ipratropium bromide,
250 µg/ml
60 × 1ml
unit-dose vial
Recipient 4.00 4.00 CRF p. 111
Ipratropium bromide,
500 µg
500-µg nebuliser
solution
Recipient 4.00 4.00 CRF p. 111
Ipratropium bromide,
2.5 mg/2.5 ml
60-unit-dose vial Recipient 2.00 2.00 CRF p. 111
Ipratropium bromide,
200 µg/ml; and
salbutamol (as sulfate),
1 mg/ml (Combivent)
60-unit dose vial Recipient 9.00 9.00 CRF p. 111
Itraconazole, 100 mg 15-capsule pack Recipient 10.00 10.00 CRF p. 111
Itraconazole,
10 mg/ml
150-ml oral
solution
Recipient 33.00 33.00 CRF p. 111
Labetalol hydrochloride,
100 mg
56-tablet pack Recipient 1.00 1.00 CRF p. 111
Labetalol hydrochloride,
200 mg
56-tablet pack Recipient 1.00 1.00 CRF p. 111
Lactulose 300-ml solution Recipient 1.00 1.00 CRF p. 111
Lansoprazole, 15 mg 28-capsule pack Recipient 1.00 1.00 CRF p. 111
Lansoprazole, 30 mg 28-tablet pack Recipient 2.00 2.00 CRF p. 111
Loratadine, 10 mg 30-tablet pack Recipient 1.00 1.00 CRF p. 111
Levomepromazine
maleate, 25 mg
84-tablet pack Recipient 1.00 1.00 CRF p. 111
Linezolid, 600 mg 10-tablet pack Recipient 2.00 2.00 CRF p. 111
Loperamide
hydrochloride, 2 mg
30-tablet pack Recipient 2.00 2.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Lorazepam, 1 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Lymecycline, 408 mg 28-capsule pack Recipient 1.00 1.00 CRF p. 111
Magnesium oxide,
160 mg
28-capsule pack Recipient 2.00 2.00 CRF p. 111
Magnesium sulfate
heptahydrate, 500 mg/ml
2-ml ampoule Recipient 98.00 98.00 CRF p. 111
Magnesium sulfate
heptahydrate, 500 mg/ml
5-ml ampoule Recipient 29.00 29.00 CRF p. 111
Magnesium sulfate
heptahydrate, 500 mg/ml
4-ml ampoule Recipient 56.00 56.00 CRF p. 111
Menadiol phosphate
(as sodium phosphate),
10 mg
100-tablet pack Recipient 1.00 1.00 CRF p. 111
Meropenem
(as trihydrate)
1-g vial Recipient 24.50 24.50 CRF p. 111
MEROCAINE 24-lozenge pack Recipient 1.00 1.00 CRF p. 111
Methylprednisolone
(as sodium succinate)
500-mg vial Recipient 26.00 26.00 CRF p. 111
Methylprednisolone
(as sodium succinate)
1-g vial Recipient 3.00 3.00 CRF p. 111
Metformin hydrochloride,
500 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Metoclopramide
hydrochloride, 10 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Metronidazole, 400 mg 21-tablet pack Recipient 2.00 2.00 CRF p. 111
Midazolam
(as hydrochloride),
1 mg/ml
5-ml ampoule Recipient 2.00 2.00 CRF p. 111
Milrinone (as lactate),
1 mg/ml
10-ml ampoule Recipient 228.00 228.00 CRF p. 111
Minocycline
(as hydrochloride),
100 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Mirtazapine, 30 mg 28-tablet pack Recipient 1.00 1.00 BNF 201450
Montelukast (as sodium),
10 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Mometasone furoate,
50 µg
140-unit dose
nasal spray
Recipient 1.00 1.00 CRF p. 111
Morphine sulfate,
1 mg/ml
10-mg disposable
syringe
Recipient 16.00 16.00 CRF p. 111
Morphine sulfate
(Oramorph), 10 mg/5ml
300-ml oral
solution
Recipient 1.00 1.00 CRF p. 111
Movicol 30-sachet pack Recipient 6.00 6.00 CRF p. 111
Moxifloxacin
(as hydrochloride),
400 mg
5-tablet pack Recipient 18.00 18.00 CRF p. 111
Multivitamins 28-capsule pack Recipient 2.00 2.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Mupirocin, 20 mg/g 15-g ointment Recipient 1.00 1.00 CRF p. 111
Micafungin (as sodium) 100-mg vial Recipient 14.00 14.00 CRF p. 111
N-acetylcysteine, 600mg 100-tablet pack Recipient 1.00 1.00 CRF p. 111
Naproxen, 500 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Nebivolol
(as hydrochloride), 5 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Nifedipine, 5 mg 84-capsule pack Recipient 1.00 1.00 CRF p. 111
Nifedipine, 10 mg 84-capsule pack Recipient 5.00 5.00 CRF p. 111
Noradrenaline base,
1 mg/ml (as noradrenaline
acid tartrate, 2 mg/ml)
4-ml ampoule Recipient 32.00 32.00 CRF p. 111
Nutrison energy
multifibre
1000-ml solution Recipient 28.00 28.00 CRF p. 111
Nystatin, 100,000 units/ml 30-ml oral
suspension
Recipient 4.00 4.00 CRF p. 111
Omeprazole
(as magnesium), 10 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Omeprazole
(as magnesium), 20 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Omeprazole
(as magnesium), 40 mg
28-capsule pack Recipient 3.00 3.00 CRF p. 111
Omeprazole (as sodium) 40-mg vial Recipient 24.00 24.00 CRF p. 111
Ondansetrol
(as hydrochloride), 2mg/ml
1-ml ampoule Recipient 1.00 1.00 CRF p. 111
Ondansetron
(as hydrochloride), 4 mg
30-tablet pack Recipient 3.00 3.00 CRF p. 111
Oxycodone
hydrochloride, 5 mg
56-tablet pack Recipient 2.00 2.00 CRF p. 111
Oxycodone
hydrochloride, 10 mg
56-capsule pack Recipient 1.00 1.00 CRF p. 111
Pabrinex vitamin B
substances with ascorbic
acid, 250 mg/10 ml
2 × 5-ml ampoule Recipient 2.00 2.00 CRF p. 111
Packed red blood cells 274-ml bag Recipient 61.00 61.00 CRF p. 111
Paracetamol, 500 mg 32-tablet pack Recipient 2.00 2.00 CRF p. 111
Paracetamol, 1 g 10mg/ml 100-ml
vial
Recipient 28.00 28.00 CRF p. 111
Peppermint water 100-ml solution Recipient 1.00 1.00 CRF p. 111
Perindopril erbumine,
4 mg
30-tablet pack Recipient 1.00 1.00 CRF p. 111
Phenoxymethylpenicillin
(as potassium), 250 mg
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Phosphate 500-ml bottle Recipient 1.00 1.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Piperacillin (as sodium),
4 g; and tazobactam
(as sodium), 500 mg
(Tazocin)
4.5-g vial Recipient 59.00 59.00 CRF p. 111
Platelets 250-ml bag Recipient 134.00 134.00 CRF p. 111
Posaconazole, 100 mg 96-tablet pack Recipient 2.00 2.00 CRF p. 111
Potassium bicarbonate,
400mg; and potassium
chloride, 600mg (Sando-K)
20 tablets Recipient 2.00 2.00 CRF p. 111
Potassium chloride,
150 mg/ml
10-ml ampoule Recipient 14.00 14.00 CRF p. 111
Pravastatin sodium,
10 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Pravastatin sodium,
20 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Pravastatin sodium,
40 mg
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Prednisolone, 5 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Pregabalin, 25 mg 56-capsule pack Recipient 1.00 1.00 CRF p. 111
Pregabalin, 50 mg 84-capsule pack Recipient 2.00 2.00 CRF p. 111
Pregabalin, 75 g 56-capsule pack Recipient 2.00 2.00 CRF p. 111
Pregabalin, 100 mg 84-capsule pack Recipient 1.00 1.00 CRF p. 111
Prochlorperazine
maleate, 3 mg
5 × 10-tablet pack Recipient 1.00 1.00 CRF p. 111
Propofol, 5 mg/ml 20-ml ampoule Recipient 2.00 2.00 CRF p. 111
Propofol, 10 mg/ml 20-ml ampoule Recipient 6.00 6.00 CRF p. 111
Propofol, 10 mg/ml 50-ml pre-filled
disposable
injection
Recipient 3.00 3.00 CRF p. 111
Ramipril, 2.5 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Ramipril, 5 mg 28-capsule pack Recipient 1.00 1.00 CRF p. 111
Ranitidine
(as hydrochloride),
25 mg/ml
2-ml ampoule Recipient 6.00 6.00 CRF p. 111
Ranitidine
(as hydrochloride),
150 mg
60-tablet pack Recipient 2.00 2.00 CRF p. 111
Ranitidine
(as hydrochloride),
300 mg
30-tablet pack Recipient 1.00 1.00 CRF p. 111
Remifentanil
(as hydrochloride)
5-mg vial Recipient 3.00 3.00 CRF p. 111
Risperidone, 500 µg 20-tablet pack Recipient 2.00 2.00 CRF p. 111
Risperidone, 2 mg 60-tablet pack Recipient 1.00 1.00 CRF p. 111
Salbutamol (as sulfate),
2.5 mg/2.5 ml
20-unit dose
nebuliser
Recipient 6.00 6.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Salbutamol (as sulfate),
200 µg
100-dose unit
inhaler
Recipient 1.00 1.00 CRF p. 111
Sennoside B
(as sennosides), 7.5 mg
60-tablet pack Recipient 1.00 1.00 CRF p. 111
Sildenafil (as citrate),
25 mg
4-tablet pack Recipient 7.00 7.00 CRF p. 111
Sodium chloride, 0.9% 20 × 2.5-ml spray Recipient 9.00 9.00 CRF p. 111
Sodium chloride, 600 mg 100-tablet pack Recipient 1.00 1.00 CRF p. 111
Sodium cromoglycate,
5 mg/dose
112-unit dose
inhaler
Recipient 1.00 1.00 CRF p. 111
Sodium dihydrogen
phosphate anhydrous,
1.936 g
100-tablet pack Recipient 2.00 2.00 CRF p. 111
Sodium valproate,
200 mg
100-tablet pack Recipient 13.00 13.00 CRF p. 111
Strepsils 24-lozenge pack Recipient 1.00 1.00 CRF p. 111
Sulfamethoxazole,
400 mg; and
trimethoprim, 80 mg
(co-trimoxazole)
28-tablet pack Recipient 1.00 1.00 CRF p. 111
Tadalafil, 20 mg 8-tablet pack Recipient 4.00 4.00 CRF p. 111
Tamsulosin
hydrochloride, 400 µg
30-capsule pack Recipient 2.00 2.00 CRF p. 111
T.E.D. compression
socks/hose (knee length)
Stocking Recipient 1.00 1.00 CRF p. 111
Teicoplanin 400-mg vial Recipient 21.00 21.00 CRF p. 111
Theophylline (Uniphyllin),
200 mg
56-tablet pack Recipient 1.00 1.00 CRF p. 111
Thiamine hydrochloride,
100 mg
100-tablet pack Recipient 1.00 1.00 CRF p. 111
Tiotropium (as bromide),
18 µg
30-capsule pack Recipient 1.00 1.00 CRF p. 111
Tobramycin, 60 mg/ml 56 × 5ml–300mg
unit
Recipient 11.00 11.00 CRF p. 111
Tobramycin, 75 mg/ml 56 × 4-ml
nebuliser
Recipient 1.00 1.00 CRF p. 111
Tramadol hydrochloride,
50 mg
30-capsule pack Recipient 1.00 1.00 CRF p. 111
Tramadol hydrochloride,
50 mg
60-capsule pack Recipient 3.00 3.00 CRF p. 111
Tramadol hydrochloride,
100 mg
60-capsule pack Recipient 2.00 2.00 CRF p. 111
Ursodeoxycholic acid,
150 mg
60-tablet pack Recipient 1.00 1.00 CRF p. 111
Ursodeoxycholic acid,
300 mg
60-tablet pack Recipient 2.00 2.00 CRF p. 111
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TABLE 51 NHS resource use: detailed table (continued )
Resource or intervention Unit
Patient
details
Mean usage
in standard
donor lung
transplantation
Mean usage
in EVLP
transplantation Resource source
Valaciclovir
(as hydrochloride),
500 mg
42-tablet pack Recipient 2.00 2.00 CRF p. 111
Valganciclovir
(as hydrochloride),
450 mg
60-tablet pack Recipient 2.00 2.00 CRF p. 111
Vancomycin
(as hydrochloride)
1-g vial Recipient 2.00 2.00 CRF p. 111
Vitamin B compound
strong
28-tablet pack Recipient 2.00 2.00 CRF p. 111
Vitamins A, D and E 30-capsule pack Recipient 1.00 1.00 CRF p. 111
Multivitamins 100-tablet pack Recipient 1.00 1.00 CRF p. 111
Voriconazole, 200 mg 28-tablet pack Recipient 3.00 3.00 CRF p. 111
Warfarin sodium, 3 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
Water for injections 5-ml ampoule Recipient 1.00 1.00 CRF p. 111
Zopiclone, 3.75 mg 28-tablet pack Recipient 1.00 1.00 CRF p. 111
CO2, carbon dioxide; N2, nitrogen; ODA, operating department assistant.
APPENDIX 7
NIHR Journals Library www.journalslibrary.nihr.ac.uk
246
Appendix 8 Trial documentation
Participant Information Sheet Main Study v 5.0, 24 May 2013 
 
To be printed on the local trust headed paper         
 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
 
Participant Information Sheet Version 5.0 
 
You are being invited to take part in our research study as you have a severe lung disease 
that makes you a candidate for a lung transplant. Before you decide if you want to take part, 
it is important for you to understand why the research is being done and what is involved in 
taking part. 
 
One of our research team will go through this information sheet with you and answer any 
questions you have about what the study involves, how your information will be used and 
what the possible benefits and risks of taking part are. Please take time to read the following 
information carefully. Talk to others about the study if you wish. Please ask if there is 
anything that is not clear or if there is anything you would like more information about. Take 
time to decide if you wish to take part. 
 
Part 1 tells you about the purpose of this study and what will happen if you take part.  
 
Part 2 gives you general information about how the study will be conducted. 
 
 
PART 1 
Study Summary 
Each year a number of patients on the transplant waiting list do not survive long enough for 
suitable matching donor lung(s) to become available. 
 
The shortage of organ donors in the United Kingdom has made it even more difficult for 
those waiting for lung transplant, as donor lungs are very delicate and often deteriorate due 
to events that happen before the lungs are removed from the donor. The effect of this is that 
currently only 1 in 5 or 20% of the potential donor lungs available in the UK are currently 
acceptable for use in lung transplant surgery. Despite a lot of effort to promote organ 
donation recently, there remains a major shortage of usable donor lungs for UK patients 
waiting for lung transplantation. 
 
In this study, a new technique called Ex-Vivo Lung Perfusion or EVLP will be tested to 
find out how effective it is at increasing numbers of lung transplants performed, by turning 
previously unusable donor lungs into lungs which can be safely used for transplant. EVLP 
involves attaching the donor lungs, after they are removed from the donor, to a modified 
heart-lung bypass machine for several hours. The modified bypass machine pumps a 
specialised nutrient liquid through them, while at the same time provides the lungs with 
oxygen via a breathing machine. The EVLP technique has been used successfully in an 
increasing number of lung transplant centres around the world to improve the condition of 
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otherwise unusable donor lungs so that they can be given successfully to patients awaiting 
lung transplant. 
 
Although, there are promising early results, the EVLP technique has not been tested in a 
controlled clinical trial that assesses whether EVLP is an effective way to increase the 
number of donor lungs available for lung transplantation. The DEVELOP-UK study will 
aim to answer this question.  
 
The UK is in a very good position to conduct this study as most of the UK lung transplant 
centres have already developed some experience with the EVLP technique with 17 patients 
on UK lung transplant waiting lists receiving EVLP assessed and improved donor lungs. By 
August 2011, this meant 25% of lung transplants performed worldwide using EVLP have 
been done in the UK. Our experience to date suggests that approximately half of the donor 
lungs treated with EVLP can be improved successfully for transplant. This means many of 
the 80% of donor lungs currently found to be unusable may have the potential to be 
improved sufficiently to be used for lung transplantation. 
 
What is the purpose of the study?  
It has been shown that the current method used to assess whether potential donor lungs are 
usable for lung transplantation is not optimal. This suggests that many donor lungs deemed 
unusable could in fact be suitable for lung transplantation. EVLP may therefore allow many 
previously unusable donor lungs to be carefully assessed and improved for safe use in lung 
transplantation. This would help to significantly increase the chances of a suitable donor 
organ being found for patients on the lung transplant waiting list. 
 
The DEVELOP-UK study has been designed to carefully assess the results of lung 
transplants performed with donor lungs which have been assessed and improved with EVLP 
compared to those done with standard donor lungs.  
 
Donor lungs offered but considered not suitable for standard transplant, will be transferred to 
the transplant centre where they will be placed on the EVLP system. The donor lungs will 
then be monitored for up to 4 hours to measure how well their function improves and to 
make sure there is no irreversible damage present. If their function improves to a level where 
they can pass a rigorous assessment, the donor lungs are then offered to a patient on the lung 
transplant waiting list who has given their prior agreement to take part in the study. 
The study will be deemed a success if it shows that survival in the first 12 months after lung 
transplant is as good in patients who have received EVLP improved donor lungs as in 
patients who received standard donor lungs. 
 
The DEVELOP-UK research team will also look to see if there are any more early 
complications, such as a longer stay on intensive care, more frequent infections or more 
episodes of transplant rejection, in patients who have received EVLP improved donor lungs 
compared to standard donor lungs. 
 
A Quality of Life Questionnaire will be used to assess whether changes in quality of life in 
the first post-transplant year in patients who received EVLP assessed and improved donor 
lungs are similar to those in patients who received standard donor lungs. 
 
Finally, the cost to the NHS of using the EVLP technology will be calculated. All the 
information generated in the study will be used by the NHS commissioners, who pay for UK 
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transplant services, to decide if this technique can be adopted as part of normal practice in 
the future. 
In addition, by carrying out detailed interviews with some of the patients agreeing to take 
part in the DEVELOP-UK study, the research team will try to understand the experiences 
and any concerns expressed by patients about undergoing transplantation with EVLP donor 
lungs. This will enable clinicians to address effectively any patient concerns in the future. 
 
Why have I been invited? 
You have been invited to participate in this study because you are 18 years old or over and 
you have either already been accepted onto an active lung transplant waiting list in the UK or 
are under serious consideration for potential lung transplantation in one of the adult lung 
transplant centers. 
 
Do I have to take part?  
It is up to you to decide whether to take part in the study. You do not have to participate if 
you do not wish to. However, if you do decide to participate, the research team will describe 
carefully to you what the study involves and give you this information sheet to keep. The 
team will explain how decisions are made about donor lungs’ usability for lung 
transplantation and why the majority are felt unusable for standard lung transplantation. 
 
They will also explain which unusable donor lungs are suitable for EVLP and how their 
function after EVLP is assessed to decide if they have become usable for lung transplant. 
The donor lungs assessed and improved by EVLP have to reach the same level of function as 
standard lungs before they will be considered usable for lung transplantation. The research 
team will provide firm reassurance that if donor lungs do not improve sufficiently after 
EVLP they will not be used for transplantation. 
 
All the questions you have about the study will be answered by the team. You will be given 
time to think this over and talk to your family and friends about it. If you agree to take part, 
you will be asked to sign either an expression of interest form and then a consent form or the 
consent form itself depending on whether the discussion with you has happened in person or 
over the telephone. 
 
As the time between going on the waiting list and getting a lung transplantation varies 
widely and can in some cases exceed 12 months, you will be asked to reconfirm your 
consent when you are called in and offered transplantation with an EVLP assessed and 
improved donor lung(s). However, if you sign the consent form on the day of transplant you 
do not need to reconfirm your consent. The clinical transplant team will inform you whether 
you are to receive an EVLP assessed and improved donor lung or a standard donor lung.  
You will not be asked to reconfirm your consent if you have signed the consent form prior to  
being called in for transplantation and are offered transplantation with standard donor 
lung(s).   
 
If you decide to take part you are still free to withdraw from the study at any time and you do 
not have to give a reason. This will not affect the standard of care you receive either now or 
in the future. If you decide not to participate, you will have equal access to donor lungs for 
standard transplant but would not be considered for donor lungs that have undergone EVLP 
assessment and improvement. 
 
What will happen to me if I take part? 
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This is an observational study. It means that no extra tests or procedures will need to be done  
on you. The EVLP process to assess whether the donor lungs have improved enough for use 
in a lung transplant is performed before any transplant surgery is started. 
 
You will not need any extra clinical visits to hospital or your GP as a result of being in the 
study. All your hospital visits will be arranged by the transplant team as a part of routine care 
after lung transplant. Collection of your information for the purposes of the study will be 
coordinated with your routine post-lung transplantation clinic visits. 
 
The research team will ask if you are willing for them to collect data that can be extracted 
from your medical records. If you were to lose capacity (become unable to decide whether to 
carry on with the study) over the follow-up period, the research team will aim to continue 
data collection from your medical notes. This will not impact on the standard of medical care 
you receive. Once you have signed an expression of interest form or informed consent form 
for the DEVELOP-UK we will ask you to complete a Quality of Life Questionnaire. It will 
take you approximately 15 to 20 minutes.  
 
When you are called in for possible transplantation, the transplant team will explain to you 
whether you are to receive EVLP-assessed and improved donor lung(s) or standard donor 
lung(s).  If you have signed consent form before the day of transplant you will be asked 
whether you wish to reconfirm your consent and continue to participate in the study if you 
are offered EVLP assessed and improved donor lung(s) but not for standard donor lung(s). If 
you sign consent form on the day of transplant you do not need to reconfirm your consent. If 
you decide not to continue in the study then any possible transplant with EVLP assessed and 
improved lungs will not go ahead. 
 
Following lung transplantation you will be asked to complete the same Quality of Life 
Questionnaire 3 months and 12 months after your lung transplant (see the diagram below). 
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Expenses and payments  
This is an observational study. As all the information needed for the study will be collected 
when you are already attending the transplant centre for routine clinic visits, there are no 
payments made to you to participate in the DEVELOP-UK study. 
What will I have to do? 
Please consider carefully the clinical and research aspects of the study.  
 
The study visits will be coordinated to coincide with your routine clinic visits at 1 month, 3 
months, 6 months and 12 months after your lung transplantation. The data we collect for this 
study will be part of your routine follow up care and recorded from your medical notes and 
from computerised results in the hospital. 
 
If you decide to participate in the DEVELOP-UK you will need to complete a Quality of 
Life Questionnaire before lung transplantation, and then at 3 and 12 months after receiving 
your lung transplant. 
 
If you have been taking part in another clinical or drug study in the past 12 months please 
discuss this with the study doctors. It may not prevent you from participating in the 
DEVELOP-UK study. After undergoing lung transplantation you should not participate in 
any clinical study that might affect your standard post-transplant care for 12 months. After 
this 12 months post-transplant period you can participate in any clinical or drug studies as 
you wish. Please contact the study doctor if you have any questions. If you wish to 
participate in any observational studies before or after lung transplant please discuss it with 
the study doctor. 
 
What are the alternatives for diagnosis or treatment? 
Before transplant Informed QoL 
Day of transplant Informed 
1 month 
Post transplant 
Data collection 
from medical 
6 months 
Post transplant 
Data collection 
from medical 
3 months 
Post transplant 
Data collection 
from medical QoL 
12 months 
Post transplant 
Data collection 
from medical QoL 
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For selected patients suffering from long lasting severe lung disease, lung transplantation is 
the only realistic therapeutic option. 
 
What are the possible disadvantages and risks of taking part? 
The main risk of taking part in the study is that you might receive an EVLP assessed and 
improved donor lung that does not function well after transplant. This could mean requiring 
a longer stay in the intensive care unit to give artificial support to the transplanted lung or 
even death. However, similar risks also exist for standard donor lungs as a significant 
proportion of standard donor lungs do not function well after lung transplant. The 
DEVELOP-UK study is designed to address the question as to how effective the EVLP 
technique is at safely increasing availability of donor lungs. By May 2013, worldwide 
experience in more than 150 patients suggests that transplanted EVLP assessed and 
improved lungs are likely to work as effectively as standard donor lungs. Any possible risks 
of taking part in the study should be balanced against the risk of not receiving a lung 
transplant at all because a standard donor lung has not been available in adequate time. 
 
Transplanted lungs, whether standard or EVLP assessed and improved, always remain 
vulnerable to the possibility of rejection and one of the main risk factors is low 
immunosuppression levels. Therefore prior to being accepted onto the transplant list you 
were counselled about the absolute necessity to comply with your treatment and to attend all 
arranged post-transplant follow-up appointments. 
 
Topics in the Quality of Life Questionnaire that you will be asked to complete will include 
your views about how much your condition affects your health, your regular daily activities 
and your emotional state. It is possible that you may find some of these questions upsetting 
due to their nature. It also includes such topics as bodily pain, depression and your social 
life. Please be assured that all of your responses are entirely confidential. 
 
What are the possible benefits of taking part? 
By agreeing to take part in the DEVELOP-UK study you may have access to a larger 
number of potential matching donor lungs for your transplant. This is because EVLP allows 
otherwise unusable donor lungs to be meticulously assessed and potentially improved for 
successful lung transplantation. This technology therefore may have the capacity to reduce 
the time an individual spends on the waiting list for lung transplant. 
 
What happens when the research study stops? 
This is an observational study. Therefore there will be no change to your standard medical 
care throughout and after the study. 
 
What if there is a problem? 
Any complaint about the way you are dealt with during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
Yes. The research team will follow ethical and legal practice and all information about you 
will be handled in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
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PART 2  
General information 
 
What if relevant new information becomes available? 
If new information about the EVLP technique, that might affect the way the study is 
conducted, becomes available, your study doctor will tell you and discuss whether you 
should continue in the study. If you decide not to carry on, your standard medical care will 
not be affected and you will have equal access to standard donor lungs for transplant. 
 
 
What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time, and without giving a reason. However, we 
might ask you if you are happy for us to record why you have decided to withdraw.  
 
If you initially agreed to participate in DEVELOP-UK but then decided to withdraw on the 
day of transplantation, then any possible transplant with EVLP assessed and improved lungs 
will not go ahead. If you are to receive standard donor lungs but decided to withdraw from 
the study then no follow up data will be collected from your medical notes. If you have 
signed initial consent, then (if necessary) reconfirmed your consent on the day of  transplant 
to receive EVLP assessed and improved donor lung(s) and then received the transplant but 
decided to withdraw later, data collected up to the point of withdrawal will be retained.  
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to the study doctor 
who will do their best to answer your questions (add local contact details). If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details of how to complain can be obtained by contacting (add local contact 
details (Trust PALS)) 
 
In the event that something does go wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for legal action for 
compensation; however you may need to meet your own legal costs. The normal National 
Health Service complaints mechanisms will still be available to you (if appropriate). NHS 
Indemnity does not offer no-fault compensation (i.e. for harm that is not anyone’s fault). 
Neither the sponsor (The Newcastle upon Tyne Hospitals NHS Foundation Trust) who has 
undertaken to manage the study, nor the management of the hospital/research centre you are 
attending for your routine treatment, is able to agree in advance to pay compensation for 
non-negligent harm.  
 
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital/surgery will 
have your name and address removed so that you cannot be identified. 
 
The data that is collected from your clinical notes will be entered onto a secure computer 
database. Access to this database will be password protected and available to your doctors 
and the research staff for the purpose of the study. All data stored on the computer will be 
coded and your name will not appear. You will be given a unique study number under which 
all data and test results will be entered. These data will be analysed to find out how well 
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EVLP assessed and improved donor lungs function in comparison with standard donor lungs 
after transplantation. The analysis of the data we obtain from Quality of Life Questionnaire 
will be used to measure the health related costs of the EVLP technique. 
 
If you join the study, some parts of your medical records and the data collected for the study 
will be looked at by authorised persons from the sponsor of this study (The Newcastle upon 
Tyne NHS Foundation Trust) or their representatives. They may also be looked at by 
authorised people from regulatory authorities and the Newcastle Clinical Trials Unit to check 
that the study is being carried out correctly. All will have a duty of confidentiality to you as a 
research participant and will do their best to meet this duty. All the information about your 
participation in this study will be kept confidential. All data will be stored for at least 15 
years and then disposed of securely. Your data will not leave the UK nor will it be passed 
onto anyone outside of this study. 
 
Involvement of the General Practitioner/Family doctor (GP) 
We will ask you specifically if you want your GP to be informed about your participation in 
DEVELOP-UK. You can refuse for your GP to be informed without giving any reasons. 
 
What will happen to any samples I give? 
No samples will be collected from you that are not part of your standard medical care. 
However at the start and at the end of the EVLP process the research team will take a small 
sample of lung tissue from the donor lung. These samples will be studied by the research 
team themselves to help understand how EVLP is working. Some of this work might be done 
in partnership with other academic organisations or companies both inside and outside the 
UK. No identifiable personal information will accompany any samples. 
 
What will happen to the results of the research study? 
The results from this study will be published in widely read medical journals which review 
the quality of the results and will be presented at national and international medical 
meetings. The results will also be reported to the Sponsor (The Newcastle upon Tyne NHS 
Foundation Trust) and Funders (National Institute for Health Research Health Technology 
Assessment Programme in the Department of Health and Cystic Fibrosis Trust), and will be 
available on the study website www.develop-uk.net. As a participant in the trial you will not 
be identified from any publication, study report or presentation. You will be informed about 
your contribution to the study at the end of the study, including a summary of the results. 
 
Who is organising and funding the research? 
The research is being organised and delivered by a team of researchers from across the UK 
including representatives from all 5 adult lung transplant centres. Professor Andrew Fisher 
from The Institute of Transplantation at Freeman Hospital, Newcastle and Newcastle 
University is the Chief Investigator and the Newcastle University Clinical Trials Unit is 
managing the study. The work is supported by a Project Grant awarded from the Department 
of Health via the National Institute for Health Research Health Technology Assessment 
Programme and by funding from The Cystic Fibrosis Trust UK. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given a 
favorable opinion by NRES Committee North East - Sunderland. The Chief Executive of the 
Newcastle upon Tyne Hospitals NHS Foundation Trust has agreed to provide indemnity for 
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the study in terms of its management. The conduct of the study at [please add Trust/centre 
name], for your treatment has indemnity cover through the normal NHS schemes. 
 
The NHS is trying to improve the quality of clinical and research standards. This is being 
achieved through ‘clinical governance’. As part of this process, this study may be reviewed 
by a clinical governance team. Such a team would need to look at any information that you 
provide us with, to make sure that the research was carried out in accordance with proper 
procedures. 
 
Further information and contact details 
For further information about the study you can speak to one of the Study Team: 
 
Dr:     PI’s name + contact details 
Research Nurse:   Name + contact details  
 
Alternatively you can speak to the Independent contact: please add local independent 
contact. 
 
Emergency out of hours contact details: Name and contact details 
 
Thank you for taking the time to read this information sheet 
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Participant Information Sheet Interview Study v 1.0, 1 November 2011 
 
To be printed on the local trust headed paper 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
Interview Study 
Participant Information Sheet Version 1.0 
 
You are being contacted because you expressed an interest in receiving more information 
about the interview component of the DEVELOP-UK study. We are sending you this 
participant information sheet to help you to decide whether you would be willing to take part 
in an interview about your views and experiences. This is entirely optional and you are 
under no obligation to take part. If you decide you do not want to be interviewed this will 
have no effect on your involvement in the rest of the DEVELOP-UK study. If you do not 
want to take part, you do not need to do anything further. We will not contact you again 
about this matter. However, if you are still willing to take part in an interview we would like 
to give you more information to help you to decide. 
 
To help you to decide if you want to take part in the interview study, it is important that you 
understand why the research is being carried out and what it will involve for you. Please take 
time to read the following information carefully, and discuss it with others if you wish. Ask 
us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. If, having read this information, you are 
interested in taking part in the interview study please either call the research team directly on 
0191 222 3805 or return the form (attached at the end of the information sheet) in the 
enclosed Stamped Addressed Envelope and they will call you to arrange the interview. 
 
Part 1 tells you the purpose of this interview study and what will happen to you if you take 
part. 
Part 2 gives you general information about the conduct of the study. 
Please ask us if there is anything that is not clear.  
 
 
PART 1 
Study Summary 
Ex-vivo lung perfusion or EVLP is a new technique that allows assessment and improvement 
of poorly functioning donor lungs so that they can be safely used in lung transplantation. To 
date research related to people’s experiences of receiving a donor organ is very limited. We 
know that waiting for a transplantation impacts on patients and their families and we would 
like to speak with patients about their experiences. We also do not know what patients think 
about EVLP. Therefore we would like to conduct interviews with patients either before or 
after lung transplantation, and with some patients both before and after. The interviews will 
help the research team to understand your experiences of waiting for lung transplantation, 
your hopes and expectations of EVLP and, if you receive EVLP assessed and improved lung, 
your views of living with an EVLP transplant.  
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What is the purpose of the study? 
The aim of this interview is to understand more about your views of EVLP before and after 
lung transplantation. 
Why have I been invited? 
You have been invited to participate in this sub-study because you have expressed an interest 
in taking part in the DEVELOP-UK Study. 
 
Do I have to take part? 
It is up to you to decide whether to join this interview sub-study. If you do decide to 
participate, we will describe carefully what is involved with the study and give this 
information sheet to keep. You will be given time to think this over and talk to your family 
and friends about it. 
 
This interview study is purely optional – you do not have to take part. It would not affect 
your participation in the DEVELOP-UK study. If you agree to take part, you can withdraw at 
any time without giving a reason and you will not be asked to participate in this interview 
study again. 
 
What will happen to me if I take part? 
Once you have indicated that you are willing to be interviewed then one of the DEVELOP-
UK research team from the Institute of Health and Society, Newcastle University will 
contact you by telephone and discuss the interview study with you and will answer any 
questions you have. 
 
We will ask you whether you prefer to be interviewed face to face either at your home or in a 
suitable hospital room, or you may choose to be interviewed by telephone. If you choose to 
be interviewed in the hospital we will arrange for the interviews to take place during your 
usual appointments at the transplant centre. 
We will ask you to sign a consent form which shows that you agree to take part. If you 
decide to be interviewed face to face, the consent form will be signed before the interview 
occurs. You can invite your relative or another person who cares for you to participate in an 
interview with you. A separate consent form will be provided for her/him. If you decide to 
have the interview by telephone we will go through the consent form with you and record 
you verbal consent.  
 
We are approaching you as we would like to speak to people at different times; we would 
like to speak to people who are waiting for a transplant or who have already had a lung 
transplantation operation. Interviews will last approximately 45-60 minutes although may be 
slightly longer or shorter. 
 
If you are waiting for a lung transplant we would like to talk about the following topics 
during the interview: 
• Your view of your health and experience of living with your condition 
• Your experience of waiting for lung transplantation 
• Your understandings of EVLP and its acceptability in comparison with other donor 
lungs 
• Your hopes and expectations for EVLP 
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If you have already had a lung transplant we would like to talk about the following topics 
during the interview: 
• Recollection of your health and experiences before the operation 
• Your accounts of waiting for a transplant 
• Your views and experiences of receiving and living with an EVLP transplant (if you 
received EVLP assessed and improved donor lung)  
 
All interviews will be recorded. This is to help the researcher listen to the discussion and 
accurately record what is being said. These tapes will be transcribed and the study team will 
securely store both the tape and transcription. All data will be confidential and all data will 
be anonymised. 
Expenses and payments  
The interviews performed in this study will be conducted either during a routine visit to the 
transplant clinic, in your own home or over the telephone. We will therefore not be able to 
pay for you to participate in the Interview study for DEVELOP-UK. If a telephone interview 
is chosen then the researcher will telephone you at our expense. 
 
What will I have to do? 
Please consider carefully all aspects of the Interview Study. This study is purely optional and 
will not affect your participation in DEVELOP-UK. You can withdraw at any time without 
giving any reason.  
 
If you like, a relative or another person who cares for you can also be interviewed with you. 
If you decide to take part you and your relative or person who cares for you will also need to 
sign a consent form. Once we receive your signed form indicating you are interested in 
taking part in the Interview Study, one of our research team members will contact you to 
arrange the time of the interview either at a place of your choice or over the telephone. Each 
interview will last approximately 45-60 minutes. 
 
What are the possible disadvantages and risks of taking part? 
You may find some of the topics and issues discussed during interviews upsetting. We would 
like to know how much your health, regular daily activities and personal relationships were 
affected before and after lung transplantation, and we will discuss specifically your views 
and experiences of EVLP. 
 
Please be reassured that all of your responses are entirely confidential. If you do become 
upset at any time you can choose to stop the interview immediately. We will only continue 
with the interview if you are happy for us to do so.  
 
What are the possible benefits of taking part? 
There are no direct benefits from taking part in this interview study but it will help us to 
understand what you think and expect from EVLP. Understanding what patients think plays 
a very important part in the possible successful introduction of this new EVLP technique to 
lung transplantation in the UK. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the Interview study will be 
addressed. Detailed information on this is given in Part 2. 
Will my taking part in the study be kept confidential? 
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Yes. We will follow ethical and legal practice and all information about you will be handled 
in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering participation, please 
read the additional information in Part 2 before making any decision. 
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PART 2  
General information 
 
What will happen if I don’t want to carry on with the Interview Study? 
You can choose to stop the interview at any time for any reason, and without giving a reason. 
If you do so you can choose whether to have the earlier part of the interview destroyed, or 
whether you are willing for the research team to use the data they have collected. 
 
If you are approached whilst you are waiting for transplantation, there is a chance we will 
contact you again after your transplant operation to find out more about your experience. 
 
You can withdraw from the Interview study at any time for any reason, and without giving a 
reason. If you decided to withdraw, data collected up to the point of withdrawal will be 
retained. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should speak to the study 
researcher who will do their best to answer your questions (Dr Catherine Exley, Institute of 
Health and Society, Newcastle University  
 
If you remain unhappy and wish to complain formally, you can do this through the NHS 
Complaints Procedure.  Details of how to complain can be obtained by contacting (Dr 
Catherine Exley, Institute of Health and Society, Newcastle University  
 
In the event that something does go wrong and you are harmed during the research and this 
is due to someone’s negligence then you may have grounds for legal action for 
compensation; however, you may need to meet your own legal costs. The normal National 
Health Service complaints mechanisms will still be available to you (if appropriate). NHS 
Indemnity does not offer no-fault compensation (ie. for harm that is not anyone’s fault).  
Neither the sponsor (The Newcastle upon Tyne Hospitals NHS Foundation Trust) who has 
undertaken to manage the study, nor the management of the hospital/research centre you are 
attending for your routine treatment, is able to agree in advance to pay compensation for 
non-negligent harm.  
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of the research will be kept 
strictly confidential, and any information about you which leaves the hospital/surgery will 
have your name and address removed so that you cannot be recognised. 
The data we collect from your interviews will be entered onto a secure database.  Access to 
this database will be password protected.  All data stored on the computer will be coded and 
your name will not appear. The analysis of your interviews will help us to improve future 
practice development. 
 
If you join the interview study, some parts of your interviews may be looked at by authorised 
persons from the sponsor of this study (Newcastle upon Tyne NHS Foundation Trust) or 
their representatives. However, none of your personal information will be linked with 
extracts of your interview. They may also be looked at by authorised people from regulatory 
authorities and the Newcastle Clinical Trials Unit to check that the study is being carried out 
correctly. All will have a duty of confidentiality to you as a research participant and will do 
their best to meet this duty. All the information about your participation in this study will be 
).
).
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kept confidential. All data will be stored for at least 15 years and then disposed of securely. 
All the information collected will be managed by the study team only and will be destroyed 
after a period of fifteen years.  
 
What will happen to the results of the research study? 
The results from this interview study will be published in professional journals where the 
quality of the results will be assessed. In addition results will be presented at national and 
international meetings. The results will also be reported to the Sponsor (the Newcastle upon 
Tyne NHS Foundation Trust) and Funder (National Institute for Health Research 
Technology Assessment Programme in the Department of Health and the Cystic Fibrosis 
Trust), and will be available on the study website www.develop-uk.net. As a participant in 
interview study you will not be identified from any publication, study report or presentation. 
 
A summary of the findings of the interview study will be made available to you at the end of 
the whole study. 
 
Who is organising and funding the research? 
The Interview study is being led by Dr Catherine Exley who is based at Newcastle 
University’s Institute of Health & Society. The people who are doing the interviews either 
work directly with Dr Exley at the University or are nurses at one of the transplant centres. 
The work is supported by a Project Grant awarded from the National Institute for Health 
Research Health Technology Assessment Programme and the Cystic Fibrosis Trust. 
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your interests. This study has been reviewed and given a 
favourable opinion by NRES Committee North East - Sunderland. The Chief Executive of 
the Newcastle upon Tyne Hospitals NHS Foundation Trust has agreed to provide indemnity 
for the study in terms of its management. The conduct of the study at (please add 
Trust/centre name), for your treatment has indemnity cover through the normal NHS 
schemes. 
 
The NHS is trying to improve the quality of clinical and research standards. This is being 
achieved through ‘clinical governance’. As part of this process, this study may be reviewed 
by a clinical governance team. Such a team would need to look at any information that you 
provide us with to make sure that the research was carried out in accordance with proper 
procedures. 
 
Further information and contact details 
For further information about the study you can speak to one of the Study Team:  
Dr Catherine Exley 
Institute of Health and Society 
Newcastle University  
 
Research Nurse:   Name + contact details. 
Alternatively you can speak to the Independent contact:  please add local independent 
contact. 
Emergency out of hours contact details: Name and contact details 
 
Thank you for taking the time to read this information sheet.  
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Please return this page to us in the enclosed stamped addressed envelope if you are 
willing to be interviewed 
 
I am interested in taking part in the Interview study. 
 
I am happy for a member of the research team at the Institute of Health and Society, 
Newcastle University to contact me to arrange a convenient time for me to take part. 
 
Please contact me: 
 
 
Name:  ---------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
Address: ---------------------------------------------------------------------------------------------- 
 
 
 
 
 
 
 
 
Telephone: ---------------------------------------------------------------------------------------------- 
 
APPENDIX 8
NIHR Journals Library www.journalslibrary.nihr.ac.uk
262
Appendix 9 Trial letters
Letter to GP v 1.0, 1 November 2011 
 
To be printed on the local trust headed paper  
 
Date: 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
Dear Dr 
 
Patient’s Name: ________________________________________ 
 
Address:  ________________________________________ 
 
   ________________________________________ 
 
DOB:   ________________________________________ 
 
 
 
Your patient has agreed to participate in the DEVELOP-UK study.  
 
This observational study aims to examine survival during the first 12 months after lung 
transplantation in recipients of ex-vivo lung perfusion (EVLP) assessed and reconditioned 
donor lungs (treatment group) compared to that of recipients of standard donor lungs (control 
group), in order to assess whether survival in the EVLP treatment group over that period is 
non-inferior to that in the standard control group. 
 
DEVELOP-UK will also evaluate early clinical outcomes and changes in Quality of Life in 
the treatment and control group in their first post-transplant year; assess (by statistical 
modeling) the survival benefit for waiting list patients and determine if EVLP is a cost-
effective intervention for the NHS to support as standard care within UK lung transplant 
centers in the future. 
 
An optional qualitative sub-study will be based on interviews with patients awaiting lung 
transplantation (and their carers) and with patients receiving EVLP reconditioned lungs to 
explore their attitudes towards and experiences of EVLP. 
 
Please find enclosed a copy of the information sheet given to your patient. 
Please do not hesitate to contact me for any queries relating to the study, or to report any 
untoward symptoms experienced by patient. I can be contacted on the following telephone 
number: 
 
(Name of local PI and contact phone number) 
 
Yours sincerely 
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Update on DEVELOP-UK Letter to Participants v 1.0, 24 May 2013 
 
To be printed on Trust Headed paper 
 
Update on DEVELOP-UK Study  
Donor Ex-vivo Lung Perfusion in United Kingdom Lung Transplantation 
 
Date 
Dear XXXX 
I am writing to update you with some new information about the DEVELOP-UK study.  
You will recall that this study is running in all the United Kingdom lung transplant centres 
and is designed to investigate a technique called ex-vivo lung perfusion (or EVLP). The 
study is assessing how effective EVLP is at improving donor lungs that are currently not 
suitable for transplant, to allow them to be safely transplanted. 
Previously, you were contacted by our research team with information about the DEVELOP-
UK study and have already signed an expression of interest form or a consent form, 
confirming your interest in taking part in the study.  
As the study has progressed, the investigators leading the study in each of the 5 UK centres 
have met regularly to review progress and to learn from other experiences with EVLP 
around the world. This information is then shared with the independent Trial Oversight 
Committees. 
Experience with the EVLP technique has been growing steadily around the world since the 
study began in April 2012. This includes experience using the specific EVLP machine that is 
being used in the DEVELOP-UK study. In particular, we were aware that an alternative way 
of using the machine, differing from our approach in only a few details, appeared to result in 
more donor lungs being available for transplant. In response to this, and with agreement 
from the Trial Oversight Committees, the investigators have made some changes to the way 
the EVLP technique is performed in the DEVELOP-UK study. 
These changes mean that we are now using the machine in a way that in some other centres, 
results in a higher proportion of lungs being available for transplant as well as with good 
early results after transplant.  
I have included with this letter an updated participant information sheet for your records. I 
encourage you to read this and if you have any questions please do not hesitate to contact us. 
In the first instance you can contact XXXX the DEVELOP-UK study research nurse at the 
hospital.  
Your participation in the study remains entirely voluntary and I would remind you that 
before any transplant with EVLP improved lungs happens, you would be given the 
opportunity to reconfirm your willingness to receive them.  
I would be very grateful if you could sign the attached acknowledgement form which 
confirms that you have received this updated information and return it to me in the 
prepaid envelope. 
Yours sincerely 
 
Signed 
 
 
Principal Investigator 
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Appendix 10 End of study information sheet
version 1.0, 22 October 2015
To be printed on the local trust headed paper 
 
DEVELOP-UK 
A Study of Donor Ex-vivo Lung Perfusion 
in United Kingdom Lung Transplantation 
ISRCTN: 44922411 
 
End of Study Information Sheet 
 
This information is being provided to you because you took part in the DEVELOP-UK 
research study while waiting for lung transplant.  The study compared a new technique 
called Ex-Vivo Lung Perfusion (EVLP) with standard lung transplant.  We asked the 
research question: is EVLP an effective way to increase the number of donor lungs available 
for lung transplantation in the UK?  The study follow-up period has now ended, and this 
Information Sheet is to inform you of what happens now, and to explain how to access the 
study results, if you wish to do so. 
 
You were informed when you gave consent what would happen to you when the study 
ended, via the Participant Information Sheet (PIS). 
 
DEVELOP-UK is an observational study that followed what happened to participants during 
their first year after transplant. Therefore you will continue to receive standard medical care 
now the study has ended, as you did throughout your participation during the first year. 
 
No samples of tissue or blood were collected from you that were not part of your standard 
medical care after transplant. However, when applicable the research team took small 
samples of lung tissue from donor lungs at the start and end of the EVLP process. These 
samples are currently being studied by the research team to help understand how EVLP 
works. Some of this work might be done in partnership with other research organisations or 
companies both inside and outside the UK. No identifiable personal information (from either 
donor or recipient) accompanies these samples. 
 
The results of this study are currently being evaluated and will be published in widely read 
medical journals that review the quality of the results, and will be presented to doctors and 
scientists at national and international medical meetings. The results will also be reported to 
the Sponsor (The Newcastle upon Tyne Hospitals NHS Foundation Trust) and Funders 
(National Institute for Health Research (NIHR) Health Technology Assessment (HTA) 
Programme, and Cystic Fibrosis Trust).  The results will also be available on the study 
website once evaluation is complete: www.develop-uk.net; you can access this, if you so 
wish. As a trial participant you will not be identified personally in any publication, study 
report or presentation. 
 
If you have any further questions, or would like to continue your involvement in clinical 
research, please contact the study team at your participating hospital. 
Many thanks for your interest and participation in the study; you have made a vital 
contribution to research and the improvement of healthcare for patients waiting for 
lung transplantation in the future. 
DOI: 10.3310/hta20850 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Fisher et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
265

Appendix 11 Forms: extracts from case report
form booklet
Date (dd/mm/yyyy)          /          / 
Hospital  
NHS BT Donor 
Number 
 
Criteria for standard transplant 
Donation after Brain Death (DBD) 
Please record the correct answers to the following questions:                
1 Satisfactory Chest X-ray reviewed by retrieval surgeon 
                   
          Yes               No 
2 Systemic arterial PO2 > 35-40 kPa on 100% FiO2 and 8 cm H2O 
PEEP 
                   
          Yes               No 
3 Selective Pulmonary Vein (PV) Gases > 30 kPa on 100% FiO2 and  
8cm H2O  PEEP 
                   
          Yes               No 
4 Peak airway pressure < 30 cm  H2O 
                   
          Yes               No 
5 Bronchoscopy – no severe inflammation of  the airway, or recurrent 
secretions in the distal airway after adequate bronchial toilet 
                   
          Yes               No 
6 Easily recruited atelectasis 
                   
          Yes               No 
7 Satisfactory deflation test on disconnecting endotracheal tube 
                   
          Yes               No 
8 Satisfactory  palpation of the lung to exclude undetermined masses, 
nodules or gross oedema 
                   
          Yes               No 
9 Satisfactory inspection of the lung after administration of  the 
preservation flush and procurement 
                   
          Yes               No 
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Donation after Circulatory Death (DCD) 
Please record the correct answers to the following questions:                
1 Satisfies criteria as for standard DBD donor lungs (if information 
available) 
                   
          Yes               No 
2 DCD Donors from Maastrict Category 2, 3 or 4 
                   
          Yes               No 
3 Systemic arterial PO2 > 40 kPa on 100% FiO2 and  8 cm H2O  
PEEP or equivalent FiO2 : PaO2 within 12 hours 
                   
          Yes               No 
4 Warm ischaemic time (WIT) < 30 minutes (WIT starts when donor 
systolic BP < 50 mmHg and / or O2 sats < 70%) 
                   
          Yes               No 
5 Withdrawal of  life support  (WLS) time < 120 minutes 
                   
          Yes               No 
 NOTE: If any of the above questions are answered “NO”, the donor’s lung is not eligible to be 
used for standard transplant.  
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DEVELOP-UK Day of transplant 
 
Date (dd/mm/yyyy)          /          / 
Hospital  
NHS BT Donor Number  
 
Criteria for EVLP Assessment and Reconditioning 
 
Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD) lungs 
Please record the correct answers to the following questions:                
1 Warm ischaemic time (WIT) > 30 minutes for DCD donors but < 60 
minutes 
                   
          Yes               No 
2 Chest X-ray findings prohibitive to standard transplantation 
                   
          Yes               No 
3 Systemic arterial PO2 < 35-40 kPa and/ or selective PV gas < 30kPa  
on 100% FiO2 and  8 cm H2O  PEEP 
                   
          Yes               No 
4 
History of aspiration with bronchoscopic inflammation/soiling of 
the airway, or recurrent but not  prohibitive secretions in the distal 
airway after adequate bronchial toilet 
                   
          Yes               No 
5 Difficult to recruit atelectasis 
                   
          Yes               No 
6 Sustained peak airway pressure > 30 cmH2O 
                   
          Yes               No 
7 Unsatisfactory deflation test on disconnecting ET tube 
                   
          Yes               No 
8 Unsatisfactory palpation of the lungs identifying undetermined  
masses, nodules or gross oedema 
                   
          Yes               No 
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9 Deterioration or cardiac arrest in the donor prior to retrieval such 
that uncertainty over assessment remains 
                   
          Yes               No 
10 Unsatisfactory inspection of the lung after administration of  the  
preservation  flush and  procurement 
                   
          Yes               No 
11 Logistical reasons that will extend donor lung ischaemic time > 10-12 hrs and prevent donor 
organ use: 
 
Viral studies awaited 
                   
          Yes               No 
 
HLA compatibility studies 
                   
          Yes               No 
 
Pathology assessment of indeterminate mass in any donor 
                   
          Yes               No 
 
Awaiting recipient admission 
                   
          Yes               No 
 
 NOTE: If any one or more questions are answered “YES”, the donor’s lung is eligible to be 
used  for EVLP assessment and reconditioning 
 
DEVELOP-UK Day of transplant 
 
Date (dd/mm/yyyy) /         /
Recipient’s Study ID  
Criteria for transplant after successful EVLP Assessment and Reconditioning 
Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD) lungs 
Please record the correct answers to the following questions:                
1 DBD and DCD donor lungs meeting criteria for standard 
transplant 
                   
          Yes             No 
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2 
 
Pulmonary artery pressure < or equal to 20 mmHg, whilst 
achieving stable perfusate flow of up to 70 ml/kg 
IBW/minute at 37°C 
                   
          Yes             No 
3
Peak airway pressure <25 cms H2O while achieving 
adequate ventilation (tidal volumes up to a max 7 mls/kg 
IBW) 
                   
          Yes             No 
4 Oxygenation capacity shown by delta PO2 of  >40kPa 
(perfusate LA PO2 - perfusate PA PO2)/FiO2 
                   
          Yes             No 
5 Selective PV gas > 30 kPa on 100% FiO2 and 5 cm H2O 
PEEP 
                   
          Yes             No 
6 Stable or improving lung compliance and stable or falling 
lung resistance 
                   
          Yes             No 
7 No pulmonary oedema build-up in the ET tube 
                   
          Yes             No 
8 Satisfactory assessment on inspection and palpation 
                   
          Yes             No 
9 Signed Consent to Continue Form by potential matched 
recipient to receive an EVLP reconditioned lung* 
                   
          Yes             No         N/A 
 
 NOTE: If any of the above questions are answered “NO”, the donor’s lung is not eligible to be 
used for transplant. 
 
* If Informed Consent Form was signed on the day of transplant the Consent to Continue Form 
is not required. Patients in standard transplant group are not required to re-confirm informed 
consent on the day of transplant if they have signed the Expression of Interest Form or the 
Informed Consent Form prior to the transplant. 
 
Criteria for failed EVLP Assessment and Reconditioning 
Donation after Brain Death (DBD) or Donation after Circulatory Death (DCD) lungs
Please record the correct answers to the following questions:                
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1 DBD and DCD donor lungs not meeting stated criteria for standard 
transplant 
                   
          Yes               No 
2 Not satisfying criteria for transplant after successful EVLP 
assessment and reconditioning 
                   
          Yes               No 
 NOTE: If any of the above questions are answered “YES”, the donor’s lung is not eligible to be 
used for transplant. 
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Appendix 12 Patient and public involvement
Two lay member representatives were appointed to the Trial Steering Committee.
During the study, they attended:
l Trial Steering Committee meeting on 14 February 2012
l Trial Steering Committee teleconference on 8 October 2012
l Trial Steering Committee meeting on 16 April 2013
l Trial Steering Committee teleconference on 21 October 2013.
The lay member representatives contributed their personal patient experiences in advising the consent
process and approaching patients, as well as designing patient-related study documents.
One lay member expressed concerns about running both the INSPIRE trial and DEVELOP-UK study at the
same time, and asked what the Research Ethics Committee view might be. As a result, the Research Ethics
Committee chairperson was contacted for further advice.
The lay representatives supported the restart of EVLP activity in the study and commented on the patient
information sheet to provide additional information on how the lungs are handled. The proposed
patient-related documents were subsequently approved by the Research Ethics Committee without
any changes.
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Appendix 13 Videos/podcasts
A video, entitled ‘Reconditioned Lungs’, with information about the study, has been posted onTransplant TV, an online channel for medical professionals, patients and carers to share scientific and
medical information and stories about organ transplantation. Transplant TV is based at the Institute of
Transplantation, Freeman Hospital, Newcastle upon Tyne (jointly between The NuTH NHS Foundation
Trust and Newcastle University). The URL for the DEVELOP-UK video is: http://transplant.tv/portfolio/
reconditioned-lungs/?id=272 (accessed 10 January 2016).
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